Fontana City Council
March 14, 2023

AZ, L.L.C.
4893. CVS RS Pima Rd. AZ, L.L.C.
4894. CVS RS Prescott AZ, L.L.C.
4895. CVS RS Riverside Parker AZ,
L.L.C.
4896. CVS RS S. Central Ave. AZ, L.L.C.
4897. CVS RS S. Dobson Mesa AZ,
L.L.C.
4898. CVS RS Scottsdale FLW AZ,
L.L.C.
4899. CVS RS Scottsdale Rd AZ, L.L.C.
4900. CVS RS Sierra Vista AZ, L.L.C.
4901. CVS RS Silver Tuc AZ, L.L.C.
4902. CVS RS Sun City West AZ, L.L.C.
4903. CVS RS Sunrise Dr AZ, L.L.C.
4904. CVS RS Sunrise Surprise AZ,
L.L.C.
4905. CVS RS Sunrise Tucson AZ, L.L.C.
4906. CVS RS Tanque Verde AZ, L.L.C.
4907. CVS RS Tatum Blvd AZ, L.L.C.
4908. CVS RS Thomas Rd AZ, L.L.C.
4909. CVS RS Thomas Scottsdale AZ,
L.L.C.
4910. CVS RS W. Glendale Rd. AZ,
L.L.C.
4911. CVS RS W. Peoria Ave AZ, L.L.C.
4912. CVS RS W. Southern AJ AZ,
L.L.C.
4913. CVS RS W. Valencia Rd. AZ,
L.L.C.
4914. CVS RS West Indian AZ, L.L.C.
4915. CVS RS Wickenburg Way AZ,
L.L.C.
4916. CVS RS Yuma AZ, L.L.C.
4917. CVS Rt. 199 Williamsburg, Inc.
4918. CVS Rx Services, Inc.
4919. CVS Rye Route 1, L.L.C.
4920. CVS Rye Store, L.L.C.
4921. CVS Safir Sourcing UK, Ltd
4922. CVS Safir Sourcing, LLC
4923. CVS Salem Stateline, L.L.C.
4924. CVS Salmon Run, L.L.C.
4925. CVS San Dimas, L.P.
4926. CVS San Jacinto CA, L.L.C.
4927. CVS Santa Ana, L.P.
4928. CVS Saratoga Springs, L.L.C.
4929. CVS Saugerties Store, L.L.C.
4930. CVS Saunders Settlement
Pharmacy, L.L.C.
4931. CVS Sayville, L.L.C.
4932. CVS SC Distribution, Inc.
1721
WITH TECHNICAL CORRECTIONS 02.03.2023
J-73
4933. CVS SC Distribution, L.L.C.
4934. CVS Scarsdale Centre, L.L.C.
4935. CVS Scarsdale Store, L.L.C.
4936. CVS Schalks Crossing, L.L.C.
4937. CVS Schoolhouse, L.L.C.
4938. CVS Sea Cliff, L.L.C.
4939. CVS Seabrook, L.L.C.
4940. CVS Second Avenue NY, L.L.C.
4941. CVS Selden Store, L.L.C.
4942. CVS Seneca Mall, Inc.
4943. CVS Seneca Street, L.L.C.
4944. CVS Setauket, L.L.C.
4945. CVS Sharon Amity Charlotte, Inc.
4946. CVS Shaw Holdings Inc.
4947. CVS Sheepshead Bay, L.L.C.
4948. CVS Sheridan Harlem Store, L.L.C.
4949. CVS Sheridan Hollywood, L.L.C.
4950. CVS Ship Bottom, L.L.C.
4951. CVS Silver Spring, Inc.
4952. CVS Sixth Avenue NY, L.L.C.
4953. CVS Skippack, Inc.
4954. CVS Solomons MD, L.L.C.
4955. CVS South Albany Store, L.L.C.
4956. CVS South Canal Chicago, L.L.C.
4957. CVS South Farmingdale, L.L.C.
4958. CVS South Ogden, L.L.C.
4959. CVS South Salina Street, L.L.C.
4960. CVS South Schenectady Store,
L.L.C.
4961. CVS Southwest Blvd, Inc.
4962. CVS SP 5897 FL, L.L.C.
4963. CVS Sparta, L.L.C.
4964. CVS State Capital, L.L.C.
4965. CVS State NY Store, L.L.C.
4966. CVS State Street, L.L.C.
4967. CVS Staten Island, L.L.C.
4968. CVS Stelton Road, L.L.C.
4969. CVS Stony Point, L.L.C.
4970. CVS Strategic Resources Private
Limited
4971. CVS Stratford Barnum, Inc.
4972. CVS Stratford Nichols, Inc.
4973. CVS Stratham, L.L.C.
4974. CVS Suffern Store, L.L.C.
4975. CVS Sunrise Highway, L.L.C.
4976. CVS Surplus 8049 MI, L.L.C.
4977. CVS Syracuse Downtown, L.L.C.
4978. CVS Tampa 2802, L.L.C.
4979. CVS Tampa 3650, L.L.C.
4980. CVS Tarrytown Store, L.L.C.
4981. CVS Teaneck, L.L.C.
4982. CVS Tenafly Town, L.L.C.
4983. CVS Terry Road, L.L.C.
4984. CVS Thompsons Station, Inc.
4985. CVS Thornwood Columbus
Avenue, L.L.C.
4986. CVS Thornwood Park, L.L.C.
4987. CVS TN Distribution, Inc.
4988. CVS TN Distribution, L.L.C.
4989. CVS Toms River, L.L.C.
4990. CVS Torrance CA, L.L.C.
4991. CVS Towson MD, L.L.C.
4992. CVS Transportation, Inc.
4993. CVS Transportation, L.L.C.
4994. CVS Trenton MI, L.L.C.
4995. CVS Trousdale Nashville, Inc.
4996. CVS Troy Fifth Street, L.L.C.
4997. CVS Troy Mall Store, L.L.C.
4998. CVS TX Holding Company, L.L.C.
4999. CVS Union, L.L.C.
5000. CVS University of Buffalo, L.L.C.
5001. CVS Upper Montclair, L.L.C.
5002. CVS Upper Valley Drug, L.L.C.
5003. CVS VA Distribution, Inc.
5004. CVS Valley Stream, L.L.C.
5005. CVS Van Nuys, L.P.
5006. CVS Vanguard, Inc.
5007. CVS Ventnor Dorset, L.L.C.
5008. CVS Vero FL Distribution, L.L.C.
5009. CVS Victory Boulevard, L.P.
5010. CVS Wading River, L.L.C.
5011. CVS Wallace Building, L.L.C.
5012. CVS Wanaque, L.L.C.
5013. CVS Wantagh Ave, L.L.C.
5014. CVS Warren, Inc.
5015. CVS Washington 6448, L.L.C.
1722
WITH TECHNICAL CORRECTIONS 02.03.2023
J-74
5016. CVS Washington Avenue, L.L.C.
5017. CVS Washington Township, L.L.C.
5018. CVS Washington Wisconsin DC,
L.L.C.
5019. CVS Washington, Inc.
5020. CVS Waterville Valley, L.L.C.
5021. CVS Waxhaw NC, L.L.C.
5022. CVS Wayne Turnpike, L.L.C.
5023. CVS Webster, L.L.C.
5024. CVS West Babylon, L.L.C.
5025. CVS West Gate, L.L.C.
5026. CVS West Haven, Inc.
5027. CVS West Hempstead, L.L.C.
5028. CVS West Islip, L.L.C.
5029. CVS West Orange, L.L.C.
5030. CVS West Park Avenue, L.L.C.
5031. CVS West Side Store, L.L.C.
5032. CVS Westbrook Maine, L.L.C.
5033. CVS Westchester Square, L.L.C.
5034. CVS Westchester Store, L.L.C.
5035. CVS Western Avenue, L.L.C.
5036. CVS Westwood LA, L.P.
5037. CVS Weyman Avenue, L.L.C.
5038. CVS Weymouth 1853, L.L.C.
5039. CVS White Plains Road, L.L.C.
5040. CVS Whittier, L.P.
5041. CVS Wilbraham MA, Inc.
5042. CVS Williamstown, L.L.C.
5043. CVS Williamsville Store, L.L.C.
5044. CVS Williston Park, L.L.C.
5045. CVS Wilton, L.L.C.
5046. CVS Wisconsin Avenue DC, L.L.C.
5047. CVS Wisteria Drive, L.L.C.
5048. CVS Woodbridge Main Street,
L.L.C.
5049. CVS Woodbury Mullica, L.L.C.
5050. CVS Woodward, Inc.
5051. CVS WWRE, Inc.
5052. CVS Wyckoff, L.L.C.
5053. CVS Wynantskill, L.L.C.
5054. CVS Yonkers Broadway, L.L.C.
5055. CVS Yonkers, L.L.C.
5056. CVS Yorktown Heights Store, Inc.
5057. CVS Yorkville, L.L.C.
5058. CVS.com OTC, L.L.C.
5059. CVS/pharmacy Charitable Trust,
Inc.
5060. CVS-SHC Kidney Care Home
Dialysis of Austin LLC
5061. CVS-SHC Kidney Care Home
Dialysis of Los Angeles LLC
5062. CVS-SHC Kidney Care Home
Dialysis of Philadelphia LLC
5063. CVS-SHC Renal Holdings LLC
5064. Cypress California CVS, Inc.
5065. Cypress Jones CVS, L.P.
5066. Cypress Naples CVS, L.L.C.
5067. Cypresswood Houston CVS, L.P.
5068. D&R Pharmaceutical Services, LLC
5069. D.A.W., LLC
5070. Dacula CVS, Inc.
5071. Dairy Ashford CVS, L.P.
5072. Dale City VA CVS, Inc.
5073. Dale Mabry CVS, Inc.
5074. Dallas GA CVS, Inc.
5075. Dallas PharmaCare Pharmacy,
L.L.C.
5076. Dallas ProCare Pharmacy, Inc.
5077. Dallas Waugh CVS, L.P.
5078. Damen Chicago CVS, L.L.C.
5079. Dan Ridge CVS, Inc.
5080. Danbury Central CVS, Inc.
5081. Danbury CVS, Inc.
5082. Danbury Fair CVS, Inc.
5083. Danbury MRC, Inc.
5084. Danbury South Main CVS, Inc.
5085. Danvers Plaza CVS, Inc.
5086. Darien CVS, Inc.
5087. Dartmouth Retailer, Inc.
5088. Davenport FL CVS, L.L.C.
5089. Davison CVS, Inc.
5090. DBD Nocigs 2019-1 LLC
5091. DBD Nocigs 2019-15 LLC
5092. DBD Nocigs 2019-16 LLC
5093. DBD Nocigs 2019-2 LLC
5094. DBD Nocigs 2019-21 LLC
1723
WITH TECHNICAL CORRECTIONS 02.03.2023
J-75
5095. DBD Nocigs 2019-22 LLC
5096. DBD Nocigs 2019-23 LLC
5097. DBD Nocigs 2019-24 LLC
5098. DBD Nocigs 2019-25 LLC
5099. DBD Nocigs 2019-29 LLC
5100. DBD Nocigs 2019-41 LLC
5101. DBD Nocigs 2019-42 LLC
5102. DBD Nocigs 2019-43 LLC
5103. DBD Nocigs 2019-44 LLC
5104. DBD Nocigs 2019-45 LLC
5105. DBD Nocigs 2019-5 LLC
5106. DBD Nocigs 2019-7 LLC
5107. DBD Nocigs 2019-8 LLC
5108. De Soto CVS, L.P.
5109. Decatur CVS, Inc.
5110. Dedham CVS, Inc.
5111. Dedham High Street CVS, Inc.
5112. Deer Park Avenue CVS, Inc.
5113. Del Amo CVS, Inc.
5114. Del Prado CVS, L.L.C.
5115. Delaware CVS Pharmacy, L.L.C.
5116. Delaware Physicians Care -
Medicare, Incorporated
5117. Delaware Physicians Care,
Incorporated
5118. Delco Apothecary, Inc.
5119. Delran CVS, Inc.
5120. Delta Health HMO, Inc.
5121. Delta Risk Management, L.L.C.
5122. Deltona CVS, L.L.C.
5123. Denver PharmaCare Pharmacy,
L.L.C.
5124. Denville CVS, Inc.
5125. Depew Broadway CVS, Inc.
5126. Depew CVS, Inc.
5127. Depot St. CVS, Inc.
5128. Deptford CVS, Inc.
5129. Derby Center CVS, Inc.
5130. Derry Street CVS, Inc.
5131. Des Plaines CVS, L.L.C.
5132. Desert Buffalo CVS, L.L.C.
5133. Desert Eastern CVS, L.L.C.
5134. Desert Inn CVS, L.L.C.
5135. Destin FL CVS, L.L.C.
5136. Detroit CVS, Inc.
5137. Detroit Greenfield CVS, Inc.
5138. Dexter Plaza CVS, Inc.
5139. DG Danville KY LLC
5140. DG Wesley Chapel FL LLC
5141. Diamond Bar CVS, Inc.
5142. Digital eHealth, LLC
5143. Digital Enterprise Realty, L.L.C.
5144. District of Columbia CVS
Pharmacy, L.L.C.
5145. Division CVS, L.L.C.
5146. Dobbs Ferry CVS, Inc.
5147. Donlon Distributing, Inc.
5148. Dorchester Lower Mills CVS, Inc.
5149. Dothan CVS, Inc.
5150. Doubleday Ballston CVS, L.L.C.
5151. Douglassville PA CVS, Inc.
5152. Douglasville CVS, Inc.
5153. Dover Delaware CVS, Inc.
5154. Dover NJ CVS, L.L.C.
5155. Dover Randolph CVS, L.L.C.
5156. Dowagiac Clinton Stores, Inc.
5157. Downers Grove CVS, L.L.C.
5158. Downingtown CVS, Inc.
5159. Downtown Miami CVS, L.L.C.
5160. Doylestown CVS, Inc.
5161. Dragon Acquisition Company
5162. Drexel Hill CVS, Inc.
5163. Driftwood Shopping Center CVS,
Inc.
5164. Drogaria Onofre Ltda.
5165. Drug World, Inc.
5166. Drugs For Less, Inc.
5167. Drumhill CVS, Inc.
5168. Duarte CVS, Inc.
5169. Dudley Street CVS, Inc.
5170. Duke Street CVS, Inc.
5171. Duluth CVS, Inc.
5172. Duncan SC CVS, Inc.
5173. Dundee Elgin CVS, L.L.C.
5174. Dunedin CVS, L.L.C.
5175. Dunellen CVS, Inc.
1724
WITH TECHNICAL CORRECTIONS 02.03.2023
J-76
5176. Dunkirk Marketplace CVS, Inc.
5177. Dunkirk Marketplace Peoples, Inc.
5178. Dunlap Phoenix CVS, L.L.C.
5179. Dunlop Farms CVS, Inc.
5180. Dupont Circle CVS Realty, Inc.
5181. Durham NC CVS, Inc.
5182. Dyckman Street CVS, L.L.C.
5183. Dynamite Phoenix CVS, L.L.C.
5184. E. Arrow Hwy CVS, L.L.C.
5185. E. T. B., Inc.
5186. e.BENEFITS, INC.
5187. Eagan MN CVS, L.L.C.
5188. Eagle Valley CVS, Inc.
5189. Eagles Landing CVS, Inc.
5190. East 161st Street CVS, Inc.
5191. East Avenue CVS, Inc.
5192. East Bay Drive CVS, Inc.
5193. East Boston CVS, Inc.
5194. East Bradford Plaza CVS, Inc.
5195. East Bridgewater CVS, Inc.
5196. East Brunswick CVS, Inc.
5197. East Flatbush CVS, L.L.C.
5198. East Greenwich CVS, Inc.
5199. East Hampton CVS, Inc.
5200. East Hanover CVS, Inc.
5201. East Hartford CVS, Inc.
5202. East Hartford-Main Street CVS,
Inc.
5203. East Haven Main Street CVS, Inc.
5204. East Haverhill Retailer, Inc.
5205. East Hills CVS, Inc.
5206. East Longmeadow CVS, Inc.
5207. East Main Bridgeport CVS, Inc.
5208. East Main St. at Westborough CVS,
Inc.
5209. East Market CVS, Inc.
5210. East Market Street CVS, L.L.C.
5211. East Northport CVS, L.L.C.
5212. East Providence CVS, Inc.
5213. East Putnam Avenue CVS, Inc.
5214. East Side CVS, Inc.
5215. East Wareham CVS, Inc.
5216. East Windsor CVS, L.L.C.
5217. Eastampton Township CVS, Inc.
5218. Eastern Avenue CVS, Inc.
5219. Eastfield CVS, Inc.
5220. Eastland CVS, Inc.
5221. Easton Ave. CVS, Inc.
5222. Easton CVS, Inc.
5223. Easton Maryland CVS, Inc.
5224. Easton Nazareth CVS, Inc.
5225. Easton Sullivan CVS, Inc.
5226. Easton Washington Street CVS, Inc.
5227. Easton, Mass. CVS, Inc.
5228. Eatontown CVS, Inc.
5229. Echo Merger Sub, Inc.
5230. Echo Merger Sub, LLC
5231. Eckerd Corporation (for assets /
pharmacies acquired by CVS)
5232. Eckerd Corporation of Florida, Inc.
5233. Eckerd Drug Company (for assets /
pharmacies acquired by CVS)
5234. Eckerd Drug Company of Florida,
Inc.
5235. Eckerd Drug Company of Texas,
Inc. (for assets / pharmacies
acquired by CVS)
5236. Eckerd Drugs of Florida, Inc. (for
assets / pharmacies acquired by
CVS)
5237. Eckerd Drugs of Georgia, Inc. (for
assets / pharmacies acquired by
CVS)
5238. Eckerd Drugs of Louisiana, Inc. (for
assets / pharmacies acquired by
CVS)
5239. Eckerd Drugs of Mississippi, Inc.
(for assets / pharmacies acquired by
CVS)
5240. Eckerd Drugs of North Carolina,
Inc. (for assets/pharmacies acquired
by CVS)
5241. Eckerd Drugs of South Carolina,
Inc. (for assets / pharmacies
acquired by CVS)
1725
WITH TECHNICAL CORRECTIONS 02.03.2023
J-77
5242. Eckerd Drugs of Texas, Inc. (for
assets / pharmacies acquired by
CVS)
5243. Eckerd Drugs, Inc. (for assets /
pharmacies acquired by CVS)
5244. Eckerd Drugsmarts, Inc. (for assets
/ pharmacies acquired by CVS)
5245. Eddystone CVS, Inc.
5246. Edgewater CVS, Inc.
5247. Edgewater NJ CVS, L.L.C.
5248. Edgewater Orlando CVS, L.L.C.
5249. Edgewood CVS, Inc.
5250. Edison Wooding CVS, Inc.
5251. Efmile, Inc.
5252. Egg Harbor NJ CVS, L.L.C.
5253. Egypt Audubon CVS, Inc.
5254. eHealth Solutions, Inc.
5255. Eighth New York CVS, L.L.C.
5256. El Camino Houston CVS, L.P.
5257. Electric Avenue CVS, Inc.
5258. Eleventh Street CVS, Inc.
5259. Elgin CVS, L.L.C.
5260. Eliot CVS, Inc.
5261. Elizabeth Westfield Avenue CVS,
Inc.
5262. Elkhorn Las Vegas CVS, L.L.C.
5263. Elkhorn NV CVS, L.L.C.
5264. Ellicott City CVS, Inc.
5265. Elliot Tempe CVS, L.L.C.
5266. Ellwood City CVS, L.L.C.
5267. Elmhurst CVS, L.L.C.
5268. Elmora CVS, Inc.
5269. Emerald Square CVS, Inc.
5270. Emmaus Avenue CVS, Inc.
5271. Emmaus, Pennsylvania, CVS, Inc.
5272. Employee Assistance Services, LLC
5273. Enfield CVS, Inc.
5274. Enfield Elm CVS, Inc.
5275. Enfield Phoenix CVS, Inc.
5276. Engleside Plaza CVS, Inc.
5277. Engleside Plaza Peoples, Inc.
5278. Englewood Cliffs CVS, Inc.
5279. Englewood CVS, Inc.
5280. Enloe Drugs LLC
5281. Ennis TX CVS, L.P.
5282. Enterprise Patient Safety
Organization, LLC
5283. Erdenheim Saints CVS, Inc.
5284. Eric C. Marshall, M.D. P.C.
5285. Erie CVS, Inc.
5286. Escalante Solutions, LLC
5287. Essence, Inc.
5288. Essex Eastern CVS, Inc.
5289. Essex Martin CVS, Inc.
5290. Essex St. (Salem) CVS, Inc.
5291. Estero Coconut CVS, L.L.C.
5292. Estero Three Oaks CVS, L.L.C.
5293. Estroff Pharmacy Incorporated
5294. ETHIX Care, Inc.
5295. ETHIX Midlands, Inc.
5296. ETHIX Northwest Public Services,
Inc.
5297. ETHIX Northwest, Inc.
5298. Euclid Square CVS, Inc.
5299. Evanston IL CVS, L.L.C.
5300. Everett MA CVS, Inc.
5301. Evergreen City CVS, L.L.C.
5302. Evergreen Pharmaceutical of
California, Inc.
5303. Evergreen Pharmaceutical of
California, LLC
5304. Evergreen Pharmaceutical, LLC
5305. Evergreen Plaza CVS, Inc.
5306. Evesboro CVS, Inc.
5307. Evesham NJ CVS, L.L.C.
5308. Ewing NJ CVS, L.L.C.
5309. Exchange Place CVS, Inc.
5310. Exeter Square CVS, Inc.
5311. Express Pharmacy Services of FL,
L.L.C.
5312. Express Pharmacy Services of MO,
L.L.C.
5313. Express Pharmacy Services of PA,
L.L.C.
5314. Fairfax CVS, Inc.
5315. Fairfax Main Street CVS, Inc.
1726
WITH TECHNICAL CORRECTIONS 02.03.2023
J-78
5316. Fairfax Mall CVS, Inc.
5317. Fairfax Peoples, Inc.
5318. Fairfax Route 29 CVS, Inc.
5319. Fairfield CVS, Inc.
5320. Fairfield Plaza CVS, Inc.
5321. Fairfield Rt. 1 CVS, Inc.
5322. Fairhaven CVS, Inc.
5323. Fairlane CVS, Inc.
5324. Fairlane Village Mall CVS, Inc.
5325. Fairmont Pasadena CVS, L.P.
5326. Fairmount CVS Store, Inc.
5327. Fairview CVS, Inc.
5328. Fairview Township CVS, Inc.
5329. Fall River Retailer, Inc.
5330. Fall River-President CVS, Inc.
5331. Fallbrook Houston CVS, L.P.
5332. Falls Church CVS, Inc.
5333. Falls of Neuse CVS, Inc.
5334. Falls Road CVS, Inc.
5335. Falmouth CVS, Inc.
5336. Falmouth Ferry CVS, Inc.
5337. Falmouth Mall CVS, Inc.
5338. Falmouth Plaza CVS, Inc.
5339. Family Health Plan (FHP), Inc.
5340. Family Health Plan Corporation
5341. Farmingdale CVS, Inc.
5342. Farmington Ave. CVS, Inc.
5343. Farmington CVS, Inc.
5344. Farmington Holdings, Inc.
5345. Farmington Plaza CVS, Inc.
5346. Farmingville CVS Store, Inc.
5347. Fashion Square CVS, Inc.
5348. FDG C41 AR Texarkana LLC
5349. FEASIBLE ALTERNATIVES

LIMITED
5350. Feasterville CVS, Inc.
5351. Federal Highway ProCare
Pharmacy, Inc.
5352. Fenton Avenue CVS, L.L.C.
5353. Ferrara & Orlando Nurse
Practictioners-Family Health P.C.
5354. Ferrara Nurse Practitioner-Family
Health, P.C.
5355. FHP Health Plan, Inc.
5356. Fifth Avenue Chess King, Inc.
5357. Fingerlakes CVS Store, Inc.
5358. Firestone Blvd CVS, L.L.C.
5359. First Avenue ProCare Pharmacy,
L.L.C.
5360. First Choice of the Midwest LLC
5361. First Choice of the Midwest, Inc.
5362. First Colony CVS, L.P.
5363. First Financial Planner Services,
Inc.
5364. First Health Group Corp.
5365. First Health Life & Health
Insurance Company
5366. First Health Strategies, Inc.
5367. First Script Network Services, Inc.
5368. Fish Lake Maple Grove CVS,
L.L.C.
5369. Fishkill CVS, Inc.
5370. Fitchburg PharmaCare Pharmacy,
Inc.
5371. Fitchburg Retailer, Inc.
5372. Flagler 87th Miami CVS, L.L.C.
5373. Flagstone Church, LLC
5374. Flamingo Jones NV CVS, L.L.C.
5375. Flamingo Road CVS, L.L.C.
5376. Flatbush Avenue CVS, Inc.
5377. Flatbush Brooklyn CVS, L.L.C.
5378. Flatlands CVS, L.L.C.
5379. Flatwoods CVS, Inc.
5380. Fleetwood CVS Store, Inc.
5381. Flemington CVS, L.L.C.
5382. Flemington NJ CVS, L.L.C.
5383. Flora Midwest, L.L.C.
5384. Floral Jericho CVS, L.L.C.
5385. Florence CVS, Inc.
5386. Florence NJ CVS, Inc.
5387. Florham Park CVS, Inc.
5388. Florida Collaborative for Health
Care Quality, LLC
5389. Florida CVS Pharmacy, L.L.C.
5390. Florida Health Plan Administrators,
LLC
1727
WITH TECHNICAL CORRECTIONS 02.03.2023
J-79
5391. Flower Mound CVS, L.P.
5392. Flushing CVS, Inc.
5393. FM 1960 Houston CVS, L.P.
5394. FM 359 TX CVS, L.L.C.
5395. FM 518 League City CVS, L.P.
5396. FM 529 Houston CVS, L.P.
5397. FOCUS Healthcare Management
Associates, Inc.
5398. FOCUS HealthCare Management,
Inc.
5399. Folsom CVS, Inc.
5400. Fontana Sierra CVS, L.L.C.
5401. Foothill La Verne CVS, Inc.
5402. Foothill Ranch CVS, Inc.
5403. Forbes Avenue CVS, Inc.
5404. Forest Drive CVS, Inc.
5405. Forest Hill MD CVS, L.L.C.
5406. Forest Hills CVS, Inc.
5407. Forest Hills NY CVS, L.L.C.
5408. Forest Hills Peoples, Inc.
5409. Forest Lane Dallas CVS, L.P.
5410. Forest Park CVS, Inc.
5411. Forest Park IL CVS, L.L.C.
5412. Forks Township CVS, Inc.
5413. Formerly Broad Axe CVS, Inc.
5414. Formerly Peoples Drug Stores, Inc
5415. Fort Foote CVS, Inc.
5416. Fort Lee Palisades CVS, Inc.
5417. Fort Mill SC CVS, Inc.
5418. Fort Pierce CVS, L.L.C.
5419. Fort Worth ProCare Pharmacy, Inc.
5420. Foster Nagle CVS, L.L.C.
5421. Foster Street CVS, Inc.
5422. Foundation Health Plan of San
Bernardino, Incorporated
5423. Foundation Health, A Florida
Health Plan, Inc.
5424. Foundation Health, An Alabama
Health Plan, Inc.
5425. Fowler Tampa CVS, Inc.
5426. Fox Run CVS, Inc.
5427. Foxboro CVS, Inc.
5428. Foxon East Haven CVS, Inc.
5429. FPS of Connecticut, Inc.
5430. Fracisquito Sunset CVS, Inc.
5431. Framingham Concord CVS, Inc.
5432. Framingham CVS, Inc.
5433. Framingham Water St. CVS, Inc.
5434. Framingham Worcester CVS, Inc.
5435. Franconia Road CVS, Inc.
5436. Frankford Avenue CVS, Inc.
5437. Frankfort CVS, Inc.
5438. Franklin Avenue CVS, Inc.
5439. Franklin Central CVS, Inc.
5440. Franklin Mahwah CVS, L.L.C.
5441. Franklin Retailer, Inc.
5442. Franklin TN CVS, Inc.
5443. Franklin W. Central St. CVS, Inc.
5444. Fraser Garfield CVS, L.L.C.
5445. Frederick CVS, Inc.
5446. Freehold NJ CVS, L.L.C.
5447. Freeport Long Beach CVS, L.L.C.
5448. Fridley MN CVS, L.L.C.
5449. Friendly Hills Healthcare Network,
Inc.
5450. Fries Mill CVS, Inc.
5451. Front Street CVS, Inc.
5452. Frontier Community Health Plans,
Inc.
5453. Ft. Lauderdale CVS, Inc.
5454. Ft. Myers CVS, L.L.C.
5455. Fullerton CVS, Inc.
5456. Futrix Inc.
5457. Futrix Limited
5458. G Street CVS, Inc.
5459. Gahanna OH CVS, Inc.
5460. Gainesville CVS, Inc.
5461. Gainesville FL CVS, L.L.C.
5462. Gaithersburg Mall CVS, Inc.
5463. Gaithersburg, MD Bob's, Inc.
5464. Gallivan CVS, Inc.
5465. Galloway CVS, Inc.
5466. Gandy CVS, Inc.
5467. Garden City CVS, Inc.
5468. Garden Grove CVS, Inc.
5469. Garden State HMO
1728
WITH TECHNICAL CORRECTIONS 02.03.2023
J-80
5470. Gardner CVS, Inc.
5471. Garfield Beach CVS, L.L.C.
5472. Garfield CVS, Inc.
5473. Garland CVS, L.P.
5474. Garson Culver CVS, Inc.
5475. Garth Baytown CVS, L.P.
5476. Garwood Chestnut CVS, Inc.
5477. Gastonia CVS, Inc.
5478. Gate City CVS, Inc.
5479. Gatti LTC Services, Inc.
5480. Generation Health, L.L.C.
5481. Genesis Health Services Corp.
5482. Genesis Health Ventures, Inc.
5483. Geneva Carol CVS, L.L.C.
5484. Geneva Clinton Stores, Inc.
5485. Geneva Woods Health Services,
LLC
5486. Geneva Woods LTC Pharmacy,
LLC
5487. Geneva Woods Management, LLC
5488. Geneva Woods Pharmacy Alaska,
LLC
5489. Geneva Woods Pharmacy
Washington, LLC
5490. Geneva Woods Pharmacy
Wyoming, LLC
5491. Geneva Woods Pharmacy, Inc.
5492. Geneva Woods Pharmacy, LLC
5493. Geneva Woods Retail Pharmacy,
LLC
5494. Genito Midlothian CVS, Inc.
5495. GenPlus Managed Care, Inc.
5496. George Safran, M.D., P.C.
5497. Georgetown CVS, Inc.
5498. Georgetown OH CVS, L.L.C.
5499. Georgia CVS Pharmacy, L.L.C.
5500. Georgia Health System, Inc.
5501. German Dobson CVS, L.L.C.
5502. Germantown Avenue CVS, Inc.
5503. Germantown MD CVS, L.L.C.
5504. Gessner Philippine Houston CVS,
L.P.
5505. Gibbsboro NJ CVS, L.L.C.
5506. Gilbert AZ CVS, L.L.C.
5507. Gilbert Guadalupe CVS, L.L.C.
5508. Gilbert Warner CVS, L.L.C.
5509. Gilbertsville CVS, Inc.
5510. Girard Avenue ProCare Pharmacy,
Inc.
5511. Gladiolus Ft. Myers CVS, L.L.C.
5512. Glastonbury CVS, Inc.
5513. Glebe Road CVS, Inc.
5514. Glebe Road Peoples, Inc.
5515. Glen Allen CVS, Inc.
5516. Glen Burnie MD CVS, L.L.C.
5517. Glen Ellyn IL CVS, L.L.C.
5518. Glen Oaks CVS, L.L.C.
5519. Glendale Avenue CVS, L.P.
5520. Glendale CVS, L.L.C.
5521. Glendale Galleria CVS, Inc.
5522. Glendale Heights CVS, L.L.C.
5523. Glendale NY CVS, L.L.C.
5524. Glendora Foothill CVS, Inc.
5525. Glenriddle CVS, Inc.
5526. Glenview CVS, L.L.C.
5527. Glenwood Avenue CVS, Inc.
5528. Global Claim Services, L.C.
5529. Gloucester Downtown CVS, Inc.
5530. Gloucester Retailer, Inc.
5531. Gloucester-Erial CVS, Inc.
5532. Godfrey Avenue CVS, Inc.
5533. Godshall Franconia CVS, Inc.
5534. Gold Star Blvd. PharmaCare
Pharmacy, Inc.
5535. Golden West CVS, Inc.
5536. Goldenrod CVS, Inc.
5537. Goodhealth Worldwide (Americas)
Limited
5538. Goodhealth Worldwide (Asia
Pacific) Limited
5539. Goodhealth Worldwide (Asia
Pacific) Ltd.
5540. Goodhealth Worldwide (Asia)
Limited
5541. Goodhealth Worldwide (Bermuda)
Limited
1729
WITH TECHNICAL CORRECTIONS 02.03.2023
J-81
5542. Goodhealth Worldwide (Europe)
Limited
5543. Goodhealth Worldwide (Global)
Limited
5544. Goodhealth Worldwide (Middle
East) LLC
5545. Goodhealth Worldwide (Shanghai)
Limited
5546. Goodhealth Worldwide
Administrators Inc.
5547. Goodhealth Worldwide Limited
5548. Goodhealth Worldwide
Management FZ-LLC
5549. Goodlette Naples CVS, L.L.C.
5550. Goodwin Park CVS, Inc.
5551. Goodyear CVS, LLC
5552. Gordon's Corner CVS, Inc.
5553. Goshen Village CVS, Inc.
5554. Governors Boulevard CVS, Inc.
5555. Grafton CVS, Inc.
5556. Grafton Street CVS, Inc.
5557. Graham Charlotte CVS, Inc.
5558. Granby CVS, Inc.
5559. Grand Baldwin CVS, Inc.
5560. Grand Bay CVS, Inc.
5561. Grand Covina CVS, Inc.
5562. Grand Prairie CVS, L.P.
5563. Grand River CVS, Inc.
5564. Grand Schaefer CVS, Inc.
5565. Grand St. Paul CVS, L.L.C.
5566. Grand Street CVS, L.L.C.
5567. Grandview Healthcare, Inc.
5568. Grandview Healthcare, LLC
5569. Grandview Pharmacy, Inc.
5570. Grandview Pharmacy, LLC
5571. Granite Run CVS, Inc.
5572. Granite Street CVS, Inc.
5573. Grapevine CVS, L.P.
5574. Gratiot CVS, Inc.
5575. Gray Houston CVS, L.P.
5576. Gray's Southgate, Inc.
5577. Grayson GA CVS, Inc.
5578. Great Valley CVS, Inc.
5579. Greece Clinton Paine, Inc.
5580. Greece CVS, Inc.
5581. Greece Towne CVS, Inc.
5582. Green Hills Plaza CVS, Inc.
5583. Greenacres CVS, Inc.
5584. Greenbelt CVS, Inc.
5585. Greenbelt-Cherrywood CVS, Inc.
5586. Greenbriar Houston CVS, L.P.
5587. Greencastle PA CVS, Inc.
5588. Greendale Mall CVS, Inc.
5589. Greenfield Federal CVS, Inc.
5590. Greenfield-Cherry Rum CVS, Inc.
5591. Greenlawn CVS, Inc.
5592. Greensboro GA CVS, Inc.
5593. Greenville CVS, Inc.
5594. Greenway Surprise CVS, L.L.C.
5595. Greenwich 99 CVS, Inc.
5596. Greenwich CVS, Inc.
5597. Greenwood Lake CVS, L.L.C.
5598. Grosse Pointe Realty, L.L.C.
5599. Groton CVS, Inc.
5600. Group Dental Service of Maryland,
Inc.
5601. Group Dental Service, Inc.
5602. Group Dental Services, Inc.
5603. Group Health Plan of Delaware,
LLC
5604. Group Health Plan, Inc.
5605. Grove City CVS, Inc.
5606. Guilford CVS, Inc.
5607. Gun Hill Road CVS, L.L.C.
5608. Gurnee CVS, L.L.C.
5609. Gwinnett CVS, Inc.
5610. GWL (UK) Limited
5611. H.M.S.S., Inc.
5612. Hackensack CVS, L.L.C.
5613. Haddon Heights CVS, L.L.C.
5614. Hadley CVS, Inc.
5615. Hallandale FL CVS, L.L.C.
5616. Haltom City CVS, L.P.
5617. Hamburg Clinton Stores, Inc.
5618. Hamburg Turnpike CVS, Inc.
5619. Hamden Plaza CVS, Inc.
1730
WITH TECHNICAL CORRECTIONS 02.03.2023
J-82
5620. Hamden Retailer, Inc.
5621. Hamden Whitney CVS, Inc.
5622. Hamilton CVS, Inc.
5623. Hamilton CVS, L.L.C.
5624. Hamilton Klockner CVS, Inc.
5625. Hamilton Parkway CVS, L.L.C.
5626. Hamilton Plaza CVS, Inc.
5627. Hamlin CVS, Inc.
5628. Hanover CVS, L.L.C.
5629. Hanover Mass. CVS, Inc.
5630. Hanover Park CVS, L.L.C.
5631. Hanover Shaw Plaza CVS, Inc.
5632. Hanover-Pembroke CVS, Inc.
5633. Hanson CVS, Inc.
5634. Harbor Mall CVS, Inc.
5635. Harbor Santa Ana CVS, L.P.
5636. Harborside CVS, Inc.
5637. Harbour Place CVS, Inc.
5638. Hard Columbus CVS, L.L.C.
5639. Hardscrabble CVS, Inc.
5640. Harlem Chicago CVS, L.L.C.
5641. Harleysville PA CVS, Inc.
5642. Harmon Las Vegas CVS, L.L.C.
5643. Harrisburg CVS, Inc.
5644. Harrisburg NC CVS, Inc.
5645. Harrison Bridge Road CVS, Inc.
5646. Harrison East Orange CVS, Inc.
5647. Harrison Township CVS, Inc.
5648. Hartford Blue Hills CVS, Inc.
5649. Hartford Main Street CVS, Inc.
5650. Harvard Square CVS, Inc.
5651. Harwich CVS, Inc.
5652. Harwichport Main Street CVS, Inc.
5653. Hatfield PA CVS, Inc.
5654. Haverford and City Line CVS, Inc.
5655. Haverford Avenue CVS, Inc.
5656. Haverhill CVS, Inc.
5657. Haverhill Lowell CVS, Inc.
5658. Havertown CVS, Inc.
5659. Haw Creek Circle CVS, Inc.
5660. Hawaiian Gardens CVS, Inc.
5661. Hawley CVS, Inc.
5662. Hawthorne CVS, Inc.
5663. Haymarket VA CVS, Inc.
5664. Hazel Crest CVS, L.L.C.
5665. Hazlet CVS, Inc.
5666. Hazleton CVS, Inc.
5667. Hazleton Plaza CVS Inc.
5668. HCP Acquisition Sub, LLC
5669. Heacock Moreno CVS, L.L.C.
5670. Health America Corporation of
Pennsylvania, Inc.
5671. Health and Human Resource Center
5672. Health and Human Resource Center
Medical Group, Inc.
5673. Health and Human Resource
Center, Inc.
5674. Health Care Management Co. Ltd.
5675. Health Care USA of Tennessee, Inc
5676. Health Cost Consultants, Inc.
5677. Health Data & Management
Solutions, Inc.
5678. Health Integration Strategies, L.P.
5679. Health Integration, Inc.
5680. Health Maintenance Organization
of New Jersey, Inc.
5681. Health Mart, Inc.
5682. Health Re, Inc.
5683. Healthagen International Limited
5684. Healthagen LLC
5685. HealthAmerica Pennsylvania, Inc.
5686. HealthAssurance Financial
Services, Inc.
5687. HealthAssurance Pennsylvania, Inc.
5688. HealthCare America Plans, Inc.
5689. HealthCare USA of Missouri L.L.C.
5690. HealthInfusion, Inc.
5691. Healthmart, Inc.
5692. Healthmaster, Inc.
5693. HealthPASS, Inc.
5694. HealthPlus, Inc.
5695. HealthWays of New York, Inc.
5696. Heartland Healthcare Services, LLC
5697. Heartland Pharmacy of Illinois LLC
5698. Heartland Pharmacy of Maryland,
LLC
1731
WITH TECHNICAL CORRECTIONS 02.03.2023
J-83
5699. Heartland Pharmacy of PA, LLC
5700. Heartland Repack Services LLC
5701. Hebron CT CVS, Inc.
5702. Hebron Parkway CVS, L.P.
5703. Hedges Pond CVS, Inc.
5704. Hellertown CVS, Inc.
5705. Hempstead Avenue CVS, Inc.
5706. Hempstead NY CVS, L.L.C.
5707. Henderson CVS, L.L.C.
5708. Henderson Horizon CVS, L.L.C.
5709. Henderson Road CVS, Inc.
5710. Hennepin Avenue CVS, L.L.C.
5711. Henry Philadelphia CVS, Inc.
5712. Henry Street CVS, L.L.C.
5713. Henrydale CVS, Inc.
5714. Hermosa Beach CVS, Inc.
5715. Hewlett CVS, Inc.
5716. HHPF, Inc.
5717. HHRC, Inc.
5718. Hialeah CVS, L.L.C.
5719. Hialeah West 49th CVS, L.L.C.
5720. Hick Hwy CVS, Inc.
5721. Hickory CVS, Inc.
5722. Hickory Hills IL CVS, L.L.C.
5723. High House Road CVS, Inc.
5724. High Ridge Road CVS, Inc.
5725. High Street CVS, Inc.
5726. Highland Avenue CVS, Inc.
5727. Highland Center CVS, Inc.
5728. Highland Cheshire CVS, Inc.
5729. Highland Leasing Corporation
5730. Highland Market CVS, Inc.
5731. Highland Park CVS, L.L.C.
5732. Highlander Plaza CVS, Inc.
5733. Highway 14 SC CVS, Inc.
5734. Highway 17 Mt. Pleasant CVS, Inc.
5735. Highway 19 Palm Harbor CVS,
L.L.C.
5736. Highway 92 CVS, Inc.
5737. Highway 98 CVS, Inc.
5738. Highway Charlotte CVS, Inc.
5739. Highway Stockbridge CVS, Inc.
5740. Hillcrest Frisco CVS, L.P.
5741. Hillcroft Houston CVS, L.P.
5742. Hilliard Darby CVS, Inc.
5743. Hilliard Park Mill CVS, Inc.
5744. Hillsboro Road CVS, L.L.C.
5745. Hillsborough Avenue CVS, L.L.C.
5746. Hillsborough CVS, Inc.
5747. Hillside Amarillo TX CVS, L.L.C.
5748. Hillside Avenue CVS, L.L.C.
5749. Hillside CVS, Inc.
5750. Hillside IL CVS, L.L.C.
5751. Hilltop Air Corporation
5752. Hilltown PA CVS, Inc.
5753. Hingham CVS, Inc.
5754. HIP Health Plan of Florida, Inc.
5755. HMIS, Inc.
5756. HMO Of Greater New York, Inc.
5757. HMO of Iowa, Inc.
5758. HMO of New Jersey, Inc.
5759. HMS Colorado, Inc.
5760. HMS Healthcare, Inc.
5761. Hoadley Rd CVS, Inc.
5762. Hokes Bluff CVS, Inc.
5763. Holbrook CVS, Inc.
5764. Holcomb CVS, Inc.
5765. Holden Common CVS, Inc.
5766. Holden PharmaCare Pharmacy, Inc.
5767. Holiday CVS, L.L.C.
5768. Holiday Hwy 19 CVS, L.L.C.
5769. Holliston CVS, Inc.
5770. Holly Springs CVS, Inc.
5771. Holyoke CVS, Inc.
5772. Holyoke Mall CVS, Inc.
5773. Holyoke South Street CVS, Inc.
5774. Home Care Pharmacy, LLC
5775. Home Pharmacy Services, LLC
5776. Homestead 312th FL CVS, L.L.C.
5777. Homestead CVS, L.L.C.
5778. Homeward Pharmacy, LLC
5779. Hook Drugs, Inc. of Michigan
5780. Hooker Avenue CVS, Inc.
5781. Hookset CVS, Inc.
5782. Hook-SupeRx Funding Corp.
5783. Hook-SupeRx, Inc.
1732
WITH TECHNICAL CORRECTIONS 02.03.2023
J-84
5784. Hook-SupeRx, L.L.C.
5785. Hooper Road CVS, Inc.
5786. Hope Mills CVS, Inc.
5787. Hopewell CVS, Inc.
5788. Hopkins CVS, L.L.C.
5789. Horatio Orlando CVS, Inc.
5790. Horizon Behavioral Services, LLC
5791. Horsham CVS, Inc.
5792. Hospital CVS, Inc.
5793. Hospitality Holdings, Inc.
5794. Houston Main Elgin CVS, L.P.
5795. Houston ProCare Pharmacy, Inc.
5796. Houston TX CVS, L.P.
5797. Howell CVS, L.L.C.
5798. Hubbard Sylmar CVS, L.P.
5799. Hudson CVS, Inc.
5800. Hudson N.H. CVS, Inc.
5801. Huffmeister CVS, L.P.
5802. Humble CVS, L.P.
5803. Hunt Valley CVS, Inc.
5804. Huntersville NC CVS, Inc.
5805. Hunting Park CVS, Inc.
5806. Huntingdon Valley CVS, Inc.
5807. Huntington Beach CVS, Inc.
5808. Huntington Center CVS, Inc.
5809. Huntington CVS, Inc.
5810. Huntington Drive CVS, Inc.
5811. Huntington Station CVS, Inc.
5812. Huntington WV CVS, Inc.
5813. Huntsville AL CVS, Inc.
5814. Huntsville Moores Mill CVS, Inc.
5815. Huntsville Whitesburg CVS, Inc.
5816. Hurley MS CVS, Inc.
5817. Hurricane WV CVS, Inc.
5818. Hurst CVS, L.P.
5819. Hwy 544 MB CVS, Inc.
5820. Hyannis CVS, Inc.
5821. Hyannis Main Street CVS, Inc.
5822. Hyattsville CVS, Inc.
5823. Hyde Park Avenue CVS, Inc.
5824. Hytree Pharmacy, Inc.
5825. I.g.G. of America, Inc.
5826. I.g.G. of America, LLC
5827. Idaho CVS Pharmacy, L.L.C.
5828. IHS Acquisition XXX, Inc.
5829. IlliniCare Health Plan, Inc.
5830. Imperial CVS, Inc.
5831. Independence MI CVS, L.L.C.
5832. Independence Plano CVS, L.P.
5833. Independent Investments, Inc.
5834. Indian 59th Phoenix CVS, L.L.C.
5835. Indian Health Organisation Private
Limited
5836. Indian School Phoenix CVS, L.L.C.
5837. Indian Trail CVS, Inc.
5838. Indiana CVS, Inc.
5839. Informed Health, LLC.
5840. Ingleside CVS, Inc.
5841. Inland Health Plan
5842. Inman Edison CVS, L.L.C.
5843. Inner Loop Georgetown CVS,
L.L.C.
5844. Innovation Health Holdings, LLC
5845. Innovation Health Insurance
Company
5846. Innovation Health Plan, Inc.
5847. Innovative Worldwide Distributors
(HK) Limited
5848. Institutional Health Care Services
LP
5849. Institutional Health Care Services,
LLC
5850. Integrated Pharmacy Solutions, Inc.
5851. InterGlobal Holdco Limited
5852. InterGlobal Insurance Company
Limited
5853. InterGlobal Japan Corporation
Limted
5854. InterGlobal Limited
5855. Interlock Pharmacy Systems, LLC
5856. Iowa CVS Pharmacy, L.L.C.
5857. Ironbound CVS Urban Renewal,
L.L.C.
5858. Irvine CA CVS, L.P.
5859. Irving CVS, L.P.
5860. Irving Park CVS, L.L.C.
1733
WITH TECHNICAL CORRECTIONS 02.03.2023
J-85
5861. Irving Streamwood CVS, L.L.C.
5862. Irving Street CVS, Inc.
5863. Island Avenue CVS, Inc.
5864. Islington CVS, Inc.
5865. Ithaca CVS Store, Inc.
5866. iTriage, LLC
5867. Ives Dairy Miami CVS, L.L.C.
5868. Ivyland CVS, Inc.
5869. Ivyland PA CVS, Inc.
5870. J.F.K. Street CVS, Inc.
5871. Jacksboro Highway CVS, L.P.
5872. Jackson Heights CVS, L.L.C.
5873. Jackson NJ CVS, Inc.
5874. Jackson North West CVS, Inc.
5875. Jackson Square CVS, Inc.
5876. Jacksonville CVS, L.L.C.
5877. Jaguar Merger Subsidiary, Inc.
5878. Jamaica CVS, L.L.C.
5879. Jamaica Plain CVS, Inc.
5880. Jamesburg CVS, L.L.C.
5881. JEC Facilities Funding II, Inc.
5882. JEC Funding, Inc.
5883. JEC Funding, LLC
5884. Jefferson CVS, Inc
5885. Jefferson Havens Corner CVS, Inc.
5886. Jefferson Woodbridge CVS, Inc.
5887. Jenkintown CVS, Inc.
5888. Jennersville CVS, Inc.
5889. Jericho Huntington CVS, L.L.C.
5890. Jericho Turnpike CVS, Inc.
5891. Jersey Shore PA CVS, Inc.
5892. Jessup Deptford CVS, L.L.C.
5893. Jewel Ventures Fund GP, LLC
5894. Jewel Ventures Fund, LP
5895. Jewel Ventures Management, LLC
5896. JHC Acquisition LLC
5897. JOCUS LIMITED
5898. Jog Boynton Beach CVS, L.L.C.
5899. Jog Road CVS, L.L.C.
5900. Johnson Hollywood CVS, Inc.
5901. Johnston Centre CVS, Inc.
5902. Joliet CVS, L.L.C.
5903. Jones Hill CVS, Inc.
5904. Jonesboro CVS, Inc.
5905. Josey Carrollton CVS, L.P.
5906. Joy Lake Rd. CVS, Inc.
5907. JRT Investment, Inc.
5908. Jumpers Hole CVS, Inc.
5909. K HOME THERAPEUTICS, INC.
5910. K Street CVS, Inc.
5911. K Street Peoples, Inc.
5912. Kankakee IL CVS, L.L.C.
5913. Kannapolis CVS, Inc.
5914. Kansas CVS Pharmacy, L.L.C.
5915. Kearny CVS, Inc.
5916. Kedzie 59th CVS, L.L.C.
5917. Keene Key CVS, Inc.
5918. Keller CVS, L.P.
5919. Kendall Miami CVS, L.L.C.
5920. Kenmore Retailer, Inc.
5921. Kenmore Village CVS, Inc.
5922. Kennedy Tampa CVS, L.L.C.
5923. Kennesaw CVS, Inc.
5924. Kennesaw Due West CVS, Inc.
5925. Kennett Square CVS, Inc.
5926. Kensington CVS, Inc.
5927. Kentucky CVS Pharmacy, L.L.C.
5928. Kentwood CVS, Inc.
5929. Kern Home Health Resources d/b/a
Coram Healthcare
5930. Key Biscayne CVS, Inc.
5931. Keyser CVS, L.L.C.
5932. Keystone Street CVS, Inc.
5933. Kildeer CVS, L.L.C.
5934. Kimberly J. Henderson, M.D., P.C.
5935. Kimberton Nutt CVS, Inc.
5936. King Cherry CVS, Inc.
5937. King Drug Company
5938. King of Prussia CVS, Inc.
5939. King Street CVS, Inc.
5940. Kings Crossing CVS, Inc.
5941. Kings Grant CVS, Inc.
5942. Kings Highway CVS, Inc.
5943. Kingsbury Square CVS, Inc.
5944. Kingsland Katy CVS, L.P.
5945. Kingston Emporium CVS, Inc.
1734
WITH TECHNICAL CORRECTIONS 02.03.2023
J-86
5946. Kingston Market CVS, Inc.
5947. Kingston Road CVS, Inc.
5948. Kingsway Plaza CVS, Inc.
5949. Kingwood CVS, L.P.
5950. Kirby Houston CVS, L.P.
5951. Kirby Pearland CVS, L.P.
5952. Kisco East Main CVS, L.L.C.
5953. Kissimmee CVS, Inc.
5954. Knox Abbott Road CVS, Inc.
5955. Knoxville Emory CVS, Inc.
5956. Kostner Chicago CVS, L.L.C.
5957. Kraemer CA CVS, L.L.C.
5958. Krocks Road CVS, Inc.
5959. L Street CVS, Inc.
5960. L.F. Hamlin, Inc.
5961. La Cienega LA CVS, L.P.
5962. La Cienega Square CVS, Inc.
5963. La Mirada CVS, Inc.
5964. La Palma CVS, Inc.
5965. La Quinta CVS, L.L.C.
5966. Ladera Ranch CA CVS, L.P.
5967. Lafayette CVS, Inc.
5968. LaGrange CVS, L.L.C.
5969. Laguna Hills CVS, Inc.
5970. Laguna Niguel CVS, Inc.
5971. Lahser CVS, Inc.
5972. Lake Charles Ryan CVS, Inc.
5973. Lake Danbury CVS, Inc.
5974. Lake Forest CVS, Inc.
5975. Lake Forest CVS, L.L.C.
5976. Lake Grove CVS, Inc.
5977. Lake in the Hills CVS, L.L.C.
5978. Lake Mead Civic CVS, L.L.C.
5979. Lake Mead Las Vegas CVS, L.L.C.
5980. Lake Pleasant Peoria CVS, L.L.C.
5981. Lake Street CVS, Inc.
5982. Lake Worth Greenacres CVS,
L.L.C.
5983. Lakeview Ave. CVS, Inc.
5984. Lakeview Plaza CVS, Inc.
5985. Lakeview Square CVS, Inc.
5986. Lakeville MN CVS, L.L.C.
5987. Lakeway TX CVS, L.L.C.
5988. Lakewood CA CVS, L.L.C.
5989. Lakewood Square CVS, Inc.
5990. Lambertville NJ CVS, L.L.C.
5991. Lancaster 10th CVS, L.L.C.
5992. Lancaster CVS, Inc.
5993. Landis Avenue CVS, Inc.
5994. Landisville CVS, Inc.
5995. Landmark Center CVS, Inc.
5996. Landstar Orlando CVS, L.L.C.
5997. Lanesborough Berkshire Mall CVS,
Inc.
5998. Langsam Health Services, LLC
5999. Langsam Medical Products, Inc.
6000. Lansdowne Avenue CVS, Inc.
6001. Lansing CVS, Inc.
6002. LaPalma Anaheim CVS, Inc.
6003. Largo ProCare Pharmacy, Inc.
6004. Las Vegas NV CVS, L.L.C.
6005. Las Vegas Riviera CVS, L.L.C.
6006. Laurel MD CVS, L.L.C.
6007. Laurens Road CVS, Inc.
6008. Lavista Road CVS, Inc.
6009. Lawndale CA CVS, L.L.C.
6010. Lawndale CVS, Inc.
6011. Lawrence Broadway CVS, Inc.
6012. Lawrence Chicago CVS, L.L.C.
6013. Lawrenceville CVS, Inc.
6014. LCPS Acquisition LLC
6015. LDG Property Company, Inc.
6016. LDG Property Company, LLC
6017. Leading Benefit Solutions, LLC
6018. League City CVS, L.P.
6019. Ledgewood NJ CVS, L.L.C.
6020. Lee Highway CVS, Inc.
6021. Lee Highway Peoples, Inc.
6022. Lee Vista Orlando CVS, L.L.C.
6023. Lehigh Street CVS, Inc.
6024. Lehigh Valley CVS, Inc.
6025. Lemec CVS, L.L.C.
6026. Lemmon Dallas CVS, L.P.
6027. Lemont CVS, L.L.C.
6028. Lenox Avenue CVS, L.L.C.
6029. Leominster CVS, Inc.
1735
WITH TECHNICAL CORRECTIONS 02.03.2023
J-87
6030. Leominster Lancaster CVS, Inc.
6031. Leominster Main Street CVS, Inc.
6032. Leominster PharmaCare Pharmacy,
Inc.
6033. Levittown PA CVS, Inc.
6034. Lewisville CVS, L.P.
6035. Lexington CVS, Inc.
6036. Lexington Sugar CVS, L.P.
6037. LHS Acquisition Sub, LLC
6038. Liberty Little Ferry CVS, L.L.C.
6039. Liberty Park CVS, Inc.
6040. Liberty Road CVS, Inc.
6041. Liberty Street CVS, Inc.
6042. Library Road CVS, Inc.
6043. Lighthouse Point CVS, L.L.C.
6044. Lilburn CVS, Inc.
6045. Lilburn Harmony Grove CVS, Inc.
6046. Lima PA CVS, Inc.
6047. Limerick CVS, Inc.
6048. Lincoln Corona CVS, Inc.
6049. Lincoln CVS, Inc.
6050. Lincoln Drive (Phil) CVS, Inc.
6051. Lincoln Harbor CVS, Inc.
6052. Lincoln Park CVS, L.L.C.
6053. Lincoln Street CVS, Inc.
6054. Lindbergh CVS, Inc.
6055. Linden Retailer, Inc.
6056. Linden Street CVS, Inc.
6057. Linden Wellesley CVS, Inc.
6058. Lindenhurst CVS, L.L.C.
6059. Linwood CVS, Inc.
6060. Lionville CVS, Inc.
6061. Litchfield Park CVS, L.L.C.
6062. Litchfield Rt. 202 CVS, Inc.
6063. Little York CVS, L.P.
6064. Littleton Road CVS, Inc.
6065. Livingston CVS, Inc.
6066. Livonia 6 Mile CVS, Inc.
6067. Lobdell Goodwood CVS, Inc.
6068. Lobos Acquisition, LLC
6069. Lockport Clinton Stores, Inc.
6070. Lockport CVS, L.L.C.
6071. Locust Philadelphia CVS, Inc.
6072. Lodi CVS, Inc.
6073. Loehmann's Plaza CVS, Inc.
6074. Lombard CVS, L.L.C.
6075. Lombard-Light Streets CVS, Inc.
6076. Lo-Med Prescription Services, LLC
6077. Lomita CVS, Inc.
6078. Lone Oak KY CVS, Inc.
6079. Lone Star Health Plan, Inc.
6080. Lonestar Holding Co.
6081. Long Beach Boulevard CVS, L.P.
6082. Long Beach CVS, Inc.
6083. Long Hill Road CVS, Inc.
6084. Long Island CVS Store, Inc.
6085. Long Shoals Road CVS, Inc.
6086. Longmeadow Massachusetts CVS,
Inc.
6087. Longmeadow Street CVS, Inc.
6088. Longs Drug Stores California, Inc.
6089. Longs Drug Stores California,
L.L.C.
6090. Longs Drug Stores Corporation
6091. Longs Drug Stores, Inc.
6092. Longs Drug Stores, L.L.C.
6093. Long-Term Care Pharmacy
Alliance, LLC
6094. Longwood Avenue CVS, Inc.
6095. Longwood CVS, Inc.
6096. Looch Hwy. CVS, Inc.
6097. Loop 610 Westheimer CVS, L.P.
6098. Loris SC CVS, Inc.
6099. Los Alamitos CVS, L.P.
6100. Los Angeles ProCare Pharmacy,
Inc.
6101. Louetta Elderidge CVS, L.P.
6102. Louisiana CVS Pharmacy, L.L.C.
6103. Louisville CVS, Inc.
6104. Lowell Bridge CVS, Inc.
6105. Lowell Discounter, Inc.
6106. Lowell Merrimack CVS, Inc.
6107. Lowell Retailer, Inc.
6108. Lower Azusa Rd CVS, L.L.C.
6109. Lower Buckeye Phoenix CVS,
L.L.C.
1736
WITH TECHNICAL CORRECTIONS 02.03.2023
J-88
6110. Lower Buckley Avondale CVS,
L.L.C.
6111. Lower Makefield CVS, Inc.
6112. Loyalty Life Insurance Company
6113. Ludlow Acquisition Corp.
6114. Ludlow CVS, Inc.
6115. Luettgens Limited
6116. LV Boulevard CVS, L.L.C.
6117. Lyell Clinton Paine, Inc.
6118. Lynn Boston Street CVS, Inc.
6119. Lynngate-Massachusetts CVS, Inc.
6120. Lynnway Lynn CVS, Inc.
6121. Lyon Twp CVS, L.L.C.
6122. M Street CVS, Inc.
6123. M Street Peoples, Inc.
6124. M Street Washington CVS, Inc.
6125. Mableton GA CVS, Inc.
6126. Mableton Parkway CVS, Inc.
6127. MacArthur Boulevard CVS, Inc.
6128. Macedon Clinton Stores, Inc.
6129. Mack Drug Co. of New Jersey, Inc.
6130. Mack Drug Co. of New York, Inc.
6131. Mack Drug Co. of Pittsfield, Inc.
6132. Macomb Township CVS, L.L.C.
6133. Madera Royale CVS, Inc.
6134. Madison Centre CVS, Inc.
6135. Madison Chicago CVS, L.L.C.
6136. Madison CVS, Inc.
6137. Madison Heights John R CVS, Inc.
6138. Magnolia Anaheim CVS, L.P.
6139. Magnum Health Plan, Inc.
6140. Main Alden CVS, Inc.
6141. Main Annapolis CVS, L.L.C.
6142. Main Devon Bartlett CVS, L.L.C.
6143. Main Harvard CVS, Inc.
6144. Main Houston CVS, L.P.
6145. Main Jefferson CVS, L.L.C.
6146. Main McKinney CVS, L.P.
6147. Main Montgomery CVS, L.L.C.
6148. Main Street Athol CVS, Inc.
6149. Main Street North CVS, Inc.
6150. Main Street Pharmacy, L.L.C.
6151. Main Vineland CVS, L.L.C.
6152. Main Wayland CVS, Inc.
6153. Maine CVS Pharmacy, L.L.C.
6154. Maine Retailer, Inc.
6155. Maine-Bangor CVS, Inc.
6156. Maineville CVS, Inc.
6157. Malaga CVS, Inc.
6158. Malden Broadway CVS, Inc.
6159. Malden Square CVS, Inc.
6160. Male Wind Gap CVS, Inc.
6161. Mall of New Hampshire CVS, Inc.
6162. Managed Care Coordinators, Inc.
6163. Managed HealthCare, Inc.
6164. Managed Healthcare, LLC
6165. Management & Network Services,
Inc.
6166. Management and Network Services,
L.L.C.
6167. Manalapan CVS, Inc.
6168. Manassas CVS, Inc.
6169. Manatee Bradenton CVS, L.L.C.
6170. Manayunk Plaza CVS, Inc.
6171. Manchester (N.H.) CVS, Inc.
6172. Manchester CVS, Inc.
6173. Manchester North Main CVS, Inc.
6174. Manhattan CVS, Inc.
6175. Manomet Route 3a CVS, Inc.
6176. Manor Road CVS, Inc.
6177. Mansfield CVS, Inc.
6178. Mansfield Shopping Center CVS,
Inc.
6179. Manton Avenue CVS, Inc.
6180. Mantua NJ CVS, L.L.C.
6181. Manville CVS, Inc.
6182. Maple Avenue CVS, Inc.
6183. Maple Avenue NJ CVS, Inc.
6184. Maple Glen CVS, Inc.
6185. Maple Grove MN CVS, L.L.C.
6186. Maplewood CVS, L.L.C.
6187. Marblehead CVS, Inc.
6188. Margate CVS, Inc.
6189. Marguerite Parkway CVS, Inc.
6190. Maricopa CVS, L.L.C.
6191. Marietta CVS, Inc.
1737
WITH TECHNICAL CORRECTIONS 02.03.2023
J-89
6192. Marietta Piedmont CVS, Inc.
6193. Mark Steven CVS, Inc.
6194. Market Street CVS, Inc.
6195. Marlboro CVS, Inc.
6196. Marlboro Village Center CVS, Inc.
6197. Marlborough Mall CVS, Inc.
6198. Marley Station CVS, Inc.
6199. Marlton Crossing CVS, Inc.
6200. Marsh Carrollton CVS, L.P.
6201. Marshalls of Citrus Heights, CA.,
Inc.
6202. Marshalls of Skokie IL, Inc.
6203. MARSHALLS OF TEMPE, AZ.,
INC.
6204. Marshfield Ocean CVS, Inc.
6205. Marshfield Webster CVS, Inc.
6206. Martin Health Services, Inc.
6207. Martin Health Services, LLC
6208. Mary Street CVS, Inc.
6209. Maryland CVS Pharmacy, L.L.C.
6210. Maryland Parkway CVS, L.L.C.
6211. Maryland St. Paul CVS, L.L.C.
6212. Mashpee CVS, Inc.
6213. Mason CVS, Inc.
6214. Maspeth NY CVS, L.L.C.
6215. Mass. Ave. and Alwife Brook CVS,
Inc.
6216. Mass. Ave. CVS, Inc.
6217. Massachusetts Avenue CVS, L.L.C.
6218. Massachusetts CVS Pharmacy, Inc.
6219. Massachusetts CVS Pharmacy,
L.L.C.
6220. Massapequa CVS, Inc.
6221. Mattapan MA CVS, Inc.
6222. Matthews CVS, Inc.
6223. Mattituck CVS, L.L.C.
6224. Mattydale Clinton Stores, Inc.
6225. MaxiCare/HealthAmerica
Pennsylvania, Inc.
6226. Maxwell & Tennyson, Inc.
6227. May Street PharmaCare Pharmacy,
Inc.
6228. Mayfield Collins CVS, L.P.
6229. Mayfield CVS, Inc.
6230. Maynard CVS, Inc.
6231. MC Diagnostic of Connecticut, P.C.
6232. MC RETAIL CORP.
6233. McCalla CVS, Inc.
6234. McDowell Phoenix CVS, L.L.C.
6235. McKeesport CVS, Inc.
6236. McKinney CVS, L.P.
6237. McNab Tamarac CVS, L.L.C.
6238. McNair Farms CVS, Inc.
6239. Mead Clinton Paine, Inc.
6240. Meadow Glen CVS, Inc.
6241. Meadowbrook Newark CVS, Inc.
6242. Meadville Clinton Stores, Inc.
6243. Med Southwest, Inc.
6244. Med World Acquisition Corp.
6245. Med World Acquisition, LLC
6246. Medco Discount Prescription
Center, Inc.
6247. Medfield CVS, Inc.
6248. Medford Downtown CVS, Inc.
6249. Medford High CVS, Inc.
6250. Medford Retailer, Inc.
6251. Medford-Malden CVS, Inc.
6252. Media 452 CVS, Inc.
6253. Media CVS, Inc.
6254. Medical Arts Health Care, Inc.
6255. Medical Arts Health Care, LLC
6256. Medical Arts Pharmacy, Inc.
6257. Medical Center Pharmacies, Inc.
6258. Medical Examinations of New
York, P.C.
6259. Medicare Drug Stores, Inc.
6260. Medicity LLC
6261. Medicity, Inc.
6262. Medisav, Inc.
6263. MedPartners Acquisition
6264. MedPartners Aviation, Inc.
6265. MedPartners Physician Services,
Inc.
6266. MedPartners Professional
Management Corporation
6267. MedPartners, Inc.
1738
WITH TECHNICAL CORRECTIONS 02.03.2023
J-90
6268. MedPartners/Mullikin, Inc.
6269. MedPartners/Talbert Medical
Management Corporation
6270. Medway CVS, Inc.
6271. Meeting House Road CVS, Inc.
6272. Melrose CVS, Inc.
6273. Melrose Park CVS, L.L.C.
6274. Melville Equipment Leasing Corp.
6275. Melville Realty Company, Inc.
6276. Melville Realty Management
Corporation
6277. MemberHealth LLC
6278. Menifee Meadows Office Park
Association
6279. Menlo Park CVS, Inc.
6280. Mental Health Associates, Inc.
6281. Mental Health Associates, Inc. of
Lousiana, Inc.
6282. Mental Health Network of New
York IPA, Inc.
6283. Merchant Plaza CVS, Inc.
6284. Merger LLC D, L.L.C.
6285. Meridan West Main CVS, Inc.
6286. Meriden CVS, Inc.
6287. Meriden Parkade CVS, Inc.
6288. Meriden Road CVS, Inc.
6289. Meridianville CVS, Inc.
6290. Meritain Health Group, Inc.
6291. Meritain Health, Inc.
6292. Merlen Drug CVS, Inc.
6293. Merrick CVS, Inc.
6294. Merrill University CVS, L.L.C.
6295. Merrimack Street CVS, Inc.
6296. Merritt Island CVS, L.L.C.
6297. Merwin IV & Specialty Pharmacy,
LLC
6298. Merwin Long Term Care, Inc.
6299. Merwin Long Term Care, LLC
6300. Merwin Rx-Compounding
Pharmacy, LLC
6301. Mesa Brown CVS, L.L.C.
6302. Mesquite CVS, L.P.
6303. Methuen Broadway CVS, Inc.
6304. Methuen CVS, Inc.
6305. Methuen Haverhill CVS, Inc.
6306. Methuen Swan CVS, Inc.
6307. MetraComp, Inc.
6308. Metro Boston CVS, Inc.
6309. MHHP Acquisition Company LLC
6310. MHNet Life and Health Insurance
Company
6311. MHNet of Florida, Inc.
6312. MHNet Specialty Services, LLC
6313. Miami 147th CVS, L.L.C.
6314. Miami 2nd Avenue CVS, Inc.
6315. Miami 8th CVS, L.L.C.
6316. Miami Flagler CVS, Inc.
6317. Michigan Chicago CVS, L.L.C.
6318. Michigan CVS, Inc.
6319. Mid Cities Boulevard CVS, L.P.
6320. Middle River CVS, Inc.
6321. Middle Smithfield Township CVS,
Inc.
6322. Middleboro CVS, Inc.
6323. Middlesex Lowell CVS, Inc.
6324. Middlesex-Mass. CVS, Inc.
6325. Middletown CVS, Inc.
6326. Middletown Township CVS, Inc.
6327. Middletown Washington CVS, Inc.
6328. Midland Clinton Stores, Inc.
6329. Midland Retailer, Inc.
6330. Midport Port St. Lucie CVS, L.L.C.
6331. Milford Broad St. CVS, Inc.
6332. Milford CVS, Inc.
6333. Milford PharmaCare Pharmacy, Inc.
6334. Milford Plaza CVS, Inc.
6335. Milford Square CVS, Inc.
6336. Military Trail CVS, Inc.
6337. Millbourne CVS, Inc.
6338. Millbury CVS, Inc.
6339. Millbury PharmaCare Pharmacy,
Inc.
6340. Millcreek CVS, Inc.
6341. Miller Place CVS, L.L.C.
6342. Millis CVS, Inc.
6343. Mills Ave SEC CVS, L.L.C.
1739
WITH TECHNICAL CORRECTIONS 02.03.2023
J-91
6344. Millville CVS, Inc.
6345. Milton Market Place CVS, Inc.
6346. Milwaukee Chicago CVS, L.L.C.
6347. Mineola Jericho CVS, Inc.
6348. Mineral Spring Ave. CVS, Inc.
6349. Minnesota CVS Pharmacy, L.L.C.
6350. Minor Health Enterprise Co, Ltd.
6351. Mint Hill CVS, Inc.
6352. Minute Clinic Diagnostic of North
Carolina, P.C.
6353. MinuteClinic Diagnostic Medical
Group of California, Inc.
6354. MinuteClinic Diagnostic Medical
Group of Orange County, Inc.
6355. MinuteClinic Diagnostic Medical
Group of San Diego, Inc.
6356. MinuteClinic Diagnostic of
Alabama, L.L.C.
6357. MinuteClinic Diagnostic of
Arizona, LLC
6358. MinuteClinic Diagnostic of
Arkansas, LLC
6359. MinuteClinic Diagnostic of
Colorado LLC
6360. MinuteClinic Diagnostic of
Connecticut, LLC
6361. MinuteClinic Diagnostic of Florida,
LLC
6362. MinuteClinic Diagnostic of
Georgia, LLC
6363. MinuteClinic Diagnostic of Hawaii,
L.L.C.
6364. MinuteClinic Diagnostic of Illinois,
LLC
6365. MinuteClinic Diagnostic of Kansas,
P.A.
6366. MinuteClinic Diagnostic of
Kentucky, L.L.C.
6367. MinuteClinic Diagnostic of
Louisiana, L.L.C.
6368. MinuteClinic Diagnostic of Maine,
L.L.C.
6369. MinuteClinic Diagnostic of
Maryland, LLC
6370. MinuteClinic Diagnostic of
Massachusetts, LLC
6371. MinuteClinic Diagnostic of
Michigan, P.C.
6372. MinuteClinic Diagnostic of
Minnesota, P.A.
6373. MinuteClinic Diagnostic of
Nebraska, L.L.C.
6374. MinuteClinic Diagnostic of New
Hampshire, L.L.C.
6375. MinuteClinic Diagnostic of New
Jersey, LLC
6376. MinuteClinic Diagnostic of New
Mexico, L.L.C.
6377. MinuteClinic Diagnostic of Ohio,
LLC
6378. MinuteClinic Diagnostic of
Oklahoma, LLC
6379. MinuteClinic Diagnostic of Oregon,
LLC
6380. MinuteClinic Diagnostic of
Pennsylvania, LLC
6381. MinuteClinic Diagnostic of Rhode
Island, LLC
6382. MinuteClinic Diagnostic of South
Carolina, L.L.C.
6383. MinuteClinic Diagnostic of
Tennessee, P.C.
6384. MinuteClinic Diagnostic of Texas,
LLC
6385. MinuteClinic Diagnostic of Utah,
L.L.C.
6386. MinuteClinic Diagnostic of
Virginia, LLC
6387. MinuteClinic Diagnostic of
Washington, LLC
6388. MinuteClinic Diagnostic of
Washington, PLLC
6389. MinuteClinic Diagnostic of
Wisconsin, L.L.C.
6390. MinuteClinic Diagnostic, P.A.
1740
WITH TECHNICAL CORRECTIONS 02.03.2023
J-92
6391. MinuteClinic Diagnostics of
Indiana, LLC
6392. MinuteClinic Online Diagnostic
Services, LLC
6393. MinuteClinic Online Virtual Care
California, P.C.
6394. MinuteClinic Physician Practice of
Texas
6395. MinuteClinic Telehealth Services of
Texas Association
6396. MinuteClinic Telehealth Services,
LLC
6397. MinuteClinic Video Virtual Care
California, P.C.
6398. MinuteClinic Video Virtual Care
North, LLC
6399. MinuteClinic Video Virtual Care of
Kansas, LLC
6400. MinuteClinic Video Virtual Care of
NC, PC
6401. MinuteClinic Video Virtual Care of
Nevada, PLLC
6402. MinuteClinic Video Virtual Care of
Wisconsin, S.C.
6403. MinuteClinic Video Virtual Care,
P.C.
6404. MinuteClinic Video Virtual Care,
PLLC
6405. MinuteClinic, L.L.C.
6406. MinuteClinic, LLC
6407. Miramar CVS, Inc.
6408. Mission Hills CVS, Inc.
6409. Mission Tremont CVS, Inc.
6410. Mission Valley CVS, Inc.
6411. Mission Viejo CVS, Inc.
6412. Mississippi CVS Pharmacy, L.L.C.
6413. Missouri Care, Incorporated
6414. Missouri City CVS, L.P.
6415. Missouri CVS Pharmacy, L.L.C.
6416. MLK Tampa CVS, L.L.C.
6417. Mobile AL CVS, Inc.
6418. Mogadore CVS, Inc.
6419. Mohawk Avenue CVS Store, Inc.
6420. Mohegan Lake CVS, L.L.C.
6421. Mokena CVS, L.L.C.
6422. Monroe CVS, Inc.
6423. Monroe NJ CVS, L.L.C.
6424. Monroe NY CVS, L.L.C.
6425. Monroe Prospect CVS, Inc.
6426. Montana CVS Pharmacy, L.L.C.
6427. Montclair CVS, Inc.
6428. Montebello CVS, Inc.
6429. Montevallo AL CVS, Inc.
6430. Montgomery AL CVS, Inc.
6431. Montgomery Sq. CVS, Inc.
6432. Montrose Chicago CVS, L.L.C.
6433. Montrose Houston CVS, L.P.
6434. Montvale Center CVS, Inc.
6435. Montvale Woburn CVS, Inc.
6436. Moorestown Mall CVS, Inc.
6437. Moorestown NJ Bob's, Inc.
6438. Moorestown West Main CVS, Inc.
6439. Moorpark CVS, Inc.
6440. Morewood Drive CVS, Inc.
6441. Morris Daytona CVS, L.L.C.
6442. Morrisville CVS, Inc.
6443. Morrow CVS, Inc.
6444. Morton Fry CVS, L.P.
6445. Mounds View MN CVS, L.L.C.
6446. Mount Carmel Plaza CVS, Inc.
6447. Mount Dora CVS, L.L.C.
6448. Mountain Avenue CVS, Inc.
6449. Mountain Brook CVS, Inc.
6450. Mountain Grove Investment Group
LLC
6451. Mountain Medical Affiliates, Inc.
6452. Mountain Middlesex CVS, Inc.
6453. Movietown Plaza CVS, Inc.
6454. MP Receivables Company
6455. MRC Henderson Devco, Inc.
6456. MRC Manchester Devco, Inc.
6457. MRC Staten Island Devco, Inc.
6458. MRC Westbury Devco, Inc.
6459. MRC Woodlands Devco, Inc.
6460. Mt. Holly CVS, Inc.
6461. Mt. Joy CVS, Inc.
1741
WITH TECHNICAL CORRECTIONS 02.03.2023
J-93
6462. Mt. Morris CVS, Inc.
6463. Mt. Pleasant CVS, Inc.
6464. Mt. Prospect CVS, L.L.C.
6465. Mundelein CVS, L.L.C.
6466. Murray CVS, Inc.
6467. Myrtle Beach CVS, Inc.
6468. N. Bayshore CVS, L.L.C.
6469. N. Sepulveda CVS, L.L.C.
6470. Nahatan Street CVS, Inc.
6471. Nanes Houston CVS, L.P.
6472. Nanuet Retailer, Inc.
6473. Naperville CVS, L.L.C.
6474. Naples CVS, L.L.C.
6475. Naples US 41 CVS, L.L.C.
6476. Nashua CVS, Inc.
6477. Nashua Hollis CVS, Inc.
6478. Nashville CVS, L.L.C.
6479. Natick Mall CVS, Inc.
6480. Natick Retailer, Inc.
6481. Natick Routes 9 and 27 CVS, Inc.
6482. National Motor Club Life &
Accident Insurance Company
6483. Naugatuck Bridge St. CVS, Inc.
6484. Naugatuck CVS, Inc.
6485. Navarro Discount Pharmacies No.
1, Inc. (for assets / pharmacies
acquired by CVS)
6486. Navarro Discount Pharmacies No.
1, LLC (for assets / pharmacies
acquired by CVS)
6487. Navarro Discount Pharmacies No.
10, Inc. (for assets / pharmacies
acquired by CVS)
6488. Navarro Discount Pharmacies No.
10, LLC (for assets / pharmacies
acquired by CVS)
6489. Navarro Discount Pharmacies No.
11, Inc. (for assets / pharmacies
acquired by CVS)
6490. Navarro Discount Pharmacies No.
11, LLC (for assets / pharmacies
acquired by CVS)
6491. Navarro Discount Pharmacies No.
12, Inc. (for assets / pharmacies
acquired by CVS)
6492. Navarro Discount Pharmacies No.
12, LLC (for assets / pharmacies
acquired by CVS)
6493. Navarro Discount Pharmacies No.
13, Inc. (for assets / pharmacies
acquired by CVS)
6494. Navarro Discount Pharmacies No.
13, LLC (for assets / pharmacies
acquired by CVS)
6495. Navarro Discount Pharmacies No.
14, Inc. (for assets / pharmacies
acquired by CVS)
6496. Navarro Discount Pharmacies No.
14, LLC (for assets / pharmacies
acquired by CVS)
6497. Navarro Discount Pharmacies No.
15, Inc. (for assets / pharmacies
acquired by CVS)
6498. Navarro Discount Pharmacies No.
15, LLC (for assets / pharmacies
acquired by CVS)
6499. Navarro Discount Pharmacies No.
16, Inc. (for assets / pharmacies
acquired by CVS)
6500. Navarro Discount Pharmacies No.
16, LLC (for assets / pharmacies
acquired by CVS)
6501. Navarro Discount Pharmacies No.
17, Inc. (for assets / pharmacies
acquired by CVS)
6502. Navarro Discount Pharmacies No.
17, LLC (for assets / pharmacies
acquired by CVS)
6503. Navarro Discount Pharmacies No.
18, Inc. (for assets / pharmacies
acquired by CVS)
6504. Navarro Discount Pharmacies No.
18, LLC (for assets / pharmacies
acquired by CVS)
1742
WITH TECHNICAL CORRECTIONS 02.03.2023
J-94
6505. Navarro Discount Pharmacies No.
19, Inc. (for assets / pharmacies
acquired by CVS)
6506. Navarro Discount Pharmacies No.
19, LLC (for assets / pharmacies
acquired by CVS)
6507. Navarro Discount Pharmacies No.
2, Inc. (for assets / pharmacies
acquired by CVS)
6508. Navarro Discount Pharmacies No.
2, LLC (for assets / pharmacies
acquired by CVS)
6509. Navarro Discount Pharmacies No.
20, Inc. (for assets / pharmacies
acquired by CVS)
6510. Navarro Discount Pharmacies No.
20, LLC (for assets / pharmacies
acquired by CVS)
6511. Navarro Discount Pharmacies No.
21, Inc. (for assets / pharmacies
acquired by CVS)
6512. Navarro Discount Pharmacies No.
21, LLC (for assets / pharmacies
acquired by CVS)
6513. Navarro Discount Pharmacies No.
22, Inc. (for assets / pharmacies
acquired by CVS)
6514. Navarro Discount Pharmacies No.
22, LLC (for assets / pharmacies
acquired by CVS)
6515. Navarro Discount Pharmacies No.
23, Inc. (for assets / pharmacies
acquired by CVS)
6516. Navarro Discount Pharmacies No.
23, LLC (for assets / pharmacies
acquired by CVS)
6517. Navarro Discount Pharmacies No.
24, Inc. (for assets / pharmacies
acquired by CVS)
6518. Navarro Discount Pharmacies No.
24, LLC (for assets / pharmacies
acquired by CVS)
6519. Navarro Discount Pharmacies No.
25, Inc. (for assets / pharmacies
acquired by CVS)
6520. Navarro Discount Pharmacies No.
25, LLC (for assets / pharmacies
acquired by CVS)
6521. Navarro Discount Pharmacies No.
26, Inc. (for assets / pharmacies
acquired by CVS)
6522. Navarro Discount Pharmacies No.
26, LLC (for assets / pharmacies
acquired by CVS)
6523. Navarro Discount Pharmacies No.
27, Inc. (for assets / pharmacies
acquired by CVS)
6524. Navarro Discount Pharmacies No.
27, LLC (for assets / pharmacies
acquired by CVS)
6525. Navarro Discount Pharmacies No.
28, Inc. (for assets / pharmacies
acquired by CVS)
6526. Navarro Discount Pharmacies No.
28, LLC (for assets / pharmacies
acquired by CVS)
6527. Navarro Discount Pharmacies No.
29, Inc. (for assets / pharmacies
acquired by CVS)
6528. Navarro Discount Pharmacies No.
29, LLC (for assets / pharmacies
acquired by CVS)
6529. Navarro Discount Pharmacies No.
3, Inc. (for assets / pharmacies
acquired by CVS)
6530. Navarro Discount Pharmacies No.
3, LLC (for assets / pharmacies
acquired by CVS)
6531. Navarro Discount Pharmacies No.
30, Inc. (for assets / pharmacies
acquired by CVS)
6532. Navarro Discount Pharmacies No.
30, LLC (for assets / pharmacies
acquired by CVS)
1743
WITH TECHNICAL CORRECTIONS 02.03.2023
J-95
6533. Navarro Discount Pharmacies No.
31, Inc. (for assets / pharmacies
acquired by CVS)
6534. Navarro Discount Pharmacies No.
31, LLC (for assets / pharmacies
acquired by CVS)
6535. Navarro Discount Pharmacies No.
32, Inc. (for assets / pharmacies
acquired by CVS)
6536. Navarro Discount Pharmacies No.
32, LLC (for assets / pharmacies
acquired by CVS)
6537. Navarro Discount Pharmacies No.
33, Inc. (for assets / pharmacies
acquired by CVS)
6538. Navarro Discount Pharmacies No.
33, LLC (for assets / pharmacies
acquired by CVS)
6539. Navarro Discount Pharmacies No.
34, Inc. (for assets / pharmacies
acquired by CVS)
6540. Navarro Discount Pharmacies No.
34, LLC (for assets / pharmacies
acquired by CVS)
6541. Navarro Discount Pharmacies No.
35, Inc. (for assets / pharmacies
acquired by CVS)
6542. Navarro Discount Pharmacies No.
35, LLC (for assets / pharmacies
acquired by CVS)
6543. Navarro Discount Pharmacies No.
36, Inc. (for assets / pharmacies
acquired by CVS)
6544. Navarro Discount Pharmacies No.
36, LLC (for assets / pharmacies
acquired by CVS)
6545. Navarro Discount Pharmacies No.
37, Inc. (for assets / pharmacies
acquired by CVS)
6546. Navarro Discount Pharmacies No.
37, LLC (for assets / pharmacies
acquired by CVS)
6547. Navarro Discount Pharmacies No.
38, Inc. (for assets / pharmacies
acquired by CVS)
6548. Navarro Discount Pharmacies No.
38, LLC (for assets / pharmacies
acquired by CVS)
6549. Navarro Discount Pharmacies No.
4, Inc. (for assets / pharmacies
acquired by CVS)
6550. Navarro Discount Pharmacies No.
4, LLC (for assets / pharmacies
acquired by CVS)
6551. Navarro Discount Pharmacies No.
5, Inc. (for assets / pharmacies
acquired by CVS)
6552. Navarro Discount Pharmacies No.
5, LLC (for assets / pharmacies
acquired by CVS)
6553. Navarro Discount Pharmacies No.
6, Inc. (for assets / pharmacies
acquired by CVS)
6554. Navarro Discount Pharmacies No.
6, LLC (for assets / pharmacies
acquired by CVS)
6555. Navarro Discount Pharmacies No.
7, Inc. (for assets / pharmacies
acquired by CVS)
6556. Navarro Discount Pharmacies No.
7, LLC (for assets / pharmacies
acquired by CVS)
6557. Navarro Discount Pharmacies No.
8, Inc. (for assets / pharmacies
acquired by CVS)
6558. Navarro Discount Pharmacies No.
8, LLC (for assets / pharmacies
acquired by CVS)
6559. Navarro Discount Pharmacies No.
9, Inc. (for assets / pharmacies
acquired by CVS)
6560. Navarro Discount Pharmacies No.
9, LLC (for assets / pharmacies
acquired by CVS)
1744
WITH TECHNICAL CORRECTIONS 02.03.2023
J-96
6561. Navarro Discount Pharmacies, Inc.
(for assets / pharmacies acquired by
CVS)
6562. Navarro Discount Pharmacies, LLC
(for assets / pharmacies acquired by
CVS)
6563. NCS Healthcare of Illinois, LLC
6564. NCS Healthcare of Indiana LLC
6565. NCS Healthcare of Indiana, Inc.
6566. NCS Healthcare of Iowa, LLC
6567. NCS Healthcare of Kansas, LLC
6568. NCS Healthcare of Kentucky, Inc.
6569. NCS Healthcare of Kentucky, LLC
6570. NCS Healthcare of Montana, Inc.
6571. NCS Healthcare of Montana, LLC
6572. NCS Healthcare of New
Hampshire, Inc.
6573. NCS Healthcare of New Mexico,
Inc.
6574. NCS Healthcare of New Mexico,
LLC
6575. NCS Healthcare of Ohio, LLC
6576. NCS Healthcare of South Carolina,
Inc.
6577. NCS Healthcare of South Carolina,
LLC
6578. NCS Healthcare of Tennessee, Inc.
6579. NCS Healthcare of Tennessee, LLC
6580. NCS Healthcare of Washington,
Inc.
6581. NCS Healthcare of Wisconsin, LLC
6582. NCS Healthcare, LLC
6583. NCS Services, Inc.
6584. NCSC Acquisition Sub, LLC
6585. NCSH Acquisition Sub, LLC
6586. Nebraska CVS Pharmacy, L.L.C.
6587. NEC Long Beach CVS, L.L.C.
6588. NEC Main CVS, Inc.
6589. NEC Montgomery CVS, L.L.C.
6590. NEC Washington CVS, L.L.C.
6591. Neck Burlington CVS, Inc.
6592. Needham Center CVS, Inc.
6593. Needham CVS, Inc.
6594. Needham St.-Newton CVS, Inc.
6595. NeighborCare Holdings, Inc.
6596. NeighborCare of Indiana, LLC
6597. NeighborCare of New Hampshire,
L.L.C.
6598. NeighborCare of Virginia, LLC
6599. NeighborCare Pharmacies, LLC
6600. NeighborCare Pharmacy of
Virginia, LLC
6601. NeighborCare Pharmacy Services,
Inc.
6602. NeighborCare Pharmacy Services,
LLC
6603. NeighborCare Repackaging, Inc.
6604. NeighborCare Services Corporation
6605. NeighborCare, Inc.
6606. NeighborCare-TCI, LLC
6607. Nelson Lake Charles CVS, Inc.
6608. Neshaminy PA CVS, Inc.
6609. Nevada CVS Pharmacy, L.L.C.
6610. Nevada Street CVS, Inc.
6611. New Albany CVS, Inc.
6612. New Britain CVS, Inc.
6613. New Britain Township CVS, Inc.
6614. New Brunswick CVS, Inc.
6615. New Canaan CVS, Inc.
6616. New City CVS, L.L.C.
6617. New Garden CVS, Inc.
6618. New Haven Crown CVS, Inc.
6619. New Haven Melbourne CVS,
L.L.C.
6620. New Hope MN CVS, L.L.C.
6621. New Hope Street CVS, Inc.
6622. New Jersey Avenue CVS, L.L.C.
6623. New Jersey CVS Pharmacy, L.L.C.
6624. New Lenox CVS, L.L.C.
6625. New London Ocean Avenue CVS,
Inc.
6626. New London Retailer, Inc.
6627. New London Turnpike CVS, Inc.
6628. New Orleans LA CVS, Inc.
6629. New Port Richey CVS, L.L.C.
6630. New Providence CVS, Inc.
1745
WITH TECHNICAL CORRECTIONS 02.03.2023
J-97
6631. New Windsor CVS, Inc.
6632. New York CVS Pharmacy, L.L.C.
6633. New York First Avenue CVS, Inc.
6634. New York Life and Health
Insurance Company
6635. New York Life/Sanus Health Plan,
Inc.
6636. NEW YORNYHT ACQUISITION,
INC.
6637. Newark Delaware CVS, Inc.
6638. Newark East Main CVS, Inc.
6639. Newark Ohio CVS, Inc.
6640. Newark ProCare Pharmacy, Inc.
6641. Newbury Street CVS, Inc.
6642. Newburyport CVS, Inc.
6643. Newington Avenue CVS, Inc.
6644. Newington Cedar CVS, Inc.
6645. Newington CVS, Inc.
6646. Newman Ave. CVS, Inc.
6647. Newnan CVS, Inc.
6648. Newnan Fayetteville CVS, Inc.
6649. Newport CVS, Inc.
6650. Newton Center St. CVS, Inc.
6651. Newton Watertown CVS, Inc.
6652. Newtonville CVS, Inc.
6653. Newtown CVS, Inc.
6654. NH Acquisition Sub, LLC
6655. Niagara Re, Inc.
6656. Nicollet Richfield CVS, L.L.C.
6657. Nihan & Martin LLC
6658. Niles Clinton Stores, Inc.
6659. Niles CVS, Inc.
6660. Niles CVS, L.L.C.
6661. Niles IL CVS, L.L.C.
6662. Niskayuna CVS Store, Inc.
6663. NIV Acquisition, LLC
6664. No. Dartmouth State Rd. CVS, Inc.
6665. Nockamixon CVS, Inc.
6666. Norfolk CVS, Inc.
6667. Norristown CVS, Inc.
6668. North Adams CVS, Inc.
6669. North American Health Plan, Inc.
6670. North Andover CVS, Inc.
6671. North Attleboro CVS, Inc.
6672. North Aurora CVS, L.L.C.
6673. North Boston Pharmacy, Inc.
6674. North Brunswick CVS, L.L.C.
6675. North Carolina Acquisition Corp.
6676. North Carolina CVS Pharmacy,
L.L.C.
6677. North Charleston SC CVS, Inc.
6678. North Fort Myers CVS, L.L.C.
6679. North Grace Lombard CVS, L.L.C.
6680. North Haven CVS, Inc.
6681. North Kent CVS, Inc.
6682. North Las Vegas CVS, L.L.C.
6683. North Lindenhurst CVS, Inc.
6684. North Miami ProCare Pharmacy,
Inc.
6685. North Naples CVS, L.L.C.
6686. North New Rochelle CVS, L.L.C.
6687. North Olmstead OH CVS, Inc.
6688. North Reading CVS, Inc.
6689. North Shore Pharmacy Services
LLC
6690. North Syracuse CVS Store, Inc.
6691. North Towne Sq. CVS, Inc.
6692. Northampton (Mass.) CVS, Inc.
6693. Northampton Main Street CVS, Inc.
6694. Northborough CVS, Inc.
6695. Northbrook IL CVS, L.L.C.
6696. Northeast Philadelphia CVS, Inc.
6697. Northern Jackson Heights CVS,
L.L.C.
6698. Northlake Palm Beach CVS, L.L.C.
6699. Northland CVS, Inc.
6700. Northridge Nordhoff CVS, Inc.
6701. Northville Sheldon CVS, L.L.C.
6702. Northville Township CVS, Inc.
6703. Northwest Highway CVS, L.L.C.
6704. Northwest K Street CVS, Inc.
6705. Northwest M Street CVS, L.L.C.
6706. Norton CVS, Inc.
6707. Norton Mansfield St. CVS, Inc.
6708. Norton Primary (Americas) Limited
6709. Norwalk Broad Street CVS, Inc.
1746
WITH TECHNICAL CORRECTIONS 02.03.2023
J-98
6710. Norwalk Square CVS, Inc.
6711. Norwich Main Street CVS, Inc.
6712. Norwood Avenue CVS, L.L.C.
6713. Norwood CVS, Inc.
6714. Nostrand Brooklyn CVS, L.L.C.
6715. Nostrand CVS, L.L.C.
6716. Notre Dame CVS, Inc.
6717. Nottingham PA CVS, Inc.
6718. Novo Innovations, LLC
6719. NovoLogix, Inc.
6720. NovoLogix, LLC
6721. NS Acquisition Sub, LLC
6722. NSPS Acquisition Sub, LLC
6723. Nutmeg CVS, L.L.C.
6724. Nutmeg Life Insurance Company
6725. NWC 63rd Chicago CVS, L.L.C.
6726. NWC 80th Minneapolis CVS,
L.L.C.
6727. NWC CVS, Inc
6728. NWC Frank Lloyd Wright CVS,
L.L.C.
6729. NWC Northdale CVS, L.L.C.
6730. NWC Rte. 59 CVS, L.L.C.
6731. NY Lexington CVS, L.L.C.
6732. Nyack CVS, L.L.C.
6733. NYLCare Dental Plans of the
Southwest, Inc.
6734. NYLCare Health Plans Northwest,
Inc.
6735. NYLCare Health Plans of
Connecticut, Inc.
6736. NYLCare Health Plans of Maine,
Inc.
6737. NYLCare Health Plans of New
Jersey, Inc.
6738. NYLCare Health Plans of New
York, Inc.
6739. NYLCare Health Plans of
Pennsylvania, Inc.
6740. NYLCare Health Plans of the Mid-
Atlantic, Inc.
6741. NYLCare Health Plans of the
Midwest, Inc.
6742. NYLCare Health Plans, Inc.
6743. NYLCare Health Plans, LLC
6744. NYLCare of New England, Inc.
6745. NYLCare of Texas, Inc.
6746. NYLCare Plus, Inc.
6747. NYLCare Preferred Services, Inc.
6748. Oak Lane CVS, Inc.
6749. Oak Park CVS, L.L.C.
6750. Oak Ridge CVS, L.L.C.
6751. Oak Ridge NC CVS, Inc.
6752. Oak Ridge Orlando CVS, L.L.C.
6753. Oaklawn Ave., Cranston CVS, Inc.
6754. Oaklyn CVS, Inc.
6755. Oakton Niles CVS, L.L.C.
6756. Oakwood CVS, Inc.
6757. Ocala CVS, L.L.C.
6758. Ocean Acquisition Sub, L.L.C.
6759. Ocean City MD CVS, L.L.C.
6760. Ocean County CVS, Inc.
6761. Ocean View Plaza CVS, Inc.
6762. Ocoee FL CVS, L.L.C.
6763. OCR Services Corporation
6764. OCR Services, LLC
6765. OCR-RA Acquisition, LLC
6766. Odd Lot Parent Corporation
6767. Odd Lot Trading, Inc.
6768. Oger Park CVS, L.L.C.
6769. Ohio CVS Pharmacy, L.L.C.
6770. Ohio CVS Stores, L.L.C.
6771. Ohio Primary Care Associates, P.C.
6772. Oklahoma CVS Pharmacy, L.L.C.
6773. Olathe 119th CVS, Inc.
6774. Olathe Ridgeview CVS, Inc.
6775. Old Buncombe Road CVS, Inc.
6776. Old Country CVS, Inc.
6777. Old Cutler Miami CVS, L.L.C.
6778. Old Greenwich CVS, Inc.
6779. Old Hickory CVS, Inc.
6780. Old Maple CVS, Inc.
6781. Old National CVS, Inc.
6782. Old Richmond Sugar Land CVS,
L.P.
6783. Old Saybrook CVS, Inc.
1747
WITH TECHNICAL CORRECTIONS 02.03.2023
J-99
6784. Old Tappan CVS, Inc.
6785. Old Winter Orlando CVS, L.L.C.
6786. Olean Center CVS Store, Inc.
6787. Olean Clinton Stores, Inc.
6788. Olive Glendale CVS, L.L.C.
6789. Olympia Fields CVS, L.L.C.
6790. Olympia Way CVS, L.L.C.
6791. Omaha Financial Life Insurance
Company
6792. Omnicare Air Transport Services,
Inc.
6793. Omnicare Canadian Holdings, Inc.
6794. Omnicare Distribution Center LLC
6795. Omnicare ESC LLC
6796. Omnicare Foundation
6797. Omnicare Headquarters LLC
6798. OmniCare Health Plan, Inc.
6799. Omnicare Holding Company
6800. Omnicare Indiana Partnership
Holding Company LLC
6801. Omnicare Management Company
6802. Omnicare of Nevada, LLC
6803. Omnicare of New York, LLC
6804. Omnicare Pharmacies of
Pennsylvania East LLC
6805. Omnicare Pharmacies of
Pennsylvania West LLC
6806. Omnicare Pharmacies of The Great
Plains Holding Company
6807. Omnicare Pharmacies of the Great
Plains Holding Company, LLC
6808. Omnicare Pharmacy and Supply
Services LLC
6809. Omnicare Pharmacy of Florida,
LLC
6810. Omnicare Pharmacy of Florida, LP
6811. Omnicare Pharmacy of Maine LLC
6812. Omnicare Pharmacy of Nebraska,
LLC
6813. Omnicare Pharmacy of North
Carolina, LLC
6814. Omnicare Pharmacy of Pueblo,
LLC
6815. Omnicare Pharmacy of Tennessee,
LLC
6816. Omnicare Pharmacy of Texas 1, LP
6817. Omnicare Pharmacy of Texas 2, LP
6818. Omnicare Pharmacy of the
Midwest, LLC
6819. Omnicare Property Management,
LLC
6820. Omnicare Purchasing Company
General Partner, Inc.
6821. Omnicare Purchasing Company
Limited Partner, Inc.
6822. Omnicare Purchasing Company LP
6823. Omnicare Resources, LLC
6824. Omnicare SCG, INC.
6825. Omnicare Senior Health Outcomes,
LLC
6826. Omnicare, Inc.
6827. Omnicare, LLC
6828. One Liberty Plaza Holdings, Inc.
6829. Oneonta Clinton Stores, Inc.
6830. Onondaga County CVS, Inc.
6831. Ontario CVS, Inc.
6832. OPGP Acquisition Sub, LLC
6833. OPM Acquisition Sub, LLC
6834. OPSS Acquisition Sub, LLC
6835. Orange Blossom CVS, Inc.
6836. Orange Central CVS, Inc.
6837. Orange City CVS, L.L.C.
6838. Orange Coast CVS, Inc.
6839. Orange CVS, Inc.
6840. Orange Winter Park CVS, L.L.C.
6841. Orange-Derby CVS, Inc.
6842. Orangethorpe CVS, L.L.C.
6843. Oregon Avenue CVS, Inc.
6844. Oregon CVS Pharmacy, L.L.C.
6845. Orland Hills CVS, L.L.C.
6846. Orland Park CVS, L.L.C.
6847. Orleans CVS, Inc.
6848. Orleans West Rd. CVS, Inc.
6849. Ormond Beach CVS, L.L.C.
6850. Owings Mills CVS, Inc.
6851. Oxford Casselberry CVS, L.L.C.
1748
WITH TECHNICAL CORRECTIONS 02.03.2023
J-100
6852. Oxford CVS, Inc.
6853. Oxford Valley CVS, Inc.
6854. Oxford Valley, PA Bob's, Inc.
6855. Oyster Bay Kay-Bee Toy, Inc.
6856. P Street CVS, Inc.
6857. PA CVS, Inc.
6858. Pacific Coast Lomita CVS, L.L.C.
6859. Pacific Long Beach CVS, L.P.
6860. PacifiCare of Utah, Inc.
6861. Palm Ave CVS, L.L.C.
6862. Palm Beach CVS, Inc.
6863. Palm Beach Gardens CVS, L.L.C.
6864. Palm Beach Military CVS, L.L.C.
6865. Palm Harbor CVS, Inc.
6866. Palmdale Rancho CVS, L.L.C.
6867. Palmer Thorndike CVS, Inc.
6868. Palos Heights CVS, L.L.C.
6869. Pamplona Saúde e Beleza LTDA
6870. Panorama City CVS, L.P.
6871. Panorama CVS Store, Inc.
6872. Panorama CVS, Inc.
6873. Paoli, PA., CVS, Inc.
6874. Paramus Park CVS, Inc.
6875. Parekh MinuteClinic of Nevada,
P.C.
6876. Paris CVS, Inc.
6877. Park Avenue South CVS, Inc.
6878. Park Boulevard CVS, Inc.
6879. Park Charlotte CVS, Inc.
6880. Park City CVS, Inc.
6881. Park City Retailer, Inc.
6882. Park Los Rios Plano CVS, L.L.C.
6883. Park Place CVS, Inc.
6884. Park Plaza CVS, Inc.
6885. Park Street CVS, Inc.
6886. Parker Plano CVS, L.P.
6887. Parker Street CVS, Inc.
6888. Parkersburg CVS, Inc.
6889. Parkhill CVS, Inc.
6890. Parkwin Bald CVS, L.L.C.
6891. Parkwood Circle CVS, Inc.
6892. Parmer Dessau CVS, L.L.C.
6893. Parsonage CVS, Inc.
6894. Part D Holding Company, L.L.C.
6895. Part D Management Services, LLC
6896. PARTNERS Health Plan of
California
6897. PARTNERS Health Plan of Florida,
Inc.
6898. PARTNERS Health Plan of
Louisiana, Inc.
6899. PARTNERS Health Plan of
Northern Ohio, Inc.
6900. PARTNERS Health Plan of
Southern California
6901. PARTNERS Health Plan of
Southern New England, Inc.
6902. PARTNERS Joint Acquisition
Company, Inc.
6903. Pasadena CVS, Inc.
6904. Pasadena CVS, L.P.
6905. Pasadena Foothill CVS, L.L.C.
6906. Passyunk Ave. (Phila.) CVS, Inc.
6907. Pataskala CVS, L.L.C.
6908. Paterson CVS, Inc.
6909. Patriot Square CVS, Inc.
6910. Paulsboro CVS, Inc.
6911. Pavilion Boulevard CVS, Inc.
6912. Pawtucket CVS, Inc.
6913. Pawtucket Plaza CVS, Inc.
6914. Pawtucket Retailer, Inc.
6915. Paxton Square CVS, Inc.
6916. PayFlex Holdings, Inc.
6917. PayFlex Systems USA, Inc.
6918. PCS Mail Services of Birmingham,
Inc.
6919. PE Holdings, LLC
6920. Peabody Lowell CVS, Inc.
6921. Peabody Lynnfield CVS, Inc.
6922. Peachtree CVS, Inc.
6923. Pearland CVS, L.P.
6924. Pecos Gilbert CVS, L.L.C.
6925. Pelham Manor CVS, Inc.
6926. Pembroke Center St. CVS, Inc.
6927. Pembroke Pines CVS, Inc.
6928. Penn - Daw CVS, Inc.
1749
WITH TECHNICAL CORRECTIONS 02.03.2023
J-101
6929. Penn - Daw Peoples, Inc.
6930. Penn Group Health Plan, Inc.
6931. Penn-Can CVS Store, Inc.
6932. Pennsauken CVS, Inc.
6933. Pennsburg CVS, Inc.
6934. Pennsylvania Ave. CVS, Inc.
6935. Pennsylvania Ave. Peoples, Inc.
6936. Pennsylvania Avenue CVS, Inc.
6937. Pennsylvania Avenue ProCare, Inc.
6938. Pennsylvania Binghamton CVS,
L.L.C.
6939. Pennsylvania CVS Pharmacy,
L.L.C.
6940. Pennsylvania Life Insurance
Company
6941. Pennsylvania LIfe, Health &
Accident Insurance Company
6942. Pennsylvania-HealthCare USA, Inc.
6943. Peoples Drug Stores
6944. Peoples Drug Stores, Inc.
6945. Peoples Drug Stores, Incorporated
6946. Peoples of East Moline, Inc.
6947. Peoples Prescription Center, Inc.,
6948. Peoples Service Drug
6949. Peoples Service Drug Stores
6950. Peoples Service Drug Stores, Inc.
6951. Peoria AZ CVS, L.L.C.
6952. Peppertree Plaza CVS, Inc.
6953. Pequannock CVS, Inc.
6954. Performax, Inc.
6955. Perry Hall CVS, L.L.C.
6956. Perry Highway CVS, Inc.
6957. Pershing Drive CVS, Inc.
6958. PersonalCare Insurance of Illinois,
Inc.
6959. Pfafftown CVS, Inc.
6960. Pharm Plus Acquisition, Inc.
6961. PharmaCare Captive RE, Ltd.
6962. PharmaCare Direct, L.L.C.
6963. PharmaCare Government Services,
Inc.
6964. PharmaCare Healthcare
Distributors, L.L.C.
6965. PharmaCare Holding Corporation
6966. Pharmacare Management Services,
L.L.C.
6967. PharmaCare Pharmacy LA, L.L.C.
6968. PharmaCare Pharmacy, Inc.
6969. PharmaCare Pharmacy, L.L.C.
6970. PharmaCare Puerto Rico Specialty
Pharmacy Holding, L.L.C.
6971. PharmaCare Puerto Rico Specialty
Pharmacy, L.L.C.
6972. PharmaCare Specialty Healthcare
Distributors, L.L.C.
6973. PharmaCare Support Services,
L.L.C.
6974. PharmaCon Corp.
6975. Pharmacy Advisory Company
6976. Pharmacy Associates of Glens
Falls, Inc.
6977. Pharmacy Associates of Glens
Falls, LLC
6978. Pharmacy Consultants, LLC
6979. Pharmacy Holding #1, LLC
6980. Pharmacy Holding #2, LLC
6981. Pharmasource Healthcare, Inc.
6982. Pharm-Corp of Maine LLC
6983. Pharmed Holdings, Inc.
6984. Pharmed Holdings, LLC
6985. Pharmore Drugs, LLC
6986. Pharmore, Inc.
6987. Pharmore, LLC
6988. Pheasant Nashua CVS, Inc.
6989. PHG Aces Acquisition, LLC
6990. PHG Acquisition Corp.
6991. PHG Mystery Acquisition, LLC
6992. Phila Sun CVS, Inc.
6993. Philadelphia Broad CVS, Inc.
6994. Philadelphia Foxchase CVS, Inc.
6995. Philadelphia Frankford CVS, Inc.
6996. Philadelphia Gallery CVS, Inc.
6997. Philadelphia Harbison CVS, Inc.
6998. Philadelphia PA CVS, Inc.
6999. Philadelphia ProCare, Inc.
7000. Philadelphia Roosevelt CVS, Inc.
1750
WITH TECHNICAL CORRECTIONS 02.03.2023
J-102
7001. Philadelphia South Street CVS, Inc.
7002. Philadelphia, PA Bob's, Inc.
7003. Phillips CVS, Inc.
7004. Phillipsburg CVS, Inc.
7005. Philly Broad Street CVS, Inc.
7006. Phoenix Data Center Hosting
Services LLC
7007. Phoenix Data Solutions LLC
7008. Phoenix Glendale CVS, L.L.C.
7009. Phoenixville PA CVS, Inc.
7010. PHPSNE Parent Corporation
7011. Physician Choice Health Plan
7012. Physicians Health Plan of
Delaware, LTD.
7013. Physicians Health Plan of Florida,
Inc.
7014. Physicians Hospital Management
Corporation
7015. Pico Rivera CVS, Inc.
7016. Pigeon Forge TN CVS, Inc.
7017. Pinal County AZ CVS, L.L.C.
7018. Pine Ocala CVS, L.L.C.
7019. Pinecrest CVS, Inc.
7020. Pinellas Park CVS, Inc.
7021. Pinnacle Peak Peoria CVS, L.L.C.
7022. Pio Nono Avenue CVS, Inc.
7023. Pioneer Parkway CVS, L.P.
7024. Piper Glen CVS, Inc.
7025. Pittsburgh Fifth Avenue CVS, Inc.
7026. Pittsfield CVS, Inc.
7027. Pittsfield Retailer, Inc.
7028. Pittston CVS, Inc.
7029. Placentia CVS, Inc.
7030. Plain CVS, Inc.
7031. Plainfield CVS, Inc.
7032. Plainfield Distribution Center, Inc.
7033. Plainfield IL CVS, L.L.C.
7034. Plainfield-Seventh St. CVS, Inc.
7035. Plainview TX CVS, L.L.C.
7036. Plainville East CVS, Inc.
7037. Plano CVS, L.P.
7038. Plantation CVS, L.L.C.
7039. Plantation Street PharmaCare
Pharmacy, Inc.
7040. Plaza Boulevard CVS, Inc.
7041. Plaza Retailer, Inc.
7042. Pleasant Fall River CVS, Inc.
7043. Pleasant Ridge CVS, L.P.
7044. Pleasant Street CVS, Inc.
7045. Pleasantville CVS, L.L.C.
7046. Plumstead CVS, Inc.
7047. Plymouth CVS, Inc.
7048. Plymouth Meeting CVS, Inc.
7049. Plymouth MN CVS, L.L.C.
7050. Plymouth Route 44 CVS, Inc.
7051. PMRP Acquisition Company, LLC
7052. Poinciana FL CVS, L.L.C.
7053. Port Chester CVS, L.L.C.
7054. Port Huron Clinton Discount Stores,
Inc.
7055. Port Huron CVS, Inc.
7056. Port Orange Realty Services, L.L.C.
7057. Port Richmond CVS, Inc.
7058. Port Washington CVS, Inc.
7059. Portage CVS, Inc.
7060. Porter Square CVS, Inc.
7061. Porters Pass CVS, Inc.
7062. Portsmouth CVS, Inc.
7063. Post Office Square CVS, Inc.
7064. Pottstown High Street CVS, Inc.
7065. Poughkeepsie CVS, L.L.C.
7066. Powell OH CVS, Inc.
7067. PP Acquisition Company, LLC
7068. PPOM, L.L.C.
7069. Prairieville LA CVS, Inc.
7070. Precision Benefit Services, Inc.
7071. President-Quincy CVS, Inc.
7072. Preston Beltline CVS, L.P.
7073. Preston Center CVS, L.P.
7074. Preston Plano CVS, L.P.
7075. Primary Healthcare Asia Limited
7076. Primary Holdings, Inc.
7077. Primary Investments, Inc
7078. Prime Net, Inc.
1751
WITH TECHNICAL CORRECTIONS 02.03.2023
J-103
7079. Prince George's Health Services
Foundation Plan, Inc.
7080. Princeton NJ CVS, L.L.C.
7081. Principal Health Care of Delaware,
Inc.
7082. Principal Health Care of Georgia,
Inc.
7083. Principal Health Care of Iowa, Inc.
7084. Principal Health Care of Kansas
City, Inc
7085. Principal Health Care of Louisiana,
Inc.
7086. Principal Health Care of Nebraska,
Inc.
7087. Principal Health Care of
Pennsylvania, Inc.
7088. PRN Pharmaceutical Services, LP
7089. ProCare 3159 General, Inc.
7090. ProCare 4268 Yankee, L.L.C.
7091. ProCare 8th Manhattan, L.L.C.
7092. ProCare 9th Avenue, L.L.C.
7093. ProCare Ave. Pharmacy, L.L.C.
7094. ProCare Boston Pharmacy, Inc.
7095. ProCare DC Pharmacy, Inc.
7096. ProCare Manhattan Pharmacy,
L.L.C.
7097. ProCare Meridian Miami, L.L.C.
7098. ProCare N.Y. Pharmacy, Inc.
7099. ProCare Pharmacy 18th Street, Inc.
7100. ProCare Pharmacy A, L.L.C.
7101. ProCare Pharmacy Avenue 1st-483,
L.L.C.
7102. ProCare Pharmacy Direct, L.L.C.
7103. ProCare Pharmacy Dryden, L.P.
7104. ProCare Pharmacy East Colonial,
Inc.
7105. ProCare Pharmacy Fairfax, Inc.
7106. ProCare Pharmacy Garden Grove,
Inc.
7107. ProCare Pharmacy Glendale
Boulevard, Inc.
7108. ProCare Pharmacy Limited of
Illinois, Inc.
7109. ProCare Pharmacy Miami 54, Inc.
7110. ProCare Pharmacy Monument
Street, L.L.C.
7111. ProCare Pharmacy North Orange,
Inc.
7112. ProCare Pharmacy of Berkeley, Inc.
7113. ProCare Pharmacy of Broad Street,
Inc.
7114. ProCare Pharmacy of Brookline
Avenue, Inc.
7115. ProCare Pharmacy of Casselberry,
Inc.
7116. ProCare Pharmacy of Chicago,
L.L.C.
7117. ProCare Pharmacy of East
Morehead, Inc.
7118. ProCare Pharmacy of Glendale, Inc.
7119. ProCare Pharmacy of Kansas City,
Inc.
7120. ProCare Pharmacy of Portland,
L.L.C.
7121. ProCare Pharmacy of San Antonio,
Inc.
7122. ProCare Pharmacy of San Diego,
Inc.
7123. ProCare Pharmacy of San
Francisco, Inc.
7124. ProCare Pharmacy of Tampa, Inc.
7125. ProCare Pharmacy of West
Hollywood, Inc.
7126. ProCare Pharmacy Orange Orlando,
Inc.
7127. ProCare Pharmacy Palo Alto, Inc.
7128. ProCare Pharmacy Phoenix, L.L.C.
7129. ProCare Pharmacy Rancho Lane,
L.L.C.
7130. ProCare Pharmacy Santa Monica,
Inc.
7131. ProCare Pharmacy Sherman Oaks,
Inc.
7132. ProCare Pharmacy South Orange,
Inc.
1752
WITH TECHNICAL CORRECTIONS 02.03.2023
J-104
7133. ProCare Pharmacy Spruce Street,
Inc.
7134. ProCare Pharmacy West Columbia,
Inc.
7135. ProCare Pharmacy West Copeland,
Inc.
7136. ProCare Pharmacy, L.L.C.
7137. Proctorville CVS, Inc.
7138. Prodigy Health Group Holdings,
Inc.
7139. Prodigy Health Group, Inc.
7140. Professional Pharmacy Services,
Inc.
7141. Professional Risk Management, Inc.
7142. Prospect CVS, Inc.
7143. Prospect Park CVS, Inc.
7144. Providence Charlotte CVS, Inc.
7145. Providence Place CVS, Inc.
7146. Providence Road CVS, Inc.
7147. Providence Street CVS, Inc.
7148. Providence Thayer Street CVS, Inc.
7149. Providence-Wayland CVS, Inc.
7150. Provider Networks of America, Inc.
7151. Prudential Center for Health Care
Research Foundation, Inc.
7152. Prudential Dental Maintenance
Organization, Inc.
7153. Prudential Health Care Plan of
California, Inc.
7154. Prudential Health Care Plan of
Connecticut, Inc.
7155. Prudential Health Care Plan of New
York, Inc.
7156. Prudential Health Care Plan, Inc.
7157. Prudential Health Plan of Georgia,
Inc.
7158. PSI Arkansas Acquisition, LLC
7159. PT Aetna Management Consulting
7160. PT Asuransi Aetna Asia
7161. PT. Aetna Global Benefits
Indonesia
7162. PT. Goodhealth Indonesia
7163. Puente Hills CVS, Inc.
7164. Puerto Rico CVS Pharmacy, L.L.C.
7165. Punta Gorda CVS, L.L.C.
7166. Putnam Pike CVS, Inc.
7167. Quaker Bridge CVS, Inc.
7168. Quakertown CVS, Inc.
7169. Quality Choice Health Plan
7170. Queen Anne Plaza CVS, Inc.
7171. Queen Anne Road CVS, L.L.C.
7172. Queen City AZ CVS, L.L.C.
7173. Queen Creek CVS, L.L.C.
7174. Queens Forest Hills CVS, L.L.C.
7175. Queens Plaza CVS, Inc.
7176. Quention Road CVS, Inc.
7177. Quincy Adams CVS, Inc.
7178. Quincy CVS, Inc.
7179. Quincy Hancock CVS, Inc.
7180. Quincy Parcel Holding Corp.
7181. Quincy Shore Drive CVS, Inc.
7182. R Parks CVS, Inc.
7183. Race Street CVS, Inc.
7184. Race Track Tampa CVS, L.L.C.
7185. Raceway CVS, Inc.
7186. Raleigh CVS, Inc.
7187. Raleigh Millbrook CVS, Inc.
7188. Ralphs Circle CVS, Inc.
7189. Ralph's Corner CVS, Inc.
7190. Ramona Blvd CVS, L.L.C.
7191. Rancho Niguel CVS, Inc.
7192. Randallstown CVS, Inc.
7193. Randolph CVS, Inc.
7194. Randolph Hills CVS, Inc.
7195. Ravenna CVS, Inc.
7196. Ray McClintock CVS, L.L.C.
7197. Rayford Spring CVS, L.P.
7198. Raynham Broadway CVS, Inc.
7199. Raynham CVS, Inc.
7200. Raynham Plaza CVS, Inc.
7201. Rea & Derick, Inc.
7202. Reading CVS, Inc.
7203. Reading, Penna., CVS, Inc.
7204. Recker Mesa CVS, L.L.C.
7205. Red Oak Houston CVS, L.P.
7206. Red Oak Lane CVS, Inc.
1753
WITH TECHNICAL CORRECTIONS 02.03.2023
J-105
7207. Red Oak Sourcing, LLC
7208. Redondo Beach CVS, Inc.
7209. Reed Street CVS, Inc.
7210. Reedy Creek CVS, Inc.
7211. Regency Park Port Richey CVS,
L.L.C.
7212. Rehoboth Beach CVS, Inc.
7213. Reidville Drive CVS, Inc.
7214. Renaisance CVS, Inc.
7215. Reseda Northridge CVS, L.P.
7216. Resources for Living, LLC
7217. Reston Plaza America CVS, Inc.
7218. Retail Acquisitions Today, L.L.C.
7219. Retrac, Inc.
7220. Revco D.S., Inc.
7221. Revco Discount Drug Centers, Inc.
(MI)
7222. Revco Discount Drug Centers, Inc.
(OH)
7223. Revco Drug Stores, Inc.
7224. Revco Golf Charities Foundation
7225. Revco Home Health Care Centers,
Inc.
7226. Revco Mail Service Pharmacy, Inc.
7227. Revir CVS, L.L.C.
7228. Reynoldsburg CVS, Inc.
7229. Rhode Island CVS Pharmacy,
L.L.C.
7230. Rhode Island Home Therapeutics,
Inc.
7231. Rice Mine Tuscaloosa CVS, Inc.
7232. Richards Investment Company
7233. Richardson CVS, L.P.
7234. Richboro Market CVS, Inc.
7235. Richland Hills CVS, L.P.
7236. Richmond CVS, Inc.
7237. Richmond Heights Acquisition
Corp.
7238. Richmond Highway 6 CVS, L.P.
7239. Richmond Highway CVS, Inc.
7240. Richmond Houston CVS, L.P.
7241. Richmond Kirby CVS, L.P.
7242. Richmond Montrose CVS, L.P.
7243. Richmond Peoples, Inc.
7244. Richmond RI CVS, Inc.
7245. Richmond Sage CVS, L.P.
7246. Richmond Woodman CVS, Inc.
7247. Richton Park IL CVS, L.L.C.
7248. Ridgefield CT CVS, Inc.
7249. Ridgefield Grove CVS, Inc.
7250. Ridgeley CVS, Inc.
7251. Ridley Acres CVS, Inc.
7252. Ridley CVS, Inc.
7253. Ringgold GA CVS, Inc.
7254. Ringwood NJ CVS, L.L.C.
7255. Rising Sun CVS, Inc.
7256. Risinger Ft. Worth CVS, L.P.
7257. River Edge CVS, Inc.
7258. River Forest CVS, L.L.C.
7259. River Road CVS, Inc.
7260. River View Marketplace CVS, Inc.
7261. Riverdale IL CVS, L.L.C.
7262. Riverside Arlington CVS, INc.
7263. Riverside Danville CVS, Inc.
7264. Riverton NJ CVS, L.L.C.
7265. Riverview FL CVS, L.L.C.
7266. Riverwatch CVS, Inc.
7267. Robbinsdale MN CVS, L.L.C.
7268. Robbinsville CVS, Inc.
7269. Robert St. Paul CVS, L.L.C.
7270. Robious CVS, Inc.
7271. Rochelle Park CVS, L.L.C.
7272. Rochester Main St. CVS Store, Inc.
7273. Rochester N.H. CVS, Inc.
7274. Rockaway (N.J.) CVS, Inc.
7275. Rockingham CVS, L.L.C.
7276. Rockingham Park CVS, Inc.
7277. Rockland CVS, Inc.
7278. Rockledge FL CVS, L.L.C.
7279. Rockville CVS, Inc.
7280. Rockville MD CVS, L.L.C.
7281. Rockville Pike CVS, Inc.
7282. Rockville Pike Peoples, Inc.
7283. Rocky Hill Cromwell CVS, Inc.
7284. Rocky Hill CVS, Inc.
7285. Roeschen's Healthcare LLC
1754
WITH TECHNICAL CORRECTIONS 02.03.2023
J-106
7286. Rolling Manassas CVS, Inc.
7287. Rolling Meadows CVS, L.L.C.
7288. Roosevelt CVS, L.L.C.
7289. Roosevelt Field CVS, Inc.
7290. Roosevelt Plaza CVS, Inc.
7291. Roper Mountain Road CVS, Inc.
7292. Rosa Narg CVS, Inc.
7293. Rosecrans Avenue CVS, Inc.
7294. Rosecrans Hawthorne CVS, L.P.
7295. Rosedale NY CVS, L.L.C.
7296. Roselle IL CVS, L.L.C.
7297. Rosemont PA CVS, Inc.
7298. Rosenberg CVS, L.P.
7299. Roslindale CVS, Inc.
7300. Roslindale MA CVS, Inc.
7301. Roslyn CVS, L.L.C.
7302. Ross Haskell CVS, L.P.
7303. Ross Park CVS, Inc.
7304. Roswell CVS, Inc.
7305. Roswell Rivermont Station CVS,
Inc.
7306. Round Lake CVS, L.L.C.
7307. Round Rock 79 CVS, L.L.C.
7308. Route 202 Whitpain CVS, Inc.
7309. Route 23 CVS, Inc.
7310. Route 27 CVS, Inc.
7311. Route 59 CVS, L.L.C.
7312. Route 83 Glastonbury CVS, Inc.
7313. Route 83 Palos Heights CVS,
L.L.C.
7314. Route 88 CVS, Inc.
7315. Rowlett TX CVS, L.L.C.
7316. Rowley CVS, Inc.
7317. Roxborough CVS, Inc.
7318. Royal Dallas CVS, L.P.
7319. Royal Oak CVS, Inc.
7320. Royersford CVS, Inc.
7321. Rte 52 IL CVS, L.L.C.
7322. Runnemede CVS, Inc.
7323. Russell Ft. Apache CVS, L.L.C.
7324. Rutherford CVS, Inc.
7325. Rx Connections, Inc.
7326. Rx Innovations 4439, L.L.C.
7327. RxAmerica LLC
7328. RXC Acquisition Company
7329. RxHub, L.L.C.
7330. S. Dartmouth CVS, Inc.
7331. S. Fair Oaks Ave CVS, L.L.C..
7332. S. Houston Lake Rd. CVS, Inc.
7333. S. Main St. CVS, Inc.
7334. S. Western Avenue CVS, Inc.
7335. SABH of Arizona, Incorporated
7336. SABH of Maricopa County,
Incorporated
7337. Saddle Brook CVS, Inc.
7338. Sagamore Ridge CVS, Inc.
7339. Sagev CVS, L.L.C.
7340. Saginaw CVS, L.P.
7341. Saginaw Lansing CVS, Inc.
7342. Saguaro Health Plan, Inc.
7343. Salem Lynnfield CVS, Inc.
7344. Salem Mall CVS, Inc.
7345. Salem Mass. CVS, Inc.
7346. Salem Pond CVS, Inc.
7347. Salem VA CVS, Inc.
7348. Sam Furr Road CVS, Inc.
7349. Samoset Avenue CVS, Inc.
7350. San Antonio CareCenter Pharmacy,
LLC
7351. San Carlos Ft. Myers CVS, L.L.C.
7352. San Clemente CVS, L.L.C.
7353. San Jose Jacksonville CVS, L.L.C.
7354. Sand Pharmacy St Albans 06306
LLC
7355. Sandusky CVS, Inc.
7356. Sandwich CVS, Inc.
7357. Sandy Plains CVS, Inc.
7358. Sandy Springs CVS, Inc.
7359. Sanford River CVS, Inc.
7360. Santa Ana CVS, Inc.
7361. Santa Marguerita CVS, L.P.
7362. Santa Monica CVS, L.P.
7363. Sanus Corp. Health Systems
7364. Sanus Dental Plan of N.J., Inc.
7365. Sanus Dental Plan of Texas, Inc.
7366. Sanus Health Plan of Illinois, Inc.
1755
WITH TECHNICAL CORRECTIONS 02.03.2023
J-107
7367. Sanus Health Plan of Pennsylvania,
Inc.
7368. Sanus of Maine, Inc.
7369. Sanus of New York and New
Jersey, Inc.
7370. SANUS of New York, Inc.
7371. Sanus Preferred Providers West,
Inc.
7372. Saugus CVS, Inc.
7373. Saugus Walnut CVS, Inc.
7374. Sayre CVS, Inc.
7375. SCAFFALE 03 PARTICIPAÇÕES
LTDA.,
7376. Schaller Anderson Acquisition,
Incorporated
7377. Schaller Anderson Behavioral
Health of Maryland, Incorporated
7378. Schaller Anderson Behavioral
Health of Tennessee, Incorporated
7379. Schaller Anderson Behavioral
Health of Texas, L.L.C.
7380. Schaller Anderson Behavioral
Health of Texas, L.P.
7381. Schaller Anderson Behavioral
Health, Incorporated
7382. Schaller Anderson Health Plans,
LLC
7383. Schaller Anderson Healthcare,
L.L.C.
7384. Schaller Anderson Medical
Administrators, Incorporated
7385. Schaller Anderson Network of
Arizona, L.L.C.
7386. Schaller Anderson of Arizona,
L.L.C.
7387. Schaller Anderson of California,
L.L.C.
7388. Schaller Anderson of Delaware,
Incorporated
7389. Schaller Anderson of Kansas,
L.L.C.
7390. Schaller Anderson of Maryland,
L.L.C.
7391. Schaller Anderson of Missouri,
L.L.C.
7392. Schaller Anderson of Oklahoma,
LLC
7393. Schaller Anderson of Tennessee,
LLC
7394. Schaller Anderson of Texas
Management, L.L.C.
7395. Schaller Anderson of Texas, L.P.
7396. Schaller Anderson, Incorporated
7397. Schaller Anderson, LLC
7398. Schaumburg CVS, L.L.C.
7399. Schmidt Video Virtual Care of
Nevada, PLLC
7400. Schnecksville CVS, Inc.
7401. Schoolcraft Detroit CVS, Inc.
7402. Schwab Road CVS, Inc.
7403. Scituate CVS, Inc.
7404. Scotch Plains CVS, Inc.
7405. Scott Houston CVS, L.P.
7406. Scottsboro AL CVS, Inc.
7407. Scottsdale CVS, L.L.C.
7408. SCP 2003C-31 LLC
7409. SCP 2003C-40 LLC
7410. SCP 2003D-66 LLC
7411. SCP 2003D-8 LLC
7412. SCP 2004E-062 LLC
7413. SCP 2005-C21-013 LLC
7414. SCP 2005-C21-074 LLC
7415. SCP 2005C-C20-016 LLC
7416. SCP 2007-C27-013 LLC
7417. SCP 2007-C27-015 LLC
7418. SCP 2007-C27-017 LLC
7419. SCP 2007-C27-025 LLC
7420. SCP 2007-C27-061 LLC
7421. SCP 2007-C27-066 LLC
7422. SCP 2007-C27-084 LLC
7423. SCP 2007-C27-096, L.L.C.
7424. SCP 2007-C27-540 LLC
7425. SCP 2007-C27-546 LLC
7426. SCP 2009-C32-502 LLC
7427. SCP 2009-C32-504 LLC
7428. SCP 2009-C32-513 LLC
1756
WITH TECHNICAL CORRECTIONS 02.03.2023
J-108
7429. SCP 2009-C32-518 LLC
7430. Scranton Davis CVS, Inc.
7431. Scranton Main CVS, Inc.
7432. Scrip World, LLC
7433. Sea Isle City CVS, Inc.
7434. Seaboard Service System, Ltd.
7435. Seaford NY CVS, L.L.C.
7436. Sears Town Mall CVS, Inc.
7437. Seaside Heights CVS, L.L.C.
7438. Seaville NJ CVS, L.L.C.
7439. SEC CVS, Inc.
7440. SEC Lincoln CVS, L.L.C.
7441. SEC Route 14 CVS, L.L.C.
7442. SEC State CVS, L.L.C.
7443. SEC University MN CVS, L.L.C.
7444. Secaucus Seven CVS, Inc.
7445. Sedalia NC CVS, Inc.
7446. Sedwick Durham CVS, L.L.C.
7447. Seekonk Mall CVS, Inc.
7448. Seminole CVS, Inc.
7449. Senip CVS, L.L.C.
7450. Setauket CVS, Inc.
7451. Seven Corners, VA Bob's, Inc.
7452. Seventh Street CVS, INc.
7453. Severn CVS, Inc.
7454. Seymour CVS, Inc.
7455. Shallowford Road CVS, Inc.
7456. Shamokin CVS, Inc.
7457. Sharon CVS, Inc.
7458. Sharon Hill CVS, Inc.
7459. Sheffield Avenue CVS, L.L.C.
7460. Shelby Township CVS, Inc.
7461. Shelbyville Main CVS, Inc.
7462. SHELFCO (NO. 967) LIMITED
7463. Shepherd Houston CVS, L.P.
7464. Sheridan Cooper CVS, L.L.C.
7465. Ship Bottom NJ CVS, L.L.C.
7466. Shirley CVS, L.L.C.
7467. Shoemakerville CVS, Inc.
7468. Shoppers Village CVS, Inc.
7469. Shoppers World CVS, Inc.
7470. Shopperstown CVS, Inc.
7471. Shore Pharmaceutical Providers,
LLC
7472. Shorewood CVS, L.L.C.
7473. Showalter CVS, Inc.
7474. Shrewsbury Retailer, Inc.
7475. SHS NewHMO, Inc.
7476. Sibley Chicago CVS, L.L.C.
7477. Sicklerville Road CVS, Inc.
7478. Sillington Road CVS, Inc.
7479. Silver Hill CVS, Inc.
7480. Silverbrook CVS, Inc.
7481. SilverScript Insurance Company
7482. SilverScript, Inc.
7483. SilverScript, L.L.C.
7484. Silverton CVS, Inc.
7485. Simi Valley CVS, Inc.
7486. Simsbury CVS, Inc.
7487. Sisson Road CVS, Inc.
7488. Skillman Mockingbird CVS, L.P.
7489. Skokie CVS, L.L.C.
7490. Sky Acquisition LLC
7491. Skyport Owner's Association
7492. Sloans Lake Holding Corporation
7493. Sloans Lake Managed Care, Inc.
7494. Sloan's Lake Management Corp.
7495. Smith Northampton CVS, Inc.
7496. Smith Palatine CVS, L.L.C.
7497. Smith Providence CVS, Inc.
7498. Smithville CVS, Inc.
7499. Smyrna Concord Road CVS, Inc.
7500. Smyrna CVS, Inc.
7501. Snellville CVS, Inc.
7502. Snellville GA CVS, Inc.
7503. Snow Road CVS, Inc.
7504. Socastee SC CVS, Inc.
7505. Solomon Office Associates, L.L.C.
7506. Solomons CVS, Inc.
7507. Somerdale CVS, Inc.
7508. Somers Point CVS, Inc.
7509. Somerset CVS, Inc.
7510. Somerville MA CVS, Inc.
7511. Somerville, MA Bob's, Inc.
7512. Sopco, Inc.
1757
WITH TECHNICAL CORRECTIONS 02.03.2023
J-109
7513. Souderton CVS, Inc.
7514. Sourcing Co, LLC
7515. South Attleboro CVS, Inc.
7516. South Boston CVS, Inc.
7517. South Bristol Street CVS, Inc.
7518. South Brook CVS, Inc.
7519. South Brunswick CVS, Inc.
7520. South Carolina CVS Pharmacy,
L.L.C.
7521. South Carolina CVS, Inc.
7522. South Dixie CVS, L.L.C.
7523. South Hills CVS Store, Inc.
7524. South Lincoln Newtown CVS, Inc.
7525. South Lyon CVS, Inc.
7526. South Mall CVS, Inc.
7527. South Merrimack CVS, Inc.
7528. South Nashua CVS, Inc.
7529. South Philadelphia CVS, Inc.
7530. South Plainfield CVS, Inc.
7531. South Post Oak CVS, L.P.
7532. South Providence CVS, Inc.
7533. South Sandwich Store Corporation
7534. South Shore League City CVS, L.P.
7535. South Shore Retailer, Inc.
7536. South Street CVS, Inc.
7537. South Wabash CVS, L.L.C.
7538. South Windsor CVS, Inc.
7539. South Yarmouth CVS, Inc.
7540. Southbridge Saga CVS, Inc.
7541. Southbury CVS, Inc.
7542. Southeast Pharmacy Consultants,
Inc.
7543. Southern Buckeye CVS, L.L.C.
7544. Southern Greenfield CVS, L.L.C.
7545. Southern Health Services, Inc.
7546. Southern Tempe CVS, L.L.C.
7547. Southington Main Street CVS, Inc.
7548. Southington Queen CVS, Inc.
7549. Southlake CVS, L.P.
7550. Southmore CVS, L.P.
7551. Southport NC CVS, Inc.
7552. Southwest Health Plan, Inc.
7553. Sparkleberry Lane CVS, Inc.
7554. Spatium, LLC
7555. Specialized Pharmacy Services,
LLC
7556. Specialty Carts, LLC
7557. Specialty Services Holding LLC
7558. Speedwell CVS Urban Renewal,
L.L.C.
7559. Speen Street CVS, Inc.
7560. Spencer Hwy CVS, L.P.
7561. Spencer Main CVS, Inc.
7562. Spencer PharmaCare Pharmacy,
Inc.
7563. Spinnaker Bidco Limited
7564. Spinnaker Topco Limited
7565. Spring CVS, L.P.
7566. Spring Cypresswood CVS, L.P.
7567. Spring Falvel TX CVS, L.L.C.
7568. Spring Valley Houston CVS, L.P.
7569. Spring Valley Richardson CVS,
L.P.
7570. Springfield Avenue CVS, Inc.
7571. Springfield CVS, Inc.
7572. Springfield Gardens CVS, L.L.C.
7573. Springfield IL CVS, L.L.C.
7574. Springfield NJ CVS, L.L.C.
7575. Springfield PA CVS, Inc.
7576. Springfield Post Road CVS, Inc.
7577. Springfield Sparns CVS, Inc.
7578. Springfield St. James CVS, Inc.
7579. Springhouse PA CVS, Inc.
7580. Sproul Broomall CVS, Inc.
7581. Spruce Street CVS, Inc.
7582. Square One CVS, Inc.
7583. SR 436 CVS, L.L.C.
7584. St. Aug Tuscan, L.L.C.
7585. St. Aug Watson, L.L.C.
7586. St. Charles CVS, L.L.C.
7587. St. Clair CVS, Inc.
7588. St. Cloud CVS, L.L.C.
7589. St. George's Avenue CVS, Inc.
7590. St. Louis Park CVS, L.L.C.
7591. St. Louis PharmaCare Pharmacy,
Inc.
1758
WITH TECHNICAL CORRECTIONS 02.03.2023
J-110
7592. St. Mary's CVS, Inc.
7593. St. Paul MN CVS, L.L.C.
7594. St. Petersburg CVS, Inc.
7595. Stamford CVS, Inc.
7596. Stamford Hope Street CVS, Inc.
7597. Stamford Ridgeway CVS, Inc.
7598. Stamford Town Center CVS, Inc.
7599. Standard Drug Company
7600. State College CVS, Inc.
7601. State Park Road CVS, Inc.
7602. State St. CVS Store, Inc.
7603. State Street CVS, L.L.C.
7604. Staten Island New York CVS, Inc.
7605. Station Avenue CVS, Inc.
7606. Steeplegate CVS, Inc.
7607. Stenton Avenue CVS, Inc.
7608. Stephens City VA CVS, Inc.
7609. Stephenville TX CVS, L.L.C.
7610. Sterling Healthcare Services, Inc.
7611. Sterling Healthcare Services, LLC
7612. Sterling Heights CVS, Inc.
7613. Sterrettania Road CVS, Inc.
7614. Steubner-Airline CVS, L.P.
7615. Stockbridge CVS, Inc.
7616. Stokes Road CVS, Inc.
7617. Stone Mountain CVS, Inc.
7618. Stoneham CVS, Inc.
7619. Stony Island Chicago CVS, L.L.C.
7620. Stoughton CVS, Inc.
7621. Strategic Resource Company
7622. Streamwood CVS, L.L.C.
7623. Stroudsburg Mall CVS, Inc.
7624. Structured Benefits Inc.
7625. Sturbridge PharmaCare Pharmacy,
Inc.
7626. Sublett Matlock CVS, L.P.
7627. Suburban Medical Services, LLC
7628. Sudbury CVS, Inc.
7629. Sudbury Wayside CVS, Inc.
7630. Suffield Agawam CVS, Inc.
7631. Suffield CVS, Inc.
7632. Sugar Land CVS, L.P.
7633. Sugarloaf Parkway CVS, Inc.
7634. Summer St. CVS, Inc.
7635. Summit Health Plan, Inc
7636. Sumner Belmont CVS, Inc.
7637. Sun City AZ CVS, L.L.C.
7638. Sun Lakes CVS, L.L.C.
7639. Sun Pharmacy, Limited Liability
Company
7640. Sunderland Road CVS, Inc.
7641. Sunlake Land CVS, L.L.C.
7642. Sunnyside NY CVS, L.L.C.
7643. Sunrise FL CVS, L.L.C.
7644. Sunset Crossing CVS, Inc.
7645. Sunset Henderson CVS, L.L.C.
7646. Superior Care Pharmacy, Inc.
7647. Superior Care Pharmacy, LLC
7648. Superior Township CVS, L.L.C.
7649. SureScripts LLC
7650. SureScripts-RxHub, LLC
7651. Surfside CVS, Inc.
7652. Surprise CVS, L.L.C.
7653. Sutter Health and Aetna
Administrative Services LLC
7654. Sutter Health and Aetna Insurance
Company
7655. Sutter Health and Aetna Insurance
Holding Company LLC
7656. Suwanee CVS, Inc.
7657. Swamp New Britain CVS, Inc.
7658. Swampscott Retailer, Inc.
7659. Swansea CVS, Inc.
7660. Swansea IL CVS, L.L.C.
7661. Swatara Square CVS, Inc.
7662. SWC Camelback CVS, L.L.C.
7663. SWC CVS, Inc.
7664. SWC M-59 CVS, L.L.C.
7665. SWC Moulton Pkwy CVS, L.L.C.
7666. SWC Progress Boulevard CVS,
L.L.C.
7667. SWC Union Hills Drive CVS,
L.L.C.
7668. Sylmar Square CVS, Inc.
7669. Synergy Merger, LLC
1759
WITH TECHNICAL CORRECTIONS 02.03.2023
J-111
7670. Syracuse Genesee St. CVS Store,
Inc.
7671. Systran Networks, Inc.
7672. T2 Medical, Inc.
7673. Tabernacle CVS, Inc.
7674. Taconic Park CVS Store, Inc.
7675. Taft Street CVS, Inc.
7676. Taft University CVS, Inc.
7677. Takoma Park CVS, Inc.
7678. Tamaqua CVS, Inc.
7679. Tampa Lynn CVS, Inc.
7680. Tanker Six, LLC
7681. Tanner Houston CVS, L.P.
7682. Tannersville CVS, Inc.
7683. Tara Boulevard CVS, Inc.
7684. Tarzana CVS, Inc.
7685. Taunton County CVS, Inc.
7686. Taunton Retailer, Inc.
7687. TCPI Acquisition Corp.
7688. TCPI Acquisition, LLC
7689. TDI Managed Care Services, Inc.
7690. Teasley Denton CVS, L.P.
7691. Telegraph CVS, Inc.
7692. Tennessee CVS Pharmacy, L.L.C.
7693. Terrace Oaks Houston CVS, L.P.
7694. Terrence D. Morton, Jr., MD, P.C.
7695. Tewksbury - Oaks, CVS., Inc.
7696. Tewksbury CVS, Inc.
7697. Texas Health + Aetna Health
Insurance Company
7698. Texas Health + Aetna Health
Insurance Holding Company LLC
7699. Texas Health + Aetna Health Plan
Inc.
7700. Texas Health Network, Inc.
7701. Texas Road CVS, Inc.
7702. The Associated Products Company
7703. The City CVS, Inc.
7704. The ETHIX Corporation
7705. The Jeskey Clinic, LLC
7706. The Lane Drug Company
7707. The Mall of Orange CVS, Inc.
7708. The New Group Health Plan, Inc.
7709. The Vasquez Group Inc.
7710. TheraCom, L.L.C.
7711. Third Avenue N.Y. CVS, Inc.
7712. Third Lake CVS, L.L.C.
7713. Third Party Claims Management,
Inc.
7714. Thomas 24th Phoenix CVS, L.L.C.
7715. Thomas 43rd Phoenix CVS, L.L.C.
7716. Thomas Avondale CVS, L.L.C.
7717. Thomas E. Emma CVS Store,
L.L.C.
7718. Thomas Phoenix CVS, L.L.C.
7719. Thomaston CVS, Inc.
7720. Thornbury CVS, Inc.
7721. Thorndale PA CVS, Inc.
7722. Thousand Oaks CVS, Inc.
7723. Three Forks Apothecary, LLC
7724. Thunderbird Phoenix CVS, L.L.C.
7725. Thundermist Aviation, Inc.
7726. Thundermist Services, LLC
7727. Tianjin An Hai Tai Hua Medical
Information Technology Co., Ltd
7728. Tinley Park CVS, L.L.C.
7729. Tinton Falls CVS, Inc.
7730. Titus Avenue CVS, Inc.
7731. Titusville CVS, L.L.C.
7732. Tiverton CVS, Inc.
7733. Tolland CVS, Inc.
7734. Tomball CVS, L.P.
7735. Tonawanda CVS, Inc.
7736. Toombs Avenue CVS, L.L.C.
7737. Topanga Canyon CVS, Inc.
7738. Torrance Blvd CVS, L.L.C.
7739. Torrance Western CVS, Inc.
7740. Torresdale CVS, Inc.
7741. Torrington Main Street CVS, Inc.
7742. Totowa CVS, Inc.
7743. Totowa Union CVS, Inc.
7744. Towamencin CVS, Inc.
7745. Towanda CVS, Inc.
7746. Tower CVS, Inc.
7747. Town Center CVS, Inc.
7748. Town Center Orlando CVS, L.L.C.
1760
WITH TECHNICAL CORRECTIONS 02.03.2023
J-112
7749. Town Plaza CVS, Inc.
7750. Towne Centre CVS, L.L.C.
7751. Towne Lake Parkway CVS, Inc.
7752. Township Line CVS, Inc.
7753. Towson CVS, Inc.
7754. Trappe CVS, Inc.
7755. Tree Merger Sub, Inc.
7756. Tremont Avenue Bronx CVS,
L.L.C.
7757. Tremont Boston CVS, Inc.
7758. Tremont CVS, Inc.
7759. Trenton CVS, Inc.
7760. Trevose Hospitality, Inc.
7761. Trumbull CVS, Inc.
7762. Trumbull Four, Inc.
7763. Trumbull One, Inc.
7764. Tucker CVS, Inc.
7765. Tucson AZ CVS, L.L.C.
7766. Turnpike Augusta CVS, Inc.
7767. Turnpike Street CVS, Inc.
7768. Tuscaloosa CVS, Inc.
7769. Twain MergerSub Corp.
7770. Twain MergerSub, L.L.C.
7771. Twenty Third Fairmount CVS, Inc.
7772. Twinsburg Claims, Inc.
7773. Twinsurance Limited
7774. Tyler Mall CVS, Inc.
7775. Tyler TX CVS, L.P.
7776. Tyrone CVS, Inc.
7777. U. S. Health Insurance Company
7778. U.S. Health Aviation Corp.
7779. U.S. Health Information Systems,
Inc.
7780. U.S. Health Insurance Company
7781. U.S. Healthcare Advantage, Inc.
7782. U.S. Healthcare Advantage, LLC
7783. U.S. Healthcare Dental Plan Inc.
7784. U.S. Healthcare Dental Plan, Inc.
7785. U.S. Healthcare Financial Services,
LLC
7786. U.S. Healthcare Holdings, LLC
7787. U.S. Healthcare of Georgia, Inc.
7788. U.S. Healthcare of New Hampshire,
Inc
7789. U.S. Healthcare of the Carolinas,
Inc.
7790. U.S. Healthcare of Washington Inc.
7791. U.S. Healthcare Properties, Inc.
7792. U.S. Healthcare, Inc.
7793. U.S. Healthcare, Inc. (Michigan)
7794. U.S. Managed Care, Inc.
7795. U.S. PatriotCare, Inc.
7796. U.S. Phoenix Corporation
7797. U.S. Quality Algorithms, Inc.
7798. UAC Holding, Inc.
7799. UC Acquisition Corp.
7800. UC Acquisition, LLC
7801. Ulster CVS Store, Inc.
7802. Uni-Care Health Services of Maine,
Inc.
7803. Uni-Care Health Services of Maine,
LLC
7804. Union Boulevard CVS, Inc.
7805. Union City CVS, Inc.
7806. Union Lehigh CVS, Inc.
7807. Union St. CVS, Inc.
7808. Uniontown CVS, Inc.
7809. United PharmaCare Services, L.P.
7810. United PM Services General, Inc.
7811. United PM Services Limited, Inc.
7812. United States Health Care System,
Inc.
7813. United States Health Care Systems
of Pennsylvania, Inc.
7814. United States Health Care Systems,
Inc.
7815. United States Home Health Care
Systems, Inc.
7816. United States Physicians Care
Systems, Inc.
7817. Universal American Corp.
7818. University CVS, Inc.
7819. University Drive-Amherst CVS,
Inc.
7820. University Mesa CVS, L.L.C.
1761
WITH TECHNICAL CORRECTIONS 02.03.2023
J-113
7821. University St. Paul CVS, L.L.C.
7822. University Tamarac CVS, L.L.C.
7823. University-Wheaton CVS, Inc.
7824. University-Wheaton Peoples, Inc.
7825. Upper Darby CVS, Inc.
7826. Upper Gwynedd CVS, Inc.
7827. Upper Hembree CVS, Inc.
7828. Upper Uwchlan CVS, Inc.
7829. US 19 Port Richey CVS, L.L.C.
7830. US Bioservices Corporation
7831. USHC Management Services
Corporation
7832. Utah CVS Pharmacy, L.L.C.
7833. Uvalde Houston CVS, L.P.
7834. Uxbridge CVS, Inc.
7835. V Memorial Houston CVS, L.P.
7836. Val Mesa Pharmacy, Inc.
7837. Valley Road CVS, Inc.
7838. Valley Verde NV CVS, L.L.C.
7839. Value Health Care Services LLC
7840. Van Buren Goodyear CVS, L.L.C.
7841. Van Houten CVS, Inc.
7842. Van Nuys Boulevard CVS, Inc.
7843. Vanoak Plaza CVS, Inc.
7844. VAPS Acquisition Company, LLC
7845. Vassar Poughkeepsie CVS, L.L.C.
7846. Vaughn Montgomery CVS, Inc.
7847. Vaughn Road CVS, Inc.
7848. Velmeir Euclid Co., L.L.C.
7849. Venice FL CVS, L.L.C.
7850. Vermont CVS Pharmacy, L.L.C.
7851. Vernon CVS, Inc.
7852. Vestal Ave. CVS Store, Inc.
7853. VHCS Acquisition Sub, LLC
7854. Victor Valley CVS, Inc.
7855. Victory Van Nuys CVS, L.P.
7856. Village Chestnut Hill CVS, Inc.
7857. Village Grove CVS, Inc.
7858. Village Plaza CVS, Inc.
7859. Villanova Street CVS, L.P.
7860. Vine & Taft CVS, Inc.
7861. Vineland CVS, Inc.
7862. Vinings Jubilee CVS, Inc.
7863. Virginia CVS Pharmacy, L.L.C.
7864. Virginia Mason Health Plan, Inc.
7865. Virtual Acute General Medical
PLLC
7866. Virtual Behavioral Health PLLC
7867. Virtual Primary Care PLLC
7868. Vista Health of South Florida, Inc.
7869. Vista Healthplan, Inc.
7870. Vital Care Infusions, Inc.
7871. VivaHealth, Incorporated
7872. Voorhees CVS, L.L.C.
7873. Vultee Street CVS, Inc.
7874. W. Imperial Hwy CVS, L.L.C.
7875. W. Mifflin CVS, Inc.
7876. W. Ponce DeLeon CVS, Inc.
7877. W. Redondo Beach Blvd CVS,
L.L.C.
7878. W. Springfield Elm CVS, Inc.
7879. Wade Hampton Blvd. CVS, Inc.
7880. Wadsworth CVS, Inc.
7881. Wadsworth High Street CVS, Inc.
7882. Wagaraw Road CVS, Inc.
7883. Wake Forest CVS, Inc.
7884. Wakefield CVS, Inc.
7885. Wakefield Mass. CVS, Inc.
7886. Waldorf MD CVS, L.L.C.
7887. Walkertown NC CVS, Inc.
7888. Wal-Lex CVS, Inc.
7889. Wallingford Acquisition, Inc.
7890. Wallingford CVS, Inc.
7891. Walmsley Blvd. Peoples, Inc.
7892. Walnut Garland CVS, L.P.
7893. Walnut Hill CVS, L.P.
7894. Walnut Hill Irving CVS, L.L.C.
7895. Walnut Hill Plaza CVS, Inc.
7896. Walnut Street CVS, Inc.
7897. Walpole CVS, Inc.
7898. Walpole Main Street CVS, Inc.
7899. Walpole Plaza CVS, Inc.
7900. Walters Houston CVS, L.P.
7901. Waltham CVS, Inc.
7902. Waltham-Moody CVS, Inc.
7903. Wappingers Falls CVS, L.L.C.
1762
WITH TECHNICAL CORRECTIONS 02.03.2023
J-114
7904. Ware CVS, Inc.
7905. Wareham CVS, Inc.
7906. Waretown CVS, L.L.C.
7907. Warm Springs Rainbow CVS,
L.L.C.
7908. Warm Springs Road CVS, L.L.C.
7909. Warminster CVS, Inc.
7910. Warminster, PA Bob's, Inc.
7911. Warner Higley Gilbert CVS, L.L.C.
7912. Warner Huntington CVS, L.P.
7913. Warner McQueen CVS, L.L.C.
7914. Warren Avenue CVS, Inc.
7915. Warren CVS, L.L.C.
7916. Warren R.I. CVS, Inc.
7917. Warrenville IL CVS, L.L.C.
7918. Warwick Centerville CVS, Inc.
7919. Warwick City Hall CVS, Inc.
7920. Warwick Main CVS, L.L.C.
7921. Warwick Neck CVS, Inc.
7922. Warwick NY CVS, L.L.C.
7923. Warwick Retailer, Inc.
7924. Warwick Shaw Plaza CVS, Inc.
7925. Warwick West Shore CVS, Inc.
7926. Washington Chicago CVS, L.L.C.
7927. Washington Connecticut CVS, Inc.
7928. Washington CVS Pharmacy, L.L.C.
7929. Washington E Street CVS, Inc.
7930. Washington Easton CVS, Inc.
7931. Washington GA CVS, L.L.C.
7932. Washington Lamb CVS, L.L.C.
7933. Washington Retailer, Inc.
7934. Washington Square CVS, Inc.
7935. Washington Wisconsin CVS, Inc.
7936. Water Street Fitchburg CVS, Inc.
7937. Waterbury Chase CVS, Inc.
7938. Waterbury West Main CVS, Inc.
7939. Waterbury Westwood CVS, Inc.
7940. Waterbury Wolcott CVS, Inc.
7941. Waterford Boston Post CVS, Inc.
7942. Watertower Plaza CVS, Inc.
7943. Watertown Main Street CVS, Inc.
7944. Waterville CVS, Inc.
7945. Waterville Valley CVS, Inc.
7946. Waterway Drive CVS, Inc.
7947. Waukegan CVS, L.L.C.
7948. Waverly Pharmacy, LLC
7949. Waverly TN CVS, Inc.
7950. Wayland CVS, Inc.
7951. Wayne Avenue CVS, Inc.
7952. Wayne CVS, Inc.
7953. Weber Medical Systems LLC
7954. Webster Avenue CVS, Inc.
7955. Webster Main St. CVS, Inc.
7956. Webster PharmaCare Pharmacy,
Inc.
7957. Webster TX CVS, L.P.
7958. Weddington NC CVS, Inc.
7959. Weir CanyonSerrano CVS, Inc.
7960. Wellesley CVS, Inc.
7961. Wellpartner, Inc.
7962. Wellpartner, LLC
7963. WellPath of South Carolina, Inc.
7964. WellPath Select Holding Company,
Inc.
7965. WellPath Select, Inc.
7966. Wesley Chapel CVS, L.L.C.
7967. West 14th Street CVS, L.L.C.
7968. West 235th Bronx CVS, L.L.C.
7969. West 42nd Street CVS, L.L.C.
7970. West Aspetuck CVS, Inc.
7971. West Avenue CVS, Inc.
7972. West Bancroft Toledo CVS, Inc.
7973. West Boylston CVS, Inc.
7974. West Bridgewater CVS, Inc.
7975. West Broad Street CVS, Inc.
7976. West Broad Street Peoples, Inc.
7977. West Broadway CVS, Inc.
7978. West Calhoun CVS, Inc.
7979. West Central Toledo CVS, Inc.
7980. West Chelten Avenue CVS, Inc.
7981. West Chester Pike CVS, Inc.
7982. West College Ave CVS, Inc.
7983. West Covina CVS, Inc.
7984. West Hartford Boulevard CVS, Inc.
7985. West Hartford CVS, Inc.
7986. West Hartford Route 4 CVS, Inc.
1763
WITH TECHNICAL CORRECTIONS 02.03.2023
J-115
7987. West Hubbard CVS, L.L.C.
7988. West Hunter Street CVS, L.L.C.
7989. West Jackson CVS, L.L.C.
7990. West Lemon CVS, Inc.
7991. West Main Freehold CVS, Inc.
7992. West Main Street CVS, Inc.
7993. West Miller CVS, Inc.
7994. West Newton Retailer, Inc.
7995. West Peabody CVS, Inc.
7996. West Pike Street CVS, L.L.C.
7997. West Roxbury CVS, Inc.
7998. West Springfield CVS, Inc.
7999. West Virginia CVS Pharmacy,
L.L.C.
8000. West Warwick CVS, Inc.
8001. West Warwick Main Street CVS,
Inc.
8002. West Warwick Providence CVS,
Inc.
8003. Westampton CVS, Inc.
8004. Westboro CVS, Inc.
8005. Westboro PharmaCare Pharmacy,
Inc.
8006. Westborough Computer Drive CVS,
Inc.
8007. Western Chic CVS, L.L.C.
8008. Western CVS, L.L.C.
8009. Western Reserve Health Plan, Inc.
8010. Western Reserve Individual
Practice Association, Inc.
8011. Westfield Franklin CVS, Inc.
8012. Westfield Little River CVS, Inc.
8013. Westfield Shops CVS, Inc.
8014. Westford CVS, Inc.
8015. Westhaven Services Co., LLC
8016. Westheimer Fondren CVS, L.P.
8017. Westheimer Houston CVS, L.P.
8018. Westland CVS, Inc.
8019. Westland MI CVS, L.L.C.
8020. Westminster Mall CVS, Inc.
8021. Westmont CVS, L.L.C.
8022. Weston Blatt CVS, L.L.C.
8023. Westwood CVS, Inc.
8024. Westwood Washington CVS, Inc.
8025. Wethersfield CVS, Inc.
8026. Weymouth Retailer, Inc.
8027. Whalley Avenue CVS, Inc.
8028. Whalon Street CVS, Inc.
8029. Wheaton CVS, L.L.C.
8030. White Bear Lake CVS, L.L.C.
8031. White Cross Stores Inc., No. 14
8032. White Lake CVS, Inc.
8033. White Plains Eastchester CVS, Inc.
8034. White Plains Lexington CVS, Inc.
8035. White Plains Retailer, Inc.
8036. Whitehall CVS, Inc.
8037. Whitestone CVS, L.L.C.
8038. Whitinsville CVS, Inc.
8039. Whitman Plaza CVS, Inc.
8040. Whitmore Lake CVS, Inc.
8041. Whitpain CVS, Inc.
8042. Whittier Blvd CVS, L.L.C.
8043. Whittier Colima CVS, Inc.
8044. Wilcrest Houston CVS, L.P.
8045. Wiles Road CVS, L.L.C.
8046. Williamsbridge Bronx CVS, L.L.C.
8047. Williamsburg CVS, Inc.
8048. Williamson Drug Company,
Incorporated
8049. Williamson Drug Company, LLC
8050. Willimantic Main Street CVS, Inc.
8051. Willingboro CVS, Inc.
8052. Willow Grove CVS, Inc.
8053. Willow Hoboken CVS, Inc.
8054. Wilmer Road CVS, L.L.C.
8055. Wilmington CVS, L.L.C.
8056. Wilmington Plaza CVS, Inc.
8057. Wilmore Washington CVS, L.L.C.
8058. Wilson Blvd. CVS, Inc.
8059. Wilson Boulevard CVS, Inc.
8060. Wilton CT CVS, Inc.
8061. Winchester CVS, Inc.
8062. Winchester Huntsville CVS, Inc.
8063. Winchester VA CVS, Inc.
8064. Wind Gap CVS, Inc.
8065. Windsor Broad Street CVS, Inc.
1764
WITH TECHNICAL CORRECTIONS 02.03.2023
J-116
8066. Windsor CVS, Inc.
8067. Windward Plaza CVS, Inc.
8068. Winfield CVS, L.L.C.
8069. Winsted CVS, Inc.
8070. Winter Park CVS, Inc.
8071. Winthrop CVS, Inc.
8072. Wisconsin Avenue CVS, Inc.
8073. Wisconsin CVS Pharmacy, L.L.C.
8074. Wise Avenue CVS, Inc.
8075. Wissahickon Payment
Administrators, Inc.
8076. Wisteria Drive Peoples, Inc.
8077. Woburn Centre CVS, Inc.
8078. Woburn Mall CVS, Inc.
8079. Wollaston Quincy CVS, Inc.
8080. Woodbridge CVS, Inc.
8081. Woodbury MN CVS, L.L.C.
8082. Woodbury/Red Bank CVS, Inc.
8083. Woodhaven CVS, Inc.
8084. Woodlawn Avenue CVS, Inc.
8085. Woodlawn Chicago CVS, L.L.C.
8086. Woodridge CVS, L.L.C.
8087. Woodruff Realty Associates, L.L.C.
8088. Woodruff Road CVS, Inc.
8089. Woodside CVS, L.L.C.
8090. Woodside NY CVS, L.L.C.
8091. Woodstock CVS, Inc.
8092. Woodstock CVS, L.L.C.
8093. Woodville CVS, Inc.
8094. Woodward Detroit CVS, L.L.C.
8095. Woodward Manalapan CVS, LL.C.
8096. Woodward Royal Oak CVS, L.L.C.
8097. Woolwich CVS, L.L.C.
8098. Woonsocket CVS, Inc.
8099. Woonsocket Prescription Center,
Incorporated
8100. Worcester - Food Village CVS, Inc.
8101. Worcester Center CVS, Inc.
8102. Worcester Park CVS, Inc.
8103. Worcester PharmaCare Pharmacy,
Inc.
8104. Worcester-June St. CVS, Inc.
8105. Worcester-Lincoln Plaza CVS, Inc.
8106. Worcester-Stafford CVS, Inc.
8107. Worcester-Tatnuck Square CVS,
Inc.
8108. Work & Family Benefits, Inc.
8109. Workers Comp Advantage, Inc.
8110. WP Smart Holdings, LLC
8111. Wrightstown CVS, Inc.
8112. Wrightwood Chicago CVS, L.L.C.
8113. Wylie CVS, L.P.
8114. Wyoming MI CVS, Inc.
8115. Yale Houston CVS, L.P.
8116. Yardley CVS, Inc.
8117. Yarmouth CVS, Inc.
8118. Yeadon (Pa.) CVS, Inc.
8119. Yonkers Bronx River CVS, L.L.C.
8120. Yonkers Central Park CVS, Inc.
8121. Yorba Linda CVS, Inc.
8122. York Mall CVS, Inc.
8123. York Road CVS, Inc.
8124. Ypsilanti Township CVS, L.L.C.
8125. Zephyrhills CVS, L.L.C.
8126. Zieglersville PA CVS, Inc.
8127. Zinc Health Services, LLC
8128. Zinc Health Ventures, LLC
8129. Zion IL CVS, L.L.C.
8130. ZS Acquisition Company, LLC
1765
WITH TECHNICAL CORRECTIONS 02.03.2023
K-1

EXHIBIT K
Subdivision Participation and Release Form
Governmental Entity: State:

Authorized Official:

Address 1:

Address 2:

City, State, Zip:

Phone:

Email:

The governmental entity identified above (“Governmental Entity”), in order to obtain and in consideration for the benefits provided to the Governmental Entity pursuant to the Settlement Agreement dated December 9, 2022 (“CVS Settlement ”), and acting through the undersigned authorized official, hereby elects to participate in the CVS Settlement, release all Released Claims against all Released Entities, and agrees as follows.

1. The Governmental Entity is aware of and has reviewed the CVS Settlement, understands that all terms in this Participation and Release Form have the meanings defined therein, and agrees that by executing this Participation and Release Form, the Governmental Entity elects to participate in the CVS Settlement and become a Participating Subdivision as provided therein.

2. The Governmental Entity shall promptly, and in any event no later than 14 days after the Reference Date and prior to the filing of the Consent Judgment, dismiss with prejudice any Released Claims that it has filed. With respect to any Released Claims pending in In re National Prescription Opiate Litigation , MDL No. 2804, the Governmental Entity authorizes the Plaintiffs’ Executive Committee to execute and file on behalf of the Governmental Entity a Stipulation of Dismissal with Prejudice substantially in the form found at [website link to national settlement website to be provided].

3. The Governmental Entity agrees to the terms of the CVS Settlement pertaining to Participating Subdivisions as defined therein.

4. By agreeing to the terms of the CVS Settlement and becoming a Releasor, the Governmental Entity is entitled to the benefits provided therein, including, if applicable, monetary payments beginning after the Effective Date.

5. The Governmental Entity agrees to use any monies it receives through the CVS Settlement solely for the purposes provided therein.

6. The Governmental Entity submits to the jurisdiction of the court in the Governmental Entity’s state where the Consent Judgment is filed for purposes limited to that court’s role as provided in, and for resolving disputes to the extent provided in, the CVS Settlement.

The Governmental Entity likewise agrees to arbitrate before the National Arbitration Panel 1766
WITH TECHNICAL CORRECTIONS 02.03.2023
2 as provided in, and for resolving disputes to the extent otherwise provided in, the CVS Settlement.

7. The Governmental Entity has the right to enforce the CVS Settlement as provided therein.

8. The Governmental Entity, as a Participating Subdivision, hereby becomes a Releasor for all purposes in the CVS Settlement, including without limitation all provisions of Section XI (Release), and along with all departments, agencies, divisions, boards, commissions, districts, instrumentalities of any kind and attorneys, and any person in their official capacity elected or appointed to serve any of the foregoing and any agency, person, or other entity claiming by or through any of the foregoing, and any other entity identified in the definition of Releasor, provides for a release to the fullest extent of its authority. As a Releasor, the Governmental Entity hereby absolutely, unconditionally, and irrevocably covenants not to bring, file, or claim, or to cause, assist or permit to be brought, filed, or claimed, or to otherwise seek to establish liability for any Released Claims against any Released Entity in any forum whatsoever. The releases provided for in the CVS Settlement are intended by the Parties to be broad and shall be interpreted so as to give the Released Entities the broadest possible bar against any liability relating in any way to Released Claims and extend to the full extent of the power of the Governmental Entity to release claims. The CVS Settlement shall be a complete bar to any Released Claim.

9. The Governmental Entity hereby takes on all rights and obligations of a Participating Subdivision as set forth in the CVS Settlement.

10. In connection with the releases provided for in the CVS Settlement, each Governmental Entity expressly waives, releases, and forever discharges any and all provisions, rights, and benefits conferred by any law of any state or territory of the United States or other jurisdiction, or principle of common law, which is similar, comparable, or equivalent to § 1542 of the California Civil Code, which reads:

General Release; extent. A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release that, if known by him or her would have materially affected his or her settlement with the debtor or released party.

A Releasor may hereafter discover facts other than or different from those which it knows, believes, or assumes to be true with respect to the Released Claims, but each Governmental Entity hereby expressly waives and fully, finally, and forever settles, releases and discharges, upon the Effective Date, any and all Released Claims that may exist as of such date but which Releasors do not know or suspect to exist, whether through ignorance, oversight, error, negligence or through no fault whatsoever, and which, if known, would materially affect the Governmental Entities’ decision to participate in the CVS Settlement.

11. Nothing herein is intended to modify in any way the terms of the CVS Settlement, to which Governmental Entity hereby agrees. To the extent this Participation and Release Form is 1767
WITH TECHNICAL CORRECTIONS 02.03.2023
3 interpreted differently from the CVS Settlement in any respect, the CVS Settlement controls.

I have all necessary power and authorization to execute this Participation and Release Form on behalf of the Governmental Entity.

Signature: _____________________________
Name: _____________________________
Title: _____________________________
Date: _____________________________
1768
WITH TECHNICAL CORRECTIONS 02.03.2023
L-1

EXHIBIT L
Settlement Fund Administrator Terms
[Exhibit to be inserted prior to the Initial Subdivision Participation Date] 1769
WITH TECHNICAL CORRECTIONS 02.03.2023
M1-1
EXHIBIT M-1: PAYMENT SCHEDULE
Payment Year Maximum
Additional
Remediation
Amount & All
Attorneys’ Fees
& Costs Funds
(Includes CB
Fee on Credits)
Maximum
Base
Payments
(38%)
Maximum
Incentive
Payment A
(62%)
Maximum
Incentive
Payment B
(28%)
Maximum
Incentive
Payment C
(28%)
Maximum
Incentive
Payment D
@ 6%
Maximum
Total
Remediation
Maximum
Overall
Total
Year 1
June 30, 2023
$125,329,964 $306,016,374 --- --- --- --- $306,016,374 $431,346,338 Year 2
June 30, 2024
$113,977,078 $81,058,849 $162,912,910 $81,456,455 $81,456,455 --- $243,971,759 $357,948,837 Year 3
June 30, 2025
$128,577,766 $161,989,258 $325,567,678 $162,783,839 $162,783,839 --- $487,556,936 $616,134,702 Year 4
June 30, 2026
$128,577,766 $161,989,258 $325,567,678 $162,783,839 $162,783,839 --- $487,556,936 $616,134,702 Year 5
June 30, 2027
$128,577,767 $161,989,258 $325,567,678 $162,783,839 $162,783,839 --- $487,556,936 $616,134,703 Year 6
June 30, 2028
--- $161,989,257 $325,567,679 $137,108,875 $137,108,874 $51,349,930 $487,556,936 $487,556,936 Year 7
June 30, 2029
--- $153,896,217 $309,302,202 $128,976,136 $128,976,136 $51,349,930 $463,198,419 $463,198,419 Year 8
June 30, 2030
--- $145,803,177 $293,036,724 $120,843,397 $120,843,397 $51,349,930 $438,839,901 $438,839,901 Year 9
June 30, 2031
--- $145,674,735 $292,778,585 $120,714,327 $120,714,328 $51,349,930 $438,453,320 $438,453,320 Year 10
June 30, 2032
--- $145,674,735 $292,778,585 $120,714,328 $120,714,327 $51,349,930 $438,453,320 $438,453,320 Total $625,040,341 $1,626,081,118 $2,653,079,719 $1,198,165,035 $1,198,165,034 $256,749,650 $4,279,160,837 $4,904,201,178 1770
WITH TECHNICAL CORRECTIONS 02.03.2023
M1-2
NOTES:

1. The Maximum Additional Remediation Amount and the state and subdivision attorneys’ fees and costs amounts are broken out into separate columns in Exhibit M-3. All payments shown in this schedule are maximum figures.

2. All annual and total figures for Maximum Additional Remediation Amount & All Attorneys’ Fees & Costs Fund are maximum figures that may never be exceeded. They are subject to reduction as set forth in the Agreement and its exhibits.

3. All annual and total figures for Maximum Base Payment, Maximum Incentive Payment A, Maximum Incentive Payment B, and Maximum Incentive Payment C are maximum figures that may never be exceeded and reflect the following:
- An assumption that all Eligible States are Settling States. - An assumption that all Settling States earn the full amount of the relevant incentive payment. - The figures are subject to reduction as set forth in the Agreement.

4. All annual and total figures for Maximum Incentive Payment D are maximum figures that reflect the following:
- An assumption that all Eligible States are Settling States. - An assumption that all Settling States earn 100% of Incentive Payment C and hence the full amount of D at a value of 6%. - Exhibit M-2 shows maximums based on Incentive Payment D values higher than 6% if Incentive Payment C is not earned in full.

As set forth in the Agreement and Exhibit M-2, any Incentive Payments D at values higher than 6% for a Settling State must be offset in full by corresponding reductions to Incentive Payment C for that Settling State in prior Payment Years and the same Payment Year, resulting in zero increase to the total Maximum Total Remediation amount ($4,279,160,837) and the total Maximum Overall Total amount ($4,904,201,178).
- The figures are subject to reduction as set forth in the Agreement.

5. All annual and total figures for Maximum Total Remediation and Maximum Overall Total are maximum payments that reflect the following:
- The credit amount of $117,882,400 for prior settlements has already been applied. - An assumption that all Eligible States are Settling States. - An assumption that all Settling States earn their full potential maximum amount of the Maximum Total Remediation through either Incentive Payment A, or Incentive Payments B, C, and D with Incentive Payment D at a value of 6%. - All annual and total figures for Maximum Total Remediation and Maximum Overall Total may never be exceeded with the sole and exclusive exception of the annual amounts for Years 6-10, which may increase based on Incentive Payment D as set forth in Exhibit M-2 when Incentive Payment C is not earned in full. Any such increases must be offset in full by corresponding reductions to Incentive Payment C in prior Payment Years and the same Payment Year for that Settling State, resulting in zero increase to the total Maximum Total Remediation amount ($4,279,160,837) and the total Maximum Overall Total amount ($4,904,201,178). - Exhibit M-2 shows maximums based on Incentive Payment D values higher than 6%. - The figures are subject to reduction as set forth in the Agreement.

6. Any offsets for Eligible States that are Non-Settling States would be deducted from Maximum Base Payment, Maximum Incentive Payment A, Maximum Incentive Payment B, Maximum Incentive Payment C, Maximum Incentive Payment D, and Maximum Total Remediation by 1771
WITH TECHNICAL CORRECTIONS 02.03.2023
M1-3
subtracting from all annual and total payments the amount of the payment times the Overall Allocation Percentage assigned to each Non- Settling State in Exhibit F-2.
1772
WITH TECHNICAL CORRECTIONS 02.03.2023
M2-1
EXHIBIT M-2: INCENTIVE D PAYMENT RANGE SCHEDULE
Payment Year
Incentive Payment
D
(6%-15%)
Total
Remediation
Maximum if
All Eligible
States Obtain
Incentive D
at 6%
Maximum if
All Eligible
States Obtain
Incentive D
at 15%
Maximum if
All Eligible
States Obtain
Full Potential
with Incentive
D at 6%
Maximum if
All Eligible
States Obtain
Full Potential
with Incentive
D at 14.4%
Year 6
June 30, 2028
$51,349,930 $128,374,825 $487,556,936 $518,314,175
Year 7
June 30, 2029
$51,349,930 $128,374,825 $463,198,419 $496,395,480
Year 8
June 30, 2030
$51,349,930 $128,374,825 $438,839,901 $474,476,784
Year 9
June 30, 2031
$51,349,930 $128,374,825 $438,453,320 $474,128,924
Year 10
June 30, 2032
$51,349,930 $128,374,826 $438,453,320 $474,128,924
Total
(Years 1-10) $256,749,650 $641,874,126 $4,279,160,837 $4,279,160,837 NOTES:

1. The ranges for Incentive Payment D show the amount earned based on all Settling States obtaining its minimum value of 6% and its maximum value of 15%, and reflect the following:
- An assumption that all Eligible States are Settling States. - An assumption that all Settling States qualify for Incentive Payment D. - The high end of the annual and total ranges for Incentive Payment D may never be exceeded and assume that all Settling States earn the full amount of the Total Remediation that they are eligible to receive by achieving, among other incentives, Incentive Payment D at a value of 14.4%. (The Incentive Payment C and Incentive Payment D payment tables do not allow Settling States earning Incentive Payment D at a value of 15% to earn their full potential amount of the Total Remediation.) - Any increase above the low end of the annual and total ranges for Incentive Payment D must be offset in full by corresponding reductions to Incentive Payment C in prior Payment Years and the same Payment Year, resulting in zero increase to the total Maximum Total Remediation amount ($4,279,160,837) and the total Maximum Overall Total amount ($4,904,201,178). 1773
WITH TECHNICAL CORRECTIONS 02.03.2023
M2-2
- The total Maximum Total Remediation amount ($4,279,160,837) and total Maximum Overall Total amount ($4,904,201,178) may never be exceeded and do not change regardless if all Settling States earn their full potential amount of the total Maximum Total Remediation through Incentive Payment D at a value of 6% or at a value of 14.4%. - The amounts are subject to reduction as set forth in the Agreement.

2. All ranges for Total Remediation payments reflect the following:
- The credit amount of $117,882,400 for prior settlements has already been applied. - An assumption that all Eligible States are Settling States. - The low end of the ranges assume that all Settling States earn their full potential amount of the Total Remediation through 100 percent of Incentive Payment B, 100 percent of Incentive Payment C, and thus Incentive Payment D at a value of 6%. - The high end of the annual ranges may never be exceeded and assume that all Settling States earn the full amount of the Total Remediation that they are eligible to receive by achieving, among other incentives, Incentive Payment D at a value of 14.4%. (The Incentive Payment C and Incentive Payment D payment tables do not allow Settling States earning Incentive Payment D at a value of 15% to earn their full potential amount of the Total Remediation.) - Any increase above the low end of the annual ranges must be offset in full by corresponding reductions to Incentive Payment C in prior Payment Years and the same Payment Year, resulting in zero increase to the total Maximum Total Remediation amount ($4,279,160,837) and the total Maximum Overall Total amount ($4,904,201,178). - The total Maximum Total Remediation amount ($4,279,160,837) and total Maximum Overall Total amount ($4,904,201,178) may never be exceeded and do not change regardless if all Settling States earn their full potential amount of the total Maximum Total Remediation through Incentive Payment D at a value of 6% or at a value of 14.4%. - The amounts are subject to reduction as set forth in the Agreement.

3. Any offsets for Eligible States that are Non-Settling States would be deducted from the Incentive Payment D and Total Remediation by subtracting from all payments the amount of the payment times the Overall Allocation Percentage assigned to each Non-Settling State in Exhibit F-2.
1774
WITH TECHNICAL CORRECTIONS 02.03.2023
M3-1
EXHIBIT M-3: PAYMENT SCHEDULE FOR FEE FUNDS, COST FUNDS AND ADDITIONAL REMEDIATION (Breakdown of Second Column in Exhibit M-1)
Payment
Year
Maximum
Exhibit R
Attorney Fee
Funds
Exhibit R
Attorney
Cost Funds
Common
Benefit Fee
on Credits
State Cost
Fund
Maximum
State Outside
Counsel Fee
Fund
Maximum
Additional
Remediation
Amount
Maximum
Total
(Shown in Ex.

M-1, 2nd
Column)
Year 1
June 30,
2023
$91,298,571 $15,000,000 $1,914,750 $9,509,246 $3,803,699 $3,803,698 $125,329,964 Year 2
June 30,
2024
$80,678,256 $15,000,000 $1,182,179 $9,509,246 $3,803,698 $3,803,699 $113,977,078 Year 3
June 30,
2025
$109,546,373 --- $1,914,750 $9,509,247 $3,803,698 $3,803,698 $128,577,766 Year 4
June 30,
2026
$109,546,372 --- $1,914,750 --- $8,558,322 $8,558,322 $128,577,766 Year 5
June 30,
2027
$109,546,372 --- $1,914,751 --- $8,558,322 $8,558,322 $128,577,767 Total $500,615,944 $30,000,000 $8,841,180 $28,527,739 $28,527,739 $28,527,739 $625,040,341 1775
WITH TECHINICAL CORRECTIONS 02.02.2023
N-1

EXHIBIT N
Additional Remediation Amount Allocation Percentages
Alabama 2.0094047523%
American Samoa 0.0215590674%
Arizona 2.9911870812%
California 12.4923284542%
Colorado 2.0922099886%
Connecticut 1.6290775863%
District of Columbia 0.2266153628%
Georgia 3.5107212404%
Guam 0.0604844794%
Hawaii 0.4087756176%
Idaho 0.6193769970%
Illinois 4.1882957440%
Indiana 2.7913607538%
Iowa 0.9341820978%
Kansas 0.9872591950%
Louisiana 1.8447419766%
Maine 0.6664875621%
Maryland 2.6575348718%
Massachusetts 2.9005058228%
Minnesota 1.6334209688%
Missouri 2.5253744735%
Montana 0.3935393398%
N. Mariana Islands 0.0210349545%
Nebraska 0.5252526469%
New Jersey 3.4690785339%
New York 6.7872003052%
North Carolina 4.0924962523%
North Dakota 0.2140841267%
Ohio 5.4856657801%
Oklahoma 1.9292810204%
Oregon 1.7302239375%
Pennsylvania 5.7772011360%
Rhode Island 0.5622563667%
South Carolina 1.9381920268%
Tennessee 3.3847318704%
Texas 7.9239877394%
1776
WITH TECHINICAL CORRECTIONS 02.02.2023
N-2
Vermont 0.3204352512%
Virgin Islands 0.0397474619%
Virginia 2.8709652916%
Washington 2.9198056809%
Wisconsin 2.2138760297%
Wyoming 0.2100401547%
1777
WITH TECHNICAL CORRECTIONS 02.03.2023
O-1

EXHIBIT O
Adoption of a State-Subdivision Agreement
A State-Subdivision Agreement shall be applied if it meets the requirements of Section V and is approved by the State and by the State’s Subdivisions as follows:

1. Requirements for Approval. A State-Subdivision Agreement shall be deemed as agreed to when it has been approved by the State and either (a) Subdivisions whose aggregate “Population Percentages,” determined as set forth below, total more than sixty percent (60%), or (b) Subdivisions whose aggregate Population Percentages total more than fifty percent (50%) provided that these Subdivisions also represent fifteen percent (15%) or more of the State’s counties or parishes (or, in the case of Settling States whose counties and parishes do not function as local governments, 15% of or more of the Settling State’s non-county Subdivisions), by number.

2. Approval Authority. Approval by the State shall be by the Attorney General. Approval by a Subdivision shall be by the appropriate official or legislative body pursuant to the required procedures for that Subdivision to agree to a legally binding settlement.

3. Population Percentage Calculation . For purposes of this Exhibit O only, Population Percentages shall be determined as follows: For States with functional counties or parishes1 the Population Percentage of each county or parish shall be deemed to be equal to (a) (1) two hundred percent (200%) of the population of such county or parish, minus (2) the aggregate population of all Primary Incorporated Municipalities located in such county or parish, divided by (b) two hundred percent (200%) of the State’s population. A “Primary Incorporated Municipality” means a city, town, village or other municipality incorporated under applicable state law with a population of at least 25,000 that is not located within another incorporated municipality. The Population Percentage of each Primary Incorporated Municipality shall be equal to its population (including the population of any incorporated or unincorporated municipality located therein) divided by two hundred percent (200%) of the State’s population; provided that the Population Percentage of a Primary Incorporated Municipality that is not located within a county shall be equal to two hundred percent (200%) of its population (including the population of any incorporated or unincorporated municipality located therein) divided by two hundred percent (200%) of the State’s population. For all States that do not have functional counties or parishes, the Population Percentage of each non-county Subdivision (including any incorporated or unincorporated municipality located therein), shall be equal to its population divided by the State’s population.

4. Preexisting Agreements and Statutory Provisions . A State may include with the notice to its Subdivisions an existing agreement, a proposed agreement, or statutory provisions regarding the distribution and use of settlement funds and have the acceptance of such an agreement or 1 Certain states do not have counties or parishes that have functional governments, including Alaska, Connecticut, Massachusetts, Rhode Island, and Vermont.
1778
WITH TECHNICAL CORRECTIONS 02.03.2023
O-2
statutory provision be part of the requirements to be an Initial Participating Subdivision.

5. Revised Agreements. A State-Subdivision Agreement that has been revised, supplemented, or refined shall be applied if it meets the requirements of Section V and is approved by the State and by the State’s Subdivisions pursuant to the terms above. 1779
WITH TECHNICAL CORRECTIONS 02.03.2023
P-1

EXHIBIT P
CVS Pharmacy Inc. Injunctive Terms
I. INTRODUCTION

1. Except where these Injunctive Terms specify a different implementation period, CVS Pharmacy, Inc. (“Settling Pharmacy”) shall implement the Injunctive Terms set forth below in Sections II through XVII by the Injunctive Terms Implementation Date (defined below).

2. To the extent that Settling Pharmacy already have in place positions, committees, departments, policies or programs that satisfy the Injunctive Terms, no re-naming or other change is required by these Injunctive Terms.

3. Overview
a. Settling Pharmacy will implement or maintain a Controlled Substance Dispensing Oversight Program (“CSDOP”).
b. The CSDOP must include written standard operating procedures and/or corporate policies (the “CSDOP Policies and Procedures”) required by these Injunctive Terms.
c. The CSDOP shall apply during the term of these Injunctive Terms, to each of Settling Pharmacy’s retail pharmacy stores that dispense Schedule II Designated Controlled Substances and are registered or licensed with each Settling State.
d. Settling Pharmacy shall provide a copy of the relevant CSDOP Policies and Procedures to each Settling State within 60 days of the Injunctive Terms Implementation Date. To the extent any implementation is expected to require additional time, the Parties agree to work together in good faith to establish a timeline for implementation. No later than 30 days after the Injunctive Terms Implementation Date, each Settling State shall identify the person or office to whom Settling Pharmacy must provide a copy of the relevant CSDOP Policies and Procedures and any other State-specific reporting required under these Injunctive Terms.
e. Settling States shall form the States Injunctive Relief Committee to serve as a point of contact for Settling Pharmacy and to perform such other roles as set forth herein. Upon the committee’s formation, Settling States shall provide notice to Settling Pharmacy of the members of the committee. 1780
WITH TECHNICAL CORRECTIONS 02.03.2023
P-2

4. Compliance with Laws
a. Each Settling Pharmacy acknowledges and agrees that its pharmacies must comply with applicable state and federal laws, regulations, and rules, including those regarding the dispensing of Controlled Substances. The requirements of these Injunctive Terms are in addition to, and not in lieu of, any other requirements of federal, state, or local law. Nothing in the Injunctive Terms shall be construed as relieving the Settling Pharmacy of the obligation of their pharmacies to comply with all federal, state and local laws, regulations or rules, nor shall any of the provisions of the Injunctive Terms be deemed as permission for Settling Pharmacy to engage in any acts or practices prohibited by such laws, regulations or rules.
b. The Injunctive Terms are not intended to and shall not be interpreted to prevent Settling Pharmacy from taking or implementing any other compliance or policy steps that are more restrictive or that are necessary to conform with federal, state, or local legal requirements, unless such steps would conflict with State or local law. The Injunctive Terms are not intended to and shall not be interpreted to require Settling Pharmacy to inventory any Controlled Substances or any particular Controlled Substances or to require dispensing of any Controlled Substances or of any individual, types, subsets or categories of Controlled Substances prescriptions.
c. In the event that a Settling Pharmacy determines that there may be a conflict between the Injunctive Terms and the express requirements of federal, state, or local laws, or interpretations of such laws articulated by an agency responsible for enforcing such laws or a court (“Express Interpretations”), such that the Settling Pharmacy determines that it cannot comply with the Injunctive Terms without violating these express requirements or Express Interpretations, Settling Pharmacy shall follow the express requirements of the federal, state or local law or Express Interpretation thereof and shall provide notice to the Settling State(s). Within thirty (30) days after receipt of a notification from a Settling Pharmacy referenced above, the Settling Pharmacy and the State shall meet and discuss the potential conflict, and the Settling Pharmacy shall comply with any reasonable requests from the Settling State as necessary to determine whether there is a conflict between the Injunctive Terms and the express requirements of federal, state, or local laws, or Express Interpretations. In the event that a Settling Pharmacy believes a court or administrative action brought by a governmental body in a Settling State has commenced against it or its pharmacists for actions required by the Injunctive Terms, then the Settling Pharmacy may notify the Attorney General of the Settling State of such pending action. If the State agrees that the court or administrative action is a result of actions required by the Injunctive Terms, the State will engage in best efforts to resolve the conflict or assist in achieving resolution of the court or 1781
WITH TECHNICAL CORRECTIONS 02.03.2023
P-3
administrative action. Nothing in this paragraph shall (i) limit the right of the Settling State to disagree with a Settling Pharmacy as to the conflict; (ii) be deemed to relieve a Settling Pharmacy from following any subsequently enacted law or regulation, or judicial decisions from a regulatory authority with jurisdiction over controlled substances that is more restrictive than the provisions of the Injunctive Terms; (iii) or from following the Injunctive Terms if they are more restrictive than applicable laws at issue in the administrative action if there is no conflict; (iv) be deemed to relieve a Settling Pharmacy from adhering to the outcome of a court or administrative determination that there is no conflict; or (v) limit a Settling State’s ability to relieve a Settling Pharmacy of a duty under these Injunctive Terms if that Settling State determines that that term is in conflict with that Settling State’s express legal requirements. d. A Settling Pharmacy shall retain all records it is required to create pursuant to its obligations hereunder for a period no shorter than three years, unless otherwise specified. Nothing in these Injunctive Terms shall prevent a Settling State from issuing a lawful subpoena or Civil Investigative Demand (CID) for records pursuant to an applicable law.

5. No Admission and No Use as Evidence. Settling Pharmacy do not admit liability or wrongdoing. These Injunctive Terms shall not be considered, construed, or represented to be (1) an admission, concession, or evidence of liability, wrongdoing, or the existence of any legal obligations or requirements other than the requirement to follow these Injunctive Terms, (2) an admission, concession or evidence of the reach, requirements, meaning or interpretation of any statute or regulation, or (3) a waiver or limitation of any defense otherwise available to Settling Pharmacy. These Injunctive Terms shall not be offered or received in evidence or otherwise relied on in any action or proceeding for any purpose other than in an action or proceeding to modify or enforce or monitor compliance with these Injunctive Terms.

II. TERM AND SCOPE

1. The term of these Injunctive Terms shall be from the Injunctive Terms Implementation Date until August 15, 2032, unless otherwise specified herein.

2. Except as otherwise stated herein, the Injunctive Terms shall apply to Settling Pharmacy’s retail pharmacy stores located in, and registered or licensed with, each Settling State that dispense Schedule II Designated Controlled Substances to Patients, including any Schedule II Designated Controlled Substances dispensed by any such retail pharmacy stores that are mailed or shipped to patients in a Settling State. Should Settling Pharmacy operate an online pharmacy that is registered or licensed to dispense Schedule II Designated Controlled Substances in any Settling State while these 1782
WITH TECHNICAL CORRECTIONS 02.03.2023
P-4
Injunctive Terms are in effect, the Injunctive Terms shall apply to such pharmacy as well.1

3. This agreement may be amended by mutual agreement of a majority of the States Injunctive Relief Committee and Settling Pharmacy. Any such amendments must be in writing.

III. DEFINITIONS

1. The term “Distributor Injunctive Terms” means Exhibit P of the Settlement Agreement, dated as of July 21, 2021, between McKesson Corporation, Cardinal Health, Inc., and AmerisourceBergen Corporation and certain States and subdivisions.

2. The term “Block” means an action taken by Settling Pharmacy preventing or otherwise prohibiting any Settling Pharmacy pharmacist from filling prescriptions for Controlled Substances from a specific identified Prescriber.

3. The term “Clearinghouse” means the system established by Section XVII of the Distributor Injunctive Terms.

4. The term “Clearinghouse Advisory Panel” is as defined in Section XVII.B.4 of the Distributor Injunctive Terms.

5. The term “Controlled Substances” means those substances designated under schedules II-V pursuant to the federal Controlled Substances Act.

6. The term “Designated Controlled Substances” shall be limited to: (a) oxycodone; (b) hydrocodone; (c) hydromorphone; (d); tramadol; (e) oxymorphone; (f) morphine; (g) methadone; and (h) fentanyl.

7. The term “Injunctive Terms Implementation Date” means 30 days after the Effective Date of the Settlement Agreement [as defined in Section TK of the full Agreement].

8. The term “National Arbitration Panel” is defined in Section TK of [title of full Agreement].

9. The term “Patient” means any individual who receives a prescription for a Designated Controlled Substance from a Prescriber, whether legally valid or not, and attempts to fill it at one of a Settling Pharmacy’s retail pharmacy stores in a Settling State.

10. The term “Prescriber” means any individual that has written a prescription for a Designated Controlled Substance, whether legally valid or not, that is presented to a Settling Pharmacy in a Settling State.
1 Caremark specialty and mail order pharmacies are not subject to, and are not online pharmacies for purposes of, these Injunctive Terms.
1783
WITH TECHNICAL CORRECTIONS 02.03.2023
P-5

11. The term “Red Flag(s)” means the enumerated Patient Red Flags, Prescription Red Flags, and Prescriber Red Flags set out in Section IX.

12. The term “Settling State(s)” means each State that is a signatory to [Title of Full Agreement].

13. The term “States Injunctive Relief Committee” means a committee representing the Settling States composed of between four and eight members designated by the Settling States. The members of the States Injunctive Relief Committee shall be employees of a Settling State’s Office of Attorney General and/or employees of another agency of a Settling State and may not include special assistant attorneys general, contractors, outside counsel, or other non-employees delegated official functions.

IV. CONTROLLED SUBSTANCE OVERSIGHT PERSONNEL

1. Settling Pharmacy shall designate a Chief Pharmacy Controlled Substances Officer, or other appropriately titled position, to be a member of the Controlled Substance Oversight Committee (described below in Section VI), and to oversee a Controlled Substance Professional Practices Department and Settling Pharmacy’s compliance with 21 C.F.R. 1306.04 and these Injunctive Terms. As used in these Injunctive Terms, the terms “Controlled Substance Oversight Committee” and “Controlled Substance Professional Practices Department” refer to the entity or entities, however titled, that carry out the functions required by these Injunctive Terms. Notwithstanding the preceding sentence, to the extent an existing position, committee or department carries out the functions required by these Injunctive Terms, any other functions undertaken by such position, committee or department shall not be subject to these Injunctive Terms or oversight by the Settling States pursuant to these Injunctive Terms. The position, committee and department discussed in these Terms may bear different names and need not be limited to the roles and functions set forth herein.

2. The Chief Pharmacy Controlled Substances Officer shall have knowledge of and experience with the laws and regulation of Controlled Substances, in particular the regulations in 21 C.F.R. 1306.04.

3. The Chief Pharmacy Controlled Substances Officer shall provide at least quarterly reports to the Controlled Substance Oversight Committee (described below in Section VI) regarding Settling Pharmacy’s compliance with these Injunctive Terms, including the implementation of any changes to the CSDOP Policies and Procedures required by these Injunctive Terms.

4. Staffing levels of Settling Pharmacy’s Controlled Substance Professional Practices Department shall be reviewed periodically, but at least on an annual basis, by Settling Pharmacy’s Controlled Substance Oversight Committee to assess whether such staffing levels are sufficient for the Controlled Substance Professional Practices Department to comply with this Agreement. This review shall include consideration of relevant developments in technology, law, and regulations.
1784
WITH TECHNICAL CORRECTIONS 02.03.2023
P-6

5. Throughout the term of these Injunctive Terms, Settling Pharmacy shall maintain a telephone and electronic submission hotline(s) (the “Hotline”) to permit employees and/or Patients and/or members of the public to anonymously report suspected inappropriate or illegitimate dispensing, prescribing or diversion of Designated Controlled Substances, violations of the CSDOP Policies and Procedures, these Injunctive Terms, Settling Pharmacy’s company policy, or other applicable law. The Hotline may be implemented by adding a dedicated option to existing systems that includes reporting regarding Designated Controlled Substances. Settling Pharmacy shall publish their Hotline contact information to its employees and Patients in the Settling States. Settling Pharmacy shall maintain for the duration of Injunctive Terms a record of each complaint made to the Hotline regarding Designated Controlled Substances and documentation regarding any investigation or response to such complaints. Nothing herein shall require Settling Pharmacy to investigate a pharmacist’s professional judgment to refuse a prescription that the pharmacist believes was prescribed or is being used for other than a legitimate medical purpose or that the pharmacist believes was not prescribed by an individual Prescriber acting in the usual course of his or her professional practice.

V. INDEPENDENCE

1. Settling Pharmacy’s Controlled Substance Professional Practices Department personnel, pharmacists and pharmacist technicians who work at Settling Pharmacy’s pharmacies within the Settling States, and field personnel who supervise pharmacists and pharmacist technicians (together, “CSDOP Employees”), shall not be compensated in whole or in part by commissions, bonuses, incentives or any other monetary or non- pecuniary benefit that depends in material part on revenue or profitability targets or expectations to sales of Controlled Substances. Nothing in these Injunctive Terms shall be interpreted to prevent compensation of employees based on sales volume, revenue or profitability targets/expectations for enterprise-, store-, or pharmacy-wide sales that include Controlled Substances.

2. No CSDOP Employees may be terminated, suspended, threatened with or face any other negative employment consequence for failing to meet any revenue or profitability targets or expectations that depends in material part on sales of Controlled Substances.

Nothing in these Injunctive Terms shall be interpreted to prevent Settling Pharmacy from taking employment action based on sales volume, revenue or profitability targets/expectations for enterprise-, store-, or pharmacy-wide sales that include Controlled Substances.

3. Personnel in Settling Pharmacy’s Controlled Substance Professional Practices Department shall not report to Settling Pharmacy’s sales, marketing, or business development departments, and sales, marketing, or business development departments shall not be authorized to make decisions regarding the promotion, compensation, demotion, admonition, discipline, commendation, periodic performance reviews, hiring, or firing of Controlled Substance Professional Practices Department personnel. 1785
WITH TECHNICAL CORRECTIONS 02.03.2023
P-7
This provision does not apply to an officer or executive to whom both the Controlled Substance Professional Practices Department and sales, marketing and/or business development departments report.

4. Settling Pharmacy’s sales, marketing and business development departments are prohibited from interfering with, obstructing, or otherwise exerting control over any Controlled Substance Professional Practices Department or Controlled Substance Committee decision-making. This provision does not apply to an officer or executive to whom both the Controlled Substance Professional Practices Department and sales, marketing and/or business development departments report.

5. To the extent necessary to comply with this section, a Settling Pharmacy’s Controlled Substance Oversight Committee shall review, modify, and direct any changes to any compensation and non-retaliation policies specific to the sale or dispensing of Designated Controlled Substances.

VI. OVERSIGHT

1. To the extent not already established, within thirty (30) business days of the Injunctive Terms Implementation Date, each Settling Pharmacy shall establish an oversight committee, however titled, that includes representatives from its respective legal, compliance, pharmacy operations and asset protection departments, however named, to provide oversight over the CSDOP and its compliance with the Injunctive Terms.

For the purposes of reference herein, this committee, however named, shall be referred to as the “Controlled Substance Oversight Committee.” Settling Pharmacy shall maintain its Controlled Substance Oversight Committee for the duration of the term of the Injunctive Terms. The Chief Pharmacy Controlled Substances Officer shall be a member of the Controlled Substance Oversight Committee.

2. A Settling Pharmacy’s Controlled Substance Oversight Committee shall have quarterly meetings during which the Chief Pharmacy Controlled Substances Officer shall report on, and the Controlled Substance Oversight Committee shall review, among other things, (a) the Prescription Validation Process, including the CSDOP Policies and Procedures on identifying and resolving Patient, Prescriber and Prescription Red Flags; (b) the training required under the Injunctive Terms; (c) proactive due diligence and site visits; (d) the Prescriber Review Processes; (e) significant new national and regional diversion trends involving Controlled Substances; (f) Settling Pharmacy’s adherence to the Injunctive Terms and applicable laws and regulations; and (g) any technology, staffing, or other resource needs for the CSDOP. The Controlled Substance Oversight Committee shall have access to all CSDOP reports described in the following subsection.

3. On an annual basis, a Settling Pharmacy’s Controlled Substance Oversight Committee shall provide a written report to the President of the Settling Pharmacy’s Retail Division, the Chief Financial Officer of the Settlement Pharmacy’s Retail Division, the Chief Legal Officer of the Settling Pharmacy’s Retail Division, and the CVS Health 1786
WITH TECHNICAL CORRECTIONS 02.03.2023
P-8
Chief Compliance Officer, outlining (a) the Settling Pharmacy’s adherence to, and any material deviations from these Injunctive Terms; (b) the allocation of resources sufficient to comply with these Injunctive Terms; and (c) any revisions to the CSDOP that the Controlled Substance Oversight Committee has approved. The CVS Health Chief Compliance Officer shall determine if and when it is appropriate to make a report to the Board or any subcommittee thereof, but shall report at least annually.

4. Settling Pharmacy, through its Controlled Substance Professional Practices Department and Oversight Committee, shall, at least once every year, review and oversee any enhancements to the CSDOP Policies and Procedures and systems for dispensing activity that the Controlled Substance Oversight Committee deems necessary.

5. The Controlled Substance Oversight Committee shall be responsible for the approval of all material revisions to the CSDOP Policies and Procedures, provided that nothing herein shall prevent Settling Pharmacy from implementing changes to the CSDOP Policies and Procedures pending such review and approval.

VII. MANDATORY TRAINING

1. The CSDOP Policies and Procedures shall be published in a form and location readily accessible to all pharmacy personnel at each of the Settling Pharmacy’s retail pharmacy locations in the Settling States. Online availability is sufficient, so long as pharmacy personnel have access to a computer with access to the CSDOP Policies and Procedures.

2. Settling Pharmacy shall launch training for all existing CSDOP Employees, to the extent practical (for example, accounting for employee leave), on the CSDOP Policies and Procedures required under these Injunctive Terms, including the Prescription Validation Process and corresponding responsibility. The training shall be launched within 120 days of the Injunctive Terms Implementation Date. All CSDOP Employee new hires, to the extent practical, shall be required to participate in such trainings within 60 days of hiring or 6 months of the Injunctive Terms Implementation Date, whichever is later. Settling Pharmacy will further require that every CSDOP Employee, to the extent practical, receive such training at least once every 3 years for the term of these Injunctive Terms.

3. On an annual basis for the duration of these Injunctive Terms, Settling Pharmacy shall test their CSDOP Employees on their knowledge regarding the CSDOP Policies and Procedures required under these Injunctive Terms, including the Prescription Validation Process and corresponding responsibility.
1787
WITH TECHNICAL CORRECTIONS 02.03.2023
P-9

4. It shall be a part of the CSDOP Policies and Procedures and all trainings of all CSDOP Employees required under these Injunctive Terms that pharmacists shall refuse to dispense Controlled Substances that they believe were prescribed or are being used for other than a legitimate medical purpose or that they believe were not prescribed by an individual Prescriber acting in the usual course of his or her professional practice.

5. All trainings required under these Injunctive Terms shall also make clear that i) Settling Pharmacy’s compensation and non-retaliation policies, including pursuant to these Injunctive Terms, prevent CSDOP Employees from being compensated or penalized in any way related to revenue or profitability targets or expectations specific to sales of Controlled Substances; and ii) pharmacists will not be penalized in any way for exercising their professional judgment to refuse to fill prescriptions for Controlled Substances pursuant to their corresponding responsibility. To the extent that trainings designed and launched prior to the Effective Date of these Injunctive Terms do not reference these policies, they shall be added by the end of 2023.

VIII. THE PRESCRIPTION VALIDATION PROCESS

1. As part of its CSDOP, Settling Pharmacy shall maintain a Prescription Validation Process in the CSDOP Policies and Procedures, as further described and set forth in this section, that each pharmacist employed by Settling Pharmacy in a Settling State must follow when dispensing a prescription for a Controlled Substance. The inclusion of an enumerated Red Flag in these Injunctive Terms shall not be considered, construed, or represented to be an admission, concession, or evidence of any factual or legal contention related to such Red Flag. A Red Flag shall not be interpreted to mean that a prescription is, or is more likely than not, illegitimate and/or not issued in the usual course of professional practice or treatment.

2. A Red Flag will be considered “resolved” if, after further investigation as described below, and given other facts and circumstances surrounding the prescription, a pharmacist determines, in his or her professional judgment, that the facts that triggered the Red Flag do not lead him or her to believe that the prescription was written or is being submitted for an illegitimate medical purpose or outside the usual course of a Prescriber’s professional practice.

3. A Settling Pharmacy’s CSDOP Policies and Procedures shall provide that if a pharmacist identifies any “Patient Red Flags” associated with a Controlled Substances prescription (described in Section IX(3) below), before filling the prescription the pharmacist must resolve them; and that the method of resolution falls within the judgment of the pharmacist and may include reviewing the Patient’s profile and history with the Settling Pharmacy, calling the Prescriber or Prescribers if appropriate, speaking with the Patient if appropriate, calling on the pharmacist’s pre-existing knowledge of the Patient or Prescriber, reviewing available Prescription Monitoring Program (“PMP” or “PDMP”) data, and/or reviewing other data or information 1788
WITH TECHNICAL CORRECTIONS 02.03.2023
P-10
available to the pharmacist.

4. Each Settling Pharmacy’s CSDOP Policies and Procedures shall provide that if forgery or fraud is suspected, or if the pharmacist identifies any other “Prescription Red Flags” associated with a Controlled Substances prescription (described in Section IX(4) below), the pharmacist must resolve the Prescription Red Flags before filling the prescription; and that the method of resolution falls within the judgment of the pharmacist and may include reviewing the Patient’s profile and history with the Settling Pharmacy, calling the Prescriber or Prescribers if appropriate, speaking with the Patient if appropriate, calling on the pharmacist’s pre-existing knowledge of the Patient or Prescriber, reviewing available PMP or PDMP data, and/or reviewing other data or information available to the pharmacist.

5. Settling Pharmacy’s CSDOP Policies and Procedures shall require that if a pharmacist identifies any “Prescriber Red Flags” associated with a Controlled Substances prescription (described in Section IX(5) below), the pharmacist must resolve them before filling the prescription; and that the method of resolution falls within the judgment of the pharmacist and may include reviewing any Settling Pharmacy records regarding the Prescriber, calling the Prescriber if appropriate, speaking with the Patient if appropriate, calling on the pharmacist’s pre-existing knowledge of the Patient or Prescriber, reviewing available PMP or PDMP data, and/or reviewing other data or information available to the Settling Pharmacy.

6. A Settling Pharmacy’s CSDOP Policies and Procedures shall provide that the resolution of all Red Flags identified by the pharmacist, as well as sufficient details to reflect the steps taken to resolve the Red Flagsmust be documented by the pharmacist.

Any such records shall be maintained for the duration of these Injunctive Terms. To the extent that a Red Flag is resolved based upon facts or circumstances that are already reflected or documented in a Settling Pharmacy’s records, further documentation of those facts or circumstances is not required for resolution of substantially the same Red Flag on subsequent prescriptions. For example, if a Patient lives 55 miles from a Settling Pharmacy but works near the pharmacy and that fact is reflected in pharmacy records, no documentation for the resolution of the Red Flag addressing the Patient’s distance from the pharmacy is required in connection with individual prescriptions dispensed for that Patient. A lack of documentation does not create a presumption that a pharmacist did not resolve any identified Red Flags.

7. Settling Pharmacy’s CSDOP Policies and Procedures shall provide that, even if all Red Flags are resolved, a pharmacist shall reject a prescription if, in his or her professional judgment, he or she believes that it was written or is being submitted for other than a legitimate medical purpose and/or was written outside the usual course of an individual Prescriber’s professional practice.
1789
WITH TECHNICAL CORRECTIONS 02.03.2023
P-11
IX. RED FLAGS

1. Settling Pharmacy shall provide quarterly to the Settling States, beginning with an initial report four months after the Injunctive Terms Implementation Date, and quarterly thereafter, (1) data reports (the “Quarterly Data Reports”) for each retail pharmacy operated by Settling Pharmacy containing data generated by the periodic proactive compliance reviews set forth in Section XI.1, subject to any potential modifications as a result of the meet and confer process set forth in Section IX.2, on cash, high MME patients, and cocktail prescriptions consistent with the sample report provided by Settling Pharmacy on November 21, 2022, (2) the top twenty-five prescribers of Designated Controlled Substances in each Settling State from CVS’s retail dispensing data, and (3) the lists of prescribers subject to disclosure in section X.5. Each Settling State shall provide contact information for receipt of the above information and shall update such contact information as necessary. A Settling State shall not disclose or provide any data provided under this provision during or after the Term of these Injunctive Terms unless required to do so by law or in a proceeding to enforce these Injunctive Terms. If a Settling State receives a request, demand or subpoena for such information or data, or intends to produce said data in a proceeding to enforce these Injunctive Terms, the Settling State shall, before producing any information or data, provide to Settling Pharmacy no less than ten (10) days’ notice, unless a shorter period is required by law, and an opportunity to object, seek a protective order, or come to an agreement on confidentiality protections, prior to the expiration of the 10-day notice period. It is CVS’s position that the information and data to be provided under these Injunctive Terms is confidential in nature, shall not be disclosed or produced by a Settling State, and is exempted from public record requests under exemptions for confidential commercial information and all other applicable exemptions and exclusions. Nothing in this paragraph shall be deemed to prevent a Settling State from sharing this material with other State or federal law enforcement agencies, provided that such agencies acknowledge and comply with the nondisclosure and notice obligations set forth in the preceding sentences.

2. Within the three months following the provision of the Annual Data Reports, either Settling Pharmacy or the States Injunctive Relief Committee may propose in writing a meet and confer to discuss potential changes to the scope of one or more categories of Red Flags. At such a meeting, Settling Pharmacy or the States Injunctive Relief Committee may provide additional research, information or data available to them beyond that provided in the Annual Data Reports. For example, a Settling Pharmacy might propose reducing the threshold for triggering a particular category of Red Flag or consolidating certain Red Flags or subcategories of Red Flags into a single metric, or the States Injunctive Relief Committee might propose increasing the threshold for triggering a particular Red Flag or expanding that Red Flag to include multiple subcategories (e.g., number of prescriptions, distance thresholds). 1790
WITH TECHNICAL CORRECTIONS 02.03.2023
P-12
a. If Settling Pharmacy and the States Injunctive Relief Committee agree on such changes to one or more Red Flags, they shall document those changes in writing and they shall become a part of these Injunctive Terms for all intents and purposes.
b. If Settling Pharmacy and the States Injunctive Relief Committee cannot agree on the proposed changes during their meeting and confer, the Party seeking the change(s) to the Red Flag(s) may seek a 5-day mediation of the issue at its own expense. If the mediation fails to resolve the dispute between the parties, the party seeking the proposed change(s) may appeal to the National Arbitration Panel to have the National Arbitration Panel modify the Red Flags on the basis that the change(s) would be consistent both with avoiding unnecessary material costs of identifying and resolving Red Flags and materially reducing the diversion of Controlled Substances. In such a proceeding, the Party seeking the proposed change(s) may provide evidence from Annual Data Reports or from other research, data and information.
c. In any such proceedings, there shall be a presumption against imposition of any proposed Red Flags, or proposed modifications to pre-existing Red Flags, that have not been identified by the United States Drug Enforcement Administration or any Settling State’s Board of Pharmacy or other Controlled Substance government regulators.
d. The Red Flags required by these Injunctive Terms shall at no point be too numerous or complex to be reasonably workable for pharmacists in the context of protecting patient safety, performing corresponding responsibility, drug utilization review, and their other responsibilities. Any dispute over whether the Red Flags required by these Injunctive Terms have become too numerous or complex to be reasonably workable for pharmacists shall be submitted to the National Arbitration Panel. In the event such a dispute is submitted to the National Arbitration Panel, it shall be the Settling Pharmacy’s burden to prove that the Red Flag(s) at issue are too numerous or complex to be reasonably workable for pharmacists. The Arbitration Panel should consider information regarding potential impacts on public health in determining if the red flag(s) at issue are too numerous or complex to be reasonably workable for pharmacists.

3. Settling Pharmacy’s CSDOP Policies and Procedures shall require their pharmacists to treat the following circumstances as “Patient Red Flags”:
1791
WITH TECHNICAL CORRECTIONS 02.03.2023
P-13
a. A Patient seeks to fill a Schedule II Designated Controlled Substance prescription more than three days prior to the contemplated exhaustion date of an earlier prescription of the same Schedule II Designated Controlled Substance (e.g., exhaustion of the days’ supply assuming the prescription has been taken in accordance with the prescribers’ directions on the face of the prescription), provided the previous prescription was also dispensed by the same Settling Pharmacy;
b. A Patient seeks to fill a Designated Controlled Substance prescription from a Prescriber after having filled Designated Controlled Substance prescriptions at the same Settling Pharmacy from more than four other Prescribers, from separate practices, in a given 6-month period;2
c. A Patient seeks to fill a Designated Controlled Substance prescription after having filled three other Designated Controlled Substance prescriptions written by multiple Prescribers with overlapping days of supply at the same Settling Pharmacy’s pharmacies within 30 days;
d. The distance between a Patient’s residence and the Settling Pharmacy receiving the Designated Controlled Substance prescription is farther than 50 miles ; e. The Patient resides more than 100 miles from the Prescriber who issued the Designated Controlled Substances prescription;
f. To the extent personally known to the pharmacist filling the prescription, a Patient seeks to fill a Designated Controlled Substance prescription after having two other prescriptions for Designated Controlled Substances subjected to refusals to fill by a Settling Pharmacy pharmacist within the past 30 days; g. A patient pays in cash for a Designated Controlled Substance despite having prescription drug insurance on file for that medication; h. Three or more Patients come to the pharmacy together to fill prescriptions for the same Designated Controlled Substances;
i. A Patient requests a Designated Controlled Substance by its slang or street description, such as “Mallinckrodt blues,” “M’s” or “the blue pill”; and j. A Patient presenting a prescription for a Designated Controlled Substance appears visibly altered, intoxicated or incoherent.

4. Settling Pharmacy’s CSDOP Policies and Procedures shall require their pharmacists to treat the following circumstances as “Prescription Red Flags:” 2 In Settling Pharmacies’ sole discretion, for administrative convenience Settling Pharmaciesmay implement this Red Flag without regard to whether Prescribers are at separate practices, thereby resulting in more instances in which the flag occurs.
1792
WITH TECHNICAL CORRECTIONS 02.03.2023
P-14
a. A Controlled Substance prescription fails to meet the requirements of law; b. A Controlled Substance prescription that appears altered, including but not limited to, a photocopied prescription or a prescription in which an altering agent, such as white out, was used;
c. A Controlled Substance prescription written with misspellings suggesting the prescription may not have been written by a valid Prescriber; d. A Controlled Substance prescription using atypical abbreviations suggesting the prescription may not have been written by a valid Prescriber; and e. A Controlled Substance prescription written with multiple colors of ink or in multiple different handwritings.

5. Settling Pharmacy’s CSDOP Policies and Procedures shall require their pharmacists to the following circumstances as “Prescriber Red Flags:”
a. A Prescriber provides a Patient with prescriptions for all three of a Schedule II Designated Controlled Substance, a benzodiazepine, and carisoprodol; b. A Prescriber has no office within 50 miles of the retail pharmacy store where a Designated Controlled Substance prescription is submitted; and c. A Prescriber of Designated Controlled Substances uses prescriptions that are preprinted or stamped with drug type and amount.

X. PRESCRIBER REVIEW

1. Settling Pharmacy shall regularly review the prescribing patterns and practices of Prescribers of Designated Controlled Substances (the “Prescriber Review Process”).

The Prescriber Review Process shall employ algorithms, or other means, to review data on Settling Pharmacy’s retail dispensing for potential Prescribers of concern.

2. Settling Pharmacy shall initiate Prescriber Review Process in the following circumstances:
a. Personnel implementing the Prescriber Review Process become aware that a Prescriber of Designated Controlled Substances located in a Settling State has been the subject of a blanket refusal to fill by one or more of the Settling Pharmacy’s retail pharmacy stores in the Settling States; b. Personnel implementing the Prescriber Review Process become aware that a Prescriber of Designated Controlled Substances located in a Settling State has been charged or indicted with a crime related to prescribing Designated Controlled Substances by the Federal Government or law enforcement in a Settling State; or
1793
WITH TECHNICAL CORRECTIONS 02.03.2023
P-15
c. A Settling Pharmacy has received a Hotline complaint that has been investigated and substantiated concerning a Prescriber’s illegitimate prescribing of Designated Controlled Substances.

3. Based on the professional judgment of the employees operating the Prescriber Review Process, a Settling Pharmacy may also initiate the Prescriber Review Process when:
a. Personnel implementing the Prescriber Review Process are notified in writing by law enforcement that a Prescriber of Designated Controlled Substances located in a Settling State is the target of an investigation regarding the prescribing of controlled substances;
b. A Prescriber of Designated Controlled Substances was flagged for review by a Settling Pharmacy pharmacist in a Settling State (other than through a refusal to fill or blanket refusal to fill) or by field personnel who supervise a Settling Pharmacy’s pharmacies in a Settling State; or c. A Prescriber of Designated Controlled Substances located in a Settling State was identified through the running of algorithms on Settling Pharmacy’s retail dispensing.

4. Once a Settling Pharmacy identifies a Prescriber for further investigation, the Settling Pharmacy shall review pertinent and available data or information pertaining to the Prescriber, which may include interviews or other information gathered in the discretion of the employees operating the Prescriber Review Process. All data and information collected or created as part of the Prescriber Review Process shall be maintained by the Settling Pharmacy for the term of these Injunctive Terms. When permitted by law, nothing contained in this Section prevents a Settling Pharmacy from taking immediate action to Block a Prescriber.

5. If after the Prescriber Review Process those making the decision have not resolved the circumstances that caused a Settling Pharmacy to further investigate the Prescriber, then the Prescriber shall be Blocked from having Controlled Substance prescriptions filled at the Settling Pharmacy’s retail pharmacies in the Settling States, when permitted by law. A Prescriber may have an opportunity at the discretion of the Settling Pharmacy to seek future reinstatement by providing information to the Settling Pharmacy that may resolve its concerns. Nothing in this Section shall limit the right or ability of an individual Settling Pharmacy pharmacists to either refuse to fill a given prescription or refuse to fill all prescriptions for Controlled Substances from a given Prescriber independent of any decision by the Settling Pharmacy to Block or not Block a given Prescriber. On written demand, on a quarterly basis, a Settling Pharmacy shall provide to each Settling State the names and DEA or NPI numbers of Prescribers of Designated Controlled Substances within that Settling State that it has Blocked. Each Settling State shall provide contact information in order to receive such information. For each of the 1794
WITH TECHNICAL CORRECTIONS 02.03.2023
P-16
Settling States, on a quarterly basis, a Settling Pharmacy shall provide to the Injunctive Relief Committee the number, names and DEA or NPI numbers of Prescribers who were: (a) blocked, and the number of prescribers who were (b) reviewed but not blocked.

XI. PROACTIVE DUE DILIGENCE AND SITE VISITS

1. During the term of these Injunctive Terms, Settling Pharmacy shall conduct periodic proactive compliance reviews of its retail pharmacy stores in the Settling States to assist with the identification of potential compliance issues related to the dispensing of Designated Controlled Substances at its retail pharmacy stores in the Settling States.

This may be satisfied by the use of algorithms, or other electronic means, to analyze data associated with each pharmacy’s dispensing of Designated Controlled Substances to identify particular pharmacies for review as required under this Section XI.

Documentation of any resulting reviews shall be maintained by the Settling Pharmacy and made accessible to all Controlled Substance Professional Practices Department personnel upon request for the duration of these Injunctive Terms.

2. During the term of these Injunctive Terms, Settling Pharmacy personnel or qualified third-party compliance consultants shall conduct site visits to each pharmacy identified for further review in a calendar year. Settling Pharmacy shall provide a list of such pharmacies to Settling States on an annual basis. These site visits shall at a minimum consist of a review of Controlled Substance dispensing documentation and recordkeeping; and a review of physical surroundings and other circumstances for any indications of potential non-compliance with these Injunctive Terms or the CSDOP Policies and Procedures, or any violations of other applicable laws and regulations related to the dispensing of Controlled Substances.

3. During site visits, Settling Pharmacy’s personnel or qualified third-party compliance consultants shall interview relevant pharmacy employees, if appropriate, about any potential areas or issues of concern, including potential violations of laws related to the dispensing of Controlled Substances, the CSDOP Policies and Procedures, and these Injunctive Terms.

4. A Settling Pharmacy’s personnel or qualified third-party compliance consultants who conduct site visits shall complete a report reflecting the findings of any site visit pursuant to this section. This report shall document areas or issues of concern, including potential violations of law related to the dispensing of Controlled Substances, the CSDOP Policies and Procedures, and these Injunctive Terms.

5. The site visit reports described above shall be maintained by the Settling Pharmacy and made accessible to all Controlled Substance Professional Practices Department personnel. Upon its request, the States Injunctive Relief Committee shall be provided 1795
WITH TECHNICAL CORRECTIONS 02.03.2023
P-17
sample reports or a report for a particular store.

XII. THEFT AND LOSS PREVENTION

1. In addition to complying with all theft and loss procedures, policies and precautions required by state and federal law, each Settling Pharmacy shall maintain for at least three years information regarding the receipt and disposition of inventory of all Designated Controlled Substances at each retail pharmacy store.

2. In addition to any other reporting obligations under state and federal law, Settling Pharmacy must provide to each Settling State on a quarterly basis any reports it has made to the Drug Enforcement Administration regarding the theft or significant loss of Designated Controlled Substances in that Settling State pursuant to 21 CFR §1301.76(b). Each Settling State shall provide contact information in order to receive such reports. There shall be no obligation to provide these reports to Settling States that receive contemporaneous reporting of thefts or significant losses of Designated Controlled Substances to a Settling State’s board of pharmacy.

XIII. REPORTING TO LAW ENFORCEMENT

1. The Settling States shall inform the Settling Pharmacy to what extent their law enforcement authorities would like to receive reports, other than those already required by law or regulation, of any confirmed forged prescriptions. To the extent not already in place, Settling Pharmacy shall implement standard operating procedures directing its employees to report any confirmed forged prescriptions for Designated Controlled Substances to those Settling States who have indicated that they want to accept it, within 5 business days of completing any review of such prescription or conduct. The Settling States shall provide contact information in order to receive such reports.

2. Settling Pharmacy shall document and for at least 2 years maintain records of any such reports that are made to Settling States regarding confirmed fraudulent or forged prescriptions, which are maintained centrally.

XIV. ENFORCEMENT OF INJUNCTIVE TERMS

1. Notice of Potential Violations and Opportunity to Cure. a. A “Potential Violation” occurs when the Settling State determines, after appropriate investigation and due diligence, that a Settling Pharmacy is not in substantial compliance with a material aspect of the Injunctive Terms. A Potential Violation may be for a single retail pharmacy. A violation of this Agreement is not presumed to occur when a pharmacist, pharmacist technician, 1796
WITH TECHNICAL CORRECTIONS 02.03.2023
P-18
or other field personnel who supervise pharmacists and/or pharmacist technicians employed by a Settling Pharmacy violates the Settling Pharmacy’s CSDOP Policies and Procedures.
b. Potential Violation Discovered by Settling State.
i. In the event of a Potential Violation identified by a Settling State, the Settling State shall notify the Settling Pharmacy in writing (the “State’s Notice”).
ii. Within thirty (30) days of receipt of the State’s Notice, the Settling Pharmacy shall provide a written response to the Settling State. The response shall include Settling Pharmacy’s position as to the act(s) of non-compliance, including, possibly, a statement setting forth why the Settling Pharmacy believes it is in substantial compliance with the relevant provision(s) or a statement explaining how the Potential Violation has been addressed.
iii. If the Settling State wishes to meet with a Settling Pharmacy, that Settling Pharmacy shall promptly make itself available for such a meeting.
c. If, after review of a written response and any meeting, the Settling State believes that a Potential Violation is ongoing or has not been substantially addressed, it will provide written notice to a Settling Pharmacy and work in conjunction with the Settling Pharmacy to devise, within thirty (30) days, a corrective action plan (“Corrective Action Plan”) to remedy such Potential Violation, including a reasonable period for implementation of such plan.
d. Within 60 and 120 days after implementing the Corrective Action Plan, the Settling Pharmacy will provide a written compliance update to the Settling State and make itself available to meet with the Settling State if requested. If after reviewing the compliance update and any meeting, the Settling State believes a Potential Violation remains ongoing or has not been substantially addressed, the Settling State may commence a 30-day mediation period. If mediation fails to resolve the dispute between the parties, the Settling State may take whatever action it deems necessary, including but not limited to bringing an action to enforce these Injunctive Terms, filing a new action (administrative or civil action) for violation of the Injunctive Terms as allowed by state law, conducting further investigation, or attempting to negotiate an updated Corrective Action Plan with the Settling Pharmacy. But the Settling State may not seek to reinstate claims that have been released as part of the Settlement. 1797
WITH TECHNICAL CORRECTIONS 02.03.2023
P-19
e. If a Settling Pharmacy fails or refuses to provide a written response, to devise or implement a Corrective Action Plan or to provide a compliance update as required by subsections 1(b), 1(c) and/or 1(d), a Settling State may bring an action to enforce these Injunctive Terms, filing a new action (administrative or civil action) for violation of the Injunctive Terms as allowed by state law, conduct further investigation, or attempt to negotiate an updated Corrective Action Plan with the Settling Pharmacy. But the Settling State may not seek to reinstate claims that have been released as part of the Settlement. f. If, after review of a written response and any meeting, pursuant to subsections 1b. or 1c., above, the Settling State concludes that a Potential Violation is not ongoing or has been substantially addressed, the Settling State will provide written notice of this conclusion to the Settling Pharmacy within 30 days of reaching its conclusion.

2. Enforcement Action. Each Settling State agrees that prior to taking any court or administrative action, other than an action that the Settling State concludes is necessary to address an immediate threat to the health, safety, or welfare of the citizens of the Settling State, or that a public emergency requiring immediate action exists, it will follow the process outlined above. If the Settling State concludes that action is necessary to address an immediate threat to the health, safety, or welfare of the citizens of the Settling State or that a public emergency requiring immediate action exists, it will make best efforts to provide reasonable notice to a Settling Pharmacy prior to initiating any such action.

XV. COMPLIANCE CERTIFICATION

1. Each Settling Pharmacy’s Chief Pharmacy Controlled Substances Officer shall, after diligent inquiry, complete an annual compliance certification as set out in Section XV(4).

2. The certification shall be filed annually for the duration of these Injunctive Terms with a Settling State’s appropriate licensing and/or regulatory agency and its Attorney General.

3. The certification shall state:
1798
WITH TECHNICAL CORRECTIONS 02.03.2023
P-20
“I understand the compliance requirements and responsibilities as they relate to [insert name of department], an area under my supervision. My job responsibilities include attempting to achieve compliance with regard to the [insert name of department] with all applicable statutory requirements, obligations of the Injunctive Terms, and applicable policies, and I have taken steps to promote such compliance. To the best of my knowledge, the [insert name of department] is in compliance with the obligations of these Injunctive Terms. I understand that this certification is being provided to and relied upon by the State of [Settling State].”

4. If the Chief Pharmacy Controlled Substances Officer is unable to provide such a certification, the Chief Pharmacy Controlled Substances Officer shall provide a written explanation of the reasons why he or she is unable to provide the certification outlined above.

XVI. DATA SHARING

1. Each Settling Pharmacy shall consent to the provision by their distributors of the Settling Pharmacy’s unblinded “867 Data” (data sent from the distributor to the manufacturer concerning the sale of its products to Settling Pharmacy) to opioid manufacturers on any particular Designated Controlled Substances manufactured by them as soon as commercially reasonable and at no cost to the manufacturers, provided that, pursuant to a prior written agreement with Settling Pharmacy, the opioid manufacturers agree (a) to ensure the confidentiality of the 867 Data, except as required by law; (b) to implement safeguards and procedures to limit access to and use of the 867 Data, except as required by law; (c) that the 867 Data shall be used solely for compliance purposes as part of their Suspicious Order Monitoring programs; and (d) that the 867 Data shall be shared only with specified personnel and shall not be shared with business or sales personnel.

2. To the extent that Settling Pharmacy provides McKesson Corporation, Cardinal Health, Inc., or AmerisourceBergen Corporation (the "Settling Distributors") with Pharmacy Customer Data (as defined in the Distributor Injunctive Terms) for use in their Controlled Substance Monitoring Programs, Settling Pharmacy agree that the Settling Distributor(s) may share such Pharmacy Customer Data with the Monitor appointed pursuant to the Distributor Injunctive Terms, provided that the Monitor agrees, pursuant to a prior written agreement with Settling Pharmacy, (a) to ensure the confidentiality of the Pharmacy Customer Data; (b) to implement safeguards and procedures to limit access to and use of the Pharmacy Customer Data; (c) that the Pharmacy Customer Data is used solely for the purpose of ensuring the Settling Distributors’ compliance with the Distributor Injunctive Terms; and (d) that the Pharmacy Customer Data shall be shared only with specified personnel.

XVII. CLEARINGHOUSE
1799
WITH TECHNICAL CORRECTIONS 02.03.2023
P-21

1. The Settling Pharmacy will confer with any Settling Distributor that distributes Designated Controlled Substances to its retail pharmacies and the States Injunctive Relief Committee for a period not to exceed six months from the Injunctive Terms Implementation Date to determine: what additional deidentified information, if any, is needed from the Settling Pharmacy for a Settling Distributor to perform suspicious order monitoring,; if additional deidentified information is needed, how the Settling Pharmacy shall provide it to a Settling Distributor; and what information provided by the Settling Pharmacy to a Settling Distributor may be deposited by the Settling Distributor into the Clearinghouse. For the avoidance of doubt “deidentified” does not refer to omission of information about Prescribers. If agreements are not reached, the matters in dispute shall be submitted to arbitration. Due to patient privacy and legal restrictions and other confidentiality and commercial concerns, in connection with any meet and confer described above, the Settling Pharmacy may not be compelled to provide individual patient-level or prescription-level data, de-identified or otherwise, to the Settling Distributors.

2. The Settling Pharmacy and Settling Distributors will also determine whether and in what amount each Settling Pharmacy will contribute to the cost of the operation of the Clearinghouse. When a Settling Pharmacy contributes to the costs of the Clearinghouse, Settling Pharmacy, Settling Distributors and all other participants in the Clearinghouse shall determine an equitable amount of the Settling Pharmacy’s contribution. If agreements are not reached, the matters in dispute shall be submitted to arbitration.

3. Any data provided by a Settling Pharmacy to a Settling Distributor and/or the Clearinghouse pursuant to these Injunctive Terms shall be treated in compliance with state and federal law, including but not limited to the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) and all applicable state and federal privacy laws.

XVIII. CHANGES & MODIFICATIONS

1. These Injunctive Terms may be amended or modified with the written consent of Settling Pharmacy and a majority of the States Injunctive Relief Committee. 1800
WITH TECHNICAL CORRECTIONS 02.03.2023
Q-1

EXHIBIT Q
[Intentionally Omitted]
1801
WITH TECHNICAL CORRECTIONS 02.03.2023
R-1

EXHIBIT R
Agreement on Attorneys’ Fees, Costs, and Expenses
This Agreement on Attorneys’ Fees, Costs, and Expenses (“Fee Agreement”) is entered between CVS and the Plaintiffs’ Executive Committee appointed in the multidistrict litigation in the Northern District of Ohio, In re National Prescription Opiate Litigation , No. 1:17-MD-2804 (“MDL PEC”), in connection with the CVS Global Opioid Settlement Agreement (“CVS Agreement”). This Fee Agreement becomes effective on the Effective Date of the CVS Agreement or the date that the Consent Judgments anticipated under the CVS Agreement become final in 25 Settling States (whichever is later).

I. Definitions
A. This Fee Agreement incorporates all defined terms in the CVS Agreement, unless otherwise defined herein, and shall be interpreted in a manner consistent with the CVS Agreement.

B. “Applicant.” Any Attorney or MDL Participating Counsel who seeks an award of attorneys’ fees from the Attorney Fee Fund pursuant to the procedures established by the MDL Court and the Fee Panel.

C. “Attorney.” Any of the following retained through a legal contingency fee or hourly fee contract: a solo practitioner, multi-attorney law firm, or other legal representative of a Participating Subdivision or MDL Participating Counsel. This does not include Subdivision in-house attorneys.

D. “Attorney Fee Fund .” An account consisting of $500,615,944 allocated to pay attorneys’ fees approved pursuant to Section II.B. of this Fee Agreement, established by Order of and under the ongoing jurisdiction of the MDL Court, as provided below.

E. “Common Benefit.” Work performed for the benefit of all Participating Subdivisions and Tribal Nations, including, but not limited to, pretrial matters, discovery, trial preparation, trial, settlement negotiations, and all other work that advances the interests of the Participating Subdivisions.

F. “Common Benefit Fund.” The sub fund of the Attorney Fee Fund described in Section II.C.

G. “Common Benefit Order.” The Ongoing Common Benefit Order (Dkt. #4428) in In re National Prescription Opiate Litigation , Case No. 1:17-md-2804, any subsequent amendments or modifications to that order, and any successor orders on Common Benefit.

H. “Contingency Fee Fund.” The sub fund of the Attorney Fee Fund described in Section II.D.
1802
WITH TECHNICAL CORRECTIONS 02.03.2023
R-2
I. “Cost and Expense Fund Administrator .” The administrator appointed by the MDL Court on August 12, 2021 (MDL Docket No. 3828), to administer the Cost Fund and its sub funds as provided in the Fee Agreement.

J. “Cost Fund.” An account consisting of $30,000,000, composed of the MDL Direct Cost Fund and the Subdivision Cost and Expense Fund, as provided below.

K. “Court Common Benefit Fund.” The Common Benefit Fund established by the MDL Court in its orders of July 22, 2021, MDL Docket No. 3794, and May 9, 2022, MDL Docket No. 4428.

L. “Fee Entitlement.” Any right, entitlement, or expectation, including but not limited to a fee contract, contingent fee contract, agreement, referral arrangement, co-counsel arrangement, State Back-Stop Agreement, or any other arrangement by which counsel could receive compensation or other consideration. For the avoidance of doubt, the scope of Fee Entitlement under paragraph II.G.3.a. does not include any Attorneys’ fees associated with representation of a State.

M. “Fee Panel.” The three-person panel appointed by the MDL Court on August 12, 2021 (MDL Docket No. 3828), to administer and make recommendations for the allocation and distribution of the Attorney Fee Fund and its sub funds as provided in the Fee Agreement.

N. “Later Litigating State. ” A State that first files a lawsuit bringing a Released Claim against a Released Entity after December 9, 2022.

O. “MDL Court.” United States District Court for the Northern District of Ohio Eastern Division, Case No. 1:17-md-2804, Judge Dan Aaron Polster.

P. “MDL Direct Cost Fund.” The cost fund described in Section II.F below.

Q. “MDL Participating Counsel.” MDL Participating Counsel includes an attorney or firm authorized by MDL 2804 Lead Counsel to perform work for the Common Benefit of Participating Subdivisions. By way of example, it would include insurance counsel and appellant counsel.

R. “MDL PEC.” The Plaintiffs’ Executive Committee appointed by the MDL Court.

S. “Non-Participating Litigating Subdivision .” A Litigating Subdivision that is not a Participating Subdivision.

T. “Non-Participating State.” A State that is not a Participating State.

U. “Participating Litigating Subdivision .” A Litigating Subdivision that is also a Participating Subdivision.
1803
WITH TECHNICAL CORRECTIONS 02.03.2023
R-3
V. “Participation Agreement.” An agreement executed by an Attorney that acknowledges the obligation to pay an appropriate MDL Common Benefit Assessment.

W. “Qualified Tribal Representation. ” Representation by an attorney of a Participating Tribal Government regarding Released Claims against Released Entities. Such counsel are eligible for Common Benefit Fee consideration. The CVS Tribal Global Settlement will provide for the contribution to the Common Benefit Fund as shall be determined by the MDL Court.

X. “Qualifying Representation.” Legal services provided for representation of the MDL PEC or Participating Litigating Subdivision regarding Released Claims against Released Entities.

Y. “State Back-Stop Agreement.” Any agreement by a Settling State and private counsel for Participating Subdivisions in that State (or legislation enacted in that State) to provide, adjust, or guarantee attorneys’ fees and costs, whether from the Attorney Fee Fund or any other source recognized in the agreement or legislation.1 Z. “Subdivision Cost and Expense Fund.” The fund created to pay approved Subdivision and Tribal Nations costs and expenses as set forth in Section II.E.

AA. “CVS” means (i) CVS Health Corporation and CVS Pharmacy Inc. and (ii) all of their respective past and present direct or indirect parents, subsidiaries, divisions, affiliates, joint ventures, predecessors, successors, and assigns.

II. Fees and Costs
A. Total Attorneys’ Fees and Costs

1. Total attorneys’ fees and costs to be paid by CVS to Attorneys under this Fee Agreement shall be up to, but in no event more than, $530,615,944, subject to the reductions and provisions set forth below. The total attorneys’ fees and costs consists of up to $500,615,944 for the Attorney Fee Fund, as set forth in Section II, and $30,000,000 in total for the Cost Fund, divided between the Subdivision Cost and Expense Fund and MDL Direct Cost Fund as set forth in Sections II.E and II.F, respectively. Additionally, CVS shall also pay $8,841,180 into the Court Common Benefit Fund as a common benefit fund assessment on the Credit set forth in Ex.

M-3, and such amount shall be paid on the schedule set forth in Ex. M-3. The maximum attorney fees and costs allowed under this Fee Agreement, subject to the reductions set forth herein, are set forth in Ex. M-3 and shall be paid on the schedule in Ex. M-3.

2. If an Eligible State does not join the Agreement by the State Participation Date and is accordingly not a Settling State, the total attorneys’ fees and costs to be 1 Nothing herein shall be understood to indicate approval for additional State Back-Stop Agreements or modifications of existing State Back-Stop Agreements.
1804
WITH TECHNICAL CORRECTIONS 02.03.2023
R-4
paid under this Fee Agreement by CVS shall be reduced by twelve point four percent (12.4%) times the Remediation Payment amount that would have been allocated to that Non-Settling State as set forth in Section IV.B of the CVS Agreement.

3. The total attorneys’ fees and costs to be paid under this Fee Agreement by CVS shall also be reduced by the amount of the Contingency Fee Fund for Attorneys representing Litigating Subdivisions in any Settling State that continue to pursue Released Claims (“Non-Participating Litigating Subdivisions ”), as set forth in Section II.D.4 and II.H.7 below.

4. If CVS settles with any Non-Settling State after December 9, 2022, and such settlement allows for the Subdivision(s) in such Non-Settling State to join the settlement, CVS agrees to withhold from the attorney fee portion of such settlement a Common Benefit Fund assessment, to be deposited in the Court Common Benefit Fund, of 7.5% times the portion of the Remediation Payment that would have been due to such State if it had participated in the CVS Settlement and been awarded its full portion of the Remediation Payment (the “ CVS State Settlement CBF Assessment”). If CVS settles with any Subdivision(s) in a Non-Settling State other than in connection with a statewide settlement that includes the relevant State after December 9, 2022, then CVS agrees to withhold from the attorney fee portion of such settlement a Common Benefit Fund assessment, to be deposited in the Court Common Benefit Fund, of 7.5% times the portion of the Remediation Payment that would have been due to such Subdivision under this Agreement (the “ CVS Subdivision CBF Assessment, ” and, along with the CVS State Settlement CBF Assessment, each a “CVS CBF Assessment”). If (a) CVS settles with a Non-Settling State after December 9, 2022, (b) such settlement does not allow for the Subdivision(s) in such Non-Settling State to join the settlement, and (c) CVS later prevails in asserting that Released Claims of Primary Subdivisions in such Non- Settling State were released as a result of such settlement, CVS agrees to deposit the CVS State Settlement CBF Assessment in the Common Benefit Fund. Any CVS CBF Assessment is inclusive of any assessment related to such settlement that would be required by the Common Benefit Order. To the extent that CVS is required to pay any additional and/or separate assessment on such settlement as a result of the Common Benefit Order, the CVS CBF Assessment shall be reduced by the amount required to be paid pursuant to the Common Benefit Order.

B. Attorney Fee Fund and Sub Funds

1. The Attorney Fee Fund shall consist of the Contingency Fee Fund and the Common Benefit Fee Fund. There shall be a split of the Attorney Fee Fund into the Contingency Fee Fund and the Common Benefit Fund. The split shall be 40% to the Contingency Fee Fund and 60% to the Common Benefit Fund.

2. The Cost Fund shall include the MDL Direct Cost Fund and the Subdivision Cost and Expense Fund. The State Counsel Fee Fund and the State Cost Fund shall 1805
WITH TECHNICAL CORRECTIONS 02.03.2023
R-5
be separate funds under the control of the Settling States and are not part of this Fee Agreement.

3. It is the intention of the Parties that the Contingency Fee Fund and the Common Benefit Fund shall be administered by the Fee Panel appointed under MDL Docket No. 3828, which will be governed by the provisions of this Fee Agreement and shall design the process and procedures for the allocation of fees pursuant to this Fee Agreement and the MDL Court’s Order. The Cost Funds shall be administered by the Cost and Expense Fund Administrator appointed under MDL Docket No. 3828, who will be governed by the provisions of this Agreement and shall design the process and procedures for the allocation of costs pursuant to this Agreement and the MDL Court’s Order.

4. The fees to be paid under this Fee Agreement are available for Attorneys engaged in Qualifying Representations and Qualified Trial Representations only.

Fees to be paid under this Fee Agreement are not available prior to the Effective Date of the CVS Agreement, or if the CVS Agreement does not proceed. Fees to be paid under this Fee Agreement are not available for representation of States, Non-Participating Subdivisions, or Non-Litigating Subdivisions and are not available for representation of private hospitals, third-party payors, NAS claimants, personal injury/wrongful death claimants, or any entity other than Participating Litigating Subdivisions. In addition, fees under this Fee Agreement are not available for representation of any individual or entity in matters other than those claims against Released Entities, but may include a reasonable share of representations that involve development of facts for pursuit of opioid-related claims against multiple defendants in the pharmacy, manufacturing, and distribution chain.

5. In no event shall CVS be required to pay more into the Attorney Fee Fund in any Payment Year than the maximum amount specified in paragraph II.A.1., which amounts are reflected in Exhibit M to the CVS Agreement. The amounts allocated to the Contingency Fee Fund and the Common Benefit Fund set by the Fee Panel shall be subject to the reductions set forth in Section II.A.2 and the reductions and refunds set forth below.

6. Awards of fees from the Contingency Fee Fund shall be available to Attorneys with Qualifying Representations of Participating Litigating Subdivisions eligible to receive an allocation under the CVS Agreement, as set forth in Exhibit G to the CVS Agreement, and shall be made by applying the Mathematical Model attached as Exhibit “A” to this Fee Agreement. The collection of the data and calculations for the Mathematical Model has been a cooperative effort among private counsel for a large number of Litigating Subdivisions. The analysis has been spearheaded by Joseph Tann and Andrew Arnold. The Fee Panel is encouraged to continue working with those counsel in application of the Model.

The Fee Panel shall oversee the application of the Model and resolve any questions or disputes concerning the eligibility of a Counsel to participate as required in 1806
WITH TECHNICAL CORRECTIONS 02.03.2023
R-6
Section II.G. The Panel is empowered to hear disputes concerning and ensure the accuracy of the mathematical calculation.

7. As to awards from the Contingency Fee Fund, there shall be no right of appeal.

8. Any appeal of an award of the Fee Panel from the Common Benefit Fund will be made to the MDL Court and be reviewed under an abuse of discretion standard.

C. Common Benefit Fund (60% of the Attorney Fee Fund)

1. The maximum potential total Common Benefit Fund payment to be made by CVS into the Attorney Fee Fund is $300,369,566.40, and in no event shall it exceed that amount. CVS’s maximum potential Common Benefit Fund payments are subject to the reductions set forth in Section II.A.2. for Non- Settling States and to the adjustments set forth below and, subject to those reductions, shall be paid on the following yearly schedule:

CVS Maximum Common Benefit
Payment
Year 1 $54,779,142.60
Payment
Year 2 $48,406,953.60
Payment
Year 3 $65,727,823.80
Payment
Year 4 $65,727,823.20
Payment
Year 5 $65,727,823.20
Total $300,369,566.40
Additionally, CVS shall also pay $8,841,180 into the Court Common Benefit Fund as a common benefit fund assessment on the Credit set forth in Ex. M-3, which shall be paid on the schedule set forth in Ex. M-3.2
2 For the avoidance of doubt, CVS is not required to pay any sums under this Agreement for matters settled prior to December 6, 2022, other than the $8,841,180 credit referenced above. 1807
WITH TECHNICAL CORRECTIONS 02.03.2023
R-7

2. The Common Benefit Fund shall be available to compensate Attorneys engaged in Qualifying Representations of Participating Litigating Subdivisions and Qualified Tribal Representation of Tribal Participating Governments who:
a. have performed work for the Common Benefit of all Participating Subdivisions and/or Tribal Nations consistent with the provisions to the guidelines established by Judge Polster set forth in MDL 2804 and the Order dated May 1, 2018, under docket number 358, which is included herein by reference; and
b. satisfy the eligibility criteria set forth in Section II.G.

For purposes of Common Benefit Fund distribution, Attorneys representing Tribal Nations litigating against CVS have also reached a settlement for Released Claims with CVS. These settlements are the subject of agreements with CVS. Attorneys representing Tribal Nations are eligible for Common Benefit consideration provided such agreements with CVS became effective under their terms. Such Attorneys must meet the eligibility criteria in Section II.G.

For purposes of Common Benefit Fund distribution, MDL Participating Counsel not engaged in Qualifying Representations of Participating Litigating Subdivisions but who performed work for the Common Benefit pursuant to authorization from the MDL Co-Leads and meet the eligibility criteria in Section II.G. shall be eligible.

3. CVS’s Common Benefit Fund payments under this Fee Agreement satisfy, at a minimum, any assessments or withholdings for the CVS Agreement that are or could be required under the Common Benefit Order for Settling States and their Participating Subdivisions. The Common Benefit Fund shall be overseen by the Fee Panel, which shall determine the allocation of funds to eligible Attorneys consistent with this Fee Agreement and the Common Benefit Order.

4. In assessing the benefits that an Applicant has conferred to Participating Subdivisions (including non-Litigating Subdivisions) and/or Tribes for purposes of any compensation decision, the Fee Panel shall give significant weight to the extent to which (i) the Applicant and his or her clients have contributed to increasing (or reducing) Initial Participation in the CVS Agreement, and (ii) the Applicant and his or her clients have contributed to increasing (or reducing) the amounts achieved under Incentive Payments A-D through participation in the CVS Agreement, including the CVS Tribal Agreement. The Fee Panel shall also consider additional fee recoveries the Applicant may potentially obtain, including, but not limited to, from attorney fee funds under other settlement agreements, State Back-Stop Agreements, representations of States or Tribal Nations, representations of other clients in opioids-related matters, or through the representation of Subdivision clients, 1808
WITH TECHNICAL CORRECTIONS 02.03.2023
R-8
whether they participated in the CVS Agreement or not. It is the intent of this provision to recognize that the goal of the CVS Agreement is to provide for maximum participation by the Subdivisions, maximum abatement funding for all Subdivisions nationally, and the maximum peace for Released Entities.

Therefore, representing one or more Non-Participating States or Non- Participating Subdivisions does not further the goal of the CVS Agreement, and should not be considered Common Benefit because it does not increase funds available to Participating Subdivisions’ abatement programs. Representing one or more Later Litigating Subdivisions or Later Litigating States is antithetical to the CVS Settlement and detracts from Common Benefit. The Fee Panel shall consider this concept of “common detriment” set forth in this paragraph in all of its decision making with respect to the allocation of the Attorney Fee Fund among Applicants, as well as, in its discretion, any reductions provided to CVS as set forth in Section II.H. 3 The Fee Panel shall consider the totality of the Applicant’s Participating Litigating Subdivisions as compared to the Applicant’s Non-Participating Litigating Subdivisions; the Parties recognize that, although the goal is for 100% participation, Applicants with a greater number of clients have a greater probability of having one or more Non- Participating Litigating Subdivisions. As used in this paragraph II.C.4, “client” or “representing” a Subdivision shall include any Litigating Subdivision as to which the Applicant has a Fee Entitlement.

5. As set forth in Section II.H, the Fee Panel must consider the factors described in paragraph II.C.4 to determine how and whether to reduce the amounts to be paid by CVS under this Fee Agreement and to determine how to allocate funds among Applicants. They may also, at their discretion, consider other factors not inconsistent with the factors set forth in paragraph II.C.4. and Section II.H.

Any reduction in payment obligation or credit to be given CVS in this Fee Agreement shall be applied against Payment Year 5 and then working backwards. Any reduction to an Applicant not credited to CVS shall be allocated to attorneys whose Litigating Subdivision clients participated in the settlement by the Initial Subdivision Participation Date.

D. Contingency Fee Fund (40% of the Attorney Fee Fund)

1. The maximum potential total Contingency Fee Fund payment to be made by CVS into the Attorney Fee Fund is $200,246,378.60, and in no event shall it exceed that amount. CVS’s maximum potential Contingency Fee Fund payment shall be subject to the reductions set forth in Section II.A.2. for Non- 3 Regardless of the status of the CT-3 bellwether counties under the CVS Agreement and this Fee Agreement, and notwithstanding any provisions in those agreements to the contrary, it is expressly agreed that the attorneys who represent or worked on behalf of the CT-3 bellwether counties in the CT-3 litigation are eligible to apply to the Fee Panel for attorneys’ fees from the Common Benefit Fund for the CT-3 representation and that the Fee Panel has discretion to determine that such representation has achieved common benefit. 1809
WITH TECHNICAL CORRECTIONS 02.03.2023
R-9
Settling States and to the adjustments set forth below and, subject to those reductions, shall be paid on the following yearly schedule:

CVS Maximum Contingency Fee
Payment
Year 1 $36,519,428.40
Payment
Year 2 $32,271,302.40
Payment
Year 3 $43,818,549.20
Payment
Year 4 $43,818,548.80
Payment
Year 5 $43,818,548.80
Total $200,246,377.60

2. The Contingency Fee Fund shall be available to compensate Attorneys engaged in Qualifying Representations of Participating Litigating Subdivisions that meet the criteria set forth in Section II.G.
a. The Contingency Fee Fund shall be available to Attorneys who represent Litigating Subdivisions that are Participating Subdivisions, whether their actions are filed in state or federal court, and meet the eligibility criteria of Section II.G.
b. Participation in the Contingency Fee Fund by counsel that have a case that is not subject to the jurisdiction of the MDL Court shall not create, provide, or waive jurisdiction of the MDL Court over that Litigating Subdivision, that case or Attorneys, other than to oversee the fairness of the distribution process, and enforcement of this Fee Agreement.

3. The amount owed by CVS to the Contingency Fee Fund shall be reduced to reflect the non-joinder of Litigating Subdivisions in Settling States by subtracting the amounts identified by the Fee Panel, pursuant to paragraph II.H.7, that would have been owed to counsel for Non-Participating Litigating Subdivisions in Settling States had such Litigating Subdivisions been Participating Subdivisions.

4. In the event that after the date of the CVS Agreement, CVS, prior to the Effective Date of the CVS Agreement, settles with any Litigating Subdivision 1810
WITH TECHNICAL CORRECTIONS 02.03.2023
R-10
that would have been eligible to participate in the CVS Agreement, and, under such settlement agreement pays attorneys’ fees, the Fee Panel shall treat those Litigating Subdivisions as Participating Litigating Subdivisions and, applying the same criteria applicable to all Attorneys for Participating Litigating Subdivisions, determine what amount they would have been paid from the Contingency Fee Fund if they had become Participating Subdivisions under the CVS Agreement without such prior settlement. That sum, rather than being paid to the Attorney for the previously settling Litigating Subdivision, shall be returned to CVS, except that such refund shall not be greater than the amount paid to the Attorneys under the Litigating Subdivision’s prior settlement agreement.

E. Subdivision Cost and Expense Fund

1. CVS shall pay $22,500,000 into the Subdivision Cost and Expense Fund on the schedule set forth below.

Cost Fund
Payment
Year 1 $11,250,000.00
Payment
Year 2 $11,250,000.00
Total $22,500,000.00

2. The Subdivision Cost and Expense Fund shall be available to compensate Attorneys for costs and expenses arising out of representation of Participating Litigating Subdivisions. No funds in the Subdivision Cost and Expense Fund may be used to compensate the costs incurred by Non-Participating Subdivisions or Non-Litigating Subdivisions or costs and expenses arising out of representation of any such Subdivision. In allocating the Subdivision Cost and Expense Fund, the Administrator shall not allocate any funds for costs incurred after December 9, 2022.

3. During the period between December 9, 2022 and the Effective Date of the CVS Agreement, the MDL PEC, as well as Litigating Subdivisions’ Attorneys, shall make best efforts to cease litigation activity against CVS, including by jointly seeking stays or severance of claims against CVS, where feasible, or postponements if a motion to stay or sever is not feasible or is denied, so long as such actions are not otherwise detrimental to the Litigating Subdivision.

4. In the event that CVS, prior to the Effective Date of the CVS Agreement, settles with any Litigating Subdivision and, under such settlement agreement, pays costs to the Litigating Subdivision or its Attorney, the MDL Cost and Expense Fund Administrator shall treat those Litigating Subdivisions as Participating Litigating Subdivisions and, using the same criteria applicable to all applicants to the Subdivision Cost and Expense Fund, determine what amount in costs the Litigating 1811
WITH TECHNICAL CORRECTIONS 02.03.2023
R-11
Subdivision or its Attorney would have been paid from the Subdivision Cost and Expense Fund if they had settled under the CVS Agreement. That sum, rather than being paid to the Attorney or the previously settling Litigating Subdivision, shall be credited and/or returned to CVS, except that such sum shall not be greater than the amount paid under the previously settled Litigating Subdivision’s settlement agreement.

5. The Cost Fund shall be administered by the Cost Fund and Expense Fund Administrator (MDL Docket No. 3828), who will be governed by the provisions of this Agreement and shall design the process and procedures for the allocation of costs pursuant to this Agreement and the MDL Court’s Order.

6. The costs of the Cost and Expense Fund Administrator shall be paid from the Cost Fund and allocated by the Cost and Expense Fund Administrator between the MDL Direct Cost Fund and the Subdivision Cost and Expense Fund to fairly charge each fund the cost incurred in implementing and supervising the specific fund.

7. The Cost and Expense Fund Administrator shall set the process and procedures for submission of and criteria for applications for payment of Subdivisions’ and Tribal Nations’ costs and expenses. The Cost and Expense Fund Administrator shall receive and evaluate applications from Participating Litigating Subdivisions and litigating Tribal Nations, whether filed in Federal Court or State Court, to seek reimbursement for eligible costs under Section II.E.2 in pursuit of claims against CVS. The process shall require a showing that the costs or expenses sought were reasonably incurred in furtherance of active litigation of a designated state or federal bellwether trial-set case, or Common Benefit. The Cost and Expense Fund Administrator shall require transparency from all applicants as to any other sources for compensating Attorneys for Subdivisions and Tribal Nations for costs incurred. If funds remain after the reimbursement of approved out-of- pocket costs, the Cost and Expense Fund Administrator may consider reasonable and appropriate payment for client time, costs, or expenses incurred by recognized trial bellwether plaintiffs. At the conclusion of the process, any funds not allocated by the Cost and Expense Fund Administrator shall be transferred to the Common Benefit Fund established in this Exhibit R.
1812
WITH TECHNICAL CORRECTIONS 02.03.2023
R-12

8. In the event that States and Subdivisions enter into an additional global settlement with a party or parties other than CVS that is (a) under the jurisdiction of the MDL Court in MDL No. 2804, (b) creates a separate cost fund, and (c) unless the parties agree to another date, such agreement has an effective date prior to June 30, 2023, the Cost and Expense Fund Administrator shall have the authority to aggregate the Cost Fund with the cost fund created under that separate global settlement agreement. The Cost and Expense Fund Administrator shall have the authority to address the appropriate procedures and required information to allow the costs to be funded from the appropriate cost fund or shared by two or more cost funds; provided, however, that the Subdivision Cost and Expense Fund shall remain subject to the requirements set forth in Section II.E.2. For the avoidance of doubt, the Subdivision Cost and Expense Fund is available only to compensate Attorneys for costs and expenses arising out of representation of Participating Litigating Subdivisions, and no funds in the Subdivision Cost and Expense Fund may be used to compensate the costs incurred by Non-Participating Subdivisions or Non- Litigating Subdivisions or costs and expenses arising out of representation of any such Subdivision.

F. MDL Direct Cost Fund

1. CVS shall pay $7,500,000 into the MDL Direct Cost Fund on the schedule set forth below.

MDL Direct Cost Fund
Payment
Year 1 $3,750,000.00
Payment
Year 2 $3,750,000.00
Total $7,500,000.00

2. The MDL Direct Cost Fund shall be released following the Effective Date of this Fee Agreement without any delay to reimburse the MDL Counsel for an agreed-to portion of the expenses incurred, as approved by the Cost and Expense Fund Administrator. The sum deposited into the MDL Direct Cost Fund will be paid directly to the MDL Opiate Capital Account. The Cost and Expense Fund Administrator may include costs incurred by the MDL PEC in furtherance of litigation, mediation, implementation, and management of the Settlement. 1813
WITH TECHNICAL CORRECTIONS 02.03.2023
R-13

3. In allocating the MDL Direct Cost Fund, the Administrator shall not allocate any funds for costs incurred after December 9, 2022, unless the Administrator determines that there are sufficient funds to cover all Subdivision costs incurred prior to December 9, 2022 and that special circumstances exist to justify costs incurred following the public announcement of the CVS Agreement, including reasonable costs related to the implementation of the CVS Agreement.

G. Eligibility

1. It is the intention of all parties participating in the Fee Panel process that there should be total transparency to the Fee Panel and to all fund participants. In connection with the process to be developed by the Fee Panel, any and all monies in attorney’s fees received or awarded, including prior or future Contingency Fees, Common Benefit Fees, referral fees, expenses paid, promises for payment, or any other Fee Entitlement, to any Applicant in any opioid litigation shall be disclosed to the Fee Panel as a condition of participating in the Attorney Fee Fund and prior to an award from the Fee Panel.

Any payment, expectation of payment or perceived entitlement to participate in a State Back-Stop Agreement or any other agreement reached with a Settling State or any Subdivision or any other source regarding payment of fees must be disclosed to the Fee Panel. Similarly, any right to payment from any other fund, for example a fund for payment to lawyers representing Settling States or Tribal Nations or Subdivisions shall be disclosed to the Fee Panel. Because it is anticipated that there will be multiple firms listed on contingent fee agreements with Litigating Subdivisions, the Fee Panel shall establish procedures, with input from Attorneys for Participating Litigating Subdivisions, for which party or parties should petition for fees from such groups and to whom the fee shall be paid and thereafter distributed to co-counsel in accordance with applicable agreements. For the avoidance of doubt, all Attorneys that are part of such groups must meet the eligibility criteria in paragraph II.G.3, must be subject to the criteria set forth in paragraph II.C.4, and must be disclosed to the Fee Panel.

2. An Applicant may apply for and recover attorneys’ fees from the Common Benefit Fund, the Contingency Fee Fund, and any fund created by a past or future State Back-Stop Agreement, provided the Applicant satisfies the requirements relevant to each such fund and requirements for disclosure to the Fee Panel.

3. An Attorney may not receive any payment from the Attorney Fee Fund (which includes both the Contingency Fee Fund and the Common Benefit Fund) unless the following eligibility criteria are met and annually certified by the Attorney:
a. The Attorney must expressly waive the enforcement against the Litigating Subdivision client of all Fee Entitlements (other than under State Back-Stop Agreements) arising out of or related to any or all Qualifying Representations of any Participating Litigating Subdivision prior to applying for attorneys’ fees from the Attorney Fee Fund. All applications 1814
WITH TECHNICAL CORRECTIONS 02.03.2023
R-14
for attorneys’ fees under this Fee Agreement shall include an affirmation by the Attorney of such waiver and notice to the client(s) of such waiver. Such waiver shall not preclude the Attorney from submitting such Fee Entitlements to the Fee Panel as a factor for consideration in allocating payments from the Attorney Fee Fund or in connection with a State Back- Stop Agreement. For the avoidance of doubt, no Attorney may recover fees under this Fee Agreement unless the Attorney expressly agrees not to enforce Fee Entitlements as to each and every Participating Litigating Subdivision represented by that Attorney, but such Attorneys may participate in and receive funds from a State Back-Stop Agreement. b. The Attorney must represent that s/he has no present intent to represent or participate in the representation of any Later Litigating Subdivision or Later Litigating State with respect to Released Claims against Released Entities. c. The Attorney must represent that s/he has not and will not engage in any advertising or solicitation related to Released Claims against Released Entities where such advertising or solicitation relates to a representation of a Subdivision eligible to be a Participating Subdivision after the Reference Date except that the Attorney may recommend participation in the Agreement.
d. The Attorney must represent s/he will not charge or accept any referral fees for any Released Claims brought against Released Entities by Later Litigating Subdivisions or Later Litigating States. This representation shall not prohibit Attorneys from receiving allocated shares of any future common benefit assessments arising out of settlements or judgments with Later Litigating Subdivisions or Later Litigating States that are the result of the MDL Court’s Common Benefit Order.
e. The Attorney may not have and must represent that s/he does not have a Fee Entitlement related to a Later Litigating Subdivision or Later Litigating State, other than a potential Common Benefit Fee.
f. The Attorney must fully disclose the participation, or the anticipation of participation, in any agreement with a Settling State or Participating Subdivision concerning fees arising out of or related to the CVS Agreement, including any fees paid or anticipated to be paid or any State Back-Stop Agreement.
g. The Attorney must identify for the Fee Panel whether s/he utilized state litigation work product or MDL work product, including but not limited to ARCOS data, document repositories, experts developed in the MDL, trial transcripts, or deposition transcripts. The Attorney must identify whether s/he signed the MDL Participation Agreement.
1815
WITH TECHNICAL CORRECTIONS 02.03.2023
R-15
h. Any Attorney who applies for fees from one or both Funds must represent that, having exercised his/her independent judgment, s/he believes the CVS Agreement to be fair and will make or has made best efforts to recommend the Agreement to his or her Subdivision clients in Settling States. For avoidance of doubt, each Attorney is expected to exercise his or her independent judgment in the best interest of each client individually before determining whether to recommend joining the settlement. All applications for attorneys’ fees or costs under this Section shall include an affirmation by the Attorney in compliance with this Subsection.

4. No Attorney receiving fees under this Fee Agreement may apply for or recover from the Attorney Fee Fund fees arising from representing a Non-Settling State or a Non-Participating Subdivision, provided, however, that this provision is not intended to prohibit Attorneys who do not represent or otherwise have a contractual agreement with such Non-Settling State or Non-Participating Subdivision from receiving allocated shares of any future common benefit assessments that arise out of settlements or judgments involving such Non- Settling State or Non-Participating Subdivision. All applications for attorneys’ fees under this Section shall include an affirmation by the Attorney of compliance with this Section.

5. An Attorney who has filed an application under this section and received an award of attorneys’ fees shall provide a certification of compliance with the requirements of this Fee Agreement annually during the years upon which they are still entitled to receive attorneys’ fee payments under this Agreement. This certification will be done as directed by the Panel.

6. If, at any time, the Attorney is unable to make the representations set forth in this Section, such representations become untrue, or the Attorney falsely represents compliance with the eligibility criteria, the Attorney shall cease to be eligible to receive funds from the Attorney Fee Fund until further review by the Fee Panel of the Attorney’s eligibility under and compliance with this Section II.

7. If an Attorney has a Fee Entitlement with a Later Litigating Subdivision or Later Litigating State or otherwise becomes unable to reaffirm compliance with the eligibility criteria set forth above, the Attorney shall notify the Fee Panel. For the avoidance of doubt, any Attorney who undertakes any new representation of, or has a Fee Entitlement with, a Later Litigating Subdivision or Later Litigating State shall be prohibited from receiving any future funds from the Attorney Fee Fund. If an Attorney fails to notify the Fee Panel of such Fee Entitlement with a Later Litigating Subdivision or Later Litigating State, the Attorney shall be required to refund amounts previously paid. The Fee Panel shall notify CVS when it receives notification.
1816
WITH TECHNICAL CORRECTIONS 02.03.2023
R-16

8. To the extent an Attorney who has received compensation from the Attorney Fee Fund based on Qualifying Representations of Participating Litigating Subdivisions under the CVS Agreement represents a Later Litigating Subdivision or Later Litigating State, such Attorney shall be obligated to refund such amounts received as compensation from the Attorney Fee Fund to CVS.

CVS or such Attorney may bring any dispute as to whether such Attorney shall be obligated to refund such amounts received from the Attorney Fee Fund to CVS, to the Fee Panel. Nothing herein shall require a multi-attorney law firm that has received compensation from the Attorney Fee Fund to refund such amounts if an attorney of the firm that is no longer affiliated with such law firm, after such departure, represents a Later Litigating Subdivision or Later Litigating State, provided that (a) neither the law firm nor any of its other attorneys have any contractual or financial arrangement regarding, stand to benefit directly or indirectly from, or directly or indirectly provide financial or other support of any kind to, the former attorney’s representation of the Later Litigating Subdivision or Later Litigating State and (b) if the former attorney was a partner or owner of the multi-attorney law firm at the time that the law firm received compensation from the Attorney Fee Fund, the former attorney shall be obligated to refund such amounts as the former attorney earned as a result of the compensation that the law firm received from the Attorney Fee Fund.

9. In the event that an Attorney is deemed ineligible by the Fee Panel (whether based on its initial application or subsequent recertification), the Fee Panel shall provide notice to the Attorney and give the Attorney 30 days to provide additional information such that the Fee Panel could re-consider the Attorney’s eligibility.

10. To the extent that an Attorney has a Fee Entitlement with a Participating Subdivision and is authorized to bring Released Claims against Released Entities, but such authorization is, in scope, less broad than the category of Released Claims set forth in the CVS Agreement, such Attorney may participate fully in both the Contingency Fee Fund and the Common Benefit Fund, without any reduction imposed by the Fee Panel due to the scope of the authorization, so long as the Participating Subdivision fully releases all Released Claims against Released Entities.

11. Attorneys applying to the Attorney Fee Fund knowingly and expressly agree to be bound by the decisions of the Fee Panel, subject to the limited appeal rights set forth in this Fee Agreement, and waive the ability to assert the lack of enforceability of the allocation reached through the procedures outlined herein.

12. Applicants are under an ongoing obligation to inform the Fee Panel in writing of any additional fees earned, expected, or received related to any Opioid litigation throughout the period of the Fee Panel’s operation. 1817
WITH TECHNICAL CORRECTIONS 02.03.2023
R-17
H. Calculation of Amounts Due

1. The Fee Panel shall be solely responsible for determining the amount of fees to be paid to each Applicant. None of the Released Entities shall have any responsibility, obligation, or liability of any kind whatsoever with respect to how attorneys’ fees are calculated under this Section, except that the Fee Panel may receive information from CVS as to (a) the identity of Participating, Non- Participating, Litigating, Later Litigating, and Non-Litigating Subdivisions; (b) the impact of non-participation by a Litigating Subdivision as is relevant to the Fee Panel’s determination in paragraph II.C.4; and (c) such other information as CVS may voluntarily elect to provide.

2. The Fee Panel shall establish procedures for making determinations under this Fee Agreement consistent with this Fee Agreement and orders of the MDL Court. Such procedures may include submission of documentary and/or other evidence, interviews with Applicants and/or other counsel (including counsel for CVS) that the Fee Panel deems appropriate, and/or other means of creating a record upon which fee awards will be based.

3. In making determinations under this Fee Agreement, the Fee Panel must apply the eligibility criteria set forth in Section II.G of this Fee Agreement and the criteria set forth in Section II. The Fee Panel shall ensure that payments are only made for Qualifying Representations of Participating Litigating Subdivisions. In addition, the Fee Panel will give consideration in regard to Common Benefit Fund awards to the Johnson factors, as well as the following factors (which factors may be applied and given relative weight in the Fee Panel’s discretion):
a. The Applicant’s contemporaneously recorded time and labor dedicated to Qualifying Representations along with the Applicant’s financial commitment to such Qualifying Representations. Claimed “time” will not be automatically accepted by the Fee Panel but will be critically reviewed and given substantially more weight and consideration if such time was subject to the audit process described in any Pretrial Order(s) governing the collection of common benefit time;
b. The novelty, time, and complexity of the Qualifying Representations; c. The skill requisite to perform legal services properly and undesirability of the case;
d. The preclusion of other employment by the Applicant due to time dedicated to Qualifying Representations;
e. The Common Benefit, if any, alleged to have been conferred by the Applicant and whether such Common Benefit work product by that Applicant was used by others in parallel litigations against Released Entities 1818
WITH TECHNICAL CORRECTIONS 02.03.2023
R-18
whether within or outside the MDL, provided that any Applicant claiming that s/he substantially benefited cases other than those in which s/he entered an appearance as counsel must substantiate such claims by proffering factual support, such as proper supporting affidavits or other documents as determined by the Fee Panel with input from Attorneys for Participating Litigating Subdivisions;
f. Any “common detriment,” as set forth in paragraph II.C.4; g. Any contingent fee agreement or other Fee Entitlement with Participating Subdivisions, enforcement of which, except for State Back-Stop Agreements, are waived in conjunction with the application, the nature and extent of any work for those Participating Subdivisions, whether such Participating Subdivisions actively litigated and, if so, the nature and procedural history of such case(s);
h. The experience, reputation, and ability of the Applicant; i. Whether the Applicant’s clients brought Released Claims against Released Entities;
j. The status of discovery in cases primarily handled by the Applicant; k. The nature of any work by the Applicant on “bellwether” cases or cases that were similarly active in litigation;
l. Any pressure points successfully asserted by the Applicant in cases against CVS or any risk for CVS created by the Applicant in cases against CVS; m. Any risk for defendants created by Applicants in cases against CVS; n. Successful and unsuccessful motion practice in cases worked on by the Applicant;
o. The date of filing of any cases filed by the Applicant; p. Obtaining consolidation of the litigation in the Applicant’s jurisdiction; q. The number and population of entities represented by the Applicant and the fees that would have been awarded under extinguished contingent fee arrangements;
r. Whether the Applicant’s clients brought claims against CVS prior to the announcement of this settlement on December 9, 2022;
1819
WITH TECHNICAL CORRECTIONS 02.03.2023
R-19
s. Whether the Applicant has had a leadership role in the litigation, whether in state or federal court;
t. Whether the Applicant has had a leadership role in any negotiations aimed at resolving the litigation;
u. Whether the Applicant’s cases have survived motions to dismiss; v. The extent to which the Applicant contributed to the work product used for the common benefit of opioids litigants, including, without limitation, work on ARCOS data, Prescription Data Monitoring Programs, IQVIA data, depositions, document production and analysis experts, motions, briefs and pleadings, trial preparations, and trials;
w. The extent to which litigation occurred prior to and contributed to completion of settlement negotiations, as distinct from litigation that occurred after the announcement of the CVS Agreement on December 9, 2022, such latter litigation both being of less value and, the case of litigation filed after the announcement of the CVS Agreement on December 9, 2022, resulting in a common detriment to the settlement process, which in both cases should be viewed less favorably; and
x. Any other factors that the Fee Panel finds to be appropriate to consider after input from Applicants to the Attorney Fee Fund.

4. It is possible that the States and Subdivisions that are litigating Opioid cases will enter additional settlements in close proximity of the time for processing the CVS Agreement. If there are additional settlements and these settlements create a Common Benefit Attorney Fee Fund to be administered by the Fee Panel, the Fee Panel may:
a. Consolidate the Common Benefit approval process to include evaluation of all Common Benefit Applications for all settlements entered after November 1, 2022;
b. Determine the fair and equitable allocation of the Aggregate Common Benefit Fees that come after December 9, 2022, including consideration of beneficial or detrimental actions taken with respect to any Settling Defendant contributing to the Common Benefit Attorney Fee Fund; c. Give consideration to the amount and timing of each settlement, including the amount and timing of Common Benefit Fees;
d. The Fee Panel shall abide by the applicable Attorney Fee Agreement in each of the Settlements in Allocating the Common Benefit Fees provided for in the Settlement; and
1820
WITH TECHNICAL CORRECTIONS 02.03.2023
R-20
e. Be guided in their work by the Orders of the Court related to Fees and Costs.

5. The Fee Panel shall develop procedures for receiving a single application, which may be updated or amended based on new information (such as participation by additional Litigating Subdivisions) from each Applicant seeking compensation from each sub fund of the Attorney Fee Fund pursuant to processes and procedures developed by the Fee Panel, which shall not be inconsistent with this Fee Agreement. Any request for attorneys’ fees not included on the single application or through the updating/amendment process designed by the Fee Panel shall be deemed waived. For purposes of transparency and to permit the Fee Panel to conduct its work, the application from each Applicant shall, at a minimum, require each Applicant to:
a. Identify all Litigating Subdivisions for which s/he is seeking payment from the Attorney Fee Fund;
b. Identify all Subdivisions in both Settling and Non-Settling States (and, where applicable, Tribal Nations) with respect to which s/he has a Fee Entitlement with respect to Relevant Claims against Released Entities, and identify all co-counsel in such cases;
c. Identify which of those Subdivisions are Participating Subdivisions and which are not (with similar information for Tribal Nations, where applicable);
d. Specify the specific fund or funds within the Attorney Fee Fund from which the Attorney is seeking compensation;
e. Demonstrate his or her eligibility for compensation from the relevant sub funds within the Attorney Fee Fund pursuant to the criteria set forth for the relevant sub fund;
f. Identify any and all Fee Entitlements from representations of States, Tribal Nations, or other plaintiffs related to Released Claims against Released Entities or in opioids-related matters;
g. Notwithstanding “a-f” above, the Panel may consider a supplemental application if the Applicant shows good cause why circumstances exist that will lead to consideration for additional Common Benefit award. Examples would include, but are not limited to, an Applicant having Non-Participating Litigating Subdivision clients that subsequently become Participating Subdivisions, a Bar Date passes that increases participation or an Allocation Agreement is reached.
1821
WITH TECHNICAL CORRECTIONS 02.03.2023
R-21

6. With respect to the Common Benefit Fund, the Fee Panel shall (subject to any applicable MDL Court Order):
a. Review the applications of all Applicants seeking compensation from the Common Benefit Fund, including determining eligibility for each Applicant as set forth in Section II.G.
b. Using criteria set forth in Sections II.C and II.G, allocate amounts from the Common Benefit Fund to eligible Applicants, including payment amounts for each Payment Year. In making such allocations, the Panel shall apply the principles set forth in paragraph II.C.5 to the amounts paid to Applicants with a Common Benefit Fee Entitlement.

7. With respect to the Contingency Fee Fund, the Fee Panel shall:
a. Review the applications of all Attorneys seeking compensation from the Litigating Subdivision Fee Fund, including determining eligibility for each Attorney as set forth in Section II.G.
b. Apply the Mathematical Model in Exhibit A.
c. Use such allocations to determine refund amounts owed to CVS from the Attorney Fee Fund, and inform CVS and the MDL PEC of all such adjustments.

8. To the extent that there is a dispute about the calculations of the Fee Panel related to the amount that CVS is required to pay (including application of any reductions or refunds under this Fee Agreement), such disputes shall be presented to the Fee Panel and any disputed funds be paid into/held in escrow.

The Fee Panel shall resolve such disputes expeditiously, with either Party having the right to seek review from the MDL Court.

9. For purposes of determination of fee or cost awards, allocations, reductions, and possible reversions under this Fee Agreement, unless specified otherwise a Subdivision will be considered a Non-Participating Subdivision if it is not a Participating Subdivision as of the deadline for the application for the fee at issue (or, if the determination does not involve a specific application, the date on which the record for such determination closes).

10. In the event that the Fee Panel, through the use of the Mathematical Model set forth in Exhibit A, allocates funds from the Contingency Fee Fund for an Attorney based on a Qualifying Representation of a Participating Litigating Subdivision and that Subdivision is in a Settling State in which the Consent Judgment has not been approved, such funds shall be placed into escrow until the Consent Judgment is approved, after which time they shall be released. 1822
WITH TECHNICAL CORRECTIONS 02.03.2023
R-22
I. Miscellaneous

1. The Fee Panel shall charge an hourly rate approved by the Court. The Pre- Effective Date costs associated with the Cost and Expense Fund Administrator shall be paid from funds in the Cost Fund. Post-Effective Date, the cost of the Fee Panel shall be charged against the applicable Fee Fund based on allocation by the Fee Panel and shall not be otherwise funded by CVS.

2. The MDL PEC will seek, and the Attorneys General for Settling States and the CVS will not oppose, a Common Benefit Fee Order requiring an assessment of

7.5% on the gross recovery (by judgment or settlement) of any Non- Participating Subdivision in a non-Settling State that is subject to the federal court jurisdiction, represented by a MDL PEC firm, represented by any Attorney receiving fees from the Common Benefit Fund, represented by any Attorney that signed a Participation Agreement or had been paid in a case otherwise under the jurisdiction of the MDL Court.

3. The MDL PEC shall provide to CVS information they have that identifies Attorneys who represent Litigating Subdivisions who are not Participating Subdivisions and who have an obligation to pay a common benefit assessment, either due to the MDL Court’s orders or pursuant to a Participation Agreement.

4. The MDL PEC and CVS agree that it is a conflict of interest for an Attorney that had represented a Participating Subdivision to represent a Later Litigating Subdivision or Later Litigating State. This Subsection shall be enforceable to the extent permitted by the equivalent to Rules 1.16 and 5.6 of the ABA Model Rules of Professional Conduct in the relevant jurisdictions. The MDL PEC represents that it will comply with this provision in the case of the CVS Agreement until the Effective Date of the CVS Agreement, as well as thereafter, if the CVS Agreement proceeds.

5. Participating Subdivisions agree to instruct their counsel to treat information, work product and expert materials as confidential under Rule 1.6 of the ABA Model Rules of Professional Conduct. Accordingly, an Attorney shall not share information or work product with, or experts or materials to, non-participants (other than the Attorney’s own current clients or their lawyers, consultants, experts or other representatives or agents). However, nothing herein shall prevent MDL Leadership or PEC Counsel from fulfilling their obligations in any MDL and the MDL Court Order.

III. Miscellaneous
1823
WITH TECHNICAL CORRECTIONS 02.03.2023
R-23
A. Termination. If the CVSAgreement does not proceedpast the Reference Date, whether because CVS does not determine to proceed or for any other reason, this Fee Agreement shall be null and void, CVS shall have no obligation to make any payments under this Fee Agreement, and CVS and the MDL PEC shall take such steps as are necessary to restore the status quo ante.

1. MDL Court Consideration. This Fee Agreement shall be attached as an exhibit to the CVS Agreement. This Fee Agreement shall also be submitted by CVS and the MDL PEC to the MDL Court for approval pursuant to the motion and order that shall be attached. The MDL Court shall have no authority to increase the payments made by CVS under this Fee Agreement beyond the amounts described in this Fee Agreement.

2. In the event that the MDL Court, through an order, makes any change to the Fee Panel’s consideration of the factors set forth in paragraph II.C.4, or any other material change to the draft Order attached as part of Exhibit B or the terms of this Fee Agreement, CVS and the MDL PEC shall meet and confer concerning such changes.

3. If CVS and the MDL PEC are unable to reach agreement and revisions to this Fee Agreement, this Fee Agreement shall be null and void, CVS shall have no obligation to make any payments under this Fee Agreement, and CVS and the MDL PEC shall take such further steps as are necessary to restore the status quo ante.

B. Amendment. Once the MDL Court has entered an order implementing this Fee Agreement, this Fee Agreement can only be amended by (1) written agreement of CVS and the MDL PEC and (2) approval by the MDL Court.

C. Jurisdiction and Enforcement . The MDL Court shall have exclusive and ongoing jurisdiction over the enforcement and implementation of this Fee Agreement as set forth herein. The MDL PEC shall be the Authorized Party to enforce this Fee Agreement, as to the payment obligations of CVS as set forth in this Fee Agreement and as to Attorneys making application to the Funds under this Fee Agreement. Solely for purposes of assessing or allocating common benefit fees, the MDL Court will continue to have jurisdiction over the work product developed in the MDL Court by and under the direction of the MDL PEC with respect to claims against CVS, including data and documents, depositions, expert reports, briefs and pleadings; and the MDL Court’s protective orders, management orders, and other decisions regarding such discovery and other work product, including but not limited to, conditions on its use, will continue in full force and effect. Nothing in this paragraph authorizes the MDL Court to act contrary to this Agreement, or provides the MDL Court with jurisdiction over the CVS Agreement.
1824
WITH TECHNICAL CORRECTIONS 02.03.2023
R-24
Description of Mathematical Model for the Allocation of the Contingency Fee Funds CVS Settlement Agreement
This document describes the Mathematical Model for allocation of the Contingency Fee Fund described in Exhibit R (Agreement of Attorneys’ Fees, Costs, and Expenses) to the CVS Settlement Agreement.4 Awards of fees from the Contingency Fee Funds shall be available to Attorneys with Qualifying Representations of Participating Litigating Subdivisions eligible to receive an allocation under the CVS Settlement Agreement. 5 A Fee Panel shall oversee the application of the Model and resolve any questions or disputes concerning the eligibility of a counsel to participate. The Panel is empowered to hear disputes concerning and ensure the accuracy of the mathematical calculations.

In general terms, allocation of the Contingency Fee Fund shall be made by (1) determining the amount of the Settlement Fund that is attributable to each Participating Litigating Subdivision; (2) making certain adjustments to these amounts based on when the Subdivision filed suit and the terms of the applicable fee contract; and (3) dividing the Contingency Fee Fund proportionately among counsel for each Participating Litigating Subdivision based on the amounts calculated in subpart 2.

To collect a fee award from the Contingency Fee Fund, a Participating Litigating Subdivision must have named CVS (or any Released Entity) in its lawsuit. The total maximum amount of the Contingency Fee Fund in the CVS Settlement Agreement is $200,246,377.60.6 Allocation of the Contingency Fee Fund shall be made according to the following steps. These calculations are made only for purpose of determining the percentage share of the Contingency Fee Fund that Attorneys for each Participating Litigating Subdivision should receive, not for determining the dollar amount each Subdivision will receive. (1) For each Settling State, attribute 50% of the settlement funds for that State to its Subdivisions according to the Subdivision Allocation Percentage in Exhibit G to the CVS Settlement Agreement.

Illustrative example:
 Assume that State A is allocated 1.00000% of the $4,279,160,837 Remediation amount [see Exhibit M of the CVS Settlement Agreement].  50% of the 1% share allocated to State A is $21,395,804.19.  Assume that, per Exhibit G of the Agreement, the Subdivision Allocation 4 See CVS Settlement Agreement, Exhibit R § II.D.2.
5 CVS Settlement Agreement, Exhibit R § II.D.2.
6 CVS Settlement Agreement, Exhibit R § II.A.1 & II.D.1. 1825
WITH TECHNICAL CORRECTIONS 02.03.2023
R-25
Percentage for City B in State A is 1.00000000%.
 For purposes of determining its counsel’s share of the Contingency Fee Fund, City B is attributed 1.00000000% of $21,395,804.19, or
$213,958.04.
(2) Adjust the amounts in paragraph 1 as follows:
a. Upward Adjustment for Early Filers. Increase the amount calculated in paragraph 1 above by 10% for any Litigating Subdivision that named CVS in a suit before December 5, 2017, the date the National Prescription Opiate Litigation MDL was formed. If the Litigating Subdivision did not name CVS in a suit before December 2, 2022, then fees from the Contingency Fee Fund will not be awarded to Attorneys with otherwise Qualifying Representations of that Participating Litigating Subdivision.

Illustrative Example:
 Assume City C is attributed $1,000,000 under paragraph 1 above.  If City C named CVS before 12/5/2017, the attributed amount would be adjusted to $1,100,000.
b. Determine Amount Due under Contingency Fee Contract. Determine the amount that would be due to Attorneys with Qualifying Representations of each Participating Litigating Subdivision under the terms of the applicable fee contract if the Participating Litigating Subdivision were to receive the amount calculated in paragraph 2.a. This amount can be referred to as the Contingency Fee Assumption.

Illustrative Example:
 Continuing the example given in paragraph 2.a, if Attorneys have a 20% contingency fee contract with City C for the relevant litigation, the amount calculated in this step would be 20% of $1,100,000, or $220,000.

In the next step, the Contingency Fee Assumption is used to determine the percentage share of the Contingency Fee Fund due to Attorneys for each Participating Litigating Subdivision.
(3) Divide the Contingency Fee Fund proportionately among Attorneys for each Participating Litigating Subdivision in two ways:
a. National Fee Pool Calculation. Determine each Litigating Subdivision’s 1826
WITH TECHNICAL CORRECTIONS 02.03.2023
R-26
percentage share of all amounts due under contingency fee contracts nationwide by dividing the Contingency Fee Assumption calculated for each Subdivision in paragraph 2.b by the sum of all Contingency Fee Assumptions. Then multiply that percentage by the Contingency Fee Fund to figure each Subdivision’s dollar share of the Contingency Fee Fund (but only if the Subdivision timely named CVS in a lawsuit).

Illustrative example:
 $220,000 [from para. 2.b] ÷ $220,000,000 [total amount owed under contingency fee contracts nationwide] = 0.1%7
 0.1%* $200,246,377.60 [Contingency Fee Fund] = $200,246.38 b. Separate State Fee Pools Calculation. Determine each Litigating Subdivision’s percentage share of all amounts due under contingency fee contracts statewide by dividing the Contingency Fee Assumption calculated for each Subdivision in paragraph 2.b by the sum of all Contingency Fee Assumptions in the same State.

Then multiply that percentage by the portion of the Contingency Fee Fund that corresponds to that State’s Overall Allocation Percentage, shown in Exhibit F of the CVS Settlement Agreement, to figure each Subdivision’s dollar share of the Contingency Fee Fund (but only if the Subdivision timely named CVS in a lawsuit).

Illustrative example:
 1% * $200,246,377.60 = $2,002,463.78 [amount of the
Contingency Fee Fund corresponding to State A]
 Assume a total of $2,500,000 is owed under contingency fee contracts for State A.
 $220,000 [from para. 2.b] ÷ $2,500,000 = 8.8%
 8.8% * $2,002,463.78 = $176,216.81
The award of fees to Attorneys with Qualifying Representations of Participating Litigating Subdivisions will be the average of the final amounts calculated in paragraphs

3.a and 3.b above, less any amounts the Fee Panel is authorized to, and does, withhold.8 Paragraph 3.a represents allocation based on a proportional share of a National Fee Pool, 7 In this example, $220 million is the amount theoretically owed under all contingency fee contracts for litigation against CVS as calculated in paragraph 2.b. This amount is illustrative only; the actual amount will not be known until all litigating subdivisions are identified and the terms of their contingency fee contracts are collected. 8 The model also enforces a maximum fee award of 20% of the amount calculated in paragraph 2.b. The description in this document of the Mathematical Model is by necessity an abstraction; the precise contours of the calculations are defined in the model itself.
1827
WITH TECHNICAL CORRECTIONS 02.03.2023
R-27
while paragraph 3.b represents allocation based on a proportional share of the Separate State Fee Pools. In other words, for the National Fee Pool described above in paragraph

3.a, the contingency fee contract rate is compared to all other contingency fee contract rates in the nation. For the Separate State Fee Pools described above in paragraph 3.b, the contingency fee contract terms are compared to the other contingency fee contract terms in that same State. The National Fee Pool and the Separate State Fee Pools are given equal weighting.

Using the first methodology, Attorneys for two Subdivisions in different States with the same amount calculated under paragraph 2.b would be assigned the same amount under paragraph 3.a. Using the second methodology, Attorneys for the same two Subdivisions would be assigned different amounts under paragraph 3.b because they are in different States. Specifically, the Subdivision in the State with a smaller proportion of Participating Litigating Subdivisions would be allocated more than the Subdivision in the State with a greater proportion of Participating Litigating Subdivisions. 1828
WITH TECHNICAL CORRECTIONS 02.03.2023
R-28
By:

Name:

Date:

On behalf of CVS
1829
WITH TECHNICAL CORRECTIONS 02.03.2023
R-29
By:

Name: Paul T. Farrell, Jr.

Date:

By:

Name: Jayne Conroy
Date:

By:

Name: Joseph F. Rice
Date:

On behalf of Plaintiffs’ Executive Committee
1830

1 EXHIBIT S

Agreement on the State Outside Counsel Fee Fund
for Chain Pharmacy Settlements

1. Definitions.

a. “Chain Pharmacy” means any of CVS, Walgreens, and Walmart, and “Chain Pharmacies” means all of the foregoing.
b. “Multistate Chain Pharmacy Settlement Agreement” means This Settlement Agreement along with any other settlement of opioids-related claims among 30 or more states and a Chain Pharmacy.
c. “This Settlement Agreement” means the settlement agreement between the Settling States and the Chain Pharmacy to which this Agreement is attached as an Exhibit.
d. “Settling Chain Pharmacy” means the Chain Pharmacy that is a party to This Settlement Agreement.
e. “Settling States” has the meaning given such term in the relevant Multistate Chain Pharmacy Settlement Agreement.

2. Creation of a State Outside Counsel Chain Pharmacies Fee Fund. The Settling States have agreed to the creation of a state outside counsel fee fund to pay reasonable attorneys’ fees of Settling States which have retained outside counsel in connection with litigation against one or more Chain Pharmacies (such fund, the “State Outside Counsel Chain Pharmacies Fee Fund”).

3. State Outside Counsel Chain Pharmacies Fee Fund Administration. The State Outside Counsel Chain Pharmacies Fee Fund shall be administered separately from any other funds for the payment of attorneys fees or costs in connection with This Settlement Agreement, including any common benefit fund, contingency fee fund for subdivision counsel, state cost fund, or MDL expense fund. If necessary, a committee of Attorneys General shall be convened to oversee the State Outside Counsel Chain Pharmacies Fee Fund (the “Chain Pharmacies Fee Fund Committee”). The Chain Pharmacies Fee Fund Committee shall be appointed by the Settling State Members of the Enforcement Committee and shall be comprised solely of Attorneys General of Settling States that engaged outside counsel to pursue litigation against one or more Chain Pharmacies. The Settlement Fund Administrator (the “Fee Fund Administrator”) shall administer the State Outside Counsel Chain Pharmacies Fee Fund according to this Exhibit and, if convened, the guidelines and directives of the Chain Pharmacies Fee Fund Committee.

4. State Outside Counsel Chain Pharmacies Fee Eligibility.

a. To receive any amount from the State Outside Counsel Chain Pharmacies Fee Fund, an outside counsel to a Settling State must have filed and maintained an WITH TECHNICAL CORRECTIONS 02.23.2023
1831

2 action in the name of a Settling State or its Attorney General against a Chain Pharmacy in a state or federal court as of November 1, 2022. No Settling State (or its outside counsel) shall receive funds from both the State Outside Counsel Chain Pharmacies Fee Fund and any “Additional Remediation Amount” as may be provided for in This Settlement Agreement. b. In addition to the eligibility criteria set forth in Paragraph 4.a, above, and for the avoidance of doubt, only Settling States under This Settlement Agreement are eligible to receive any funds paid into the State Outside Counsel Chain Pharmacies Fee Fund as a result of This Settlement Agreement.

5. State Outside Counsel Chain Pharmacies Fee Fund Amount. The Settling Chain Pharmacy shall pay funds into the State Outside Counsel Chain Pharmacies Fee Fund in an amount equal to, and on the schedule identified in, Exhibit M (the “Contribution”). The Settling Chain Pharmacy’s Contribution shall subject to a reduction as described in Paragraph 8, below.

6. State Outside Counsel Chain Pharmacies Fee Fund Availability and Calculation of Amount.

a. The State Outside Counsel Chain Pharmacies Fee Fund shall be available to compensate private outside counsel for Settling State Attorneys General for approved fees arising out of representation of the Settling State pursuant to the schedule attached to this agreement as Schedule I (the “Fee Schedule”). b. The Fee Schedule is intended to reflect the fee calculation in subparagraph

6.c, below (the “Fee Calculation”). Subject to adjustments required by Paragraph 8, below, in the event of any discrepancy between the Fee Schedule and the Fee Calculation, the Fee Schedule shall control. Each Settling State, by becoming a Participating State in This Settlement Agreement, agrees that the Fee Schedule reflects the Fee Calculation and waives any right to contest the accuracy of the Fee Schedule, absent manifest error, the exclusion of a Settling State, or the inclusion of a Non-Settling State. The version of the Fee Schedule reflecting any necessary adjustments shall be the “Final Fee Schedule.”
c. Fees shall be aggregated across the Multistate Chain Pharmacy Settlement Agreements and be calculated by adding two components: (a) a fixed amount consisting of fifty percent (50%) of the amount of remediation funds allocated to a Settling State and its Subdivisions pursuant to the Multistate Chain Pharmacy Settlement Agreements multiplied by 4.5% (or, if lower, the applicable contingency fee percentage in the Settling State’s outside counsel contract); and (b) a proportional percentage of the remaining fee due under that Settling State’s contract with its outside counsel assuming that fifty percent (50%) of the Settling State’s recovery is allocable to a Settling State (rather than allocable to the Settling State’s Participating Subdivisions) so that the fees of all eligible Settling States (minus the fixed amount that would have been allocated to any Non-Settling States had they become Settling States) WITH TECHNICAL CORRECTIONS 02.23.2023
1832

3 exhausts the State Outside Counsel Chain Pharmacies Fee Fund. The proportional share percentage will be the same for each Settling State included in the State Outside Counsel Chain Pharmacies Fee Fund. Fees shall be split proportionally among each Multistate Chain Pharmacy Settlement Agreement, as set forth on the Fee Schedule.
d. All amounts paid will be less any costs or fees of the Fee Fund Administrator.

The Fee Schedule reflects a holdback amount of $50,000 for such administrative expenses of the Fee Fund Administrator. The remainder of any unused administrative expenses shall be disbursed pro rata to States receiving monies from the State Outside Counsel Chain Pharmacies Fee Fund at the conclusion of such administration.

7. Payment by the Fee Fund Administrator.
a. The Fee Fund Administrator shall hold the Contribution in escrow until the earlier of (1) the last of the three Multistate Chain Pharmacy Settlement Agreements becomes effective or (2) when instructed by the Settling State Members of the Enforcement Committee.
b. Subject to eligibility pursuant to Paragraph 4, above, a Settling State’s outside counsel may receive funds from the State Outside Counsel Chain Pharmacies Fee Fund in the following scenarios (“Payment Scenarios”):

1. The Settling State’s outside counsel agrees that the amount listed for such state on the Final Fee Schedule either satisfies in full or exceeds the amounts owed to all such Settling State’s outside counsel and such counsel has provided written notice waiving all entitlement to additional fee in respect of any Multistate Chain Pharmacy Settlement Agreement.

2. The Settling State and its outside counsel enter into a signed writing establishing the amount owed to the counsel, which includes an agreement on the payment of the amount listed for such state on the Final Fee Schedule and waives any right of the State or its outside counsel to additional amounts from the State Outside Counsel Chain Pharmacies Fee Fund.

3. A final judgment is entered that is no longer appealable, which judgement adjudicates the amount owed to the Settling State’s counsel in respect of This Settlement Agreement and directs the Chain Pharmacies Fee Fund Committee how to pay the amount listed on the Final Fee Schedule for such State.

If no Payment Scenario is applicable with respect to a Settling State, then the Settling State’s share shall be placed in an interest-bearing escrow account (less reasonable expenses of the Fee Fund Administrator) and held unless and until a Payment Scenario is applicable.
c. Upon the applicability of a Payment Scenario 1 with respect to a Settling State, the Fee Fund Administrator shall pay that Settling State’s outside counsel the amount identified on the Final Fee Schedule for such state or WITH TECHNICAL CORRECTIONS 02.23.2023
1833

4 such lesser amount that satisfies the Settling State’s obligation to its outside counsel in full. Any remaining allocation to such State shall be paid to the Settling State.
d. Upon the applicability of a Payment Scenario 2 or 3 with respect to a Settling State, the Fee Fund Administrator shall release monies from the State Outside Counsel Chain Pharmacies Fee Fund in either the amount held by the Fee Fund Administrator, if the amount of the agreement or judgment is equal to or more than the amount held, or the amount indicated in the agreement or in the final judgment, if the amount in the agreement or judgment is less than the amount held.
e. Nothing herein, including the amounts listed in Paragraph 6 above or on any Fee Schedule, shall prevent a Settling State from arguing in any proceeding with its outside counsel that (i) its recovery was less than fifty percent (50%) of the recovery in the settlement agreement down to and including fifteen percent (15%) of the total recovery; (ii) any payment should be discounted by an appropriate discount rate commensurate to the risk of the settlement agreement and the timeline that the Settling State is receiving its payments; (iii) the settlement amount should be lower because the amount a Settling State receives was reduced because such Settling State’s outside counsel failed to obtain joinder from a Settling State’s Subdivision(s) that the outside counsel also represented; or (iv) any limitation placed by the Settling Chain Pharmacy bars payment of a higher fee to outside counsel. f. In the event the amount due to the Settling State’s outside counsel from an escrow account is less than the total amount of funds escrowed on the account of the Settling State, the balance shall be paid to the Settling State. In no event, other than a State becoming a Non-Settling State, shall funds revert to a Chain Pharmacy.

8. Reduction of Amounts owed
a. Non-Settling States; Reversion and Redistribution. Amounts owed by the Settling Chain Pharmacy to the State Outside Counsel Chain Pharmacies Fee Fund shall be reduced by amounts allocated to the fixed amount for such State under This Settlement Agreement in the event that a listed State becomes a Non-Settling State. Specifically, the reduction in the amount owed by the Settling Chain Pharmacy shall be calculated as 2.25% times the total Remediation Payments that would have been allocated to the Non-Settling State had it been a Settling State. The payments for the other Settling States reflected in the Fee Schedule shall be adjusted by the Fee Fund Administrator to reflect a recalculated proportional percentage under the Fee Calculation. b. Settling States; Redistribution. If a Settling State under This Settlement Agreement (i) would otherwise be entitled to a payment from the State Outside Counsel Chain Pharmacies Fee Fund and (ii) is eligible to be a “Settling State” under either of the two other Multistate Chain Pharmacy WITH TECHNICAL CORRECTIONS 02.23.2023
1834

5 Settlement Agreements but does not become such a “Settling State”, then that Settling State’s payment from the State Outside Counsel Chain Pharmacies Fee Fund shall be reduced to an amount equal to the Contribution times the Settling State’s allocation percentage on Exhibit F, which shall be treated as an additional remediation payment in lieu of a fee payment. The payments for the other Settling States reflected in the Fee Schedule shall be adjusted by the Fee Fund Administrator to reflect a recalculated proportional percentage under the Fee Calculation.
c. If either or both of the other Chain Pharmacies fail to enter into a Multistate Chain Pharmacy Settlement Agreement, or if such Multistate Chain Pharmacy Settlement Agreements fail to take effect by December 15, 2023, then the Settling Chain Pharmacy and the Enforcement Committee shall renegotiate the terms of Paragraph 8.b in order to permit prompt payment to Settling States that terminated contested litigation with the Settling Chain Pharmacy, and permitting additional time if necessary to finalize payments to the other Settling States. In no event will such renegotiation result in additional reversion of monies in the State Outside Counsel Chain Pharmacies Fee Fund to the Settling Chain Pharmacy.

9. Interpretation.

a. This Agreement shall be an Exhibit to each Multistate Chain Pharmacy Settlement Agreement and shall include the Fee Schedule setting forth the presumptive payment calculations for each eligible Settling State. By joining This Settlement Agreement, each State agrees on the presumptive accuracy of the Fee Schedule, absent manifest error, the inclusion of a Non-Settling State, or the exclusion of a Settling State.
b. It is the intent of all parties that the State Outside Counsel Chain Pharmacies Fee Fund function in a similar manner, with similar calculations and mechanics, as the “State Outside Counsel Fee Fund” established in Exhibit S of that certain settlement agreement dated as of July 21, 2021 setting forth the terms of settlement between and among McKesson Corporation, Cardinal Health, Inc., and AmerisourceBergen Corporation, on the one hand, and certain settling states and certain participating subdivisions, on the other hand.

WITH TECHNICAL CORRECTIONS 02.23.2023
1835

6 Schedule I to Exhibit S

Fee Schedule

[This Fee Schedule is subject to adjustment pursuant to Paragraph 6.b of Exhibit S)]

State
Total Fee Walgreens Share Walmart Share CVS Share
Alaska $1,851,826.21 $691,943.15 $416,884.80 $742,998.26 Arkansas $4,873,566.77 $1,821,030.03 $1,097,141.78 $1,955,394.96 Delaware $3,726,440.37 $1,392,401.12 $838,899.65 $1,495,139.61 Kentucky $7,773,195.40 $2,904,489.25 $1,749,908.82 $3,118,797.34 Michigan $22,162,404.67 $8,281,081.68 $4,989,220.69 $8,892,102.29 Mississippi $4,641,790.38 $1,734,425.75 $1,044,964.07 $1,862,400.56 Nevada $9,363,802.33 $3,498,826.64 $2,107,987.70 $3,756,987.99 New
Hampshire
$5,985,080.61 $2,236,352.15 $1,347,366.79 $2,401,361.67 New Mexico
$2,748,895.55 $2,748,895.55 $- $-
Puerto
Rico
$6,893,516.73 $2,575,793.38 $1,551,874.76 $2,765,848.60 South Dakota $1,101,349.40 $411,524.13 $247,936.78 $441,888.49 Utah $2,884,152.67 $1,204,171.82 $603,818.18 $1,076,162.67 West Virginia $2,399,292.74 $2,399,292.74 $- $- Admin Expense Holdback $20,875.66 $10,467.86 $18,656.48 Total $31,921,103.05 $16,006,471.88 $28,527,738.91

Excluded States:
• Florida (Walgreens; Walmart; CVS)
• New Mexico (Walmart; CVS)
• West Virginia (Walmart; CVS)

WITH TECHNICAL CORRECTIONS 02.23.2023
1836
WITH TECHNICAL CORRECTIONS 02.03.2023
T-1

EXHIBIT T
Agreement on the Joint State Cost Fund

1. Definitions.
a. “Opioids Defendant” means Walmart, or such other defendant in opioids- related litigation that enters into a Multistate Settlement after November 1, 2022, and “Opioids Defendants” means all of the foregoing. b. “Multistate Settlement” means this Settlement Agreement along with any other settlement of opioids-related claims among 30 or more states and an Opioids Defendant.
c. “Settlement Agreement” means the settlement agreement between the Settling States and the Opioids Defendant to which this Agreement is attached as an Exhibit.
d. “Settling Opioids Defendant” means the Opioids Defendant that is a party to the Settlement Agreement.
e. “Settling States” has the meaning given such term in the Settlement Agreement.

2. Creation of a State Cost Fund. The Settling Opioids Defendant and the Settling States agree to the creation of a fund to pay costs and expenses associated with litigation and investigations related to the opioids litigation (such fund, the “State Cost Fund”). The State Cost Fund shall be administered separately from any other funds for the payment of attorneys fees or costs in connection with the Settlement Agreement, including any common benefit fund, contingency fee fund for subdivision counsel, subdivision cost fund, or MDL expense fund. However, the State Cost Fund shall be administered jointly with similar “State Cost Funds” created in other Multistate Settlements after November 1, 2022; any state cost funds jointly administered in this manner shall be referred to as the “Joint State Cost Fund.” To the extent permissible and feasible, the Joint State Cost Fund may also be jointly administered with any fund for reimbursement of states’ litigation and investigation costs established by a bankruptcy plan, including the Mallinckrodt bankruptcy plan, any plans that may emerge from the bankruptcies of Purdue and Endo, and any similar bankruptcies of opioids defendants. To the extent feasible, the Joint State Cost Fund may also be jointly administered with the State Cost Funds established pursuant to the Distributors Multistate Settlement and the Janssen Multistate Settlement.

3. State Cost Fund Amount. The Settling Opioids Defendant shall pay into the State Cost Fund in the amount listed on, and on the schedule set forth in, Exhibit M (the “Settling Opioids Defendant’s Contribution”) for the purpose paying States’ costs and expenses associated with to the opioid litigation.

4. Joint State Cost Fund Committee. A committee of Attorneys General or their designated 1837
WITH TECHNICAL CORRECTIONS 02.03.2023
T-2
representatives (such committee, the “Joint State Cost Fund Committee”) shall oversee the Joint State Cost Fund. The committee shall be appointed by the Settling State Members of the Enforcement Committee, who shall aim to (i) have equal representation between states that retained contingency fee outside counsel and states that did not retain contingency fee outside counsel with respect to opioids-related litigation, and (ii) maintain consistency of committee membership across state cost funds that compose the Joint State Cost Fund. The Settling State Members of the Enforcement Committee may by majority vote add to or change the composition of the Joint State Cost Fund Committee.

5. Joint State Cost Fund Administrator.
a. The Joint State Cost Fund Committee may select an administrator (the “Joint State Cost Fund Administrator”), who shall administer the Joint State Cost Fund and direct payments to Settling States according to the guidelines and directives of the Joint State Cost Fund Committee. While the expenses of the Joint State Cost Fund Administrator shall be reimbursable pursuant to the principles and guidelines listed below, the Joint State Cost Fund Administrator shall first rely on any separate funds that may be set aside for such purpose in any Multistate Settlement. b. The Joint State Cost Fund Administrator shall be responsible, under the direction and supervision of the Joint State Cost Fund Committee, for receiving and reviewing applications for reimbursement from the Joint State Cost Fund. This may include the creation of an audit process to ensure the integrity of submissions, as well as reimbursement rules to incentivize accurate submissions.

6. State Cost Fund Guidelines and Principles.
a. Monies in the State Cost Fund shall be released without any delay to reimburse Settling States for documented costs incurred or paid in connection with litigation and investigation related to the opioid litigation. b. In allocating the Joint State Cost Fund, the Joint State Cost Fund Committee shall seek to comply with the following principles:

1. Each State Cost Fund should be used to reimburse costs incurred by States that are Settling States in the Multistate Settlement from which funds are paid. (However, the foregoing sentence does not preclude a Non-Settling State that joins a separate Multistate Settlement from participating in the Joint State Cost Fund with respect to contributions made by other Opioids Defendants.)

2. Funds in any State Cost Fund shall be primarily used to reimburse costs incurred prior to the date on which the relevant Multistate Settlement was first made available for participation to eligible States. Regardless of other factors considered in prioritizing payments, all costs incurred prior to January 1, 2023, shall be paid 1838
WITH TECHNICAL CORRECTIONS 02.03.2023
T-3
before any costs incurred after that date are paid.

3. The Joint State Cost Fund shall prioritize the reimbursement of the following over reimbursement of any State’s litigation or investigation costs:
•the reasonable costs of the Joint State Cost Fund
Administrator;
•repayment of National Association of Attorneys General grants made in connection with opioid litigation, without regard to when the grants were made;
•repayment of state-attributable costs of any mediator in connection with negotiations of a Multistate Settlement;

4. The Joint State Cost Fund shall seek to prioritize costs in the following order:
•litigation-related costs; then
•investigation-related costs; then
•settlement and negotiation related costs; then
•cost shares.

5. Costs incurred by a State’s outside counsel that the State is contractually obligated to reimburse shall be treated as costs incurred by a State.

6. As between similar categories of costs (e.g., defendant-specific litigation-related costs), the Joint State Cost Fund shall first reimburse costs incurred by a State’s outside counsel that the State is contractually obligated to reimburse out of its recovery, and then reimburse costs directly incurred by States.

7. The Joint State Cost Fund shall be available to reimburse only those costs which have not yet been reimbursed to a State from any other source, including any other fund set aside in a Multistate Settlement or bankruptcy plan for the reimbursement of costs or any individual state settlements.

8. The Joint State Cost Fund should not reimburse expenses that are expected to be reimbursed from another source, such as a bankruptcy debtor, unless such expected reimbursements do not come to fruition within a reasonable amount of time. This includes cost shares paid by states.
1839
WITH TECHNICAL CORRECTIONS 02.03.2023
T-4

9. When coordinating among different state cost funds that each could be used to reimburse a given expense, the Joint State Cost Fund Committee may set guidelines to equitably distribute reimbursements across all state cost funds in a manner that prioritizes costs unlikely to be otherwise reimbursed to a similarly situated State.

10. The Joint State Cost Fund may deny reimbursement of costs, on either an individual basis or a categorical basis, that a supermajority (75%+) of the Joint State Cost Fund Committee determines to be unreasonable.

11. After all costs identified in the foregoing have been reimbursed, the remaining funds in the Joint State Cost Fund shall be distributed to states in proportion to their allocation of remediation payments in the Mallinckrodt bankruptcy plan. Such distribution shall be treated as a reimbursement for States’ unenumerated costs of administering the Multistate Settlements and no subdivision shares shall be carved out of such disbursement, nor shall any attorney’s fees be assessed against such distribution (unless individually agreed to by a State).
c. In applying the foregoing principles, the Joint State Cost Fund Committee shall have the discretion to vary their application in order to ensure equity among similarly situated states and to facilitate the ease and speed of administering the Joint State Cost Fund. The Joint State Cost Fund Committee may also apply percentages to approximate costs attributable to a particular Opioids Defendant (or categories of Opioids Defendants) in a manner that seeks to treat similarly situated states equitably. d. The Joint State Cost Fund Committee shall establish guidelines for the submission and approval of expenses eligible for reimbursement from the Joint State Cost Fund, which guidelines may be coordinated and consolidated with any similar cost funds in other state opioid settlements for purposes of joint administration and efficiency.
e. Unless waived by the Joint State Cost Fund Committee, the Joint State Cost Fund Administrator shall, in accordance with such guidelines, receive from Settling States records sufficient to demonstrate the incurrence and payment of each expense.
f. Where the Joint State Cost Fund Committee determines by a supermajority vote (75%+) that outside counsel for a Settling State has failed to exercise reasonable diligence in reviewing submitted costs for allowability, and such failure has resulted in the reimbursement of unallowed costs to such outside counsel, the Committee shall have the discretion to reduce or recover payments made to such outside counsel in an amount calculated to 1840
WITH TECHNICAL CORRECTIONS 02.03.2023
T-5
incentivize the exercise of reasonable diligence.

7. State Undertakings. Each State submitting for reimbursement of costs from the Joint State Cost Fund agrees:
a. to only submit costs allowable under this Joint State Cost Fund Agreement; b. to provide all back-up documentation that may be requested with respect to any submitted cost and to make itself available for any questions related to such costs;
c. to exercise reasonable diligence to ensure that all submitted costs are allowable under (i) this Joint State Cost Fund Agreement, (ii) the State’s contract with its outside counsel, if relevant, (iii) state law, and (iv) the policies and procedures applicable to the State’s retention of outside counsel, if relevant; and
d. to promptly return any excess payments made to the State or its outside counsel from the Joint State Cost Fund, including payments made for costs that were reimbursed from another source or are not allowable hereunder. 1841
@ilg 1098-F
"L_p( D[ho[ls ,*,,#
=[n( Hi( 1+-2,<
Fines, Penalties, and
Other Amounts
>_j[lng_hn i` nb_ Nl_[mols ' Chn_lh[f L_p_ho_ M_lpc]_
Copy A
For
Internal Revenue
Service Center
File with Form 1096.

IG< Hi( +/./',,2.
@il Jlcp[]s ;]n [h^
J[j_lqile L_^o]ncih
;]n Hinc]_& m__ nb_
current General
Instructions for
Certain Information
Returns.
0303
@il ][f_h^[l s_[l
,*
PIC> =ILL?=N?>
@CF?L!M h[g_& mnl__n [^^l_mm& ]cns il niqh& mn[n_ il jlipch]_& ]iohnls& TCJ il `il_cah jimn[f ]i^_& [h^ n_f_jbih_ hi(
@CF?L!M NCH J;S?L!M NCH
J;S?L!M h[g_
Mnl__n [^^l_mm "ch]fo^cha [jn( hi(#
=cns il niqh& mn[n_ il jlipch]_& ]iohnls& [h^ TCJ il `il_cah jimn[f ]i^_ 1 $
2 ;giohn ni \_ j[c^ `il
pcif[ncih il jin_hnc[f pcif[ncih
$
3 L_mncnoncih)l_g_^c[ncih
[giohn
$
4 =igjfc[h]_ [giohn
$
5 >[n_ i` il^_l)[al__g_hn
6 =ioln il _hncns
7 =[m_ hog\_l
8 =[m_ h[g_ il h[g_m i` j[lnc_m ni mocn& il^_l& il [al__g_hn 9 =i^_
@ilg 1098-F "L_p( +',*,,# qqq(clm(aip)@ilg+*32@
"M ,MR !SR MP 1CN?P?RC $MPKQ ML 2FGQ .?EC ¯ "M ,MR !SR MP 1CN?P?RC $MPKQ ML 2FGQ .?EC CVS Health Corporation
One CVS Drive
Woonsocket, RI, USA, 02895
[Appropriate Official]
[Designated State]
[Address]

XX-XXXXXXX
*

0.00 *

0.00 * Amounts to be completed following confirmation of settlement participation.

U.S. District Court for the Northern District of Ohio and jurisdictions of other cases settled under the Settlement Agreement entered into by CVS and the Settling States (as defined in such agreement), dated as of [___].
05-0494040
A,B
No. 1:17-md-2804 and other cases settled under the
Settlement Agreement entered into by CVS and the
Settling States (as defined in such agreement), dated as of [___].

National Prescription Opiate Litigation
XX/XX/2023
23 U-1

EXHIBIT U
IRS Form 1098-F
WITH TECHNICAL CORRECTIONS 02.03.2023
1842
WITH TECHNICAL CORRECTIONS 02.03.2023
V-1

EXHIBIT V
CVS Settlement Agreement Sign-On Form
This form indicates whether an Eligible State has determined to become a Settling State under the CVS Settlement Agreement. Each Settling State’s Attorney General represents that he or she has obtained (or will obtain no later than the Initial Subdivision Participation Date) the authority set forth in Section XI.G of the CVS Settlement Agreement. Attorneys General of Eligible States that determine to become Settling States are committing to obtaining any necessary additional State releases prior to the Effective Date.

The State/Commonwealth/Territory of ____________________________ has determined:
☐ to become or
☐ not to become
a Settling State under the CVS Settlement Agreement
_____________________________________ _______________
Signature Date
_____________________________________ _______________
Printed Name Title
(1) Primary Contact for Your Office
Name:

Title:

Email:

Direct Phone Number:
(2) Secondary Contact for Your Office
Name:

Title:

Email:

Direct Phone Number:
1843
WITH TECHNICAL CORRECTIONS 02.03.2023
V-2
(3) DEADLINE: SATURDAY, DECEMBER 31, 2022 AT 5:00 PM ET Please email your completed form to the following:

For CVS:

Alexandra W. Miller
Paul B. Hynes, Jr.

Zuckerman Spaeder LLP
1800 M Street, N.W., Suite 1000
Washington, D.C. 20003
[email protected]
[email protected]
For the Attorneys General:

Josh Stein, Attorney General
North Carolina Department of Justice
Attn: Daniel Mosteller, Deputy General Counsel
PO Box 629
Raleigh, NC 27602
[email protected]
1844
WITH TECHNICAL CORRECTIONS 02.03.2023
W-1

EXHIBIT W
Non-Litigating Threshold Subdivisions1

1. Alexander City city, Alabama

2. Anniston city, Alabama

3. Autauga County, Alabama*

4. Barbour County, Alabama

5. Blount County, Alabama*

6. Butler County, Alabama

7. Center Point city, Alabama

8. Chambers County, Alabama*

9. Choctaw County, Alabama

10. Clarke County, Alabama

11. Clay County, Alabama

12. Cleburne County, Alabama

13. Coosa County, Alabama

14. Covington County, Alabama*

15. Crenshaw County, Alabama

16. Dale County, Alabama*

17. DeKalb County, Alabama*

18. Dothan city, Alabama*

19. Escambia County, Alabama*

20. Etowah County, Alabama*

21. Eufaula city, Alabama

22. Fairfield city, Alabama

23. Fort Payne city, Alabama

24. Geneva County, Alabama

25. Hale County, Alabama

26. Henry County, Alabama

27. Houston County, Alabama*

28. Lee County, Alabama*

29. Leeds city, Alabama

30. Limestone County, Alabama*

31. Macon County, Alabama

32. Madison city, Alabama*

33. Monroe County, Alabama

34. Montgomery city, Alabama*

35. Montgomery County, Alabama*

36. Muscle Shoals city, Alabama

37. Oxford city, Alabama
1 Entities denoted with an asterisk (*) indicate a population of greater than 30,000.

38. Pell City city, Alabama

39. Russell County, Alabama*

40. Scottsboro city, Alabama

41. Shelby County, Alabama*

42. St. Clair County, Alabama*

43. Sumter County, Alabama

44. Tallapoosa County, Alabama*

45. Washington County, Alabama

46. Anchorage municipality, Alaska*

47. Fairbanks city, Alaska*

48. Fairbanks North Star Borough,
Alaska*

49. Juneau city and borough, Alaska*

50. Kenai Peninsula Borough, Alaska*

51. Matanuska-Susitna Borough,
Alaska*

52. Apache County, Arizona*

53. Apache Junction city, Arizona*

54. Avondale city, Arizona*

55. Buckeye city, Arizona*

56. Bullhead City city, Arizona*

57. Casa Grande city, Arizona*

58. Chandler city, Arizona*

59. Coconino County, Arizona*

60. El Mirage city, Arizona*

61. Flagstaff city, Arizona*

62. Fountain Hills town, Arizona

63. Gila County, Arizona*

64. Gilbert town, Arizona*

65. Glendale city, Arizona*

66. Goodyear city, Arizona*

67. Graham County, Arizona*

68. La Paz County, Arizona

69. Lake Havasu City city, Arizona*

70. Marana town, Arizona*

71. Maricopa city, Arizona*

72. Mesa city, Arizona*
1845
WITH TECHNICAL CORRECTIONS 02.03.2023
W-2

73. Oro Valley town, Arizona*

74. Peoria city, Arizona*

75. Pima County, Arizona*

76. Pinal County, Arizona*

77. Prescott city, Arizona*

78. Prescott Valley town, Arizona*

79. Queen Creek town, Arizona*

80. Sahuarita town, Arizona*

81. San Luis city, Arizona*

82. Santa Cruz County, Arizona*

83. Scottsdale city, Arizona*

84. Sierra Vista city, Arizona*

85. Surprise city, Arizona*

86. Tempe city, Arizona*

87. Tucson city, Arizona*

88. Yavapai County, Arizona*

89. Yuma city, Arizona*

90. Arkadelphia city, Arkansas

91. Arkansas County, Arkansas

92. Ashley County, Arkansas

93. Batesville city, Arkansas

94. Baxter County, Arkansas*

95. Bella Vista city, Arkansas

96. Benton city, Arkansas*

97. Benton County, Arkansas*

98. Bentonville city, Arkansas*

99. Blytheville city, Arkansas
100. Boone County, Arkansas*
101. Bradley County, Arkansas
102. Bryant city, Arkansas
103. Cabot city, Arkansas
104. Camden city, Arkansas
105. Carroll County, Arkansas
106. Centerton city, Arkansas
107. Chicot County, Arkansas
108. Clark County, Arkansas
109. Clay County, Arkansas
110. Cleburne County, Arkansas
111. Columbia County, Arkansas
112. Conway city, Arkansas*
113. Conway County, Arkansas
114. Craighead County, Arkansas*
115. Crawford County, Arkansas*
116. Crittenden County, Arkansas*
117. Cross County, Arkansas
118. Desha County, Arkansas
119. Drew County, Arkansas
120. El Dorado city, Arkansas
121. Faulkner County, Arkansas*
122. Fayetteville city, Arkansas*
123. Forrest City city, Arkansas
124. Fort Smith city, Arkansas*
125. Franklin County, Arkansas
126. Fulton County, Arkansas
127. Garland County, Arkansas*
128. Grant County, Arkansas
129. Greene County, Arkansas*
130. Harrison city, Arkansas
131. Helena-West Helena city, Arkansas
132. Hempstead County, Arkansas
133. Hot Spring County, Arkansas*
134. Hot Springs city, Arkansas*
135. Howard County, Arkansas
136. Independence County, Arkansas*
137. Izard County, Arkansas
138. Jackson County, Arkansas
139. Jacksonville city, Arkansas
140. Jefferson County, Arkansas*
141. Johnson County, Arkansas
142. Jonesboro city, Arkansas*
143. Lawrence County, Arkansas
144. Lincoln County, Arkansas
145. Little River County, Arkansas
146. Little Rock city, Arkansas*
147. Logan County, Arkansas
148. Lonoke County, Arkansas*
149. Madison County, Arkansas
150. Magnolia city, Arkansas
151. Malvern city, Arkansas
152. Marion city, Arkansas
153. Marion County, Arkansas
154. Maumelle city, Arkansas
155. Miller County, Arkansas*
156. Mississippi County, Arkansas*
157. Mountain Home city, Arkansas
158. North Little Rock city, Arkansas*
1846
WITH TECHNICAL CORRECTIONS 02.03.2023
W-3
159. Ouachita County, Arkansas
160. Paragould city, Arkansas
161. Perry County, Arkansas
162. Phillips County, Arkansas
163. Pike County, Arkansas
164. Pine Bluff city, Arkansas*
165. Poinsett County, Arkansas
166. Polk County, Arkansas
167. Pope County, Arkansas*
168. Pulaski County, Arkansas*
169. Randolph County, Arkansas
170. Rogers city, Arkansas*
171. Russellville city, Arkansas
172. Saline County, Arkansas*
173. Scott County, Arkansas
174. Searcy city, Arkansas
175. Sebastian County, Arkansas*
176. Sevier County, Arkansas
177. Sharp County, Arkansas
178. Sherwood city, Arkansas*
179. Siloam Springs city, Arkansas
180. Springdale city, Arkansas*
181. St. Francis County, Arkansas
182. Stone County, Arkansas
183. Texarkana city, Arkansas
184. Union County, Arkansas*
185. Van Buren city, Arkansas
186. Van Buren County, Arkansas
187. Washington County, Arkansas*
188. West Memphis city, Arkansas
189. White County, Arkansas*
190. Yell County, Arkansas
191. Adelanto city, California*
192. Alameda city, California*
193. Alhambra city, California*
194. Aliso Viejo city, California*
195. Antioch city, California*
196. Apple Valley town, California*
197. Arcadia city, California*
198. Atascadero city, California*
199. Azusa city, California*
200. Bakersfield city, California*
201. Baldwin Park city, California*
202. Banning city, California*
203. Beaumont city, California*
204. Bell city, California*
205. Bell Gardens city, California*
206. Bellflower city, California*
207. Berkeley city, California*
208. Beverly Hills city, California*
209. Brea city, California*
210. Brentwood city, California*
211. Buena Park city, California*
212. Burbank city, California*
213. Burlingame city, California*
214. Calexico city, California*
215. Camarillo city, California*
216. Campbell city, California*
217. Carlsbad city, California*
218. Carson city, California*
219. Cathedral City city, California*
220. Ceres city, California*
221. Cerritos city, California*
222. Chino city, California*
223. Chino Hills city, California*
224. Citrus Heights city, California*
225. Claremont city, California*
226. Clovis city, California*
227. Coachella city, California*
228. Colton city, California*
229. Compton city, California*
230. Concord city, California*
231. Contra Costa County, California*
232. Corona city, California*
233. Covina city, California*
234. Culver City city, California*
235. Cupertino city, California*
236. Cypress city, California*
237. Daly City city, California*
238. Dana Point city, California*
239. Danville town, California*
240. Davis city, California*
241. Delano city, California*
242. Diamond Bar city, California*
243. Downey city, California*
244. Eastvale city, California*
1847
WITH TECHNICAL CORRECTIONS 02.03.2023
W-4
245. El Cajon city, California*
246. El Centro city, California*
247. El Monte city, California*
248. El Paso de Robles (Paso Robles)
city, California*
249. Elk Grove city, California*
250. Escondido city, California*
251. Fairfield city, California*
252. Folsom city, California*
253. Fontana city, California*
254. Foster City city, California*
255. Fountain Valley city, California*
256. Fremont city, California*
257. Fresno city, California*
258. Garden Grove city, California*
259. Gardena city, California*
260. Gilroy city, California*
261. Glendale city, California*
262. Glendora city, California*
263. Glenn County, California
264. Goleta city, California*
265. Hanford city, California*
266. Hawthorne city, California*
267. Hayward city, California*
268. Hemet city, California*
269. Hesperia city, California*
270. Highland city, California*
271. Hollister city, California*
272. Huntington Park city, California*
273. Indio city, California*
274. Inglewood city, California*
275. Irvine city, California*
276. Jurupa Valley city, California*
277. Kern County, California*
278. Kings County, California*
279. La Mirada city, California*
280. La Puente city, California*
281. La Quinta city, California*
282. La Verne city, California*
283. Laguna Hills city, California*
284. Laguna Niguel city, California*
285. Lake County, California*
286. Lake Elsinore city, California*
287. Lake Forest city, California*
288. Lakewood city, California*
289. Lancaster city, California*
290. Lawndale city, California*
291. Lincoln city, California*
292. Livermore city, California*
293. Lodi city, California*
294. Lompoc city, California*
295. Long Beach city, California*
296. Los Altos city, California*
297. Los Banos city, California*
298. Los Gatos town, California*
299. Lynwood city, California*
300. Madera city, California*
301. Manhattan Beach city, California*
302. Manteca city, California*
303. Martinez city, California*
304. Menifee city, California*
305. Menlo Park city, California*
306. Merced city, California*
307. Milpitas city, California*
308. Mission Viejo city, California*
309. Modesto city, California*
310. Monrovia city, California*
311. Montclair city, California*
312. Montebello city, California*
313. Monterey Park city, California*
314. Moorpark city, California*
315. Moreno Valley city, California*
316. Morgan Hill city, California*
317. Mountain View city, California*
318. Napa city, California*
319. National City city, California*
320. Newark city, California*
321. Newport Beach city, California*
322. Norwalk city, California*
323. Novato city, California*
324. Oakland city, California*
325. Oakley city, California*
326. Oceanside city, California*
327. Ontario city, California*
328. Orange city, California*
329. Orange County, California*
1848
WITH TECHNICAL CORRECTIONS 02.03.2023
W-5
330. Pacifica city, California*
331. Palm Desert city, California*
332. Palm Springs city, California*
333. Palmdale city, California*
334. Palo Alto city, California*
335. Paramount city, California*
336. Pasadena city, California*
337. Perris city, California*
338. Petaluma city, California*
339. Pico Rivera city, California*
340. Pittsburg city, California*
341. Pleasant Hill city, California*
342. Pleasanton city, California*
343. Pomona city, California*
344. Porterville city, California*
345. Poway city, California*
346. Rancho Cordova city, California*
347. Rancho Cucamonga city,
California*
348. Rancho Palos Verdes city,
California*
349. Rancho Santa Margarita city,
California*
350. Redding city, California*
351. Redlands city, California*
352. Redondo Beach city, California*
353. Redwood City city, California*
354. Rialto city, California*
355. Richmond city, California*
356. Riverside city, California*
357. Rocklin city, California*
358. Rohnert Park city, California*
359. Rosemead city, California*
360. Roseville city, California*
361. Salinas city, California*
362. San Benito County, California*
363. San Bernardino city, California*
364. San Bruno city, California*
365. San Buenaventura (Ventura) city,
California*
366. San Carlos city, California*
367. San Diego city, California*
368. San Dimas city, California*
369. San Francisco city / San Francisco
County, California*
370. San Gabriel city, California*
371. San Jacinto city, California*
372. San Joaquin County, California*
373. San Juan Capistrano city,
California*
374. San Luis Obispo city, California*
375. San Marcos city, California*
376. San Mateo city, California*
377. San Mateo County, California*
378. San Pablo city, California*
379. San Rafael city, California*
380. San Ramon city, California*
381. Santa Barbara city, California*
382. Santa Barbara County, California*
383. Santa Clara city, California*
384. Santa Clarita city, California*
385. Santa Cruz city, California*
386. Santa Maria city, California*
387. Santa Monica city, California*
388. Santa Rosa city, California*
389. Santee city, California*
390. Saratoga city, California*
391. Seaside city, California*
392. Simi Valley city, California*
393. Siskiyou County, California*
394. Solano County, California*
395. South Gate city, California*
396. South San Francisco city,
California*
397. Stanislaus County, California*
398. Stanton city, California*
399. Stockton city, California*
400. Sunnyvale city, California*
401. Temecula city, California*
402. Temple City city, California*
403. Thousand Oaks city, California*
404. Torrance city, California*
405. Tracy city, California*
406. Turlock city, California*
407. Tustin city, California*
408. Union City city, California*
1849
WITH TECHNICAL CORRECTIONS 02.03.2023
W-6
409. Upland city, California*
410. Vacaville city, California*
411. Vallejo city, California*
412. Victorville city, California*
413. Visalia city, California*
414. Vista city, California*
415. Walnut Creek city, California*
416. Watsonville city, California*
417. West Covina city, California*
418. West Hollywood city, California*
419. West Sacramento city, California*
420. Whittier city, California*
421. Wildomar city, California*
422. Woodland city, California*
423. Yorba Linda city, California*
424. Yuba City city, California*
425. Yucaipa city, California*
426. Alamosa County, Colorado
427. Arvada city, Colorado*
428. Boulder city, Colorado*
429. Castle Rock town, Colorado*
430. Centennial city, Colorado*
431. Chaffee County, Colorado
432. Colorado Springs city, Colorado*
433. Delta County, Colorado*
434. Douglas County, Colorado*
435. Eagle County, Colorado*
436. El Paso County, Colorado*
437. Englewood city, Colorado*
438. Fort Collins city, Colorado*
439. Fountain city, Colorado*
440. Garfield County, Colorado*
441. Grand Junction city, Colorado*
442. La Plata County, Colorado*
443. Lafayette city, Colorado*
444. Lakewood city, Colorado*
445. Las Animas County, Colorado
446. Littleton city, Colorado*
447. Longmont city, Colorado*
448. Loveland city, Colorado*
449. Montrose County, Colorado*
450. Otero County, Colorado
451. Parker town, Colorado*
452. Pueblo city, Colorado*
453. Summit County, Colorado*
454. Weld County, Colorado*
455. Wheat Ridge city, Colorado*
456. Windsor town, Colorado*
457. Ansonia town / Ansonia city,
Connecticut
458. Danbury city / Danbury town,
Connecticut*
459. Derby city / Derby town,
Connecticut
460. Glastonbury town, Connecticut*
461. Greenwich town, Connecticut*
462. Groton town, Connecticut*
463. Hamden town, Connecticut*
464. Hartford city / Hartford town,
Connecticut*
465. Manchester town, Connecticut*
466. Meriden city / Meriden town,
Connecticut*
467. New Britain town / New Britain
city, Connecticut*
468. New Haven town / New Haven city,
Connecticut*
469. New London city / New London
town, Connecticut
470. Newington town, Connecticut*
471. Norwalk city / Norwalk town,
Connecticut*
472. Stamford city / Stamford town,
Connecticut*
473. Trumbull town, Connecticut*
474. Wallingford town, Connecticut*
475. West Hartford town, Connecticut*
476. New Castle County, Delaware*
477. Newark city, Delaware*
478. Wilmington city, Delaware*
479. Alpharetta city, Georgia*
480. Bacon County, Georgia
481. Barrow County, Georgia*
482. Berrien County, Georgia
483. Brookhaven city, Georgia*
484. Brooks County, Georgia
1850
WITH TECHNICAL CORRECTIONS 02.03.2023
W-7
485. Brunswick city, Georgia
486. Bryan County, Georgia*
487. Calhoun city, Georgia
488. Canton city, Georgia*
489. Chamblee city, Georgia*
490. Chatham County, Georgia*
491. Colquitt County, Georgia*
492. Coweta County, Georgia*
493. Crawford County, Georgia
494. Dalton city, Georgia*
495. Doraville city, Georgia
496. Douglas County, Georgia*
497. Douglasville city, Georgia*
498. Dunwoody city, Georgia*
499. East Point city, Georgia*
500. Fannin County, Georgia
501. Floyd County, Georgia*
502. Gilmer County, Georgia*
503. Gordon County, Georgia*
504. Grady County, Georgia
505. Harris County, Georgia*
506. Heard County, Georgia
507. Hinesville city, Georgia*
508. Johns Creek city, Georgia*
509. Kennesaw city, Georgia*
510. LaGrange city, Georgia*
511. Lanier County, Georgia
512. Lawrenceville city, Georgia*
513. Marietta city, Georgia*
514. McDonough city, Georgia
515. Meriwether County, Georgia
516. Milton city, Georgia*
517. Moultrie city, Georgia
518. Newnan city, Georgia*
519. Paulding County, Georgia*
520. Peachtree City city, Georgia*
521. Peachtree Corners city, Georgia*
522. Pickens County, Georgia*
523. Pierce County, Georgia
524. Pooler city, Georgia
525. Richmond Hill city, Georgia
526. Roswell city, Georgia*
527. Smyrna city, Georgia*
528. Snellville city, Georgia
529. South Fulton city, Georgia*
530. Statesboro city, Georgia*
531. Stonecrest city, Georgia*
532. Telfair County, Georgia
533. Thomas County, Georgia*
534. Tucker city, Georgia*
535. Valdosta city, Georgia*
536. Villa Rica city, Georgia
537. Walker County, Georgia*
538. Ware County, Georgia*
539. Warner Robins city, Georgia*
540. White County, Georgia*
541. Winder city, Georgia
542. Woodstock city, Georgia*
543. Hawaii County, Hawaii*
544. Honolulu County, Hawaii*
545. Maui County, Hawaii*
546. Bonner County, Idaho*
547. Caldwell city, Idaho*
548. Coeur d'Alene city, Idaho*
549. Idaho Falls city, Idaho*
550. Kootenai County, Idaho*
551. Lewiston city, Idaho*
552. Madison County, Idaho*
553. Meridian city, Idaho*
554. Nampa city, Idaho*
555. Nez Perce County, Idaho*
556. Post Falls city, Idaho*
557. Adams County, Illinois*
558. Addison township, Illinois*
559. Addison village, Illinois*
560. Algonquin township, Illinois*
561. Algonquin village, Illinois*
562. Arlington Heights village, Illinois*
563. Aurora city, Illinois*
564. Aurora township, Illinois*
565. Avon township, Illinois*
566. Bartlett village, Illinois*
567. Batavia township, Illinois*
568. Belleville city, Illinois*
569. Bellwood village, Illinois
570. Bensenville village, Illinois
1851
WITH TECHNICAL CORRECTIONS 02.03.2023
W-8
571. Berwyn city, Illinois*
572. Berwyn township, Illinois*
573. Bloom township, Illinois*
574. Bloomingdale township, Illinois*
575. Bloomington City township,
Illinois*
576. Bloomington city, Illinois*
577. Bolingbrook village, Illinois*
578. Bourbonnais township, Illinois*
579. Bremen township, Illinois*
580. Bridgeview village, Illinois
581. Bristol township, Illinois*
582. Buffalo Grove village, Illinois*
583. Burbank city, Illinois
584. Calumet City city, Illinois*
585. Capital township, Illinois*
586. Carbondale city, Illinois
587. Carol Stream village, Illinois*
588. Carpentersville village, Illinois*
589. Caseyville township, Illinois*
590. Champaign City township, Illinois*
591. Champaign city, Illinois*
592. Chicago Heights city, Illinois
593. Chicago Ridge village, Illinois
594. Cicero town / Cicero township,
Illinois*
595. Clinton County, Illinois*
596. Collinsville township, Illinois*
597. Crystal Lake city, Illinois*
598. Cunningham township, Illinois*
599. Danville city, Illinois*
600. Decatur city, Illinois*
601. Decatur township, Illinois*
602. DeKalb city, Illinois*
603. DeKalb township, Illinois*
604. Des Plaines city, Illinois*
605. Dolton village, Illinois
606. Downers Grove township, Illinois*
607. Downers Grove village, Illinois*
608. Du Page township, Illinois*
609. Dundee township, Illinois*
610. Edwardsville township, Illinois*
611. Effingham County, Illinois*
612. Ela township, Illinois*
613. Elgin city, Illinois*
614. Elgin township, Illinois*
615. Elk Grove township, Illinois*
616. Elk Grove Village village, Illinois*
617. Elmhurst city, Illinois*
618. Evanston city, Illinois*
619. Evergreen Park village, Illinois
620. Forest Park village, Illinois
621. Frankfort township, Illinois*
622. Franklin Park village, Illinois
623. Fremont township, Illinois*
624. Fulton County, Illinois*
625. Galesburg City township, Illinois*
626. Galesburg city, Illinois*
627. Glendale Heights village, Illinois*
628. Glenview village, Illinois*
629. Grafton township, Illinois*
630. Granite City city, Illinois
631. Grundy County, Illinois*
632. Gurnee village, Illinois*
633. Hanover Park village, Illinois*
634. Hanover township, Illinois*
635. Harlem township, Illinois*
636. Harvey city, Illinois
637. Hoffman Estates village, Illinois*
638. Homer township, Illinois*
639. Jackson County, Illinois*
640. Jersey County, Illinois
641. Joliet city, Illinois*
642. Joliet township, Illinois*
643. Kankakee city, Illinois
644. Knox County, Illinois*
645. La Grange Park village, Illinois
646. Lake County, Illinois*
647. Lake Villa township, Illinois*
648. LaSalle County, Illinois*
649. Lee County, Illinois*
650. Leyden township, Illinois*
651. Libertyville township, Illinois*
652. Lisle township, Illinois*
653. Livingston County, Illinois*
654. Lockport township, Illinois*
1852
WITH TECHNICAL CORRECTIONS 02.03.2023
W-9
655. Lombard village, Illinois*
656. Lyons township, Illinois*
657. Lyons village, Illinois
658. Madison County, Illinois*
659. Maine township, Illinois*
660. Massac County, Illinois
661. Maywood village, Illinois
662. McHenry township, Illinois*
663. McLean County, Illinois*
664. Melrose Park village, Illinois
665. Milton township, Illinois*
666. Moline city, Illinois*
667. Monroe County, Illinois*
668. Moraine township, Illinois*
669. Morgan County, Illinois*
670. Mount Prospect village, Illinois*
671. Mundelein village, Illinois*
672. Naperville city, Illinois*
673. Naperville township, Illinois*
674. New Lenox township, Illinois*
675. New Trier township, Illinois*
676. Niles township, Illinois*
677. Normal town, Illinois*
678. Normal township, Illinois*
679. Northbrook village, Illinois*
680. Northfield township, Illinois*
681. Northlake city, Illinois
682. Nunda township, Illinois*
683. Oak Lawn village, Illinois*
684. Oak Park township, Illinois*
685. Oak Park village, Illinois*
686. Ogle County, Illinois*
687. Orland Park village, Illinois*
688. Orland township, Illinois*
689. Oswego township, Illinois*
690. Oswego village, Illinois*
691. Palatine township, Illinois*
692. Palatine village, Illinois*
693. Palos Heights city, Illinois
694. Palos Hills city, Illinois
695. Palos township, Illinois*
696. Park Ridge city, Illinois*
697. Pekin city, Illinois*
698. Peoria City township, Illinois*
699. Peoria city, Illinois*
700. Peoria County, Illinois*
701. Plainfield township, Illinois*
702. Plainfield village, Illinois*
703. Proviso township, Illinois*
704. Quincy city, Illinois*
705. Quincy township, Illinois*
706. Randolph County, Illinois*
707. Rich township, Illinois*
708. River Forest village, Illinois
709. Rock Island city, Illinois*
710. Rockford township, Illinois*
711. Romeoville village, Illinois*
712. Schaumburg township, Illinois*
713. Schaumburg village, Illinois*
714. Schiller Park village, Illinois
715. Shields township, Illinois*
716. Skokie village, Illinois*
717. South Moline township, Illinois*
718. Springfield city, Illinois*
719. St. Charles city, Illinois*
720. St. Charles township, Illinois*
721. St. Clair County, Illinois*
722. St. Clair township, Illinois*
723. Stickney township, Illinois*
724. Streamwood village, Illinois*
725. Streator city, Illinois
726. Summit village, Illinois
727. Tazewell County, Illinois*
728. Thornton township, Illinois*
729. Tinley Park village, Illinois*
730. Troy township, Illinois*
731. Urbana city, Illinois*
732. Vermilion County, Illinois*
733. Vernon township, Illinois*
734. Warren township, Illinois*
735. Washington County, Illinois
736. Waukegan city, Illinois*
737. Waukegan township, Illinois*
738. Wayne township, Illinois*
739. West Deerfield township, Illinois*
740. Wheatland township, Illinois*
1853
WITH TECHNICAL CORRECTIONS 02.03.2023
W-10
741. Wheaton city, Illinois*
742. Wheeling township, Illinois*
743. Wheeling village, Illinois*
744. Whiteside County, Illinois*
745. Williamson County, Illinois*
746. Winfield township, Illinois*
747. Wood River township, Illinois*
748. Woodford County, Illinois*
749. Woodridge village, Illinois*
750. Worth township, Illinois*
751. York township, Illinois*
752. Aboite township, Indiana*
753. Adams County, Indiana*
754. Adams township, Indiana*
755. Anderson city, Indiana*
756. Anderson township, Indiana*
757. Bartholomew County, Indiana*
758. Boone County, Indiana*
759. Calumet township, Indiana*
760. Carmel city, Indiana*
761. Cass County, Indiana*
762. Center township, Delaware County,
Indiana*
763. Center township, Howard County,
Indiana*
764. Center township, Lake County,
Indiana*
765. Center township, Marion County,
Indiana*
766. Center township, Porter County,
Indiana*
767. Center township, Vanderburgh
County, Indiana*
768. Clark County, Indiana*
769. Clay township, Hamilton County,
Indiana*
770. Clay township, St. Joseph County,
Indiana*
771. Clinton County, Indiana*
772. Columbus city, Indiana*
773. Columbus township, Indiana*
774. Concord township, Indiana*
775. Crown Point city, Indiana*
776. Daviess County, Indiana*
777. Dearborn County, Indiana*
778. Decatur township, Indiana*
779. DeKalb County, Indiana*
780. Delaware township, Indiana*
781. Dubois County, Indiana*
782. Elkhart city, Indiana*
783. Elkhart County, Indiana*
784. Elkhart township, Indiana*
785. Fairfield township, Indiana*
786. Fall Creek township, Hamilton
County, Indiana*
787. Fayette County, Indiana
788. Floyd County, Indiana*
789. Franklin township, Marion County,
Indiana*
790. Gibson County, Indiana*
791. Goshen city, Indiana*
792. Grant County, Indiana*
793. Greene County, Indiana*
794. Guilford township, Indiana*
795. Hamilton County, Indiana*
796. Hancock County, Indiana*
797. Harrison township, Vigo County,
Indiana*
798. Hendricks County, Indiana*
799. Henry County, Indiana*
800. Hobart township, Indiana*
801. Huntington County, Indiana*
802. Jasper County, Indiana*
803. Jefferson County, Indiana*
804. Jeffersonville township, Indiana*
805. Johnson County, Indiana*
806. Knight township, Indiana*
807. Knox County, Indiana*
808. Kokomo city, Indiana*
809. Kosciusko County, Indiana*
810. LaGrange County, Indiana*
811. Lawrence township, Indiana*
812. Lincoln township, Indiana*
813. Madison city, Indiana
814. Madison County, Indiana*
815. Merrillville town, Indiana*
1854
WITH TECHNICAL CORRECTIONS 02.03.2023
W-11
816. Miami County, Indiana*
817. Michigan City city, Indiana*
818. Mishawaka city, Indiana*
819. Montgomery County, Indiana*
820. New Albany city, Indiana*
821. New Albany township, Indiana*
822. Noble County, Indiana*
823. Noblesville township, Indiana*
824. North township, Indiana*
825. Ohio township, Indiana*
826. Orange County, Indiana
827. Penn township, Indiana*
828. Perry township, Allen County,
Indiana*
829. Perry township, Marion County,
Indiana*
830. Perry township, Monroe County,
Indiana*
831. Pike township, Indiana*
832. Pleasant township, Johnson County,
Indiana*
833. Portage city, Indiana*
834. Portage township, Indiana*
835. Portage township, Indiana*
836. Putnam County, Indiana*
837. Ross township, Indiana*
838. Shelby County, Indiana*
839. Shelbyville city, Indiana
840. St. John township, Indiana*
841. St. Joseph township, Indiana*
842. Steuben County, Indiana*
843. Valparaiso city, Indiana*
844. Wabash County, Indiana*
845. Wabash township, Indiana*
846. Warren township, Indiana*
847. Warrick County, Indiana*
848. Washington township, Allen
County, Indiana*
849. Washington township, Hamilton
County, Indiana*
850. Washington township, Hendricks
County, Indiana*
851. Washington township, Marion
County, Indiana*
852. Wayne County, Indiana*
853. Wayne township, Allen County,
Indiana*
854. Wayne township, Marion County,
Indiana*
855. Wayne township, Wayne County,
Indiana*
856. Wea township, Indiana*
857. White River township, Indiana*
858. Whitley County, Indiana*
859. Ames city, Iowa*
860. Ankeny city, Iowa*
861. Bettendorf city, Iowa*
862. Cedar Falls city, Iowa*
863. Cedar Rapids city, Iowa*
864. Council Bluffs city, Iowa*
865. Davenport city, Iowa*
866. Des Moines city, Iowa*
867. Dubuque city, Iowa*
868. Dubuque County, Iowa*
869. Iowa City city, Iowa*
870. Linn County, Iowa*
871. Marion city, Iowa*
872. Marshall County, Iowa*
873. Sioux City city, Iowa*
874. Story County, Iowa*
875. Urbandale city, Iowa*
876. Wapello County, Iowa*
877. Warren County, Iowa*
878. Waterloo city, Iowa*
879. West Des Moines city, Iowa*
880. Woodbury County, Iowa*
881. Butler County, Kansas*
882. Cherokee County, Kansas
883. Crawford County, Kansas*
884. Douglas County, Kansas*
885. Ford County, Kansas*
886. Geary County, Kansas*
887. Harvey County, Kansas*
888. Hutchinson city, Kansas*
889. Lawrence city, Kansas*
1855
WITH TECHNICAL CORRECTIONS 02.03.2023
W-12
890. Leavenworth city, Kansas*
891. Leawood city, Kansas*
892. Lenexa city, Kansas*
893. Lyon County, Kansas*
894. Manhattan city, Kansas*
895. Miami County, Kansas*
896. Montgomery County, Kansas*
897. Neosho County, Kansas
898. Olathe city, Kansas*
899. Riley County, Kansas*
900. Salina city, Kansas*
901. Saline County, Kansas*
902. Shawnee city, Kansas*
903. Shawnee County, Kansas*
904. Topeka city, Kansas*
905. Allen County, Kentucky
906. Anderson County, Kentucky
907. Barren County, Kentucky*
908. Bath County, Kentucky
909. Bell County, Kentucky
910. Bowling Green city, Kentucky*
911. Breathitt County, Kentucky
912. Bullitt County, Kentucky*
913. Caldwell County, Kentucky
914. Calloway County, Kentucky*
915. Campbell County, Kentucky*
916. Campbellsville city, Kentucky
917. Carter County, Kentucky
918. Casey County, Kentucky
919. Christian County, Kentucky*
920. Clay County, Kentucky
921. Clinton County, Kentucky
922. Daviess County, Kentucky*
923. Elizabethtown city, Kentucky*
924. Fleming County, Kentucky
925. Florence city, Kentucky*
926. Garrard County, Kentucky
927. Georgetown city, Kentucky*
928. Grant County, Kentucky
929. Graves County, Kentucky*
930. Harrison County, Kentucky
931. Hart County, Kentucky
932. Hopkinsville city, Kentucky*
933. Knox County, Kentucky*
934. Larue County, Kentucky
935. Laurel County, Kentucky*
936. Letcher County, Kentucky
937. Lewis County, Kentucky
938. Lincoln County, Kentucky
939. Logan County, Kentucky
940. Martin County, Kentucky
941. Mason County, Kentucky
942. Mercer County, Kentucky
943. Monroe County, Kentucky
944. Morgan County, Kentucky
945. Mount Washington city, Kentucky
946. Muhlenberg County, Kentucky*
947. Murray city, Kentucky
948. Nelson County, Kentucky*
949. Nicholasville city, Kentucky*
950. Owen County, Kentucky
951. Owensboro city, Kentucky*
952. Powell County, Kentucky
953. Richmond city, Kentucky*
954. Rowan County, Kentucky
955. Russell County, Kentucky
956. Shepherdsville city, Kentucky
957. Spencer County, Kentucky
958. Taylor County, Kentucky
959. Todd County, Kentucky
960. Union County, Kentucky
961. Wayne County, Kentucky
962. Webster County, Kentucky
963. Whitley County, Kentucky*
964. Winchester city, Kentucky
965. Acadia Parish, Louisiana*
966. Bienville Parish, Louisiana
967. Covington city, Louisiana
968. De Soto Parish, Louisiana
969. Gretna city, Louisiana
970. Iberville Parish, Louisiana*
971. Lafayette city, Louisiana*
972. Lincoln Parish, Louisiana*
973. Livingston Parish, Louisiana*
974. Morgan City city, Louisiana
975. Natchitoches city, Louisiana
1856
WITH TECHNICAL CORRECTIONS 02.03.2023
W-13
976. Pointe Coupee Parish, Louisiana
977. Sabine Parish, Louisiana
978. St. Bernard Parish, Louisiana*
979. Tangipahoa Parish, Louisiana*
980. Terrebonne Parish, Louisiana*
981. Franklin County, Maine*
982. Hancock County, Maine*
983. Oxford County, Maine*
984. Annapolis city, Maryland*
985. Anne Arundel County, Maryland*
986. Baltimore County, Maryland*
987. Cecil County, Maryland*
988. College Park city, Maryland*
989. Gaithersburg city, Maryland*
990. Queen Anne's County, Maryland*
991. Rockville city, Maryland*
992. Salisbury city, Maryland*
993. Westminster city, Maryland
994. Worcester County, Maryland*
995. Amherst town, Massachusetts*
996. Andover town, Massachusetts*
997. Arlington town, Massachusetts*
998. Attleboro city, Massachusetts*
999. Barnstable County, Massachusetts*
1000. Boston city, Massachusetts*
1001. Bristol County, Massachusetts*
1002. Dartmouth town, Massachusetts*
1003. Dracut town, Massachusetts*
1004. Franklin Town city, Massachusetts*
1005. Lawrence city, Massachusetts*
1006. Lexington town, Massachusetts*
1007. Marlborough city, Massachusetts*
1008. Nantucket town, Massachusetts
1009. Needham town, Massachusetts*
1010. Newton city, Massachusetts*
1011. Norfolk County, Massachusetts*
1012. Plymouth County, Massachusetts*
1013. Shrewsbury town, Massachusetts*
1014. Taunton city, Massachusetts*
1015. Waltham city, Massachusetts*
1016. Westfield city, Massachusetts*
1017. Allegan County, Michigan*
1018. Ann Arbor city, Michigan*
1019. Barry County, Michigan*
1020. Battle Creek city, Michigan*
1021. Bay City city, Michigan*
1022. Bay County, Michigan*
1023. Bedford township, Michigan*
1024. Bloomfield charter township,
Michigan*
1025. Brownstown charter township,
Michigan*
1026. Cheboygan County, Michigan
1027. Chesterfield township, Michigan*
1028. Clare County, Michigan*
1029. Commerce charter township,
Michigan*
1030. Dearborn city, Michigan*
1031. Dearborn Heights city, Michigan*
1032. Delta charter township, Michigan*
1033. Eastpointe city, Michigan*
1034. Emmet County, Michigan*
1035. Farmington Hills city, Michigan*
1036. Flint charter township, Michigan*
1037. Flint city, Michigan*
1038. Georgetown charter township,
Michigan*
1039. Grand Blanc charter township,
Michigan*
1040. Harrison charter township,
Michigan
1041. Holland charter township,
Michigan*
1042. Holland city, Michigan*
1043. Huron County, Michigan*
1044. Independence charter township,
Michigan*
1045. Jackson County, Michigan*
1046. Kalamazoo city, Michigan*
1047. Kentwood city, Michigan*
1048. Lapeer County, Michigan*
1049. Lincoln Park city, Michigan*
1050. Macomb township, Michigan*
1051. Mecosta County, Michigan*
1052. Meridian charter township,
Michigan*
1857
WITH TECHNICAL CORRECTIONS 02.03.2023
W-14
1053. Midland city, Michigan*
1054. Midland County, Michigan*
1055. Muskegon city, Michigan*
1056. Novi city, Michigan*
1057. Orion charter township, Michigan*
1058. Ottawa County, Michigan*
1059. Plainfield charter township,
Michigan*
1060. Portage city, Michigan*
1061. Redford charter township,
Michigan*
1062. Rochester Hills city, Michigan*
1063. Roseville city, Michigan*
1064. Royal Oak city, Michigan*
1065. Saginaw charter township,
Michigan*
1066. Saginaw city, Michigan*
1067. Shelby charter township, Michigan*
1068. Southfield city, Michigan*
1069. St. Clair Shores city, Michigan*
1070. St. Joseph County, Michigan*
1071. Sterling Heights city, Michigan*
1072. Taylor city, Michigan*
1073. Troy city, Michigan*
1074. Van Buren County, Michigan*
1075. Warren city, Michigan*
1076. Waterford charter township,
Michigan*
1077. West Bloomfield charter township,
Michigan*
1078. White Lake charter township,
Michigan*
1079. Wyoming city, Michigan*
1080. Ypsilanti charter township,
Michigan*
1081. Andover city, Minnesota*
1082. Apple Valley city, Minnesota*
1083. Becker County, Minnesota*
1084. Beltrami County, Minnesota*
1085. Benton County, Minnesota*
1086. Blaine city, Minnesota*
1087. Bloomington city, Minnesota*
1088. Blue Earth County, Minnesota*
1089. Brooklyn Center city, Minnesota*
1090. Brooklyn Park city, Minnesota*
1091. Burnsville city, Minnesota*
1092. Carlton County, Minnesota*
1093. Carver County, Minnesota*
1094. Chisago County, Minnesota*
1095. Clay County, Minnesota*
1096. Cottage Grove city, Minnesota*
1097. Crow Wing County, Minnesota*
1098. Dakota County, Minnesota*
1099. Douglas County, Minnesota*
1100. Eagan city, Minnesota*
1101. Eden Prairie city, Minnesota*
1102. Edina city, Minnesota*
1103. Freeborn County, Minnesota*
1104. Goodhue County, Minnesota*
1105. Hennepin County, Minnesota*
1106. Inver Grove Heights city,
Minnesota*
1107. Isanti County, Minnesota*
1108. Itasca County, Minnesota*
1109. Kandiyohi County, Minnesota*
1110. Lakeville city, Minnesota*
1111. Mankato city, Minnesota*
1112. Maple Grove city, Minnesota*
1113. Maplewood city, Minnesota*
1114. McLeod County, Minnesota*
1115. Meeker County, Minnesota
1116. Minneapolis city, Minnesota*
1117. Minnetonka city, Minnesota*
1118. Moorhead city, Minnesota*
1119. Morrison County, Minnesota*
1120. Mower County, Minnesota*
1121. Nicollet County, Minnesota*
1122. Olmsted County, Minnesota*
1123. Otter Tail County, Minnesota*
1124. Plymouth city, Minnesota*
1125. Polk County, Minnesota*
1126. Ramsey County, Minnesota*
1127. Rice County, Minnesota*
1128. Richfield city, Minnesota*
1129. Roseau County, Minnesota
1130. Roseville city, Minnesota*
1858
WITH TECHNICAL CORRECTIONS 02.03.2023
W-15
1131. Savage city, Minnesota*
1132. Scott County, Minnesota*
1133. Shakopee city, Minnesota*
1134. Sherburne County, Minnesota*
1135. Sibley County, Minnesota
1136. St. Cloud city, Minnesota*
1137. St. Louis County, Minnesota*
1138. St. Louis Park city, Minnesota*
1139. Stearns County, Minnesota*
1140. Steele County, Minnesota*
1141. Waseca County, Minnesota
1142. Washington County, Minnesota*
1143. Winona County, Minnesota*
1144. Woodbury city, Minnesota*
1145. Wright County, Minnesota*
1146. Alcorn County, Mississippi*
1147. Attala County, Mississippi
1148. Biloxi city, Mississippi*
1149. Brookhaven city, Mississippi
1150. Chickasaw County, Mississippi
1151. Clarke County, Mississippi
1152. Cleveland city, Mississippi
1153. Columbus city, Mississippi
1154. Copiah County, Mississippi
1155. Gautier city, Mississippi
1156. George County, Mississippi
1157. Greene County, Mississippi
1158. Hancock County, Mississippi*
1159. Holmes County, Mississippi
1160. Itawamba County, Mississippi
1161. Jackson County, Mississippi*
1162. Jefferson Davis County, Mississippi
1163. Jones County, Mississippi*
1164. Lafayette County, Mississippi*
1165. Lamar County, Mississippi*
1166. Lauderdale County, Mississippi*
1167. Lawrence County, Mississippi
1168. Lee County, Mississippi*
1169. Lincoln County, Mississippi*
1170. Lowndes County, Mississippi*
1171. Marion County, Mississippi
1172. Marshall County, Mississippi*
1173. Monroe County, Mississippi*
1174. Moss Point city, Mississippi
1175. Neshoba County, Mississippi
1176. Ocean Springs city, Mississippi
1177. Oktibbeha County, Mississippi*
1178. Olive Branch city, Mississippi*
1179. Panola County, Mississippi*
1180. Perry County, Mississippi
1181. Pike County, Mississippi*
1182. Pontotoc County, Mississippi*
1183. Rankin County, Mississippi*
1184. Southaven city, Mississippi*
1185. Starkville city, Mississippi
1186. Sunflower County, Mississippi
1187. Tallahatchie County, Mississippi
1188. Tishomingo County, Mississippi
1189. Tupelo city, Mississippi*
1190. Union County, Mississippi
1191. Vicksburg city, Mississippi
1192. Walthall County, Mississippi
1193. Warren County, Mississippi*
1194. Wayne County, Mississippi
1195. Yalobusha County, Mississippi
1196. Adair County, Missouri
1197. Andrew County, Missouri
1198. Ballwin city, Missouri*
1199. Barry County, Missouri*
1200. Blue Springs city, Missouri*
1201. Butler County, Missouri*
1202. Cape Girardeau city, Missouri*
1203. Cape Girardeau County, Missouri*
1204. Chesterfield city, Missouri*
1205. Christian County, Missouri*
1206. Clay County, Missouri*
1207. Clinton County, Missouri
1208. Columbia city, Missouri*
1209. Crawford County, Missouri
1210. DeKalb County, Missouri
1211. Dent County, Missouri
1212. Dunklin County, Missouri
1213. Florissant city, Missouri*
1214. Greene County, Missouri*
1215. Henry County, Missouri
1216. Independence city, Missouri*
1859
WITH TECHNICAL CORRECTIONS 02.03.2023
W-16
1217. Iron County, Missouri
1218. Jasper County, Missouri*
1219. Jefferson City city, Missouri*
1220. Joplin city, Missouri*
1221. Laclede County, Missouri*
1222. Lafayette County, Missouri*
1223. Lawrence County, Missouri*
1224. Lee's Summit city, Missouri*
1225. Liberty city, Missouri*
1226. Livingston County, Missouri
1227. Madison County, Missouri
1228. McDonald County, Missouri
1229. New Madrid County, Missouri
1230. Newton County, Missouri*
1231. Nodaway County, Missouri
1232. O'Fallon city, Missouri*
1233. Perry County, Missouri
1234. Pike County, Missouri
1235. Platte County, Missouri*
1236. Polk County, Missouri*
1237. Ralls County, Missouri
1238. Ray County, Missouri
1239. Scott County, Missouri*
1240. St. Charles city, Missouri*
1241. St. Louis city, Missouri*
1242. St. Peters city, Missouri*
1243. Ste. Genevieve County, Missouri
1244. Stone County, Missouri*
1245. Taney County, Missouri*
1246. Texas County, Missouri
1247. University City city, Missouri*
1248. Vernon County, Missouri
1249. Washington County, Missouri
1250. Wentzville city, Missouri*
1251. Wildwood city, Missouri*
1252. Billings city, Montana*
1253. Bozeman city, Montana*
1254. Butte-Silver Bow, Montana*
1255. Flathead County, Montana*
1256. Helena city, Montana*
1257. Lewis and Clark County, Montana*
1258. Missoula County, Montana*
1259. Ravalli County, Montana*
1260. Yellowstone County, Montana*
1261. Adams County, Nebraska*
1262. Bellevue city, Nebraska*
1263. Buffalo County, Nebraska*
1264. Dodge County, Nebraska*
1265. Grand Island city, Nebraska*
1266. Hall County, Nebraska*
1267. Kearney city, Nebraska*
1268. Lancaster County, Nebraska*
1269. Lincoln city, Nebraska*
1270. Madison County, Nebraska*
1271. Omaha city, Nebraska*
1272. Platte County, Nebraska*
1273. Scotts Bluff County, Nebraska*
1274. South Sioux City city, Nebraska
1275. Douglas County, Nevada*
1276. Elko County, Nevada*
1277. Fernley city, Nevada
1278. Humboldt County, Nevada
1279. Lyon County, Nevada*
1280. Reno city, Nevada*
1281. Dover city, New Hampshire*
1282. Merrimack County, New
Hampshire*
1283. Rochester city, New Hampshire*
1284. Atlantic City city, New Jersey*
1285. Belleville township, New Jersey*
1286. Berkeley township, New Jersey*
1287. Bloomfield township, New Jersey*
1288. Brick township, New Jersey*
1289. Bridgewater township, New Jersey*
1290. Camden city, New Jersey*
1291. Cape May County, New Jersey*
1292. Cherry Hill township, New Jersey*
1293. City of Orange township, New
Jersey*
1294. Cumberland County, New Jersey*
1295. Deptford township, New Jersey*
1296. East Brunswick township, New
Jersey*
1297. East Orange city, New Jersey*
1298. Edison township, New Jersey*
1299. Egg Harbor township, New Jersey*
1860
WITH TECHNICAL CORRECTIONS 02.03.2023
W-17
1300. Evesham township, New Jersey*
1301. Ewing township, New Jersey*
1302. Fair Lawn borough, New Jersey*
1303. Fort Lee borough, New Jersey*
1304. Franklin township, Somerset
County, New Jersey*
1305. Freehold township, New Jersey*
1306. Galloway township, New Jersey*
1307. Garfield city, New Jersey*
1308. Gloucester County, New Jersey*
1309. Gloucester township, New Jersey*
1310. Hackensack city, New Jersey*
1311. Hamilton township, Mercer County,
New Jersey*
1312. Hillsborough township, New
Jersey*
1313. Hoboken city, New Jersey*
1314. Howell township, New Jersey*
1315. Irvington township, New Jersey*
1316. Jackson township, New Jersey*
1317. Kearny town, New Jersey*
1318. Lakewood township, New Jersey*
1319. Lawrence township, New Jersey*
1320. Linden city, New Jersey*
1321. Livingston township, New Jersey*
1322. Long Branch city, New Jersey*
1323. Manalapan township, New Jersey*
1324. Manchester township, New Jersey*
1325. Marlboro township, New Jersey*
1326. Mercer County, New Jersey*
1327. Middlesex County, New Jersey*
1328. Middletown township, New Jersey*
1329. Monmouth County, New Jersey*
1330. Monroe township, Gloucester
County, New Jersey*
1331. Monroe township, Middlesex
County, New Jersey*
1332. Montclair township, New Jersey*
1333. Morris County, New Jersey*
1334. Mount Laurel township, New
Jersey*
1335. New Brunswick city, New Jersey*
1336. Newark city, New Jersey*
1337. North Bergen township, New
Jersey*
1338. North Brunswick township, New
Jersey*
1339. Old Bridge township, New Jersey*
1340. Parsippany-Troy Hills township,
New Jersey*
1341. Passaic city, New Jersey*
1342. Pennsauken township, New Jersey*
1343. Perth Amboy city, New Jersey*
1344. Piscataway township, New Jersey*
1345. Plainfield city, New Jersey*
1346. Princeton, New Jersey*
1347. Salem County, New Jersey*
1348. Sayreville borough, New Jersey*
1349. Somerset County, New Jersey*
1350. South Brunswick township, New
Jersey*
1351. Teaneck township, New Jersey*
1352. Toms River township, New Jersey*
1353. Union City city, New Jersey*
1354. Union County, New Jersey*
1355. Union township, New Jersey*
1356. Warren County, New Jersey*
1357. Washington township, Gloucester
County, New Jersey*
1358. Wayne township, New Jersey*
1359. West New York town, New Jersey*
1360. West Orange township, New
Jersey*
1361. Willingboro township, New Jersey*
1362. Winslow township, New Jersey*
1363. Woodbridge township, New Jersey*
1364. Amherst town, New York*
1365. Bethlehem town, New York*
1366. Binghamton city, New York*
1367. Brighton town, New York*
1368. Carmel town, New York*
1369. Cattaraugus County, New York*
1370. Cayuga County, New York*
1371. Chautauqua County, New York*
1372. Cheektowaga town, New York*
1373. Chemung County, New York*
1861
WITH TECHNICAL CORRECTIONS 02.03.2023
W-18
1374. Chenango County, New York*
1375. Cicero town, New York*
1376. Clarence town, New York*
1377. Clay town, New York*
1378. Clifton Park town, New York*
1379. Colonie town, New York*
1380. Cortlandt town, New York*
1381. Delaware County, New York*
1382. Eastchester town, New York*
1383. Essex County, New York*
1384. Freeport village, New York*
1385. Greece town, New York*
1386. Greenburgh town, New York*
1387. Guilderland town, New York*
1388. Hamburg town, New York*
1389. Henrietta town, New York*
1390. Irondequoit town, New York*
1391. Lancaster town, New York*
1392. Livingston County, New York*
1393. Madison County, New York*
1394. Manlius town, New York*
1395. Mount Pleasant town, New York*
1396. Mount Vernon city, New York*
1397. New Rochelle city, New York*
1398. Newburgh town, New York*
1399. Niagara Falls city, New York*
1400. North Tonawanda city, New York*
1401. Orleans County, New York*
1402. Ossining town, New York*
1403. Otsego County, New York*
1404. Penfield town, New York*
1405. Perinton town, New York*
1406. Putnam County, New York*
1407. Rye town, New York*
1408. Salina town, New York*
1409. Spring Valley village, New York*
1410. Tioga County, New York*
1411. Tonawanda town, New York*
1412. Union town, New York*
1413. Wappinger town, New York
1414. Warren County, New York*
1415. Warwick town, New York*
1416. Wayne County, New York*
1417. Webster town, New York*
1418. West Seneca town, New York*
1419. White Plains city, New York*
1420. Yates County, New York
1421. Yorktown town, New York*
1422. Alexander County, North Carolina*
1423. Alleghany County, North Carolina
1424. Apex town, North Carolina*
1425. Asheville city, North Carolina*
1426. Bertie County, North Carolina
1427. Burlington city, North Carolina*
1428. Cary town, North Carolina*
1429. Caswell County, North Carolina
1430. Chapel Hill town, North Carolina*
1431. Charlotte city, North Carolina*
1432. Cherokee County, North Carolina
1433. Chowan County, North Carolina
1434. Concord city, North Carolina*
1435. Cornelius town, North Carolina*
1436. Currituck County, North Carolina
1437. Durham city, North Carolina*
1438. Edgecombe County, North
Carolina*
1439. Fuquay-Varina town, North
Carolina*
1440. Garner town, North Carolina*
1441. Gastonia city, North Carolina*
1442. Goldsboro city, North Carolina*
1443. Greene County, North Carolina
1444. Greenville city, North Carolina*
1445. Harnett County, North Carolina*
1446. Henderson County, North Carolina*
1447. High Point city, North Carolina*
1448. Hoke County, North Carolina*
1449. Holly Springs town, North
Carolina*
1450. Huntersville town, North Carolina*
1451. Indian Trail town, North Carolina*
1452. Jackson County, North Carolina*
1453. Johnston County, North Carolina*
1454. Kannapolis city, North Carolina*
1455. Lenoir County, North Carolina*
1456. Macon County, North Carolina*
1862
WITH TECHNICAL CORRECTIONS 02.03.2023
W-19
1457. Matthews town, North Carolina*
1458. Monroe city, North Carolina*
1459. Mooresville town, North Carolina*
1460. Nash County, North Carolina*
1461. Pender County, North Carolina*
1462. Raleigh city, North Carolina*
1463. Rocky Mount city, North Carolina*
1464. Salisbury city, North Carolina*
1465. Sanford city, North Carolina*
1466. Stanly County, North Carolina*
1467. Transylvania County, North
Carolina*
1468. Union County, North Carolina*
1469. Wake County, North Carolina*
1470. Wake Forest town, North Carolina*
1471. Warren County, North Carolina
1472. Washington County, North Carolina
1473. Wilson city, North Carolina*
1474. Wilson County, North Carolina*
1475. Cass County, North Dakota*
1476. Fargo city, North Dakota*
1477. Grand Forks city, North Dakota*
1478. Minot city, North Dakota*
1479. Morton County, North Dakota*
1480. West Fargo city, North Dakota*
1481. Adams County, Ohio
1482. Allen County, Ohio*
1483. Alliance city, Ohio
1484. Anderson township, Ohio*
1485. Athens township, Athens County,
Ohio*
1486. Aurora city, Ohio
1487. Austintown township, Ohio*
1488. Bath township, Greene County,
Ohio*
1489. Beavercreek city, Ohio*
1490. Beavercreek township, Ohio*
1491. Boardman township, Ohio*
1492. Bowling Green city, Ohio*
1493. Brunswick city, Ohio*
1494. Canton city, Ohio*
1495. Carroll County, Ohio
1496. Clark County, Ohio*
1497. Clear Creek township, Ohio*
1498. Cleveland Heights city, Ohio*
1499. Colerain township, Hamilton
County, Ohio*
1500. Columbiana County, Ohio*
1501. Columbus city, Ohio*
1502. Concord township, Miami County,
Ohio*
1503. Deerfield township, Ohio*
1504. Defiance County, Ohio*
1505. Delaware city, Ohio*
1506. Dublin city, Ohio*
1507. Fairborn city, Ohio*
1508. Fostoria city, Ohio
1509. Franklin township, Warren County,
Ohio*
1510. Gahanna city, Ohio*
1511. Green township, Hamilton County,
Ohio*
1512. Greene County, Ohio*
1513. Grove City city, Ohio*
1514. Hancock County, Ohio*
1515. Hardin County, Ohio*
1516. Harrison County, Ohio
1517. Highland County, Ohio*
1518. Hilliard city, Ohio*
1519. Holmes County, Ohio*
1520. Huber Heights city, Ohio*
1521. Jackson township, Franklin County,
Ohio*
1522. Jackson township, Stark County,
Ohio*
1523. Kent city, Ohio
1524. Kettering city, Ohio*
1525. Lancaster city, Ohio*
1526. Liberty township, Butler County,
Ohio*
1527. Liberty township, Delaware
County, Ohio*
1528. Lima city, Ohio*
1529. Madison County, Ohio*
1530. Mahoning County, Ohio*
1531. Mansfield city, Ohio*
1863
WITH TECHNICAL CORRECTIONS 02.03.2023
W-20
1532. Marietta city, Ohio
1533. Marion city, Ohio*
1534. Marion township, Marion County,
Ohio*
1535. Mason city, Ohio*
1536. Massillon city, Ohio*
1537. Medina County, Ohio*
1538. Mentor city, Ohio*
1539. Miami County, Ohio*
1540. Miami township, Clermont County,
Ohio*
1541. Miami township, Logan County,
Ohio*
1542. Mifflin township, Franklin County,
Ohio*
1543. Monroe County, Ohio
1544. Morrow County, Ohio*
1545. Newark city, Ohio*
1546. Norwalk city, Ohio
1547. Norwich township, Franklin
County, Ohio*
1548. Orange township, Delaware
County, Ohio*
1549. Ottawa County, Ohio*
1550. Pickaway County, Ohio*
1551. Pike County, Ohio
1552. Plain township, Stark County,
Ohio*
1553. Preble County, Ohio*
1554. Putnam County, Ohio*
1555. Ravenna city, Ohio
1556. Reynoldsburg city, Ohio*
1557. Sandusky city, Ohio
1558. Springfield city, Ohio*
1559. Springfield Township, Hamilton
County, Ohio*
1560. Sylvania township, Ohio*
1561. Union County, Ohio*
1562. Union township, Clermont County,
Ohio*
1563. Upper Arlington city, Ohio*
1564. Vinton County, Ohio
1565. Violet township, Ohio*
1566. Warren County, Ohio*
1567. Washington township, Franklin
County, Ohio*
1568. Washington township, Montgomery
County, Ohio*
1569. West Chester township, Ohio*
1570. Westerville city, Ohio*
1571. Westlake city, Ohio*
1572. Wood County, Ohio*
1573. Wyandot County, Ohio
1574. Youngstown city, Ohio*
1575. Ada city, Oklahoma
1576. Bartlesville city, Oklahoma*
1577. Bethany city, Oklahoma
1578. Broken Arrow city, Oklahoma*
1579. Bryan County, Oklahoma*
1580. Canadian County, Oklahoma*
1581. Carter County, Oklahoma*
1582. Cherokee County, Oklahoma*
1583. Edmond city, Oklahoma*
1584. Garfield County, Oklahoma*
1585. Guthrie city, Oklahoma
1586. Lawton city, Oklahoma*
1587. Moore city, Oklahoma*
1588. Muskogee city, Oklahoma*
1589. Muskogee County, Oklahoma*
1590. Mustang city, Oklahoma
1591. Norman city, Oklahoma*
1592. Owasso city, Oklahoma*
1593. Ponca City city, Oklahoma
1594. Pontotoc County, Oklahoma*
1595. Sequoyah County, Oklahoma*
1596. Wagoner County, Oklahoma*
1597. Albany city, Oregon*
1598. Beaverton city, Oregon*
1599. Bend city, Oregon*
1600. Benton County, Oregon*
1601. Clackamas County, Oregon*
1602. Clatsop County, Oregon*
1603. Columbia County, Oregon*
1604. Corvallis city, Oregon*
1605. Curry County, Oregon
1606. Deschutes County, Oregon*
1864
WITH TECHNICAL CORRECTIONS 02.03.2023
W-21
1607. Douglas County, Oregon*
1608. Eugene city, Oregon*
1609. Grants Pass city, Oregon*
1610. Gresham city, Oregon*
1611. Hillsboro city, Oregon*
1612. Jackson County, Oregon*
1613. Josephine County, Oregon*
1614. Keizer city, Oregon*
1615. Klamath County, Oregon*
1616. Lake Oswego city, Oregon*
1617. Lane County, Oregon*
1618. Lincoln County, Oregon*
1619. Linn County, Oregon*
1620. Malheur County, Oregon*
1621. Marion County, Oregon*
1622. McMinnville city, Oregon*
1623. Medford city, Oregon*
1624. Multnomah County, Oregon*
1625. Oregon City city, Oregon*
1626. Polk County, Oregon*
1627. Redmond city, Oregon*
1628. Salem city, Oregon*
1629. Springfield city, Oregon*
1630. Tigard city, Oregon*
1631. Umatilla County, Oregon*
1632. Washington County, Oregon*
1633. Yamhill County, Oregon*
1634. Abington township, Pennsylvania*
1635. Allentown city, Pennsylvania*
1636. Altoona city, Pennsylvania*
1637. Beaver County, Pennsylvania*
1638. Berks County, Pennsylvania*
1639. Bethel Park municipality,
Pennsylvania*
1640. Bethlehem city, Pennsylvania*
1641. Blair County, Pennsylvania*
1642. Butler County, Pennsylvania*
1643. Centre County, Pennsylvania*
1644. Cheltenham township,
Pennsylvania*
1645. Chester city, Pennsylvania*
1646. Cranberry township, Pennsylvania*
1647. Crawford County, Pennsylvania*
1648. Cumberland County, Pennsylvania*
1649. Erie city, Pennsylvania*
1650. Falls township, Pennsylvania*
1651. Hampden township, Pennsylvania*
1652. Harrisburg city, Pennsylvania*
1653. Haverford township, Pennsylvania*
1654. Hempfield township, Pennsylvania*
1655. Huntingdon County, Pennsylvania*
1656. Jefferson County, Pennsylvania*
1657. Lancaster city, Pennsylvania*
1658. Lancaster County, Pennsylvania*
1659. Lebanon County, Pennsylvania*
1660. Lower Macungie township,
Pennsylvania*
1661. Lower Merion township,
Pennsylvania*
1662. Lower Paxton township,
Pennsylvania*
1663. Lower Southampton township,
Pennsylvania
1664. Manheim township, Pennsylvania*
1665. McKean County, Pennsylvania*
1666. Mifflin County, Pennsylvania*
1667. Millcreek township, Pennsylvania*
1668. Monroe County, Pennsylvania*
1669. Montgomery County,
Pennsylvania*
1670. Mount Lebanon township,
Pennsylvania*
1671. New Castle city, Pennsylvania
1672. North Huntingdon township,
Pennsylvania*
1673. Northampton township,
Pennsylvania*
1674. Penn Hills township, Pennsylvania*
1675. Perry County, Pennsylvania*
1676. Radnor township, Pennsylvania*
1677. Reading city, Pennsylvania*
1678. Ridley township, Pennsylvania*
1679. Ross township, Pennsylvania*
1680. Scranton city, Pennsylvania*
1681. Snyder County, Pennsylvania*
1682. Somerset County, Pennsylvania*
1865
WITH TECHNICAL CORRECTIONS 02.03.2023
W-22
1683. State College borough,
Pennsylvania*
1684. Susquehanna County,
Pennsylvania*
1685. Union County, Pennsylvania*
1686. Upper Darby township,
Pennsylvania*
1687. Upper Merion township,
Pennsylvania*
1688. Venango County, Pennsylvania*
1689. Warren County, Pennsylvania*
1690. Wayne County, Pennsylvania*
1691. York city, Pennsylvania*
1692. York County, Pennsylvania*
1693. Adjuntas Municipio, Puerto Rico
1694. Arroyo Municipio, Puerto Rico
1695. Barceloneta Municipio, Puerto Rico
1696. Bayamón Municipio, Puerto Rico*
1697. Caguas Municipio, Puerto Rico*
1698. Carolina Municipio, Puerto Rico*
1699. Cataño Municipio, Puerto Rico
1700. Cayey Municipio, Puerto Rico*
1701. Ceiba Municipio, Puerto Rico
1702. Cidra Municipio, Puerto Rico*
1703. Coamo Municipio, Puerto Rico*
1704. Corozal Municipio, Puerto Rico*
1705. Guayama Municipio, Puerto Rico*
1706. Guaynabo Municipio, Puerto Rico*
1707. Gurabo Municipio, Puerto Rico*
1708. Humacao Municipio, Puerto Rico*
1709. Las Piedras Municipio, Puerto
Rico*
1710. Mayagüez Municipio, Puerto Rico*
1711. San Sebastián Municipio, Puerto
Rico*
1712. Toa Baja Municipio, Puerto Rico*
1713. Villalba Municipio, Puerto Rico
1714. Yauco Municipio, Puerto Rico*
1715. Providence city, Rhode Island*
1716. Aiken city, South Carolina*
1717. Columbia city, South Carolina*
1718. Darlington County, South Carolina*
1719. Florence city, South Carolina*
1720. Goose Creek city, South Carolina*
1721. Greenville city, South Carolina*
1722. Greer city, South Carolina*
1723. Hilton Head Island town, South
Carolina*
1724. Rock Hill city, South Carolina*
1725. Spartanburg city, South Carolina*
1726. Sumter city, South Carolina*
1727. Brookings County, South Dakota*
1728. Brown County, South Dakota*
1729. Lincoln County, South Dakota*
1730. Minnehaha County, South Dakota*
1731. Pennington County, South Dakota*
1732. Rapid City city, South Dakota*
1733. Sioux Falls city, South Dakota*
1734. Bartlett city, Tennessee*
1735. Bedford County, Tennessee*
1736. Brentwood city, Tennessee*
1737. Cannon County, Tennessee
1738. Carter County, Tennessee*
1739. Chattanooga city, Tennessee*
1740. Cheatham County, Tennessee*
1741. Clarksville city, Tennessee*
1742. Cleveland city, Tennessee*
1743. Coffee County, Tennessee*
1744. Collierville town, Tennessee*
1745. Columbia city, Tennessee*
1746. Cookeville city, Tennessee*
1747. Crockett County, Tennessee
1748. Crossville city, Tennessee
1749. Cumberland County, Tennessee*
1750. Decatur County, Tennessee
1751. DeKalb County, Tennessee
1752. Dickson County, Tennessee*
1753. Dyer County, Tennessee*
1754. Fayette County, Tennessee*
1755. Fentress County, Tennessee
1756. Franklin city, Tennessee*
1757. Gallatin city, Tennessee*
1758. Germantown city, Tennessee*
1759. Gibson County, Tennessee*
1760. Giles County, Tennessee
1761. Hamblen County, Tennessee*
1866
WITH TECHNICAL CORRECTIONS 02.03.2023
W-23
1762. Haywood County, Tennessee
1763. Henderson County, Tennessee
1764. Hendersonville city, Tennessee*
1765. Henry County, Tennessee*
1766. Jackson city, Tennessee*
1767. Johnson City city, Tennessee*
1768. Johnson County, Tennessee
1769. Kingsport city, Tennessee*
1770. La Vergne city, Tennessee*
1771. Lauderdale County, Tennessee
1772. Lawrence County, Tennessee*
1773. Lawrenceburg city, Tennessee
1774. Lebanon city, Tennessee*
1775. Lewisburg city, Tennessee
1776. Lincoln County, Tennessee*
1777. Marshall County, Tennessee*
1778. Maryville city, Tennessee
1779. Maury County, Tennessee*
1780. McMinnville city, Tennessee
1781. Montgomery County, Tennessee*
1782. Morgan County, Tennessee
1783. Morristown city, Tennessee*
1784. Mount Juliet city, Tennessee*
1785. Murfreesboro city, Tennessee*
1786. Nashville-Davidson metropolitan
government, Tennessee*
1787. Obion County, Tennessee*
1788. Overton County, Tennessee
1789. Putnam County, Tennessee*
1790. Robertson County, Tennessee*
1791. Scott County, Tennessee
1792. Shelbyville city, Tennessee
1793. Smith County, Tennessee
1794. Smyrna town, Tennessee*
1795. Spring Hill city, Tennessee*
1796. Sullivan County, Tennessee*
1797. Sumner County, Tennessee*
1798. Tipton County, Tennessee*
1799. Warren County, Tennessee*
1800. Wayne County, Tennessee
1801. Weakley County, Tennessee*
1802. White County, Tennessee
1803. Wilson County, Tennessee*
1804. Abilene city, Texas*
1805. Allen city, Texas*
1806. Amarillo city, Texas*
1807. Anderson County, Texas*
1808. Arlington city, Texas*
1809. Atascosa County, Texas*
1810. Austin city, Texas*
1811. Austin County, Texas*
1812. Bastrop County, Texas*
1813. Baytown city, Texas*
1814. Beaumont city, Texas*
1815. Bedford city, Texas*
1816. Bee County, Texas*
1817. Bell County, Texas*
1818. Blanco County, Texas
1819. Brazoria County, Texas*
1820. Brown County, Texas*
1821. Brownsville city, Texas*
1822. Bryan city, Texas*
1823. Burleson city, Texas*
1824. Burleson County, Texas
1825. Burnet County, Texas*
1826. Caldwell County, Texas*
1827. Calhoun County, Texas
1828. Cameron County, Texas*
1829. Carrollton city, Texas*
1830. Cass County, Texas*
1831. Cedar Hill city, Texas*
1832. Cedar Park city, Texas*
1833. Chambers County, Texas*
1834. Cibolo city, Texas*
1835. Cleburne city, Texas*
1836. College Station city, Texas*
1837. Collin County, Texas*
1838. Colorado County, Texas
1839. Comal County, Texas*
1840. Conroe city, Texas*
1841. Cooke County, Texas*
1842. Coppell city, Texas*
1843. Copperas Cove city, Texas*
1844. Corpus Christi city, Texas*
1845. Dallas city, Texas*
1846. Deer Park city, Texas*
1867
WITH TECHNICAL CORRECTIONS 02.03.2023
W-24
1847. Del Rio city, Texas*
1848. Denton city, Texas*
1849. Denton County, Texas*
1850. DeSoto city, Texas*
1851. Dimmit County, Texas
1852. Duncanville city, Texas*
1853. Ector County, Texas*
1854. Edinburg city, Texas*
1855. El Paso city, Texas*
1856. El Paso County, Texas*
1857. Erath County, Texas*
1858. Euless city, Texas*
1859. Falls County, Texas
1860. Fannin County, Texas*
1861. Farmers Branch city, Texas*
1862. Flower Mound town, Texas*
1863. Fort Bend County, Texas*
1864. Fort Worth city, Texas*
1865. Franklin County, Texas
1866. Friendswood city, Texas*
1867. Frisco city, Texas*
1868. Galveston city, Texas*
1869. Galveston County, Texas*
1870. Garland city, Texas*
1871. Georgetown city, Texas*
1872. Grand Prairie city, Texas*
1873. Grapevine city, Texas*
1874. Grayson County, Texas*
1875. Gregg County, Texas*
1876. Guadalupe County, Texas*
1877. Hale County, Texas*
1878. Haltom City city, Texas*
1879. Hardin County, Texas*
1880. Harker Heights city, Texas*
1881. Harlingen city, Texas*
1882. Harris County, Texas*
1883. Harrison County, Texas*
1884. Hays County, Texas*
1885. Hidalgo County, Texas*
1886. Hill County, Texas*
1887. Hood County, Texas*
1888. Hopkins County, Texas*
1889. Houston city, Texas*
1890. Houston County, Texas
1891. Howard County, Texas*
1892. Hunt County, Texas*
1893. Huntsville city, Texas*
1894. Hurst city, Texas*
1895. Irving city, Texas*
1896. Jasper County, Texas*
1897. Jefferson County, Texas*
1898. Jones County, Texas
1899. Keller city, Texas*
1900. Kendall County, Texas*
1901. Kerr County, Texas*
1902. Killeen city, Texas*
1903. Kyle city, Texas*
1904. La Porte city, Texas*
1905. Lancaster city, Texas*
1906. League City city, Texas*
1907. Leander city, Texas*
1908. Leon County, Texas
1909. Leon Valley city, Texas
1910. Lewisville city, Texas*
1911. Liberty County, Texas*
1912. Limestone County, Texas
1913. Little Elm city, Texas*
1914. Longview city, Texas*
1915. Lubbock city, Texas*
1916. Lubbock County, Texas*
1917. Lufkin city, Texas*
1918. Madison County, Texas
1919. Mansfield city, Texas*
1920. Matagorda County, Texas*
1921. McAllen city, Texas*
1922. McKinney city, Texas*
1923. Medina County, Texas*
1924. Mesquite city, Texas*
1925. Midland city, Texas*
1926. Midland County, Texas*
1927. Midlothian city, Texas*
1928. Milam County, Texas
1929. Mission city, Texas*
1930. Missouri City city, Texas*
1931. Morris County, Texas
1932. Nacogdoches city, Texas*
1868
WITH TECHNICAL CORRECTIONS 02.03.2023
W-25
1933. Nacogdoches County, Texas*
1934. Navarro County, Texas*
1935. New Braunfels city, Texas*
1936. Newton County, Texas
1937. Nolan County, Texas
1938. North Richland Hills city, Texas*
1939. Nueces County, Texas*
1940. Odessa city, Texas*
1941. Orange County, Texas*
1942. Panola County, Texas
1943. Parker County, Texas*
1944. Pasadena city, Texas*
1945. Pearland city, Texas*
1946. Pflugerville city, Texas*
1947. Pharr city, Texas*
1948. Plano city, Texas*
1949. Port Arthur city, Texas*
1950. Potter County, Texas*
1951. Randall County, Texas*
1952. Red River County, Texas
1953. Richardson city, Texas*
1954. Robertson County, Texas
1955. Rockwall city, Texas*
1956. Rosenberg city, Texas*
1957. Round Rock city, Texas*
1958. Rowlett city, Texas*
1959. San Angelo city, Texas*
1960. San Juan city, Texas*
1961. San Marcos city, Texas*
1962. San Patricio County, Texas*
1963. Schertz city, Texas*
1964. Shelby County, Texas
1965. Sherman city, Texas*
1966. Socorro city, Texas*
1967. Southlake city, Texas*
1968. Starr County, Texas*
1969. Sugar Land city, Texas*
1970. Taylor County, Texas*
1971. Temple city, Texas*
1972. Texarkana city, Texas*
1973. Texas City city, Texas*
1974. The Colony city, Texas*
1975. Tom Green County, Texas*
1976. Travis County, Texas*
1977. Trinity County, Texas
1978. Tyler city, Texas*
1979. Upshur County, Texas*
1980. Uvalde County, Texas
1981. Val Verde County, Texas*
1982. Van Zandt County, Texas*
1983. Victoria city, Texas*
1984. Victoria County, Texas*
1985. Waco city, Texas*
1986. Waller County, Texas*
1987. Washington County, Texas*
1988. Waxahachie city, Texas*
1989. Weatherford city, Texas*
1990. Weslaco city, Texas*
1991. Wharton County, Texas*
1992. Wichita Falls city, Texas*
1993. Wilson County, Texas*
1994. Wise County, Texas*
1995. Wood County, Texas*
1996. Wylie city, Texas*
1997. American Fork city, Utah*
1998. Bountiful city, Utah*
1999. Box Elder County, Utah*
2000. Carbon County, Utah
2001. Cedar City city, Utah*
2002. Clearfield city, Utah*
2003. Cottonwood Heights city, Utah*
2004. Davis County, Utah*
2005. Draper city, Utah*
2006. Duchesne County, Utah
2007. Eagle Mountain city, Utah*
2008. Emery County, Utah
2009. Herriman city, Utah*
2010. Holladay city, Utah*
2011. Iron County, Utah*
2012. Juab County, Utah
2013. Kaysville city, Utah*
2014. Kearns metro township, Utah*
2015. Layton city, Utah*
2016. Lehi city, Utah*
2017. Logan city, Utah*
2018. Midvale city, Utah*
1869
WITH TECHNICAL CORRECTIONS 02.03.2023
W-26
2019. Millard County, Utah
2020. Millcreek city, Utah*
2021. Murray city, Utah*
2022. Ogden city, Utah*
2023. Orem city, Utah*
2024. Pleasant Grove city, Utah*
2025. Provo city, Utah*
2026. Riverton city, Utah*
2027. Roy city, Utah*
2028. Salt Lake City city, Utah*
2029. Salt Lake County, Utah*
2030. San Juan County, Utah
2031. Sandy city, Utah*
2032. Sanpete County, Utah*
2033. Saratoga Springs city, Utah*
2034. South Jordan city, Utah*
2035. Spanish Fork city, Utah*
2036. Springville city, Utah*
2037. St. George city, Utah*
2038. Syracuse city, Utah*
2039. Taylorsville city, Utah*
2040. Tooele city, Utah*
2041. West Jordan city, Utah*
2042. West Valley City city, Utah*
2043. Addison County, Vermont*
2044. Bennington County, Vermont*
2045. Brattleboro town, Vermont
2046. Burlington city, Vermont*
2047. Chittenden County, Vermont*
2048. Franklin County, Vermont*
2049. Rutland County, Vermont*
2050. Washington County, Vermont*
2051. Windham County, Vermont*
2052. Windsor County, Vermont*
2053. Albemarle County, Virginia*
2054. Augusta County, Virginia*
2055. Bedford County, Virginia*
2056. Blacksburg town, Virginia*
2057. Campbell County, Virginia*
2058. Caroline County, Virginia*
2059. Charlottesville city, Virginia*
2060. Gloucester County, Virginia*
2061. Grayson County, Virginia
2062. Hampton city, Virginia*
2063. Hanover County, Virginia*
2064. Harrisonburg city, Virginia*
2065. James City County, Virginia*
2066. Leesburg town, Virginia*
2067. Lynchburg city, Virginia*
2068. Manassas city, Virginia*
2069. Newport News city, Virginia*
2070. Orange County, Virginia*
2071. Petersburg city, Virginia*
2072. Rockingham County, Virginia*
2073. Russell County, Virginia
2074. Spotsylvania County, Virginia*
2075. Suffolk city, Virginia*
2076. York County, Virginia*
2077. Anacortes city, Washington
2078. Auburn city, Washington*
2079. Bellevue city, Washington*
2080. Bellingham city, Washington*
2081. Benton County, Washington*
2082. Bothell city, Washington*
2083. Bremerton city, Washington*
2084. Burien city, Washington*
2085. Clallam County, Washington*
2086. Clark County, Washington*
2087. Cowlitz County, Washington*
2088. Des Moines city, Washington*
2089. Douglas County, Washington*
2090. Edmonds city, Washington*
2091. Everett city, Washington*
2092. Federal Way city, Washington*
2093. Grant County, Washington*
2094. Grays Harbor County, Washington*
2095. Issaquah city, Washington*
2096. Kennewick city, Washington*
2097. Kent city, Washington*
2098. Kirkland city, Washington*
2099. Kittitas County, Washington*
2100. Lacey city, Washington*
2101. Lake Stevens city, Washington*
2102. Lakewood city, Washington*
2103. Lincoln County, Washington
2104. Longview city, Washington*
1870
WITH TECHNICAL CORRECTIONS 02.03.2023
W-27
2105. Lynnwood city, Washington*
2106. Marysville city, Washington*
2107. Mason County, Washington*
2108. Mount Vernon city, Washington*
2109. Okanogan County, Washington*
2110. Olympia city, Washington*
2111. Pasco city, Washington*
2112. Pullman city, Washington*
2113. Puyallup city, Washington*
2114. Redmond city, Washington*
2115. Renton city, Washington*
2116. Richland city, Washington*
2117. Sammamish city, Washington*
2118. San Juan County, Washington
2119. Seattle city, Washington*
2120. Sedro-Woolley city, Washington
2121. Shoreline city, Washington*
2122. Skagit County, Washington*
2123. Snohomish County, Washington*
2124. Spokane Valley city, Washington*
2125. Stevens County, Washington*
2126. University Place city, Washington*
2127. Vancouver city, Washington*
2128. Walla Walla city, Washington*
2129. Wenatchee city, Washington*
2130. Whitman County, Washington*
2131. Yakima city, Washington*
2132. Yakima County, Washington*
2133. Appleton city, Wisconsin*
2134. Beloit city, Wisconsin*
2135. Brookfield city, Wisconsin*
2136. Eau Claire city, Wisconsin*
2137. Fitchburg city, Wisconsin*
2138. Fond du Lac city, Wisconsin*
2139. Green Bay city, Wisconsin*
2140. Janesville city, Wisconsin*
2141. La Crosse city, Wisconsin*
2142. Madison city, Wisconsin*
2143. Manitowoc city, Wisconsin*
2144. Menomonee Falls village,
Wisconsin*
2145. Mount Pleasant village, Wisconsin
2146. New Berlin city, Wisconsin*
2147. Oshkosh city, Wisconsin*
2148. Polk County, Wisconsin*
2149. Racine city, Wisconsin*
2150. Sheboygan city, Wisconsin*
2151. Sun Prairie city, Wisconsin*
2152. Wausau city, Wisconsin*
2153. Wauwatosa city, Wisconsin*
2154. West Bend city, Wisconsin*
2155. Albany County, Wyoming*
2156. Campbell County, Wyoming*
2157. Carbon County, Wyoming
2158. Casper city, Wyoming*
2159. Cheyenne city, Wyoming*
2160. Fremont County, Wyoming*
2161. Gillette city, Wyoming*
2162. Green River city, Wyoming
2163. Laramie city, Wyoming*
2164. Laramie County, Wyoming*
2165. Natrona County, Wyoming*
2166. Riverton city, Wyoming
2167. Rock Springs city, Wyoming
2168. Sheridan County, Wyoming*
2169. Sweetwater County, Wyoming*
1871
WITH TECHNICAL CORRECTIONS 02.03.2023
X-1

EXHIBIT X
Governor’s Release of Opioid-Related Claims Pursuant to the CVS Settlement Agreement
I, [NAME], Governor of the [Commonwealth]/[State]/[Territory] of [Commonwealth]/[State]/[Territory], hereby authorize Attorney General [NAME] to settle and release, to the maximum extent of my power as Governor, all Released Claims of (1) all of [Commonwealth]/[State]/[Territory]’s past and present executive departments, agencies, divisions, boards, commissions and instrumentalities with regulatory authority to enforce state and federal controlled substances acts and (2) all of [Commonwealth]/[State]/[Territory]’s past and present executive departments, agencies, divisions, boards, commissions and instrumentalities that have the authority to bring Claims related to Alleged Harms and/or Covered Conduct seeking money (including abatement and/or remediation) or revocation of a pharmaceutical distribution or dispensing license. The foregoing authorization is given in connection with Section XI.G of the CVS Settlement Agreement dated as of December [], 2022 setting forth the terms of settlement between and among CVS, on the one hand, and the Settling States and Participating Subdivisions, on the other hand. This release is intended to be a “release from a State’s Governor” as contemplated in such section. Capitalized terms used herein and defined in the Settlement Agreement have the meanings given to them in such settlement agreement.
____________________________
[Name]
Governor of the [Commonwealth]/[State]/[Territory] of [Commonwealth]/[State]/[Territory] Date: ___________________
1872

1 December 20, 2022

TEVA GLOBAL OPIOID SETTLEMENT AGREEMENT

I. Definitions ........................................................................................................................................ 2 II. Participation by States and Condition to Preliminary Agreement ........................................... 17 III. Cessation of Litigation Activities ................................................................................................. 18 IV. Injunctive Relief ............................................................................................................................ 19 V. Release ............................................................................................................................................ 19 VI. Monetary Relief Overview and Maximum Payments ................................................................ 24 VII. Annual Payments to Settlement Fund ......................................................................................... 25 VIII. Allocation and Use of Settlement Funds ..................................................................................... 36 IX. Settlement Product ........................................................................................................................ 43 X. Participation by Subdivisions and Special Districts .................................................................. 44 XI. Condition to Effectiveness of Agreement and Filing of Consent Judgment ............................ 48 XII. Potential Payment Adjustments................................................................................................... 49 XIII. Additional Restitution Amount .................................................................................................... 50 XIV. Plaintiffs’ Attorneys’ Fees and Costs .......................................................................................... 50 XV. Enforcement and Dispute Resolution .......................................................................................... 50 XVI. Miscellaneous ................................................................................................................................. 56 1873

2 December 20, 2022

TEVA GLOBAL OPIOID SETTLEMENT AGREEMENT

Whereas, the Settling States, Participating Subdivisions, Participating Special Districts, and Teva (as those terms are defined below) share a common desire to resolve disputes between them relating to opioid medications according to the terms set out in this agreement dated as of November 22, 2022 (the “Agreement”);

Whereas, the Parties, Participating Subdivisions, and Participating Special Districts agree and understand that u pon satisfaction of the conditions set forth in Sections II and XI, this Agreement will be binding on the Settling States, Teva, Participating Subdivisions , and Participating Special Districts;

Whereas, the Parties, Participating Subdivisions, and Participating Special Districts agree and understand that t his Agreement will then be filed as part of Consent Judgments in the respective courts of each of the Settling States, pursuant to the terms set forth in Section III;

Whereas, the Parties, Participating Subdivisions, and Participating Special Districts agree and understand that they shall at all times act in good faith to implement and execute their obligations under this Agreement and shall not act in any way to purposefully frustrate the right of any party to receive the benefits due under the Agreement;

Whereas, it is recognized that Naloxone Hydrochloride Nasal Spray is a medication that counteracts the life-threatening effects of opioid overdose and significantly reduces opioid - overdose mortality;

Whereas, the Parties, Participating Subdivisions, and Participating Special Districts to this Agreement now desire to avoid further expense and proceedings and to settle their disputes under the terms and conditions of this Agreement as set forth below;

NOW, THEREFORE, IT IS HEREBY AGREED by and between the Parties, Participating Subdivisions, and Participating Special Districts by and through their respective counsel, as follows:

I. Definitions
Unless otherwise specified, the following definitions apply:

1. “Abatement Accounts Fund” means a component of the Settlement Fund described in subsection VIII.F.

2. “Actavis Generic Entities” means Actavis LLC (f/k/a Actavis Inc.) , Actavis Elizabeth LLC, Actavis Kadian LLC, Actavis Pharma, Inc. (f/k/a Watson Pharma, Inc.), Actavis Kadian LLC, Actavis Laboratories UT , Inc. (f/k/a Watson Laboratories, Inc. - Utah), Actavis Mid Atlantic LLC, Actavis Totowa LLC, Actavis Laboratories FL, Inc. (f/k/a Watson Laboratories, Inc. - Florida), Actavis South Atlantic LLC, Warner Chilcott Company LLC, and Watson Laboratories, Inc.
1874

3 December 20, 2022

3. “Additional Restitution Amount ” means the amount available to Settling States listed in Exhibit M-3 of $28,669,762.00.

4. “Agreement” means this Teva Global Opioid Agreement, inclusive of all exhibits.

5. “Alleged Harms” means the alleged past, present, and future financial or societal and related expenditures arising out of the alleged misuse and abuse of opioid products, non-exclusive examples of which are described in the documents listed on Exhibit A, that have allegedly arisen as a result of the physical and bodily injuries sustained by individuals suffering from opioid -related addiction, abuse, death, and other related diseases and disorders, and that have allegedly been caused by Teva.

6. “Allergan” means Allergan Finance, LLC (f/k/a Actavis, Inc., which, in turn, was f/k/a/ Watson Pharmaceuticals, Inc.) and Allergan Limited (f/k/a Allergan plc, which, in turn, was f/k/a Actavis plc).

7. “Allergan Global Opioid Settlement Agreement ” means the settlement agreement between and among States, Participating Subdivisions, Participating Special Districts, and Allergan to resolve opioid-related Claims against Allergan and other released entities (as defined therein).

8. “Allocation Statute” means a state law that governs allocation, distribution, and/or use of some or all of the Settlement Fund amounts allocated to that State and/or its Subdivisions and/or its Special Districts. In addition to modifying the allocation, as set forth in subsection V III.E.2, an Allocation Statute may, without limitation, contain a Statutory Trust, further restrict expenditure of funds, form an advisory committee, establish oversight and reporting requirements, or address other default provisions and other matters related to the funds. An Allocation Statute is not required to address all three (3) types of f unds comprising the Settlement Fund or all default provisions.

9. “Annual Payment” means the total amount of the Net Abatement Amount payable into the Settlement Fund by Teva on each Payment Date (including the Initial Year Payment), as calculated by the Settlement Fund Administrator pursuant to subsection V II.B.4 or agreed to pursuant to subsection VII.B.5, which shall not exceed the maximum payment for any given year as set forth in Exhibit M-1. This term does not include the Additional Restitution Amount , the Settlement Product Cash Conversion Amount, or amounts paid pursuant to Section XIV.

10. “Appropriate Official” means the official defined in subsection XVI.F.3.

11. “Attorney Fee and Cost Payment” means the total amount of the Global Settlement Attorney Fee Amount payable by Teva on the Payment Date of each year into the (1) Attorney Fee and Cost Fund, described in Exhibit R, (2) the State Cost Fund described in Exhibit S, and (3) the State Outside Counsel Fee Fund described in Exhibit T, for attorneys’ fees, expenses, and costs of the Settling States, and Participating Subdivisions.
1875

4 December 20, 2022

12. “Attorney Fee and Cost Fund” means an account consisting of $331,295,027.54 to pay attorneys’ fees and costs of Litigating Subdivisions that become Participating Subdivisions and the MDL Expense Fund amounts pursuant to the agreement on attorneys’ fees and costs attached as Exhibit R.

13. “Bar” means either (1) a ruling by the highest court of the State, or the intermediate court of appeals when not subject to further review by the highest court of the State in a State with a single intermediate court of appeals , setting forth the general principle that no Subdivisions or Special Districts in the State may maintain Released Claims against Released Entities, whether on the ground of the Agreement (or the release in it) or otherwise; (2) a law barring Subdivisions and Special Districts in the State from maintaining or asserting Released Claims against Released Entities (either through a direct bar or through a grant of authority to release claims and that authority is exercised in full); or (3) a Settlement Class Resolution in the State with full force and effect. For the avoidance of doubt, a law or ruling that is conditioned or predicated upon payment by a Released Entity (apart from payments by Teva incurred under the Agreement) shall not constitute a Bar.

14. “Base Payment” means the payments made pursuant to subsection VII.D.

15. “Case-Specific Resolution” means either (1) a law barring specified Subdivisions or Special Districts from maintaining Released Claims against Released Entities (either through a direct Bar or through a grant of authority to release claims and that authority is exercised in full) or (2) a ruling by a court of competent jurisdiction over a particular Subdivision or Special District that has the legal effect of barring the Subdivision or Special District from maintaining any Released Claims at issue against Released Entities, whether on the ground of the Agreement (or the release in it) or otherwise. For the avoidance of doubt, a law, ruling, or release that is conditioned or predicated upon a post-Effective Date payment by a Released Entity (apart from payments by Teva incurred under the Agreement or injunctive relief obligations incurred by it) shall not constitute a Case-Specific Resolution.

16. “Claim” means any past, present or future cause of action, claim for relief, cross - claim or counterclaim, theory of liability, demand, derivative claim, request, assessment, charge, covenant, damage, debt, lien, loss, fine, penalty, restitution, reimbursement, disgorgement, expenses, judgment, right, obligation, dispute, suit, contract, controversy, agreement, parens patriae claim, promise, performance, warranty, omission, or grievance of any nature whatsoever, whether legal, equitable, statutory, regulatory or administrative, whether arising under federal, state or local common law, statute, regulation, guidance, ordinance or principles of equity, whether filed or unfiled, whether asserted or unasserted, whether known or unknown, whether accrued or unaccrued, whether foreseen, unforese en or unforeseeable, whether discovered or undiscovered, whether suspected or unsuspected, whether fixed or contingent, and whether existing or hereafter arising, in all such cases, including but not limited to any request for declaratory, injunctive, or equitable relief, compensatory, punitive, or statutory damages, absolute liability, strict liability, restitution, subrogation, contribution, indemnity, apportionment, disgorgement, reimbursement, attorney fees, expert fees, consultant fees, fines, 1876

5 December 20, 2022
penalties, expenses, costs or any other legal, equitable, civil, administrative, or regulatory remedy whatsoever. Claim does not include any individuals’ personal injury or wrongful death cause of action.

17. “Claim Over” means a Claim asserted by a Non-Released Entity against a Released Entity on the basis of contribution, indemnity, or other claim -over on any theory relating to a Non-Party Covered Conduct Claim asserted by a Releasor.

18. “Compensatory Restitution Amount” means the aggregate amount of payments by Teva hereunder other than amounts paid as attorneys’ fees and costs or identified pursuant to subsection VIII.C as being used to pay attorneys’ fees and investigation costs or litigation costs , plus the actual aggregate cost of Settlement Product provided to the Settling States by Teva.

19. “Consent Judgment” means a state-specific consent judgment, the general terms of which shall be agreed by the Settling States and Teva prior to the Reference Date and shall include (1) approval of this Agreement and (2) the release set forth in Section V, including the full and final resolution of any Released Claims that the Settling State has brought against Released Entities.

20. “Court” means the respective court for each Settling State to which the Agreement and the Consent Judgment are presented for approval and/or entry as to that Settling State, or the Northern District of Ohio for purposes of administering the Attorney Fee and Cost Fund and any related fee and cost agreements.

21. “Covered Conduct ” means any actual or alleged act, f ailure to act, negligence, statement, error, omission, breach of any duty, conduct, event, transaction, agreement, service, work, misstatement, misleading statement, or other activity of any kind whatsoever from the beginning of time through the Reference Date of this Agreement (and any past, present, or future consequence of any such act, failure to act, negligence, statement, error , omission, breach of duty, conduct, event, transaction, agreement, service, work, misstatement, misleading statement, or other activity) arising from or relating in any way to (a) the availability, discovery, research, development, manufacture, packaging, repackaging, marketing, promotion, advertising, labeling , relabeling , recall, withdrawal, distribution, delivery, monitoring, reporting, supply, sale, prescribing, dispensing, physical security, warehousing, use or abuse of, or operating procedures relati ng to, any Product, or any system, plan, policy, procedure, or advocacy relating to any Product or class of Products, including , but not limited to , any unbranded or branded promotion, marketing, or advertising, unbranded information, patient support or assistance, educational programs, consultancy, research, or other programs, campaigns, lobbying, or grants, sponsorships, charitable donations, or other funding relating to any Product or class of Products; (b) the characteristics, properties, risks, or benefits of any Product or class of Products; (c) the monitoring, reporting, disclosure, non-monitoring, non-reporting, or non-disclosure to federal, state, or other regulators of orders for any Product or class of Products ; (d) the selective breeding, harvesting, extracting, purifying, exporting, importing, applying for quota for, procuring quota for, handling, promoting, manufacturing, processing, 1877

6 December 20, 2022
packaging, supplying, distributing, converting, or selling of, or otherwise engaging in any activity relating to, precursor or component Products, including but not limited to natural, synthetic, semi -synthetic, or chemical raw materials, starting materials, finished active pharmaceutical ingredients, drug substances, or any related intermediate Products; or (e) diversion control programs or suspicious order monitoring related to any Product. The foregoing is not intended to apply to claims alleging contamination of products.

22. “Covered Special District” means a Special District that is (1) a school district with K-12 student enrollment of at least 25,000 or 0.12% of a State’s population, whichever is greater; (2) a fire district that covers a population of 25,000, or 0.20% of a State’s population if a State’s population is greater than 18 million (though, if a fire district’s population is not easily calculable from state data sources and agreed to between the State and Teva, it is calculated by dividing the population of the county or counties a fire district serves by the number of fire districts in the county or counties); or (3) a healthcare district or hospital district with at least 125 hospital beds in one or more hospitals rendering services in that district.

23. “Designated State” means New York.

24. “Effective Date” means the date sixty (60) days after the Reference Date.

25. “Eligible State” means a State that is not a Prior Settling State and is thus eligible to participate in this Agreement and become a Settling State.

26. “Enforcement Committee” means a committee consisting of representatives of the Settling States and of the Participating Subdivisions. Exhibit B contains the organizational bylaws of the Enforcement Committee. Notice pursuant to subsection X VI.P shall be provided when there are changes in membership or contact information.

27. “Exhibit G Participant” means a Participating Subdivision or Participating Special District that appears in Exhibit G at the relevant point in time. Nothing about the use of the term Exhibit G Participant changes the ability to amend the list of entities listed on Exhibit G pursuant to this Agreement.

28. “Force Majeure Event ” means any event reasonably beyond the control of Teva that prevents Teva from manufacturing or distributing Settlement Product , including wars, hostilities, revolution, riots, civil commotion, national emergency, unavailability of supplies, epidemics, fire, flood, earthquake, force of nature, explosion, terrorist act, embargo, or any act of God, or any law, regulation, ordinance, or other act or order of any court or governmental authority.

29. “Global Settlement Abatement Amount ” means the total abatement amount of $3,611,561,762.00. (This figure does not reflect the application of the Prior Settlements Credit or potential offsets. It also does not include amounts paid to the Additional Restitution Amount, which may be used for abatement.) 1878

7 December 20, 2022

30. “Global Settlement Amount” means $4,246,567,371.76 and consists of the Global Settlement Abatement Amount , the Global Settlement Attorney Fee Amount , the Additional Restitution Amount, and the Settlement Product Cash Conversion Amount.

31. “Global Settlement Attorney Fee Amount” means $366,335,847.76, which consists of the Attorney Fee and Cost Fund, the State Outside Counsel Fee Fund, and the State Cost Fund.

32. “Implementation Administrator” means the v endor agreed to by the Parties and retained by Teva and Allergan to provide notice pursuant to subsection X.A and to manage the initial joinder period for Subdivisions and Special Districts , including the issuance and receipt of Settlement Participation Forms.

33. “Implementation Costs ” means the cost s for the Implementation Administrator , which shall be paid for pursuant to subsection VI.C.

34. “Incentive A” means the incentive payment described in subsection VII.E.5.

35. “Incentive B” means the incentive payment described in subsection VII.E.6.

36. “Incentive C” means the incentive payment described in subsection VII.E.7.

37. “Incentive D” means the incentive payment described in subsection VII.E.8.

38. “Incentive Payment” means the payments made pursuant to subsection VII.E.

39. “Initial Participating Special District ” means a Special District that meets the requirements set forth in subsection X.L.

40. “Initial Participating Subdivision ” means a Subdivision that meets the requirements set forth in subsection X.D.

41. “Initial Participation Date” means the date ninety (90) days after the Preliminary Agreement Date, unless it is extended by written agreement of Teva and the Enforcement Committee.

42. “Initial Year Payment” means the first Annual Payment of the Net Abatement Amount payable into the Settlement Fund by Teva on the Payment Date as calculated by the Settlement Fund Administrator pursuant to subsection VII.B.4 or agreed to pursuant to subsection VII.B.5, which shall not exceed the maximum payment for the Initial Year Payment as set forth in Exhibit M-1.

43. “Injunctive Relief Terms” means the terms described in Section IV and set forth in Exhibit P.

44. “Later Litigating Special District ” means a Special Distr ict (or Special District official asserting the right of or for the Special District to recover for Alleged Harms to the Special District and/or the people thereof) that is not a Litigating Special 1879

8 December 20, 2022
District and that files a lawsuit bringing a Released Claim against a Released Entity, or that adds such a Claim to a pre-existing lawsuit, after the Preliminary Agreement Date. It may also include a Litigating Special District whose Claims were resolved by a Bar or Case -Specific Resolution , which is later revoked following the execution date of this Agreement, when such Litigating Special District takes any affirmative step in its lawsuit other than seeking a stay , removal or dismissal with prejudice.

45. “Later Litigating Subdivision ” means a Subdivision (or Subdivision official asserting the right of or for the Subdivision to recover for Alleged Harms to the Subdivision and/or the people thereof) that is not a Litigating Subdivision and that files a lawsuit b ringing a Released Claim against a Released Entity, or that adds such a Claim to a pre -existing lawsuit, after the Preliminary Agreement Date . It may also include a Litigating Subdivision whose Claims were resolved by a Bar or Case-Specific Resolution, which is later revoked following the execution date of this Agreement, when such Litigating Subdivision takes any affirmative step in its lawsuit other than seeking a stay, removal, or dismissal with prejudice.

46. “Later Participating S pecial District” means a Participating S pecial District that meets the requirements of subsection X.M but is not an Initial Participating Special District.

47. “Later Participating Subdivision” means a Participating Subdivision that meets the requirements of subsection X.E but is not an Initial Participating Subdivision.

48. “Litigating Special District ” means a Special District (or Special District official asserting the right of or for the Special District to recover for Alleged Harms to the Special District and/or the people thereof) that brought any Released Claims against any Released Entities on or before the Preliminary Agreement Date that were not separately resolved prior to that date. Exhibit C includes an agreed list of the Litigating Special Districts. Exhibit C will be updated (including with any corrections) periodically, and a final version of Exhibit C will be attached hereto as of the Effective Date.

49. “Litigating Subdivision” means a Subdivision (or Subdivision official asserting the right of or fo r the Subdivision to recover for Alleged Harms to the Subdivision and/or the people thereof) that brought any Released Claim s against any Released Entities on or before the Preliminary Agreement Date that were not separately resolved prior to that date. A Prior Settling Subdivision shall not be considered a Litigating Subdivision. Exhibit C includes an agreed list of the Litigating Subdivisions. Exhibit C will be updated (including with any corrections) periodically, and a final version of Exhibit C will be attached hereto as of the Effective Date.

50. “National Arbitration Panel” means the panel described in subsection XV.G.4.

51. “National Disputes” means the disputes described in subsection XV.G.4.a. 1880

9 December 20, 2022

52. “Net Abatement Amount” means $2,945,529,111.00, which is the Global Settlement Abatement Amount adjusted for the Prior Settlements Credit pursuant to subsection VII.C.2.

53. “Non-Litigating Covered Special District” means a Covered Special District that is not a Litigating Special District.

54. “Non-Litigating Special District” means a Special District that is neither a Litigating Special District nor a Later Litigating Special District.

55. “Non-Litigating Subdivision ” means a Subdivision that is not (1) a Litigating Subdivision, (2) a Later Litigating Subdivision, or (3) a Prior Settling Subdivision.

56. “Non-Participating Special District ” means a Special District that is not a Participating Special District.

57. “Non-Participating Subdivision” means a Subdivision that is not a Participating Subdivision. For the avoidance of doubt, Non -Participating Subdivision also includes Prior Settling Subdivisions.

58. “Non-Party Covered Conduct Claim ” means a Claim against any Non -Released Entity involving, arising out of, or related to Covered Conduct (or conduct that would be Covered Conduct if engaged in by a Released Entity).

59. “Non-Party Settlement” means a settlement by any Releasor that settles any Non - Party Covered Conduct Claim and includes a release of any Non-Released Entity.

60. “Non-Released Entity” means an entity that is not a Released Entity.

61. “Non-Settling State” means a State that is an Eligible State but not a Settling State.

62. “Opioid Remediation” means care, treatment, and other programs and expenditures (including reimbursement for past such programs or expenditures except where this Agreement restricts the use of funds solely to future Opioid Remediation) designed to (1) address the misuse and abuse of opioid products, (2) treat or mitigate opioid use or related disorders, or (3) mi tigate other alleged effects of the opioid abuse crisis, including on those injured as a result of the opioid abuse crisis. Exhibit E provides a non-exhaustive list of expenditures that qualify as being paid for Opioid Remediation. Qualifying expenditures may include reasonable related administrative expenses.

63. “Participating Special District” means a Special District that signs the Settlement Participation Form annexed hereto as Exhibit K and meets the requirements for becoming a Participating Special District under Section X. Participating Special Districts include both Initial Participating Special Districts and Later Participating Special Districts.

64. “Participating Subdivision ” means a Subdivision that signs a Settlement Participation Form annexed hereto as Exhibit K and meets requirements for 1881

10 December 20, 2022
becoming a Participating Subdivision under Section X. Participating Subdivisions include both Initial Participating Subdivisions and Later Participating Subdivisions.

65. “Parties” means Teva and the Settling States (each, a “Party”).

66. “Payment Date ” means the date on which Teva makes its Annual Payments (including its Initial Year Payment) , Additional Restitution Payments, Settlement Product Cash Conversion Amount, and Attorney Fee and Cost Payments, pursuant to Section VII and XIII and Exhibit M. The first Payment Date is thirty (30) days after the Effective Date. The second Payment Date is July 15, 2024. The Payment Date is July 15 in all subsequent years.

67. “Payment Year ” means the calendar year during which the applicable Annual Payment is due pursuant to subsection V II.B. Payment Year 1 is 2023, Payment Year 2 is 2024 and so forth. References to payment “for a Payment Year” mean the Annual Payment due that year. References to eligibility “for a Payment Year” mean eligibility in connection with the Annual Payment due during that year.

68. “Preliminary Agreement Date” means the date on which Teva gives notice to the Settling States and MDL Plaintiffs’ Executive Committee of its determination that a sufficient number of States have agreed to be Settling States to proceed with notice pursuant to subsection X.A. This date shall be no more than fourte en (14) days after the end of the notice period to States (as set forth in subsection II.A) unless it is extended by written agreement of Teva and the Enforcement Committee.

69. “Primary Subdivision ” means a Subdivision that has a population of 30,000 or more. A list of Primary Subdivisions in each State is provided in Exhibit I , and such list shall be updated if any Primary Subdivision is inadvertently missed or included.

70. “Prior Settlements Credit” means the credit of $666,032,651.00, reflecting that the allocations for Prior Settling States and Prior Settling Subdivisions for Claims related to the Covered Conduct against Teva and/or other Released Entities were or will be separately settled. The credit is applied pursuant to subsection VI.A.1.

71. “Prior Settling State” means Florida, Louisiana, Rhode Island, Texas, and West Virginia and all Subdivisions and Special Districts within those States, and Oklahoma,1 whose Claims were released as part of those States’ settlements

72. “Prior Settling Subdivision” means the City and County of San Francisco, California, Cuyahoga County, Ohio, and Summit County, Ohio.

73. “Product” means any chemical substance, whether used for medicinal or non - medicinal purposes, and whether natural, synthetic, or semi -synthetic, or any

1 Claims of Oklahoma Subdivisions and Special Districts were not released as part of Teva’s settlement with Oklahoma and therefore have the opportunity to participate . Terms related to Oklahoma Subdivisions and Special Districts are to be addressed in Exhib it H, which shall be prepared by Teva and presented to the Oklahoma Subdivisions and Special Districts during the notice period to States. 1882

11 December 20, 2022
finished pharmaceutical product made from or with such substance, that is an opioid or opiate, as well as any product containing any such substance. It also includes: 1) the following when used in combination with opioids or opiates: benzodiazepine, carisoprodol, zolpidem, or gabapentin; and 2) a combination or “cocktail” of any stimulant or other chemical substance prescribed, sold, bought, or dispensed to be used togethe r that includes opioids or opiates. For the avoidance of doubt, “Product” does not include benzodiazepine, carisoprodol, zolpidem, or gabapentin when not used in combination with opioids or opiates. “ Product” includes but is not limited to any substance consisting of or containing buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, meperidine, methadone, morphine, naloxone, naltrexone, oxycodone, oxymorphone, pentazocine, propoxyphene, tapentadol, tramadol, opium, heroin, carfentanil, any variant of these substances, or any similar substance. “ Product” also includes any natural, synthetic, semi - synthetic or chemical raw materials, starting materials, finished active pharmaceutical ingredients, drug substances, and any related intermediate products used or created in the manufacturing process for any of the substances described in the preceding sentence.

74. “Reference Date” means the date on which Teva is to inform the Settling States and MDL P laintiffs’ Executive Committee of its determination whether there is sufficient resolution of Claims and potential Claims at the Subdivision level to go forward with the settlement. The Reference Date shall be no later than thirty (30) days after the Initial Participation Date, unless it is extended by written agreement of Teva and the Enforcement Committee.

75. “Released Claims” means any and all Claims that directly or indirectly are based on, arise out of, or in any way relate to or concern the Covered Conduct occurrin g prior to the Reference Date. Without limiting the foregoing, “Released Claims” include any Claims that have been asserted against the Released Entities by any Settling State or any of its Litigating Subdivisions or Litigating Special Districts in any fed eral, state or local action or proceeding (whether judicial, arbitral, or administrative) based on, relating to, in whole or in part, the Covered Conduct, or any such Claims that could be or could have been asserted now or in the future in those actions or in any comparable action or proceeding brought by a State, any of its Subdivisions or Special Districts, or any Releasors (whether or not such State, Subdivision, Special District, or Releasor has brought such action or proceeding).

Released Claims also i nclude all Claims against Released Entities asserted in any proceeding to be dismissed pursuant to the Agreement, whether or not such claims relate to Covered Conduc t. “Released Claims” shall be interpreted broadly. This Agreement does not release Claims by private individuals. Claims by private individuals shall be treated in accordance with applicable law. Released Claims is also used herein to describe Claims brought by a Later Litigating Su bdivision or other non -party Subdivision or Special District that would have been Released Claims if they had been brought by a Releasor against a Released Entity.

76. “Released Entities” means Teva; and (1) all of Teva’s respective past and present direct or indirect parents, subsidiaries, divisions, affiliates, joint ventures (but excluding joint venture partners), predecessors, successors and assigns; (2) Teva’s 1883

12 December 20, 2022
insurers (solely in their role as insurers with respect to the Released Claims ); and (3) Teva’s past and present officers, directors, members, shareholders (solely in their capacity as shareholders of the foregoing entities), partners, trustees, employees, agents and attorneys (for actions that occurred during and related to their work for, or employment with, Teva). Any person or entity described in clauses (2)-(3) shall be a Released Entity solely in the capacity described in such clause. A list of all of the indirect parents, subsidiaries, affiliates and joint ventures released pursuant to clause (1) is attached as Exhibit J. For the avoidance of doubt, any entity acquired, or joint venture entered into, by Teva after the Reference Date is not a Released Entity, regardless of whether they are listed on Exhibit J.

77. “Releasors” means (1) each Settling State; (2) each Participating Subdivision; (3) each Participating Special District; and ( 4) without limitation and to the maximum extent of the power of each Settling State’s Attorney General and/or Participating Subdivision and Participating Special District to release Claims, (a) the Settling State’s, Participating Subdivision’s, and Participating Special District’s departments, agencies, divisions, boards, commissions, Subdivisions, districts, instrumentalities of any kind and attorneys, including its Attorney General, and any person in their official capacity whether elected or appointed to serve any of the foregoing and any agency, person, or other entity claiming by or through any of the foregoing, (b) any public entities, pub lic instrumentalities, public educational institutions, unincorporated districts, fire districts, irrigation districts, water districts, emergency services districts, school districts, healthcare districts, hospital districts, Sheriffs and law enforcement districts, library districts, coroner’s offices, and public transportation authorities, and other Special Districts in a Settling State, including those with the regulatory authority to enforce state and federal controlled substances acts or the authority to bring Claims related to Covered Conduct seeking money (including abatement (or remediation and/or restitution)) or revoke a pharmaceutical distribution license, and (c) any person or entity acting in a parens patriae, sovereign, quasi-sovereign, private attorney general, qui tam, taxpayer, or other capacity seeking relief , including but not limited to, fines , penalties, or punitive damages, on behalf of or generally applicable to the general public with respect to a Settling State or a Subdivision or Special District in a Settling State, whether or not any of them participate in the Agreement. “Releasors” does not include persons acting in an individual capacity, regardless of the type of relief sought. The inclusion of a specific reference to a type of entity in this definition shall not be construed as meaning that the entity is not a Subdivision. In addition to being a Releasor as provided herein, Participating Subdivision s and Participating Special Districts shall also provide a Settlement Participation Form providing for a release to the fullest extent of the Participating Subdivision’s and Participating Special District’s authority, which is attached as Exhibit K . Each Settling State’s Attorney General represents that he or she has or has obtained (or will obtain no later than the Effective Date) the authority set forth in the Representation and Warranty subsection of Section V.

78. “Revocation Event” means with respect to a Bar, Settlement Class Resolution, or Case-Specific Resolution, a legislative amendment or a revocation, rescission, 1884

13 December 20, 2022
reversal, overruling, or interpretation that in any way limits the effect of such Bar, Settlement Class Resolution, or Case -Specific Resolution on Released Claims or any other action or event that otherwise deprives the Bar, Settlement Class Resolution or Case-Specific Resolution of force or effect in any material respect.

79. “Settlement Class Resolution ” means a class action resolution in a court of competent jurisdiction in a Settling State with respect to a class of Subdivisions and Special Districts in that State that (1) conforms with that Settling State’s statutes, case law, and/or rules of procedure regarding class actions; (2) is approved and entered as an order of a court of competent jurisdiction in that State and has become final as defined in “State-Specific Finality”; (3) is binding on all Non-Participating Subdivisions and Non-Participating Special Districts in that State (other than opt outs as permitted under the next sentence); (4) provides that all such Non - Participating Subdivisions or Non-Participating Special Districts may not bring Released Claims against Released Entities, whether on t he ground of the Agreement (or the releases herein) or otherwise; and (5) does not impose any costs or obligations on Teva other than those provided for in the Agreement, or contain any provision inconsistent with any provision of the Agreement. If applicable state law requires that opt-out rights be afforded to members of the class, a class action resolution otherwise meeting the foregoing requirements shall qualify as a Settlement Class Resolution unless Subdivisions collectively representing more than 1% of the total population of all of that State’s Subdivisions listed in Exhibit G opt out. In seeking certification of any Settlement Class, the applicable State and Participating Subdivisions shall make clear that certification is sought solely for settlement purposes and shall have no applicability beyond approval of the settlement for which certification is sought. Nothing in this Agreement constitutes an admission by any Party that class certification would be appropriate for litigation purposes in any case.

80. “Settlement Fund ” means the interest -bearing fund established under the Agreement into which Annual Payments by Teva are made pursuant to Section VII.

The Settlement Fund comprises the Abatement Accounts Fund, State Fund, and Subdivision Fund.

81. “Settlement Fund Administrator ” means the entity that determines the Annual Payments (including calculating Incentive Payments pursuant to Section V I and any amounts subject to offset pursuant to Sections VII.C and XII), and administers and distributes amounts into the Settlement Fund. It shall also administer and distribute the Additional Restitution Amount pursuant to Section XIII. The duties of the Settlement Fund Administrator shall be governed by this Agreement. Prior to the Initial Participation Date, the Parties shall agree to selection and removal processes for and a detailed description of the Settlement Fund Administrator’s duties all of which shall be appended to the Agreement as Exhibit L.

82. “Settlement Fund Administrator Costs ” means any costs and fees associated with or arising out of the duties of the Settlement Fund Administrator with regard to Teva and Allergan’s payments to the Settlement Fund as described in Exhibit L and 1885

14 December 20, 2022
elsewhere in this Agreement, including those arising from the use of a bank or other financial institution to receive and disburse payments.

83. “Settlement Fund Escrow ” means the interest -bearing escrow fund established pursuant to this Agreement to hold disputed payments made under this Agreement.

84. “Settlement Participation Form” means the form attached as Exhibit K that Participating Subdivisions and Participating Special Districts must execute and provide to Teva and the Implementation Administrator or Settlement Fund Administrator, and which shall (1) make such Participating Subdivisions and Participating Special Districts signatories to this Agreement, (2) include a full and complete release of any and all of such Participating Subdivisions’ and Participating Special Districts’ Claims and (3) require prompt cessation of litigation activity as set forth in Section III, and request for dismissal with prejudice of any Released Claims that have been filed agains t Released Entities by any such Participating Subdivisions or Participating Special Districts within fourteen (14) business days after the Reference Date.

85. “Settlement Payment Schedule ” means the schedule of payments attached to this Agreement as Exhibit M. Actual payment amounts are subject to adjustments consistent with this Agreement.

86. “Settlement Product ” means finished good kits (two (2) devices per kit) of “Naloxone Hydrochloride N asal Spray” (4 mg strength) that is listed in Teva’s then-current generics catalog, which can be viewed at www.tevagenerics.com, and is provided to the Settling State as part of the settlement, at no cost as set forth in Section IX and Exhibit D.

87. “Settlement Product Cash Conversion Amount” means the resulting dollar amount from when a Settling State has elected to convert all or a portion of its Settlement Product allocation into a cash payment pursuant to Section IX and Exhibit D. The aggregate, maximum amount that could be paid from the conversion of Settlement Product into cash is $240,000,000.00.

88. “Settlement Product Election Form” means the form a Settling State uses to submit its election of the Settling State’s allocation of Settlement Product or cash conversion of Settlement Product pursuant to Section IX and Exhibit D.

89. “Settling State” means any Eligible State that has entered into this Agreement.

90. “Special District” means (1) formal and legally recognized sub-entities of a State recognized by the U.S. Census Bureau 2 and those listed on Exhibit C , and (2) any person, official, or entity thereof acting in an official capacity. Special Districts do not include sub -entities of a State that provide general governance for a defined

2 All such entities are found on the “Special District,” “School District,” and “DEP School District” tabs of the Census Bureau’s 2017 Government Units Listing spreadsheet available at https://www2.census.gov/programs-surveys/gus/datasets/2017/govt_units_2017.ZIP. 1886

15 December 20, 2022
area that would qualify as a Subdivision. Entities that include any of the following words or phrases in its name shall not be considered a Special District: mosquito, pest, insect, spray, vector, animal, air quality, air pollution, clean air, coastal water, tuberculosis, and sanitary.

91. “State” means any state of the United States of America, the District of Columbia, American Samoa, Guam, the Northern Mariana Islands, Puerto Rico, and the U.S.

Virgin Islands. Additionally, the use of non -capitalized “state” to describe something (e.g., “state court”) shall also be read to include parallel entities in commonwealths, territories, and the District of Columbia (e.g., “territorial court”).

92. “State Allocation Percentage” means the allocation percentages for Eligible States as set forth in Exhibit F -2, which have been adjusted from the State Global Allocation Percentages to account for the Prior Settlements Credit.

93. “State Cost Fund” means the fund totaling $6,371,058.22 and described in Exhibit S.

94. “State Global Allocation Percentage ” means the allocation percentages for all States as set forth in Exhibit F -1, which represents allocations before the Prior Settlements Credit is applied.

95. “State Fund” means a component of the Settlement Fund described in subsection VIII.D.

96. “State Outside Counsel Fee Fund ” means the fund totaling $28,669,762.00 and described in Exhibit T.

97. “State-Specific Finality” means, with respect to the Settling State in question:
a. the Agreement and the Consent Judgment have been approved and entered by the Court as to Teva, including the release of all Released Claims against Released Entities as provided in this Agreement;
b. for all lawsuits brought by the Settling State against Released Entities for Released Claims, either previously filed or filed as part of the entry of t he Consent Judgment, the Court has stated in the Consent Judgment or otherwise entered an order finding that all Released Claims against Released Entities asserted in the lawsuit have been resolved by agreement; and
c. (1) the time for appeal or to seek review of or permission to appeal from the approval and entry as described in subsection (a) hereof and entry of such order described in subsection (b) hereof has expired; or (2) in the event of an appeal, the appeal has been dismissed or denied, or the approva l and entry described in (a) hereof and the order described in subsection (b) hereof have been affirmed in all material respects (to the extent challenged in the appeal) by the court of last resort to which such appeal has been taken and 1887

16 December 20, 2022
such dismissal or affirmance has become no longer subject to further appeal (including, without limitation, review by the United States Supreme Court).

98. “State-Subdivision Agreement” means an agreement that a Settling State reaches with the Subdivisions in that State regarding the allocation, distribution, and/or use of funds allocated to that State and to Exhibit G Participants in that State. A State- Subdivision Agreement shall be effective if approved pursuant to the provisions of Exhibit O or if adopted by statute. Preexis ting agreements addressing funds other than those allocated pursuant to this Agreement shall qualify if the approval requirements of Exhibit O are met. A State and its Subdivisions may revise, supplement, or refine a State -Subdivision Agreement if approved pursuant to the provisions of Exhibit O or if adopted by statute.

99. “Statewide Payment Amount” means the amount from an Annual Payment to be paid to a Settling State, its separate types of funds (if applicable), and its Exhibit G Participants.
100. “Statutory Tr ust” means a trust fund established by state law to receive funds allocated to a State’s Abatement Accounts Fund and restrict their expenditure to Opioid Remediation purposes subject to reasonable administrative expenses. A State may give a Statutory Trust authority to allocate one or more of the three Settlement Funds, but this is not required.
101. “Subdivision” means (1) a formal and legally recognized sub-entity of a State that provides general governance for a defined area, such as a municipality, county, parish, city, town, incorporated township, village, borough, or any other entities that provide municipal-type government within a State, and (2) any person, official, or entity thereof acting in an official capacity on behalf of the Subdivision (including, without limitation, district attorneys, county attorneys, city attorneys, Sheriffs, and any other official, employee, or representative) . Unless otherwise specified, “Subdivision” inc ludes all functional counties and parishes and other functional levels of sub -entities of a State that provide general governance for a defined area. Historic, non-functioning sub-entities of a State (such as Connecticut counties) are not Subdivisions, unl ess the entity has filed a lawsuit that includes a Released Claim against a Released Entity in a direct, parens patriae, or any other capacity. For purposes of this Agreement, the term Subdivision does not include Special Districts.
102. “Subdivision and Special District Allocation Percentage” means for Subdivisions and Special Districts in a Settling State that are eligible to receive an allocation from the Subdivision Fund pursuant to subsection VIII.D or subsection VIII.E, the percentage as set forth in Exhibit G. The aggregate Subdivision and Special District Allocation Percentage of all Subdivisions and Special Districts receiving a Subdivision and Special District Allocation Percentage in each State shall equal 100%. Immediately upon the effective ness of any State -Subdivision Agreement, Allocation Statute, Statutory Trust, or voluntary redistribution allowed by subsection V III.E.3 (or upon the effectiveness of an amendment to any State - Subdivision Agreement, Allocation Statute, Statutory Trust, or voluntary 1888

17 December 20, 2022
redistribution allowed by subsection V III.E.3) that addresses allocation from the Subdivision Fund, whether before or after the Initial Participation Date, Exhibit G will automatically be amended to reflect the allocation from the Subdivision Fun d pursuant to the State -Subdivision Agreement, Allocation Statute, Statutory Trust, or voluntary redistribution allowed by subsection VIII.E.3. The Subdivision and Special District Allocation Percentages contained in Exhibit G may not change once notice is distributed pursuant to subsection X.A, except upon the effectiveness of any State -Subdivision Agreement, Allocation Statute, Statutory Trust, or voluntary redistribution allowed by subsection VIII.E.3 (or upon the effectiveness of an amendment to any State -Subdivision Agreement, Allocation Statute, Statutory Trust, or voluntary redistribution allowed by subsection VI II.E.3) that addresses allocation from the Subdivision Fund. For t he avoidance of doubt, no Subdivision or Special District not listed on Exhibit G shall receive an allocation from the Subdivision Fund and no provision of this Agreement shall be interpreted to create such an entitlement.
103. “Subdivision Fund ” means a compon ent of the Settlement Fund described in subsection VIII.D.
104. “Teva” means (i) Teva Pharmaceutical Industries Ltd. and (ii) all of its respective past and present direct or indirect parents, subsidiaries, divisions, affiliates, joint ventures, predecessors, successors, assigns, including but not limited to Teva Pharmaceuticals USA, Inc., the Actavis Generic Entities, and Anda Inc. 105. “Threshold Motion” means a motion to dismiss or equivalent dispositive motion made at the outset of litigation under applicable procedure. A Threshold Motion must include as potential grounds for dismissal, any applicable Bar or the relevant release by a Se ttling State , Participating Subdivision , or Participating Special District provided under this Agreement and, where appropriate under applicable law, any applicable limitations defense.

II. Participation by States and Condition to Preliminary Agreement A. Notice to States. On November 22, 2022, this Agreement shall be distributed to all Eligible States. The Eligible States’ Attorneys General shall then have a period of thirty (30) days to decide whether to become Settling States. Eligible States will decide whether to become Settling States for both this Agreement and the Allergan Global Opioid Settlement Agreement, or decline participation in both settlements. If a State is only an Eligible State with respect to one of the Agreements, the State need only decide whether to become a Settling State with respect to the Agreement for which it is an Eligible State . States that determine to become Settling States shall so notify the Enforcement Committee and Teva within thirty (30) days after November 22, 2022, and shall further commit to obtaining any 1889

18 December 20, 2022
necessary additional State releases prior to the Effective Date. This notice period for States may be extended by written agreement of Teva and the Enforcement Committee.

B. Ineligible States. Non-Settling States and Prior Settling States shall not be eligible for any payments or have any rights in connection with this Agr eement, except for Subdivisions and Special Districts within Oklahoma as specified in Exhibit H.

C. Condition to Preliminary Agreement . Following the notice period to Eligible States set forth in subsection II.A above, Teva shall determine on or before the Preliminary Agreement Date whether, in its sole discretion enough States have agreed to become Settling States to proceed with notice to Subdivisions as set forth in Section X below. The determination to proceed shall be i n the sole discretion of Teva and may be based on any criteria or factors deemed relevant by Teva. If Teva determines that this condition has been satisfied, and that notice to the Subdivisions should proceed, it will so notify the Settling States by providing notice to the Enforcement Committee on the Preliminary Agreement Date. If Teva determines that this condition has not been satisfied, it will so notify the Settling States by providing notice to the Enforcement Committee, and this Agreement will have no further effect and all releases and other commitments or obligations contained herein will be void other than Teva’s funding of Implementation Costs incurred to date .

The Preliminary Agreement Date may be extended by written agreement of Teva and the Enforcement Committee.

D. Later Joinder by States. After the Preliminary Agreement Date, an Eligible State may only become a Settling State with the consent of Teva, in its sole discretion. If a State becomes a Settling State more than thirty (30) days after the Preliminary Agreement Date, the Subdivisions and Special Districts in that State that become Participating Subdivisions and Participating Special Districts w ithin ninety (90) days of the State becoming a Settling State shall be considered Initial Participating Subdivisions or Initial Participating Special Districts.

III. Cessation of Litigation Activities
A. Following the Preliminary Agreement Date, if Teva has determined to proceed with notice pursuant to subsection X.A, all Litigating States that intend to become Settling States and that are engaged in or have engaged in discovery and/or substantive motion practice (“Active Litigation ”) against a Released Entity shall make reasonable efforts to immediately cease litigation activity (e.g., written and document discovery, depositions, expert disclosures, and motion practice) against Teva, where feasible, or to minimize litigation activity by means o f agreed deadline extensions and agreed postponement of depositions, document productions, and motion practice . Teva shall cooperate in such efforts. The obligations under this subsection do not extend past the Reference Date if Teva determines it is not going forward with the Agreement. This subsection III.A does not apply to Litigating States with a trial date within six (6) months of the Preliminary Agreement Date, though such Litigating States and Teva shall engage in good faith discussions regarding the potential cessation of litigation activity.

B. Following the execution of the Settlement Participation Form, attached as Exhibit K, indicating its intention to participate in the global settlement, a Litigating Subdivision 1890

19 December 20, 2022
or Litigating Special District shall take reasonable steps to immediately cease all litigation activity (e.g., written and document discovery, depositions, expert disclosures, and motion practice) against Teva, where feasible, or minimize litigation activity by means of an agreed upon temporary “stay” of litigation and/or deadline extensions or postponement of litigation activity including depositions, document productions, and motion practice, unless the Litigating Subdivision or Litigating Special District reasonably concludes that it would be prejudiced by doing so. Teva shall cooperate in such efforts. The obligations under this subsection do not extend past the Reference Date if Teva determines it is not going forward with the settlement. This paragraph III.B does not apply to Litigating Subdivisions and Litigating Special Distric ts with a trial date within six (6) months of the Preliminary Agreement Date, though such Litigating Subdivisions and Litigating Special Districts and Teva shall engage in good faith discussions regarding the potential cessation of litigation activity.

C. Following the Reference Date, the Settling States shall endeavor to file Consent Judgments (the contents of which must be agreed upon with Teva) within thirty (30 ) days of the Reference Date. Participating Subdivisions and Participating Special Districts, as applicable, shall request dismissal of their actions with prejudice within fourteen (14) days of the Reference Date . The Settling States, Participating Subdivisions, and Participating Special Districts shall use best efforts to get Consent Judgments or orders of dismissal with prejudice, as applicable, entered promptly after filing.

IV. Injunctive Relief
A. Entry of Injunctiv e Relief . As part of the Consent Judgment, the Parties agree to the Injunctive Relief Terms attached as Exhibit P.

V. Release
A. Scope. As of the Effective Date, the Released Entities will be released and forever discharged from all of the Releasors’ Released Cl aims. Each Settling State (for itself and its Releasors) and Participating Subdivision (for itself and its Releasors), and Participating Special District (for itself and its Releasors) will, on or before the Effective Date, absolutely, unconditionally, and irrevocably covenant not to bring, file, or claim, or to cause, assist in bringing, or permit to be brought, filed, or claimed, or to otherwise seek to establish liability for any Released Claims against any Released Entity in any forum whatsoever. The releases provided for in the Agreement are intended to be broad and shall be interpreted so as to give the Released Entities the broadest possible bar against any liability relating in any way to Released Claims and extend to the full extent of the power of each Settling State and its Attorney General to release Claims. The Release shall be a complete bar to any Released Claim.
1891

20 December 20, 2022
B. Claim Over and Non-Party Settlement.

1. Statement of Intent. It is the intent of the Parties that:
a. Released Entities should not seek contribution or indemnification (other than pursuant to an insurance contract) from other parties for their payment obligations under this Agreement;
b. the payments made under this Agreement shall be the sole payments made by the Released Entities to the Releasors involving, arising out of, or related to Covered Conduct (or conduct that would be Covered Conduct if engaged in by a Released Entity);
c. Claims by Releasors against non -Parties should not result in additional payments by Released Entities, whether through contribution, indemnification or any other means; and
d. the Settlement meets the requirements of the Uniform Contribution Among Joint Tortfeasors Act and any similar state law or doctrine that reduces or discharges a r eleased party’s liability to any other parties. Any amounts payable by Teva pursuant to this Agreement, including but not limited to the Net Abatement Amount and any attorneys’ fees, shall not be reduced or otherwise affected by any obligation by Teva to p ay any contractual indemnity or agreed-to contribution amount to Allergan.

The provisions of this subsection V.B are intended to be implemented consistent with these principles. This Agreement and the releases and dismissals provided for herein are made in good faith.

2. Contribution/Indemnity Prohibited. No Released Entity shall seek to recover for amounts paid under this Agreement based on indemnification, contribution, or any other theory from a manufacturer, pharmacy, hospital, pharmacy benefit manager, health insurer, third -party vendor, trade association, distributor, or health care practitioner, provided that a Released Entity shall be relieved of this prohibition with respect to any entity that asserts a Claim Over against it. For the avoidance of doubt, nothing herein shall prohibit a Released Entity from recovering amounts owed pursuant to insurance contracts.

3. Non-Party Settlement . To the extent that, on or after the Reference Date, any Releasor enters into a Non -Party Settlement, including in any bank ruptcy case or through any plan of reorganization (whether individually or as a class of creditors), the Releasor will include (or in the case of a Non -Party Settlement made in connection with a bankruptcy case, will cause the debtor to include), unless prohibited from doing so under applicable law, in the Non -Party Settlement a prohibition on contribution or indemnity of any kind substantially equivalent to that required from Teva in subsection V.B.2, or a release from such Non -Released Entity in favor of the Released Entities (in a form equivalent to the releases contained in this Agreement) of any Claim Over. However, and notwithstanding 1892

21 December 20, 2022
the foregoing, this provision shall not preclude Allergan from seeking indemnification under its agreement with Teva . The obligation to obtain the prohibition and/or release required by this subsection is a material term of this Agreement.

4. Claim Over. In the event that any Releasor obtains a judgment with respect to Non- Party Covered Conduct against a Non -Released Entity that does not contain a prohibition like that in subsection V.B.3, or any Releasor files a Non-Party Covered Conduct Claim against a Non-Released Entity in bankruptcy or a Releasor is prevented for any reason from obtaining a prohibition/release in a Non -Party Settlement as provided in subsection V.B.3, and such Non-Released Entity asserts a Claim Over against a Released Entity, that Releasor and Teva shall take the following actions to ensure that the Released Entities do not pay more with respect to Covered Conduct to Releasors or to Non -Released Entities than the amounts owed under this Agreement by Teva:
a. Teva shall notify that Releasor of the Claim-Over within sixty (60) days of the assertion of the Claim -Over or sixty (60) days of the Effective Date of this Agreement, whichever is later;
b. Teva and that Releasor shall meet and confer concerning the means to hold Released Entities harmless and ensure that it is not required to pay more with respect to Covered Conduct than the amounts owed by Teva under this Agreement;
c. That Releasor and Teva shall take steps sufficient and permissible under the law of the State of the Releasor to hold Released Entities harmless from the Claim-Over and ensure Released Entities are not required to pay more with respect to Covered Conduct t han the amounts owed by Teva under this Agreement. Such steps may include, where permissible:
(i) Filing of motions to dismiss or such other appropriate motion by Teva or Released Entities, and supported by Releasors, in response to any Claim filed in litigation or arbitration;
(ii) Reduction of that Releasor’s Claim and any judgment it has obtained or may obtain against such Non -Released Entity by whatever amount or percentage is necessary to extinguish such Claim -Over under applicable law, up to the amount that Re leasor has obtained, may obtain, or has authority to control from such Non -Released Entity;
(iii) Placement into escrow of funds paid by the Non -Released Entities such that those funds are available to satisfy the Claim-Over; (iv) Return of monies paid by Teva to tha t Releasor under this Agreement to permit satisfaction of a judgment against or settlement with the Non-Released Entity to satisfy the Claim-Over; 1893

22 December 20, 2022
(v) Payment of monies to Teva by that Releasor to ensure it is held harmless from such Claim-Over, up to the amount that Releasor has obtained, may obtain, or has authority to control from such Non - Released Entity;
(vi) Credit to Teva under this Agreement to reduce the overall amounts to be paid under the Agreement such that it is held harmless from the Claim-Over; and
(vii) Such other actions as that Releasor and Teva may devise to hold Teva harmless from the Claim Over.
d. The actions of that Releasor and Teva taken pursuant to paragraph (c) must, in combination, ensure Teva is not required to pay more with respect to Covered Conduct than the amounts owed by Teva under this Agreement. e. In the event of any dispute over the sufficiency of the actions taken pursuant to paragraph (c), that Releasor and Teva may seek review by the National Arbitration Panel, provided that, if the Parties agree, such dispute may be heard by the state Court where the relevant Consent Judgment was filed.

The National Arbitration Panel shall have authority to require Releasors to implement a remedy that includes one or more of the actions specified in paragraph (c) sufficient to hold Released Entities fully harmle ss. In the event that the panel’s actions do not result in Released Entities being held fully harmless, Teva shall have a Claim for breach of this Agreement by Releasors, with the remedy being payment of sufficient funds to hold Teva harmless from the Clai m Over. For the avoidance of doubt, the prior sentence does not limit or eliminate any other remedy that Teva may have.

5. To the extent that the Claim Over is based on a contractual indemnity, the obligations under subsection V.B.4 shall extend solely to a N on-Party Covered Conduct Claim against a pharmacy, clinic, hospital or other purchaser or dispenser of Products, a manufacturer that sold Products, a consultant, and/or a pharmacy benefit manager or other third-party payor. Teva shall notify the Settling States, to the extent permitted by applicable law, in the event that any of these types of Non- Released Entities asserts a Claim-Over arising out of contractual indemnity against it.

C. General Release . In connection with the releases provided for in the Agree ment, each Settling State (for itself and its Releasors) , Participating Subdivision and Participating Special District expressly waives, releases, and forever discharges any and all provisions, rights, and benefits conferred by any law of any state or territory of the United States or other jurisdiction, or principle of common law, which is similar, comparable, or equivalent to § 1542 of the California Civil Code, which reads:

General Release; extent. A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release that, if known by him or her, would 1894

23 December 20, 2022
have materially affected his or her settlement with the debtor or released party.

A Releasor may thereafter discover facts other than or different from those which it knows, believes, or assumes to be true with respect to the Released Claims, but each Settling State (for itself and its Releasors) , Participating Subdivision and Participating Special District hereby expressly waives and fully, finally, and forever settles, releases, and discharges, upon the Effective Date, an y and all Released Claims that may exist as of such date but which Releasors do not know or suspect to exist, whether through ignorance, oversight, error, negligence or through no fault whatsoever, and which, if known, would materially affect the Settling States’ decision to enter into the Agreement , the Participating Subdivisions’ decision to participate in the Agreement , or the Participating Special District’s decision to participate in the Agreement.

D. Res Judicata. Nothing in the Agreement shall be deemed to reduce the scope of the res judicata or claim preclusive effect that the settlement memorialized in the Agreement, and/or any Consent Judgment or other judgment entered on the Agreement, gives rise to under applicable law.

E. Representation and Warranty. The signatories hereto on behalf of their respective Settling States, its Participating Subdivisions , and its Participating Special Districts expressly represent and warrant that they will obtain on or before the Effective Date (or have obtained) the authority to settle and release, to the maximum extent of the State’s power, all Released Claims of (1) their respective Settling States; (2) any of the respective Settling State’s past and present executive departments, state agencies, divisions, boards, commissions and instrumentalities with the regulatory authority to enforce state and federal controlled substances acts; (3) any of their respecti ve Settling State’s past and present executive departments, agencies, divisions, boards, commissions and instrumentalities that have the authority to bring Claims related to Covered Conduct seeking money (including abatement and/or remediation) or revocati on of a pharmaceutical distribution license; (4) any Participating Subdivisions ; and (5) any Participating Special District . For the purposes of clause (3) above, executive departments, agencies, divisions, boards, commissions, and instrumentalities are those that are under the executive authority or direct control of the State’s Governor. Also, for the purposes of clause (3), a release from a State’s Governor is sufficient to demonstrate that the appropriate releases have been obtained.

F. Effectiveness. The releases set forth in the Agreement shall not be impacted in any way by any dispute that exists, has existed, or may later exist between or among the Releasors. Nor shall such releases be impacted in any way by any current or future law, regulation, ordinance, or court or agency order limiting, seizing, or controlling the distribution or use of the Settlement Fund or any portion thereof, or by the enactment of future laws, or by any seizure of the Settlement Fund or any portion thereof.

G. Cooperation. Releasors (i) will not encourage any person or entity to bring or maintain any Released Claim against any Released Entity and (ii) will reasonably cooperate with and not oppose any effort by a Released Entity to secure the prompt dismissal of any and all Released Claims.
1895

24 December 20, 2022
H. Non-Released Claims. Notwithstanding the foregoing or anything in the definition of Released Claims, the Agreement does not waive, release or limit any criminal liability, Claims for any outstanding liability under any tax or securities law, Claims against parties who are not Released Entities, Claims by private individuals, Claims for Medicaid rebates, Claims asserted, or that could be asserted, by any State or Subdivision, related to the causes of action in In re: Generic Pharmaceuticals Pricing Antitrust Litigation , in the United States District court for the District of Pennsylvania, MDL No. 2724, and any related action (such excluded claims include, but are not limited to, all antitrust claims and any claims related to any non-opioid generic drugs), and any claims arising under the Agreement for enforcement of the Agreement.

VI. Monetary Relief Overview and Maximum Payments
A. Excluding Teva’s share of Implementation Costs and Settlement Fund Administrator Costs, there are four main categories of monetary payments:

1. Annual Payments to the Settlement Fund. These payments are generally addressed in Section VII. The maximum amount Teva shall pay in Annual Payments to the Settlement Fund is the Net Abatement Amount of $2,945,529,111.00, which reflects the application of the Prior Settlements Credit to the Global Settlement Abatement Amount. Annual Payments will be made over thirteen (13) years on the Payment Dates. The actual amount paid will depend on, among other things, the level of participation of Eligible States, their Subdivisions, and their Special Districts.

2. Cash Conversion of Settlement Product . These potential monetary payments are generally addressed in Section IX. The maximum monetary amount Teva shall pay for the cash conversion of Settlement Product is $ 240,000,000.00. Payments for cash conversion of Settlement Product will be made over twelve (12) years on the Payment Dates. The actual amount paid will depend on, among other things, the level of participation of Eligible States and the number of Settling States opting for cash conversion.

3. Additional Restitution Amount. These payments are generally addressed in Section XIII. The maximum amount Teva shall pay for the Additional Restitution Amount is $28,669,762.00. Payments for the Additional Restitution Amount will be made over six (6) years on the Payment Dates . The actual amount paid will depend on the number of Eligible States listed in Exhibit F-2 that become Settling States.

4. Attorney Fee and Cost Payments . These payments are generally addressed in Section XIV and Exhibits M, R, S and T. They consist of payments for the State Outside Counsel Fee Fund, the State Cost Fund, and the Attorney Fee and Cost Fund. These payments will be made over six (6) years on the Payment Dates. The maximum amount Teva shall pay into these funds is the Global Settlement Attorney Fee Amount of $366,335,847.76.

B. The aggregate maximum amount Teva shall pay for these for these payment categories is $3,580,534,720.76. This figure does not include costs related to injunctive relief and 1896

25 December 20, 2022
document disclosure addressed in Exhibits P and V, Implementation Costs and Settlement Fund Administrator Costs addressed in this Agreement , or WAC value of Settlement Product.

C. Settlement Fund Administrator and Implementation Costs . If this Agreement becomes effective, Teva shall be responsible for one -third of the Implementation Costs. The full amount of the Implementation Costs shall be jointly advanced by Teva and Allergan. If this Agreement becomes effective, then Teva shall deduct from Teva’s Initial Year Payment the difference between the excess amount it advanced for Implementation Costs and its one-third obligation for such costs . Settlement Fund Administrator Costs shall be paid out of interest accrued on the Settlement Fund. Should such interest prove insufficient to fully cover the costs, the remaining cost amounts shall be paid one -third by Teva, one- third by Allergan and one -third from the Settlement Fund through the disbursement of Teva’s final Annual Payment.

VII. Annual Payments to Settlement Fund
A. Structure of Payments to Settlement Fund

1. All payments under this Section VII shall be made into the Settlement Fund, except that where specified, they shall be made into the Settlement Fund Escrow. The Settlement Fund shall be allocated and used only as specified in Section VIII.

2. Teva shall pay into the Settlement Fund the Net Abatement Amount consisting of $2,945,529,111.00 minus: (1) any offsets specified in subsection V II.C below ; (2) any unearned Incentive Payments under subsection V II.E below; and (3) any adjustments under Section XII below.

3. The payments to the Settlement Fund shall be divided into Base Payments and Incentive Payments as provided in subsections V II.D and VII.E below and set out in Exhibit M-1.

B. Settlement Fund Payment Process

1. Except as otherwise provided in this Agreement, Teva shall make one Initial Year Payment (the first Annual Payment) and twelve (12) additional Annual Payments of equal installments of the Net Abatement Amount (after all applicable offsets) into the Settlement Fund. The Settlement Payment Schedule is set forth in Exhibit M. Annual Payments shall be made on the Payment Date, provided that the necessary wire instructions and W-9 form for the Settlement Fund are provided to Teva at least twenty-one (21) days before the relevant payment is due. If there is a delay in making a payment because wire instructions and/or a W-9 form were not provided at least twenty-one (21) days in advance of the Payment Date, then the Annual Payment will be made within twenty-one (21) days of both the wire instructions and W-9 form being provided.

2. The Initial Year Payment shall consist of only Base Payments (after all applicable offsets). The other twelve (12) Annual P ayments shall each consist of Base 1897

26 December 20, 2022
Payments (after all applicable offsets) and Incentive Payments (after all applicable offsets). The amount of the Initial Year Payment and each other Annual Payment, payable by Teva shall not exceed the maximum amounts allocated to each Payment Year in Exhibit M.

3. To determine each Annual Payment for Payment Year 2 forward , the Settlement Fund Administrator shall use the data in its records sixty (60) days prior to the Payment Date for each payment. Prior to the Effective Date, the Parties will include an exhibit to the Agreement setting forth in detail the process for the Settlement Fund Administrator obtaining relevant data and for distributing fund s to Settling States and Exhibit G Participants consistent with the terms of this Agreement as quickly as practical.

4. The Settlement Fund Administrator shall determine the Annual Payment and the Statewide Payment Amount for each Settling State, consistent with the provisions in Exhibit L, by:
a. determining, for each Settling State, the amount of Base Payments and Incentive Payments to which the State is entitled by applying the criteria in this Section;
b. applying any reductions or offsets required by Sections VII and XII; and c. determining the total amount owed by Teva to all Settling States and Exhibit G Participants.

5. If, no later than fifty (50) days prior to the Payment Date for each payment for Payment Year 2 forward , Teva and the Enforcement Committ ee inform the Settlement Fund Administrator that they agree on the amount of the Annual Payment and the Statewide Payment Amount for each Settling State, Teva shall pay the agreed-upon Annual Payment amount on the Payment Date and the Settlement Fund Administrator shall treat those amounts as the determination described in subsection VII.B.4. If the Settlement Fund Administrator is not so informed, it shall give notice to Teva, the Settling States, and the Enforcement Committee of the amount of the Ann ual Payment, and the Statewide Payment A mount for each Settling State, following the determination described in subsection VII.B.4, and the following timeline shall apply:
a. Within twenty-one (21) days of the notice provided by the Settlement Fund Administrator, Teva, any Settling State or the Enforcement Committee may dispute, in writing, the calculation of the Annual Payment, or the Statewide Payment Amount for a Settling State. Such disputing party must provide a written notice of dispute to the Settlement Fund Administrator, the Enforcement Committee, any affected Settling State, and Teva identifying the nature of the dispute, the amount of money that is disputed, and the Settling State(s) affected.
1898

27 December 20, 2022
b. Within twenty-one (21) days of the sending of a written n otice of dispute, any affected party may submit a response, in writing, to the Settlement Fund Administrator, the Enforcement Committee, any affected Settling State, and Teva identifying the basis for disagreement with the notice of dispute. c. If no response is filed, the Settlement Fund Administrator shall adjust the amount calculated consistent with the written notice of dispute, and Teva shall pay the adjusted amount as the Annual Payment on the Payment Date.

If a written response to the writ ten notice of dispute is timely sent to the Settlement Fund Administrator, the Settlement Fund Administrator shall notify Teva of the preliminary amount to be paid, which shall be the greater of the amount originally calculated by the Settlement Fund Admin istrator or the amount that would be consistent with the notice of dispute, provided, however that in no circumstances shall the preliminary amount to be paid be higher than the maximum amount of Base Payments and Incentive Payments for that payment as set forth in Exhibit M. For the avoidance of doubt, a transfer of payments from the Settlement Fund Escrow for other Payment Years does not count toward determining whether the amount to be paid is higher than the maximum amount of Base Payments and Incentive Payments for that payment as set forth in Exhibit M.
d. The Settlement Fund Administrator shall place any disputed amount of the preliminary amount paid by Teva into the Settlement Fund Escrow and shall disburse any undisputed amount to each Settling State a nd its Exhibit G Participants.

6. If a Settling State informs the Settlement Fund Administrator that it and its Exhibit G Participants have reached consensus on the amount of its Statewide Payment Amount, determined pursuant to subsections VII.B.3 or VII.B.4, to be distributed to the Settling State, among its separate types of funds (if applicable), and among its Exhibit G Participants, the Settlement Administrator shall disburse the Statewide Payment Amount pursuant to the consensus distribution amounts prov ided by the Settling State. For a Settling States that do es not so notify the Settlement Fund Administrator, the Settlement Fund Administrator shall allocate the Settling State’s Statewide Payment Amount, pursuant to Section VII, among the separate types of funds for the Settling State (if applicable), and among its Exhibit G Participants using the following procedures:
a. As soon as possible for each payment and following the determination described in subsection s VII.B.3 and V II.B.4, the Settlement Fund Administrator shall give notice to the relevant Settling States and their Exhibit G Participants of the amount to be received by each Settling State, the amount to be received by the separate types of funds for each Settling State (if applicable), and the amount to be received by each Settling State’s Exhibit G Participants.
b. Within twenty-one (21) days of the notice provided by the Settlement Fund Administrator, any Settling State or Exhibit G Participant may dispute, in 1899

28 December 20, 2022
writing, the calculation of the amount t o be received by a Settling State and/or its Exhibit G Participants. A dispute will be deemed invalid and disregarded if it challenges the allocations adopted by a State -Subdivision Agreement approved pursuant to the provisions of Exhibit O or by statute.

Such disputing party must provide a written notice of dispute to the Settlement Fund Administrator, any affected Settling State , and any affected Exhibit G Participant identifying the nature of the dispute, the amount of money that is disputed, and the Settling State(s) affected. c. Within twenty-one (21) days of the sending o f a written notice of dispute, any affected Settling State or any affected Exhibit G Participant may submit a response, in writing, to the Settlement Fund Administrator, any affected Settling State and any affected Exhibit G Participant identifying the bas is for disagreement with the notice of dispute.
d. If no response is filed, the Settlement Fund Administrator shall adjust the amount calculated consistent with the written notice of dispute. e. The Settlement Fund Administrator shall place any disputed amount into the Settlement Fund Escrow and shall disburse any undisputed amount to the Settling State and its Exhibit G Participants.

7. Disputes described in this subsection (other than those for which no response is filed under subsections VII.B.5.c or VII.B.6.d) shall be resolved in accordance with the terms of Section XV.

8. The Settlement Fund Administrator may combine the disbursements of Annual Payments with disbursement of funds under other comparable opioid settlements.

In determining when disbursements for e ach Annual Payment will be made, the Settlement Fund Administrator may take into account the timeline for the availability of disbursements under other comparable opioid settlements.

9. For the avoidance of doubt, Subdivisions and Special Districts not listed on Exhibit G shall not receive an allocation from the Subdivision Fund.

C. Offsets to Annual Payments to the Settlement Fund for Non-Settling States

1. An offset equal to the Net Abatement Amount of $2,945,529,111.00 times the State Allocation Percentage assigned to each Non -Settling State in Exhibit F -2 shall be deducted from the total amount to be paid by Teva to the Settlement Fund.

2. Non-Settling States shall not be eligible for any payments or have any rights in connection with this Agreement. Accordingly, the stated maximum dollar amounts of the Annual Payments specified in Exhibit M are reduced by the aggregate State Allocation Percentage of Non-Settling States as set forth in Exhibit F-2. 1900

29 December 20, 2022
D. Base Payments

1. Teva shall make Base Payments into the Settlement Fund in an amount equal to 45% of the Net Abatement Amount of $2,945,529,111.00 minus any offsets for Non-Settling States specified in subsection VII.C.1. The maximum total for Base Payments is $1,325,488,100.00. The Base Payments will be paid in accordance with the Settlement P ayment Schedule specified by Exhibit M -1, subject to potential offsets for Non-Settling States as provided in subsection VII.C.1.

2. The Base Payments will be allocated by Settling State proportionate to each Settling State’s State Allocation Percentage in Exhibit F-2, adjusted for any Non -Settling State.

E. Incentive Abatement Payments

1. Teva shall make potential Incentive Payments totaling up to a maximum of 55% of the Net Abatement Amount of $2,945,529,111.00 for all Settling States with the actual amount depending on whether and the extent to which the criteria set forth below are met in each Settling State. The maximum total for Incentive Payments is $1,620,041,011.00.

2. The maximum total Incentive Payment for any Settling State shall be no more than the maximum total for Incentive Payments listed in subsection VII.E.1 times the Settling State’s State Allocation Percentage specified in Exhibit F-2. Incentive Payments are state -specific, with each Settling State receiving an Incentive Payment based on the incentives for which it is eligible for that year under the criteria set forth below and any offset specified in Section XII.

3. The Incentive Payments shall be divided among four (4) categories, referred to as Incentives A–D. Incentives A–C will be due in installments over the twelve (12) Payment Years beginning with Payment Year 2, and Incentive D will be due in installments over ten (10) years beginning with Payment Year 4, as shown on Exhibit M-1. The total amount of Incentive Payments in an Annual Payment shall be the sum of the Incentive Payments for which individual Settling States are eligible for that Payment Year under the criteria set forth below. The Incentive Payments shall be made with respect to a specific Settlin g State based on its eligibility for that Payment Year under the criteria set forth below.

4. The maximum amount available for Incentive Payments, $1,620,041,011.00, is divided into two pools. The maximum amount of Incentive Payments for Incentives A-C shall be $ 1,413,853,973.00, which is 48% of the maximum Net Abatement Amount. A Settling State may be eligible for its full allocable share of this payment by either achieving Incentive A or by fully earning both Incentives B and C. The maximum amount of Incentive Payments for Incentive D shall be $206,187,038.00, which is 7% of the maximum Net Abatement Amount. (These figures represent maximum payments prior to being adjusted for any offsets and assumes every State is a Settling State and will satisfy the requirements specified below to earn its maximum incentive amount. The Incentive Payments will be paid in accordance 1901

30 December 20, 2022
with the payment schedule in Exhibit M -1, subject to potential deductions as provided herein .) A Settling State qualifies to receive Incentive Payments in addition to Base Payments if it meets the incentive eligibility requirements specified below. Settling States may qualify for Incentive Payments in four ways.

If a Settling State qualifies for Incentive A, it will become entitled to receive the maximum payment allocable to the State for Incentives A-C as stated in subsection VII.E.5. If a Settling State does not qualify for Incentive A, it can alternatively qualify for Incentive B and/or Incentive C. A Settling State can qualify for Incentive D regardless of whether it qualifies for another Incentive Payment.

5. Incentive A: Full Participation or Fully Released Claims of Litigating Subdivisions, Litigating Special Districts, Non -Litigating Subdivisions with Population Greater Than 10,000, and Non-Litigating Covered Special Districts. a. A Settling State’s total potential Incentive A payment allocation is $1,413,853,973.00 times the percentage allocation assigned that Settling State in Exhibit F-2.
b. A State qualifies for Incentive A by: (1) complete participation in the form of releases consistent with Section V above from all Litigating Subdivisions, Litigating Special Districts , and Subdivisions with a population of 10,000 or more , and Non-Litigating Covered Special Districts; (2) a Bar; or (3) a combination of approaches in clauses (1) -(2) that achieves the same level of resolution of Subdivision and Special District Claims (e.g., a law barring future litigation combined with full joinder by Litigating Subdivisions and Litiga ting Special Districts). For purposes of Incentive A, a Subdivision or Special District is considered a “Litigating Subdivision” or “Litigating Special District” if it has brought Released Claims against Released Entities on or before the Reference Date; all other Subdivisions and Special Districts are considered “Non - Litigating.” For purposes of Incentive A, Non -Litigating Covered Special Districts shall not include a Special District with any of the following words or phrases in its name: mosquito, pest, insect, spray, vector, animal, air quality, air pollution, clean air, coastal water, tuberculosis, and sanitary. c. If a Settling State qualifies for Incentive A after receiving an Incentive Payment under Incentives B or C, described below, the Settling State ’s payments under Incentive A will equal the remainder of its total potential Incentive A payments less any payments previously received under Incentives B or C. A Settling State that receives all of its total potential Incentive A payment allocation shall not receive additional Incentive Payments under Incentives B or C.
d. A Settling State that is not eligible for Incentive A as of two (2) years after the Effective Date shall not be eligible for Incentive A for that Payment Year or any subsequent Payment Years.
1902

31 December 20, 2022

6. Incentive B: Early Participation or Released Claims by Litigating Subdivisions and Litigating Special Districts.
a. If a Settling State does not qualify for Inc entive A, it may still qualify to receive up to 60% of its total potential Incentive A payment allocation under Incentive B.
b. A Settling State can qualify for an Incentive B payment if Litigating Subdivisions and Litigating Special Districts collectively re presenting at least 75% of the Settling State’s litigating population are either Participating Subdivisions, Participating Special Districts, or have their claims resolved through Case-Specific Resolutions.
(i) A Settling State’s litigating population is the sum of the population of all Litigating Subdivisions and Litigating Special Districts. A Settling State’s litigating population shall include all Litigating Subdivisions and Litigating Special Districts whose populations overlap in whole or in part with other Litigating Subdivisions and Litigating Special Districts, for instance in the case of a Litigating Special District, city, or township contained within a county. (ii) For example, if School District A is a Litigating Special District in City B with a population of 1, City B is itself a Litigating Subdivision with a population of 8, and City B is located within County C, and County C is a Litigating Subdivision with a population 10, then each of their individual populations shall be added to gether (i.e., 1 + 8 +10) to determine the total litigating population (i.e., 19).
c. The following time periods apply to Incentive B payments:
(i) Period 1 : Zero to two hundred ten (210) days after the Effective Date.
(ii) Period 2 : Two hundred eleven (211) days t o one year after the Effective Date.
(iii) Period 3: One year and one day to two years after the Effective Date. d. Within Period 1: If Litigating Subdivisions and Litigating Special Districts collectively representing at least 75% of a Settling State’s litigating population are Participating Subdivisions or Participating Special Districts, or have their Claims resolved through Case -Specific Resolutions during Period 1, then a sliding scale will determine the share of the funds available under Incentive B , with a maximum of 60% of the Settling State’s total potential Incentive Payment allocation available. Under that sliding scale, if Litigating Subdivisions and Litigating Special Districts collectively representing 75% of a Settling State’s litigating pop ulation become 1903

32 December 20, 2022
Participating Subdivisions or Participating Special Districts, or achieve Case-Specific Resolution status by the end of Period 1, a Settling State will receive 50% of the total amount available to it under Incentive B. If more Litigating Sub divisions and Litigating Special Districts become Participating Subdivisions or Participating Special Districts, or achieve Case-Specific Resolution status, the Settling State shall receive an increased percentage of the total amount available to it under Incentive B as shown in the table below.

Participation or Case-Specific
Resolution Levels
(As percentage of litigating
population)
Incentive B Award
(As percentage of total
amount available to Settling State
for Incentive B)
75% 50%
76% 52%
77% 54%
78% 56%
79% 58%
80% 60%
85% 70%
90% 80%
95% 90%
100% 100%
e. Within Period 2 : If a Settling State did not qualify for an Incentive B payment in Period 1 but Litigating Subdivisions and Litigating Special Districts collectively representing at least 75% of the Settling State’s litigating population become Participating Subdivisions or Participating Special Districts, or achieve Case -Specific Resolution status by the end of Period 2, then the Settling State qualifies for 75% of the Incentive B payment it would have qualified for in Period 1.
f. Within Period 3 : If a Settling State did not qualify for an Incentive B payment in Periods 1 or 2, but Litigating Subdivis ions and Litigating Special Districts collectively representing at least 75% of the Settling State’s litigating population become Participating Subdivisions or Participating Special Districts, or achieve Case -Specific Resolution status by the end of Period 3, then the Settling State qualifies for 50% of the Incentive B payment it would have qualified for in Period 1. g. A Settling State that receives the Incentive B payment for Periods 1 and/or 2 can receive additional payments if it secures participation from additional Litigating Subdivisions and/or Litigating Special Districts (or Case-Specific Resolutions of their Claims) during Periods 2 and/or 3. Those additio nal payments would equal 75% (for additional participation or Case -Specific Resolutions during Period 2) and 50% (for additional participation or Case- Specific Resolutions during Period 3) of the amount by which the increased 1904

33 December 20, 2022
litigating population levels w ould have increased the Settling State’s Incentive B payment if they had been achieved in Period 1. h. The percentage of the available Incentive B amount for which a Settling State is eligible by the end of Period 3 shall cap its eligibility for that Payment Year and all subsequent Payment Years. If Litigating Subdivisions and Litigating Special Districts that have become Participating Subdivisions or Participating Special Districts, or achieved Case -Specific Resolution status collectively represent less than 75% of a Settling State’s litigating population by the end of Period 3, the Settling State shall not receive any Incentive B payment.
i. If there are no Litigating Subdivisions or Litigating Special Districts in a Settling State, and that Settling State is ot herwise eligible for Incentive B, that Settling State will receive its full allocable share of Incentive B. j. Incentives earned under Incentive B shall accrue after each of Periods 1, 2, and 3. Calculations to increase Incentive Payments in later periods based on additional joinder shall not reduce any amount already vested at the end of a prior period.

7. Incentive C: Participation or Release of Claims by Primary Subdivisions a. If a Settling State does not qualify for Incentive A, it may still qualify to receive up to 40% of its total potential Incentive A payment allocation under Incentive C, which has two parts.
b. Part 1: Under Incentive C, Part 1, a Settling State can receive up to 75% of its Incentive C allocation. A Settling State can qualify for a payment under Incentive C , Part 1 only if Primary Subdivisions (whether Litigating Primary Subdivisions or Non -Litigating Primary Subdivisions as of the Reference Date) collectively representing at least 60% of the Settling State’s Primary Subdivision population become Participating Subdivisions or achieve Case-Specific Resolution status.
(i) A Settling State’s Primary Subdivision population is the sum of the population of all Primary Subdivisions (whether Litigating Primary Subdivisions or Non -Litigating Primary S ubdivisions as of the Reference Date). A Settling State’s Primary Subdivision population shall include all Primary Subdivisions whose populations overlap in whole or in part with other Primary Subdivisions, for instance in the case of a Primary Subdivision that is a city contained within a Primary Subdivision that is a county. Because Primary Subdivisions include Subdivisions whose populations overlap in whole or in part with other Subdivisions , the Settling State’s Primary Subdivision population may be greater than the Settling State’s total population. (Special Districts are not relevant for purposes of Incentive C calculations.)
1905

34 December 20, 2022
(ii) For example, if City A is a Primary Subdivision with a population of 1 within County B, and County B is a Primary Subdivision w ith a population of 10, then each of their individual populations shall be added together (i.e., 1+10) to determine the total Primary Subdivision population (i.e., 11).
c. A sliding scale will determine the share of the funds available under Incentive C, Part 1 to Settling States meeting the minimum 60% threshold.

Under that sliding scale, if a Settling State secures participation or Case - Specific Resolutions from Primary Subdivisions representing 60% of its total Primary Subdivision population, it will re ceive 40% of the total amount potentially available to it under Incentive C , Part 1 . If a Settling State secures participation or Case -Specific Resolutions from Primary Subdivisions representing more than 60% of its Primary Subdivision population, the Settling State shall be entitled to receive a higher percentage of the total amount potentially available to it under Incentive C, Part 1, on the scale shown in the table below. If there are no Primary Subdivisions, and that Settling State is otherwise eligibl e for Incentive C, that Settling State will receive its full allocable share of Incentive C, Part 1.

Participation or Case-Specific
Resolution Levels
(As percentage of total Primary
Subdivision population)
Incentive C, Part 1 Award
(As percentage of total
amount available to Settling State
for Incentive C, Part 1)
60% 40%
70% 45%
80% 50%
85% 55%
90% 60%
91% 65%
92% 70%
93% 80%
94% 90%
95% 100%
d. Part 2: If a Settling State qualifies to receive an incentive under Incentive C, Part 1, the Settling State can also qualify to receive an additional incentive amount equal to 25% of its total potential Incentive C allocation by securing 100% participation of th e ten (10) largest Subdivisions by population in the Settling State. (Special Districts are not relevant for purposes of this calculation.) If a Settling State does not qualify for any amount under Incentive C, Part 1, it cannot qualify for Incentive C, Part 2. e. Incentives earned under Incentive C shall accrue on an annual basis up to three years after the Effective Date. At one, two, and three years after the Effective Date, the Settlement Fund Administrator will conduct a lookback to assess which Subdiv isions had agreed to participate or had their Claim 1906

35 December 20, 2022
resolved through a Case -Specific Resolution that year. Based on the look - back, the Settlement Fund Administrator will calculate the incentives accrued under Incentive C for the year . The percentage of the available Incentive C amount, for both Part 1 and Part 2, for which a Settling State is eligible three years after the Effective Date shall cap its eligibility for that Payment Year and all subsequent Payment Years.

8. Incentive D: No Qualifying Lawsuits Surviving Threshold Motions at Two Look- Back Dates.
a. A Settling State’s total potential Incentive D payment allocation is $206,187,038.00 times the percentage allocation assigned that Settling State in Exhibit F-2.
b. If, at any time within fi ve and one -half (5.5) years of the Preliminary Agreement Date, any Subdivision or Special District within a Settling State files litigation pursuing Released Claims against any Released Entity (a “Qualifying Lawsuit”), then Teva shall, within thirty (30) days of Teva or any Released Entity being served or otherwise informed of the prosecution of such Released Claims, provide notice to the Settling State in which such Released Claims are being pursued and shall give the relevant Settling State a reasonable opportunity to extinguish the Released Claims without any payment or any other obligations being imposed upon any Released Entities (apart from the Global Settlement Amount payable by Teva under the Agreement or the Injunctive Re lief Terms incurred by it) . The relevant Settling State and Teva shall confer and use reasonable efforts to promptly resolve a Qualifying Lawsuit so that it is dismissed with prejudice. Nothing in this subsection creates an obligation for a Settling State to make a monetary payment or incur any other obligation to an entity filing a Qualifying Lawsuit.
c. Part 1: Under Incentive D, Part 1, a Settling State shall receive 50% of its total potential Incentive D payment allocation if, at two years after the Effective Date (the “First Look-Back Date”), there are no pending Released Claims from a Qualifying Lawsuit that survived a Threshold Motion within the Settling State against any Released Entities.
(i) After the First Look-Back Date, a Settling State can become re - eligible for Incentive Payment D, Part 1 if the lawsuit that survived a Threshold Motion is dismissed pu rsuant to a later motion on grounds included in the Threshold Motion, in which case the Settling State shall become eligible for Incentive Payment D less any litigation fees and cost incurred by the Released Entity in the interim, except that if the dismis sal motion occurs after the 1907

36 December 20, 2022
completion of opening statements in such action, the Settling State shall not be eligible for Incentive Payment D.
d. Part 2: Under Incentive D, Part 2, a Settling State shall receive 50% of its total potential Incentive D payment allocation if, at five and one -half (5.5) years after the Preliminary Agreement Date (the “ Second Look -Back Date”), there are no pending Released Claims from a Qualifying Lawsuit that survived a Threshold Motion within the Settling State against any Released Entities.

VIII. Allocation and Use of Settlement Funds
A. Components of Settlement Fund. The Settlement Fund shall be comprised of an Abatement Accounts Fund, a State Fund, and a Subdivision Fund for each Settling State. The payments under Section VI into the Settlement Fund shall be initially allocated among those three (3) sub-funds and distributed and used as provided below or as provided for by a State - Subdivision Agreement (or other State -specific allocation of funds). Unless otherwise specified herein, payments placed into the Settlement Fund do not revert back to Teva.

B. Use of Settlement Payments. It is the intent of the Parties that the payments disbursed from the Settlement Fund to Settling States and Exhibit G Participants be for Opioid Remediation, subject to limited exceptions that must be documented in accordance with subsection VIII.C. In no event may less than 85% of Teva’s payments pursuant to subsection VI.A.1–4 over the entirety of all Payment Years (but not any single Payment Year) be spent on Opioid Remediation.

C. While disfavored by the Parties, a Settling State or Exhibit G Participant may use monies from the Settlement Fund (that have not been restricted by this Agreement solely to future Opioid Remediation) for purposes that do not qualify as Opioid Remediation. If, at any time, a Settling State or Exhibit G Participant uses any monies from the Settlement Fund for a purpose that does not qualify as Opioid Rem ediation, such Settling State or Exhibit G Participant shall identify such amounts and report to the Settlement Fund Administrator and Teva how such funds were used, including if used to pay attorneys’ fees, investigation costs, litigation costs, or costs related to the operation and enforcement of this Agreement.

It is the intent of the Parties that the reporting under this subsection VIII.C shall be available to the public. For the avoidance of doubt, (a) any amounts not identified under this subsection VIII.C as used to pay attorneys’ fees, investigation costs, or litigation costs shall be included in the “Compensatory Restitution Amount” for purposes of subsection VIII.G and (b) Participating Subdivisions not listed on Exhibit G or Participating Special Districts that receive monies from the Settlement Fund indirectly may only use such monies from the Settlement Fund for purposes that qualify as Opioid Remediation.

D. Allocation of Settlement Fund. The allocation of the Settlement Fund allows for different approaches to be taken in different states, such as through a State-Subdivision Agreement.

Given the uniqueness of States and their Subdivisions, Settling States and Participating Subdivisions are encouraged to enter into State-Subdivision Agreements in order to direct the allocation of their portion of the Settlement Fund. As set out below, the Settlement Fund Administrator will make an initial allocation to three (3) state -level sub-funds. The 1908

37 December 20, 2022
Settlement Fund Administrator will then, for each Settling Stat e and its Exhibit G Participants, apply the terms of this Agreement and any relevant State -Subdivision Agreement, Statutory Trust, Allocation Statute, or voluntary redistribution of funds as set out below before disbursing the funds.

1. Base Payments. The Settlement Fund Administrator will allocate Base Payments under subsection VII.D among the Settling States in proportion to their respective State Allocation Percentages. Base Payments for each Settling State will then be allocated 15% to its State Fund, 70% to its Abatement Accounts Fund, and 15% to its Subdivision Fund. Amounts may be reallocated and will be distributed as provided in subsection VIII.E.

2. Incentive Payments . The Settlement Fund Administrator will treat Incentive Payments under subsection VII.E on a State-specific basis. Incentive payments for which a Settling State is eligible under subsection V II.E will be allocated 15% to its State Fund, 70% to its Abatement Accounts Fund, and 15% to its Subdivision Fund. Amounts may be reallocated and will be distributed as provided in subsection VIII.E.

3. Application of Adjustments. If any offset under Section XII applies with respect to a Settling State, the offset shall be applied proportionally to all amounts that would otherwise be ap portioned and distributed to the State Fund, the Abatement Accounts Fund, and the Subdivision Fund for that State.

4. Settlement Fund Administrator. Prior to the Initial Participation Date, Teva and the Enforcement Committee will agree to a detailed mechanism consistent with the foregoing for the Settlement Fund Administrator to follow in allocating, apportioning, and distributing payments, which shall be appended hereto as Exhibit L.

E. Settlement Fund Reallocation and Distribution . As set forth below, within a particular Settling State’s account, amounts contained in the Settlement Fund sub -funds may be reallocated and distributed per a State -Subdivision Agreement or other means. If the apportionment of amounts is not addressed and controlled under subsections V III.E.1–2, then the default provisions of subsection V III.E.4 apply. It is not necessary that a State - Subdivision Agreement or other means of allocating funds pursuant to subsectio ns VIII.E.1–2 address all of the Settlement Fund sub -funds. For example, a Statutory Trust might only address disbursements from a Settling State’s Abatement Accounts Fund.

1. Distribution by State -Subdivision Agreement . If a Settling State has a State - Subdivision Agreement, amounts apportioned to that State’s State Fund, Abatement Accounts Fund, and Subdivision Fund under subsection VIII.D shall be reallocated and distributed as provided by that agreement. Any State -Subdivision Agreement entered into or amended after July 26, 2022 shall be applied only if it requires: (1) that all amounts be used for Opioid Remediation except as allowed by subsection VIII.C, and (2) that at least 70% of amounts be used solely for future Opioid Remediation (references to “futur e Opioid Remediation” include amounts paid to satisfy any future demand by another governmental entity to make a 1909

38 December 20, 2022
required reimbursement in connection with the past care and treatment of a person related to the Alleged Harms). For a State-Subdivision Agreement to be applied to the relevant portion of an Annual Payment, notice must be provided to Teva and the Settlement Fund Administrator at least sixty (60) days prior to the Payment Date.

2. Distribution by Allocation Statute . If a Settling State has an Allocation Statute and/or a Statutory Trust that addresses allocation or distribution of amounts apportioned to such State’s State Fund, Abatement Accounts Fund, and/or Subdivision Fund and that, to the extent any or all such sub -funds are addressed, requires (1) all amounts to be used for Opioid Remediation except as allowed by subsection VIII.C, and (2) at least 70% of all amounts to be used solely for future Opioid Remediation, then, to the extent allocation or distribution is addressed, the amounts apportioned to that State’s State Fund, Abatement Accounts Fund, and Subdivision Fund under subsection V III.D shall be allocated and distributed as addressed and provided by the applicable Allocation Statute or Statutory Trust. For the avoidance of doubt, an A llocation Statute or Statutory Trust need not address all three (3) sub -funds that comprise the Settlement Fund, and if the applicable Allocation Statute or Statutory Trust does not address distribution of all or some of these three (3) sub-funds, the applicable Allocation Statute or Statutory Trust does not replace the default provisions in subsection V III.E.4 of any such unaddressed fund. For example, if an Allocation Statute or Statutory Trust that meets the requirements of this subsection VIII.E only addresses funds restricted to abatement, then the default provisions in this Agreement concerning allocation among the three (3) sub-funds comprising the Settlement Fund and the distribution of the State Fund and Subdivision Fund for that State would still a pply, while the distribution of the applicable State’s Abatement Accounts Fund would be governed by the qualifying Allocation Statute or Statutory Trust.

3. Voluntary Redistribution. A Settling State may choose to reallocate all or a portion of its State Fund to its Abatement Accounts Fund. A n Exhibit G Participant may choose to reallocate all or a portion of its allocation from the Subdivision Fund to the State’s Abatement Accounts Fund or to another Participating Subdivision or Participating Special District. The Settlement Fund Administrator is not required to honor voluntary redistribution for which notice is provided to it less than sixty (60) days prior to the Payment Date.

4. Distribution in the Absence of a State-Subdivision Agreement, Allocation Statute, or Statutory Trust . If subsections V III.E.1–2 do not apply, and subject to any voluntary redistribution pur suant to subsection VIII.E.3, amounts apportioned to that State’s State Fund, Abatement Accounts Fund, and Subdivision Fund under subsection VII.D shall be distributed as follows:
a. Amounts apportioned to that State’s State Fund shall be distributed to that State.
b. Amounts apportioned to that State’s Abatement Accounts Fund shall be distributed consistent with subsection V III.F. Each Settling State shall 1910

39 December 20, 2022
submit to the Settlement Fund Administrator a designation of a lead state agency or other entity to serve as the single point of contact for that Settling State’s funding requests from the Abatement Accounts Fund and other communications with the Settlement Fund Administrator. The designation of an individual entity is for administrative purposes only an d such designation shall not limit funding to such entity or even require that such entity receive funds from this Agreement. The designated entity shall be the only entity authorized to request funds from the Settlement Fund Administrator to be disbursed from that Settling State’s Abatement Accounts Fund. If a Settling State has established a Statutory Trust , then that Settling State’s single point of contact may direct the Settlement Fund Administrator to release the State’s Abatement Accounts Fund to the Statutory Trust.
c. Amounts apportioned to that State’s Subdivision Fund shall be distributed to Participating Subdivisions in that State listed on Exhibit G per the Subdivision Allocation Percentage listed in Exhibit G. Subsection X.I shall govern amounts t hat would otherwise be distributed to Non -Participating Subdivisions listed in Exhibit G.
d. Special Districts shall not be allocated funds from the Subdivision Fund, except through a voluntary redistribution allowed by subsection VIII.E.3. A Settling State m ay allocate funds from its State Fund or Abatement Accounts Fund for Special Districts.

5. Restrictions on Distribution. No amounts may be distributed from the Subdivision Fund contrary to Section X, i.e., no amounts may be distributed directly to Non - Participating Subdivisions or to Later Participating Subdivisions in excess of what is permissible under subsection X.E. Amounts allocated to the Subdivision Fund that cannot be distributed by virtue of the preceding sentence shall be distributed into the sub-account in the Abatement Accounts Fund for the Settling State in which the Subdivision is located, unless those payments are redirected elsewhere by a State-Subdivision Agreement described in subsection VIII.E.1 or by an Allocation Statute or a Statutory Trust described in subsection VIII.E.2.

F. Provisions Regarding Abatement Accounts Fund.

1. State-Subdivision Agreement, Allocation Statute, and Statutory Trust Fund Provisions. A State-Subdivision Agreement, Allocation Statute, or Statutory Trust may govern the operation and use of amounts in that State’s Abatement Accounts Fund so long as it complies with the requirements of subsection s VIII.E.1 or VIII.E.2 as applicable, and all direct payments to Subdivisions comply with subsections X.E–H.

2. Absence of a State-Subdivision Agreement, Allocation Statute, or Statutory Trust.

In the absence of a State -Subdivision Agreement, Allocation Statute, or Statutory Trust that addresses distribution, the Abatement Accounts Fund will be used solely 1911

40 December 20, 2022
for future Opioid Remediation and the following shall apply with respect to a Settling State:
a. Regional Remediation.
(i) At least 50% of distributions for remediation from a State’s Abatement Accounts Fund shall be annually allocated and tracked to the regional level. A Settling State may allow the Advisory Committee established pursuant to subsectio n VIII.F.2.d to define its regions and assign regional allocations percentages. Otherwise, a Settling State shall (1) define its initial regions, which shall consist of one (1) or more Subdivisions and which shall be designated by the State agency with pri mary responsibility for substance abuse disorder services employing, to the maximum extent practical, existing regions established in that State for opioid abuse treatment or other public health purposes; and (2) assign initial regional allocation percenta ges to the regions based on the Subdivision Allocation Percentages in Exhibit G and an assumption that all Subdivisions listed on Exhibit G will become Participating Subdivisions.
(ii) This minimum regional expenditure percentage is calculated on the Settling S tate’s initial Abatement Accounts Fund allocation and does not include any additional amounts a Settling State has directed to its Abatement Accounts Fund from its State Fund, or any other amounts directed to the fund. A Settling State may dedicate more than 50% of its Abatement Accounts Fund to the regional expenditure and may annually adjust the percentage of its Abatement Accounts Fund dedicated to regional expenditures as long as the percentage remains above the minimum amount. (iii) The Settling State (1) has the authority to adjust the definition of the regions, and (2) may annually revise the percentages allocated to each region to reflect the number of Subdivisions in each region that are Non-Participating Subdivisions.
b. Subdivision Block Grants. Certain Subdivisions listed on Exhibit G shall be eligible to receive regional allocation funds in the form of a block grant for future Opioid Remediation. A Participating Subdivision listed on Exhibit G eligible for block grants is a county or parish (or in the cas e of States that do not have counties or parishes that function as political subdivisions, a city) that (1) does not contain a Litigating Subdivision or a Later Litigating Subdivision for which it has the authority to end the litigation through a release, Bar, or other action; (2) either (i) has a population of 400,000 or more or (ii) in the case of California has a population of 750,000 or more; and (3) has funded or otherwise managed an established health care or treatment infrastructure (e.g., health dep artment or similar agency). Each 1912

41 December 20, 2022
Subdivision listed on Exhibit G eligible to receive block grants shall be assigned its own region.
c. Small States . Notwithstanding the provisions of subsection V III.F.2.a, Settling States with populations under four (4) million that do not have existing regions described in subsection V III.F.2.a shall not be required to establish regions. However, such a Settling State that contains one (1) or more Subdivisions listed on Exhibit G eligible for block grants under subsection VIII.F.2.b shall be divided regionally so that each block -grant eligible Subdivision listed on Exhibit G is a region and the remainder of the State is a region.
d. Advisory Committee . The Settling State shall designate an Opioid Settlement Remediation Advisory Committee (the “ Advisory Committee”) to provide input and recommendations regarding remediation spending from that Settling State’s Abatement Accounts Fund. A Settling State may elect to use an existing advisory committee or similar entity (created outside of a State -Subdivision Agreement or Allocation Statute); provided, however, the Advisory Committee or similar entity shall meet the following requirements:
(i) Written guidelines that establish the formation and composition of the Advisory Committee, terms of service for members, contingency for removal or resignation of members, a schedule of meetings, and any other administrative details;
(ii) Composition that includes at least an equal number of local representatives as state representatives;
(iii) A process for receiving input from Subdivisions and other communities regarding how the opioid crisis is affecting thei r communities, their abatement need s, and proposals for abatement strategies and responses; and
(iv) A process by which Advisory Committee recommendations for expenditures for Opioid Remediation will be made to and considered by the appropriate state agencies.

3. Abatement Accounts Fund Reporting . The Settlement Fund Administrator shall track and assist in the report of remediation disbursements as agreed to among the Parties.

G. Nature of Payment. Teva, the Settling States, the Participating Subdivisions, and the Participating Special Districts, acknowledge and agree that notwithstanding anything to the contrary in this Agreement, including, but not limited to, the scope of the Released Claims:

1. Teva has entered into this Agreement to avoid the delay, expense, inconvenience, and uncertainty of further litigation;
1913

42 December 20, 2022

2. The Settling States, the Participating Subdivisions, and the Participating Special Districts sought compensatory restitution (within the meaning of 26 U.S.C. § 162(f)(2)(A)) as damages for the Alleged Harms allegedly suffered by the Settling States, Participating Subdivisions and Participating Special Districts;

3. By executing this Agreement the Settling States, the Participating Subdivisions, and the Participating Special Districts certify that: (a) the Compensatory Restitution Amount is no great er than the amount, in the aggregate, of the Alleged Harms allegedly suffered by the Settling States , Participating Subdivisions and Participating Special Districts; and (b) the portion of the Compensatory Restitution Amount received by each Settling State, Participating Subdivision or Participating Special Districts is no greater than the amount of the Alleged Harms allegedly suffered by such Settling State , Participating Subdivision or Participating Special Districts;

4. The payment of the Compensatory Restitution Amount by Teva constitutes, and is paid for, compensatory restitution (within the meaning of 26 U.S.C. § 162(f)(2)(A)) for alleged damage or harm (as compensation for alleged damage or harm arising out of alleged bodily injury) allegedly caused by Teva;

5. The Compensatory Restitution Amount is being paid as compensatory restitution (within the meaning of 26 U.S.C. § 162(f)(2)(A)) in order to restore, in whole or in part, the Settling States , Participating Subdivisions and Participating Special Districts to the same position or condition that they would be in had the Settling States, Participating Subdivisions and Participating Special Districts not suffered the Alleged Harms;

6. No portion of the Compensatory Restitution A mount represents reimbursement to any Settling State, Participating Subdivision, Participating Special District, or other person or entity for the costs of any investigation or litigation . The entire Compensatory Restitution Amount is properly characterize d as described in subsection VIII.G. No portion of the Compensatory Restitution Amount constitutes disgorgement or is properly characterized as the payment of statutory or other fines, penalties, punitive damages, other punitive assessments, or attorneys’ fees; and

7. The Designated State, on behalf of all Settling States, Participating Subdivisions, and Participating Special Districts (the “Form 1098 -F Filer”) shall complete and file Form 1098 -F with the Internal Revenue Service on or before February 28 (March 31 if filed electronically) of the year following the calendar year in which the order entering this Agreement becomes binding. On the Form 1098-F, the Form 1098-F Filer shall identify the entire Compensatory Restitution Amount received by the Form 1098 -F Filer as remediation/restitution , including the provision of Settlement Product set out in Section IX below. The Form 1098-F Filer shall also, on or before January 31 of the year following the calendar year in which the order entering this Agreement becomes binding, furnish Copy B of such Form 1098 -F (or an acceptable substitute statement) to Teva.
1914

43 December 20, 2022
IX. Settlement Product
A. The Settlement Product is Naloxone Hydrochloride Nasal Spray (generic Narcan®), a medication that counteracts the life-threatening effects of opioid overdose and significantly reduces opioid-overdose mortality.

B. For the purposes of this Agreement, T eva has agreed to provide the Settling States Settlement Product valued at $1,200,000,000, which equals 9,600,000 kits of Settlement Product, valued at a fixed WAC of $125 per kit, allocated in accordance with the allocation percentage as reflected in Exhibit D-1. Teva shall cover the cost of the Settlement Product distribution set forth in this Agreement. For the avoidance of doubt, Participating Subdivisions and Participating Special Districts are not eligible to make a Settlement Product election pursuant to this Agreement.

C. Consistent with the Settlement Product Election Form contained in Exhibit D, each Settling State shall have the discretion to convert any portion of the Settlement Product allocated to the Settling State into a cash value equaling twenty percent (20%) of the WAC value of the Settling State’s allocated Settlement Product in the following years: 2023, 2025, 2027, 2029, and 2031. The State’s election shall apply and remain in place for each following year until the next election date.

D. Within thirty (30) days of the Effective Date, each Settling State shall notify Teva and the Settlement Fund Administrator of its Settlement Product election by submitting the Settlement Product Election Form reflected in Exhibit D.

E. Settling States that do n ot make a Settlement Product Election within 30 days of the Effective Date shall be deemed to have elected to receive the full Settlement Product Cash Conversion Amount for the first two -year period, allocated in accordance with the State Allocation Percentage as reflected in Exhibit D-1. Commencing within thirty (30) days of the Effective Date, the Settling States that have submitted a Settlement Product Election Form may place periodic orders for Settlement Product consistent with Section IX and Exhibit D.

F. By or before January 1, 2025, 2027, 2029 and 2031, each Settling State may submit a new or updated Settlement Product Election Form, which will be effective beginning with the Forecast submitted on the same date for the following calendar year. Settling States that do not submit a new or updated Settleme nt Product Election Form will be deemed to have made no changes to their most recent Settlement Product Election Form.

G. As is reflected in Exhibit D and the Settlement Product Election Form contained therein, Settling States may elect to convert all or a percentage of their allocation of Settlement Product into a Settlement Product Cash Conversion Amount, in the manner and method described in Exhibit D.

H. Teva will make Settlement Product Cash Conversion Amount payments to Settling States that have elected to receive a full or partial Settlement Product Cash Conversion beginning with its second Annual Payment in accordance with the Settlement Payment Schedule as set forth in Exhibit M-2.
1915

44 December 20, 2022
I. The Parties understand that the provision of Settlement Product constitutes compensatory restitution within the meaning of 26 U.S.C. § 162(f)(2)(A) and that the receipt of Settlement Product must be reported on IRS Form 1098-F consistent with subsection VIII.G.7 above.

J. In addition to offering Naloxone Hydroch loride Nasal Spray per this Section IX and Exhibit D, Teva, at its sole discretion, may also offer Settling States different versions or greater amounts of Settlement Product or different products that can be accepted by the Settling State in lieu of its f ull allotment of the Settlement Product or Settlement Product Cash Conversion Amount. Distribution and other terms related to such substitute product shall be set out in Teva’s offer. Nothing in this subsection IX.J changes the terms of this Agreement regarding the provision of Settlement Product or the calculation or availability of the Settlement Product Cash Conversion Amount. With regard to the annual product delivery schedule, to the extent that the Settling State’s needs for each drug varies from year to year, such that the Settling State needs a reasonably lesser quantity one year to be offset by a reasonably greater quantity the next year, Teva will use reasonable commercial efforts to be flexible in meeting that variation in demand.

K. In the event of a Force Majeure Event, Teva shall promptly provide written notice to the Settling States. Teva and the States shall meet and confer within seven (7) days of such written notice to establish a commercially reasonable plan to resolve any inability to supply as quickly as reasonably possible, it being understood that, unless otherwise agreed to by the Parties, it is Teva’s obligation to use reasonable efforts which are consistent with accepted industry practices to resume performance as soon as practicable und er the circumstances.

X. Participation by Subdivisions and Special Districts
A. Notice. No later than fifteen (15) days after the Preliminary Agreement Date, the Settling States, with the cooperation of Teva, shall send individual written notice (which may be delivered via e -mail or other electronic means) of the opportunity to participate in this Agreement and the requirements of participation to all Subdivisions and Special Districts in the Settling State that are (1) Litigating Subdivisions or Litigating Special Districts, or (2) Non -Litigating Subdivisions listed in Exhibit G . 3 To the ext ent a Non-Litigating Special District is entitled to an allocation for a direct payment through its inclusion in Exhibit G pursuant to a State-Subdivision Agreement, Allocation Statute, Statutory Trust, or voluntary redistribution, the Settling States shall also send individual written notice (which may be delivered via e -mail or other electronic means) of the opportunity to participate i n this Agreement and the requirements of participation to such Special Districts. Unless otherwise agreed by the Parties, the version of Exhibit G used for notice shall be the one in place as of the Preliminary Agreement Date. Teva’s share of costs of the written notice shall be paid by Teva as part of the Implementation Costs. Notice (which may be delivered via e -mail or other electronic means) shall also be provided simultaneously to counsel of record for Litigating Subdivisions , Litigating Special

3 Because Teva has settled with Oklahoma, but not with Oklahoma Subdivisions and Special Districts, Teva shall send individual written notice of the opportunity to participate in this Agreement and the requirements of participation to all Oklahoma Subdivisions and Special Districts. For purposes of this Section X, references to a “Subdivision in a Settling State” or “Special District in a Settling State” shall include Subdivisions and Special Districts in Oklahoma. 1916

45 December 20, 2022
Districts, and known counsel for Non-Litigating Subdivisions listed on Exhibit G and Non- Litigating Special Districts listed on Exhibit G. The notice will include that the deadline for becoming an Initial Participating Subdivision or Initial Participating Special District is the Initial Participation Date. Nothing contained herein shall preclude a Settling State from providing further notice to or otherwise contacting any of its Subdivisions or Special Districts about becoming a Participating Subdivision or Part icipating Special District , including beginning any of the activities described in this paragraph prior to the Preliminary Agreement Date.

B. Requirements for Becoming a Participating Subdivision: Non -Litigating Subdivisions. A Non-Litigating Subdivision in a Settling State may become a Participating Subdivision by returning an executed Settlement Participation Form to the Implementation Administrator or Settlement Fund Administrator (which may be executed and returned by ele ctronic means established by the Implementation Administrator or Settlement Fund Administrator) specifying (1) that the Subdivision agrees to the terms of this Agreement pertaining to Subdivisions, (2) that the Subdivision releases all Released Claims agai nst all Released Entities, (3) that the Subdivision agrees to use monies it receives, if any, from the Settlement Fund pursuant to the applicable requirements of Section V III, and (4) that the Subdivision submits to the jurisdiction of the Court where the Consent Judgment is filed for purposes limited to that Court’s role under the Agreement. The required Settlement Participation Form is attached as Exhibit K. A Non -Litigating Subdivision will decide whether to become a Participating Subdivision for both th is Agreement and the Allergan Global Opioid Settlement Agreement, or neither.

C. Requirements for Becoming a Participating Subdivision: Litigating Subdivisions/Later Litigating Subdivisions . A Litigating Subdivision or Later Litigating Subdivision in a Settling State may become a Participating Subdivision by returning an executed Settlement Participation Form to the Implementation Administrator or Settlement Fund Administrator (which may be executed and returned by electronic means established by the Implementation Administrator or Settlement Fund Administrator) that, in addition to the requirements set out in subsection X.B for Non -Litigating Subdivisions , commits it to promptly dismissal its legal action. The required Settlement Participation Form is attached as Exhibit K. A Litigating Subdivision or Later Litigating Subdivision will decide whether to become a Participating Subdivision for both this Agreement and the Allergan Global Opioid Settlement Agreement, or neither. Except for trials begun before the Initial Participation Date, a Litigating Subdivision or a Later Litigating Subdivision may not become a Participating Subdivision after the completion of opening statements in a trial of a legal action it brought that includes a Released Claim against a Released Entity.

D. Initial Participating Subdivisions. A Subdivision qualifies as an Initial Participating Subdivision if it meets the applicable requirements for becoming a Participating Subdivision set forth in subsections X.B or X.C by the Initial Participation Date. Provided however, all Subdivision Settlement Participation Forms shall be held by the Implementation Administrator until Teva provides the notice in subsection XI.B that it intends to proceed with the settlement, at which time the obligations created by such forms become effective. If Teva determines not to proceed, all Settlement Participation Forms shall be returned to Counsel for Litigating Subdivisions or to the Subdivisions not 1917

46 December 20, 2022
represented by counsel or destroyed to the extent that such destruction is not prohibited by then existing document preservation obligations.

E. Later Participating Subdivisions. A Subdivision that is not an Initial Participating Subdivision may become a Later Participating Subdivision by meeting the applicable requirements for becoming a Participating Subdivision after the Initial Participation Date and agreeing to be subject to the terms of a State -Subdivision Agreement (if any) or any other structure adopted or applicable pursuant to subsections V III.E or VIII.F. The following provisions govern what a Later Participating Subdivision can receive (but do not apply to Initial Participating Subdivisions):

1. A Later Participating Subdivision shall not receive any share of any Base or Incentive Payments paid to the Subdivision Fund that were due before it became a Participating Subdivision.

2. A Later Participating Subdivision that becomes a Participating Subdivision after Initial Participation Date but before June 15, 2023 shall receive 75% of the share of the Initial Year Payment that it would have received had it become a n Initial Participating Subdivision (unless the Later Participating Subdivision is subject to subsections X.E.3 or X.E.4 below). A Later Participating Subdivision that becomes a Participating Subdivision after June 15, 2023 shall receive no share of the Initial Year Payment.

3. A Later Participating Subdivision that, after the Initial Participation Date, maintains a lawsuit for a Rele ased Claim(s) against a Released Entity and has judgment entered against it on every such Claim before it became a Participating Subdivision (other than a consensual dismissal with prejudice) shall receive 50% of the share of future Base Payments or Incentive Payments that it would have received had it become a Later Participating Subdivision prior to such judgment; provided, however, that if the Subdivision appeals the judgment and the judgment is affirmed with finality before the Subdivision becomes a Par ticipating Subdivision, the Subdivision shall not receive any share of any Base Payments or Incentive Payments.

4. A Later Participating Subdivision that becomes a Participating Subdivision while a Bar or Case-Specific Resolution involving a different Subdivision exists in its State shall receive 25% of the share of future Base Payments or Incentive Payments that it would have received had it become a Later Participating Subdivision without such Bar or Case-Specific Resolution.

F. No Increase in Payments . Amounts to be received by Later Participating Subdivisions or Later Participating Special Districts shall not increase the payments due from Teva.

G. Ineligible Subdivisions and Special Districts. Except for Subdivisions and Special Districts in Oklahoma, prior Settling Subdivisions, and Subdivisions and Special District s in Non- Settling States or Prior Settling States are not eligible to be Participating Subdivisions or Participating Special Districts.
1918

47 December 20, 2022
H. Non-Participating Subdivisions and Non -Participating Speci al Districts . Non - Participating Subdivisions and Non -Participating Special Districts shall not directly receive any portion of any Base Payments or Incentive Payments, including from the State Fund and direct distributions from the Abatement Accounts Fund; however, a Settling State may choose to fund future Opioid Remediation that indirectly benefits Non -Participating Subdivisions and Non-Participating Special Districts.

I. Unpaid Allocations to Later Participating and Non-Participating Subdivisions. Any Base Payments and Incentive Payments allocated pursuant to subsection VIII.E to a Later Participating or Non -Participating Subdivision or a Later Participating or Non - Participating Special District that cannot be paid pursuant to Section X, will be allocated to the Abatement Accounts Fund for the Settling State in which the Subdivision is located, unless those payments are redirected elsewhere by a State-Subdivision Agreement or by a Statutory Trust.

J. Requirements for Becoming a Participating Speci al District: Non -Litigating Special Districts. A Non-Litigating Special District in a Settling State may become a Participating Special District by returning an executed Settlement Participation Form to the Implementation Administrator or Settlement Fund Administrator (which may be executed and returned by electronic means established by the Implementation Administrator or Settlement Fund Administrator) specifying (1) that the Special District agrees to the terms of this Agreement pertaining to S pecial Districts, (2) that the S pecial District releases all Released Claims against all Released Entities, (3) that the S pecial District agrees to use monies it receives, if any, from the Settlement Fund pursuant to the applicable requirements of Section VIII, and (4) that the S pecial District submits to the jurisdiction of the Court where the Consent Judgment is filed for purposes limited to that Court’s role under the Agreement. The required Settlement Participation Form is attached as Exhibit K. A Non- Litigating Special District will decide whether to become a Participating Special District for both this Agreement and the Allergan Global Opioid Settlement Agreement, or neither.

K. Requirements for Becoming a Participating Special District: Litigating Special Districts/Later Litigating Special Districts. A Litigating Special District or Later Litigating Special District in a Settling State may become a Participating Special District by returning an executed Settlement Participation Form to the Implementation Administrator or Settlement Fund Administrator (which may be executed and returned by electronic means established by the Implementation Administrator or Settlement Fund Administrator) that, in addition to the requirements set out in subsection X. J for Non -Litigating S pecial Districts, commits it to promptly dismiss its legal action . The required Settlement Participation Form is attached as Exhibit K. A Litigating Special District or a Later Litigating Special District will decide whether to become a Participating Special District for both this Agreement and the Allergan Global Opioid Settlement Agreement, or neither.

Except for trials begun before the Initial Participation Date, a Litigating Special District or a Later Litigating Special District may not become a Participating Special District after the completion of opening statements in a trial of a legal action it brought that includes a Released Claim against a Released Entity.

L. Initial Participating Special Districts. A Special District qualifies as an Initial Participating Special District if it meets the applicable requirements for becoming a Participating Special 1919

48 December 20, 2022
District set forth in subsections X.J or X.K by the Initial Participation Date. Provided however, all Special District Settlement Participation Forms shall be held by the Implementation Administrator until Teva provides the notice in subsection XI.B that it intends to proceed with the settlement, at which time the obligations created by such forms become effective.

M. Later Participating Special Districts. A Special District that is not an Initial Participating Special District may become a Later Participating Special District by meeting the applicable requirements for becoming a Pa rticipating Special District after the Initial Participation Date and agreeing to be subject to the terms of a State-Subdivision Agreement (if any) or any other structure adopted or applicable pursuant to subsections VIII.E or VIII.F. or any agreement reached by the applicable Settling State with Initial Participating Special Districts. The following provisions govern what a Later Participating Special District can receive (but do not apply to Initial Participating Special Districts):

1. Except for the Initial Year Payment, a Later Participating Special District shall not receive any share of any Base or Incentive Payments paid to the Subdivision Fund that were due before it became a Participating Special District.

2. A Later Participating Special District that becomes a Participating Special District after Initial Participation Date but before June 15, 2023 shall receive 75% of the share of the Initial Year Payment that it would have received had it become an Initial Participating Special District (unless the Later Participating Special District is subject to subsections X. M.3 or X. M.4 below). A Later Participating Special District that becomes a Participating Special District after June 15, 2023 shall receive no share of the Initial Year Payment.

3. A Later Participating Special District that, after the Initial Participation Date, maintains a lawsuit for a Released Claim(s) against a Released Entity and has judgment entered against it on every such Claim before it became a Participating Special District (other than a consensual dismissal with prejudice) shall receive 50% of the share of future Base Payments or Incentive Payments that it would have received had it become a Later Participating Special District prior to such judgment; provided, however , that if the Special District appeals the judgment and the judgment is affirmed with finality before the Special District becomes a Participating Special District, the Special District shall not receive any share of any Base Payments or Incentive Payments.

4. A Later Participating Special District that becomes a Participating Special District while a Bar or Case-Specific Resolution involving a different Special District exists in its State shall receive 25% of the share of future Base Payments or Incentive Payments that it would have received had it become a Later Participating Special District without such Bar or Case-Specific Resolution.

XI. Condition to Effectiveness of Agreement and Filing of Consent Judgment A. Determination to Proceed With Settlement. Teva will determine on or before the Reference Date whether there has been a sufficient resolution of the Claims of the Litigating 1920

49 December 20, 2022
Subdivisions and Litigating Special Districts in the Settling States (through participation under Section X, Case-Specific Resolution(s), and Bar(s)) to proceed with this Agreement.

The determination shall be in the sole discretion of Teva, in good faith, and may be based on any criteria or factors deemed relevant by Teva.

B. Notice by Teva. On or before the Reference Date, Teva shall inform the Settling States and MDL Plaintiffs’ Executive Committee of its determination pursuant to subsection XI.A. If Teva determines to proceed, the Parties will proceed to file the Consent Judgments. If Teva determines not to proceed, this Agreement wi ll have no further effect and all releases (including those given by Participating Subdivisions and Special Districts ) and other commitments or obligations contained herein will be void and Settlement Participation Forms shall be returned to the Subdivision or Special District or destroyed to the extent not prohibited by then existing legal obligations or document holds.

XII. Potential Payment Adjustments
A. Settlement Class Resolution Opt Outs. If a Settling State is eligible for Incentive A on the basis of a Settlement Class Resolution, and a Primary Subdivision that opted out of the Settlement Class Resolution maintains a lawsuit asserting a Released Claim against a Released Entity, the following shall apply: If the lawsuit asserting a Released Claim either survives a Threshold Motion or has an unresolved Threshold Motion fewer than sixty (60) days prior to the scheduled start of a trial involving a Released Claim, and is resolved with finality on terms requiring payment by the Released Entity, Teva shall receive a dollar-for- dollar offset for the amount paid against its obligation to make remaining Incentive A payments that would be apportioned to that State or Participating Subdivisions listed on Exhibit G.

B. Revoked Bar, Settlement Class Resolution, or Case-Specific Resolution.

1. If Teva made a payment as a result of the existence of a Bar, Settlement Class Resolution, or Case-Specific Resolution in a Settling State, and that Bar, Settlement Class Resolution, or Case -Specific Resolution is subject to a Revocatio n Event, Teva shall receive a dollar-for-dollar offset against its obligation to make remaining payments that would be apportioned to that State and its Exhibit G Participants .

This offset will be calculated as the dollar amount difference between (1) the total amount of Incentive Payments paid by Teva during the time the Bar, Settlement Class Resolution, or Case-Specific Resolution subject to the Revocation Event was in effect, and (2) the total amount of Incentive Payments that would have been due from Teva during that time without the Bar, Settlement Class Resolution, or Case- Specific Resolution subject to the Revocation Event being in effect. The amount of Incentive Payments that would have been due, referenced in (2) above, will be calculated based on considering any Subdivision or Special District that provides a release within one hundred eighty (180) days after the Revocation Event as having been a Participating Subdivision or Participating Special District (in addition to all other Participating Subdivisions and Participating Special Districts) during the time that the Bar, Settlement Class Resolution, or Case -Specific Resolution subject to the Revocation Event was in effect. If a Revocation Event causes a Settling State to no longer qualify for one or both parts of Incentive D, the Settling State and its 1921

50 December 20, 2022
Exhibit G participants shall return to Teva all relevant payments made under Incentive D through offsets as set forth above.

2. Notwithstanding anything to the contrary in paragraph 1 above, if a Ba r or Case- Specific Resolution is reinstated by the Settling State, either through the same or different means as the initial Bar or Case -Specific Resolution, Teva’s right to an offset is extinguished and any amounts withheld to offset amounts paid on account of the revoked, rescinded, reversed, or overruled Bar or Case -Specific Resolution shall be returned to the Settling State, less and except any Incentive Payments that would have been paid during the period in which the Bar or Case -Specific Resolution was revoked, rescinded, reversed, or overruled.

XIII. Additional Restitution Amount
Additional Restitution Amount. Teva shall pay an Additional Restitution Amount to each Settling State listed in Exhibit N in the amount and on the schedule set forth in Exhibit M-3. The maximum Additional Restitution Amount of $28,669,762.00 shall be reduced by the allocation set forth on Exhibit F-2 for any Non-Settling States listed on Exhibit N. The Settlement Fund Admini strator shall allocate such funds among and within the Settling States listed in Exhibit N at the same time as its allocation of Annual Payments pursuant to subsection VII.B.

Additional Restitution Amount funds shall not be subject to allocation as provided in Sections VIII.D through VIII.F
XIV. Plaintiffs’ Attorneys’ Fees and Costs
Attorneys’ fees and costs are addressed in the following exhibits and are incorporated herein by reference:

1. The State Outside Counsel Fee Fund is addressed in Exhibit T.

2. The State Cost Fund is addressed in Exhibit S.

3. The Attorney Fee and Cost Fund is addressed and the Agreement on Attorneys’ Fees, Expenses and Costs is set forth in Exhibit R.

XV. Enforcement and Dispute Resolution
A. Enforceability. The terms of the Agreement and Consent Judgment applicable to or in a Settling State will be enforceable solely by that Settling State and Teva. Settling States or Participating Subdivisions shall not have enforcement rights with respect either to the terms of this Agreement that apply only to or in other States or to any Consent Judgment entered into by another Settling State. Participating Subdivisions shall not have enforcement rights against Teva with respect to the Agreement or any Consent Judgment except as to payments that would b e allocated to the Subdivision Fund or Abatement Accounts Fund pursuant to Section VII ; provided, however , that each Settling State shall allow 1922

51 December 20, 2022
Participating Subdivisions in that State to notify it of any perceived violations of the Agreement or Consent Judgment.

B. Consent to Jurisdiction and Service of Process . Teva consents to the jurisdiction of the Court in which the Consent Judgment is filed, and any appellate court thereof, limited to resolution of disputes identified in subsection XV.G.2; for a civil action for any appropriate relief to enforce compliance with the Parties’ Agreement for Injunctive Relief pursuant to Exhibit P, subsection K.5 herein; and for any proceedings for or related to the enforcement or collection of any payments on the Consent Judgment for resolution in the Court in which the Consent Judgment is filed. Teva further agrees any service of process or notice required for such action or proceeding may be effectuated on Teva through delivery of all required papers by hand or by a nationally recognized private courier on Teva’s representatives identified in subsection XVI.P herein. To be clear, for the purposes of this Agreement only, Teva consents to personal jurisdiction before such courts, and will not contend service must be effectuated through personal service of the Hague Convention process.

C. Specific Terms Dispute Resolution.

1. Any dispute that is addressed by the provisions set forth in the Injunctive Relief Terms in Exhibit P shall be resolved as provided therein and pursuant to subsection XV.E.3 herein.

2. In the event Teva believes the 85% threshold established in subsection V III.B is not being satisfied, any Party may request that Teva and the Enforcement Committee meet and confer regarding the use of funds under subsection V III.B.

The completion of such meet-and-confer process is a precondition to further action regarding any such dispute. Further action concerning subsection V III.B shall: (i) be limited to Teva seeking to reduce its Annual Payments by no more than 5% of the difference between the actual amount of Opioid Remediation and the 85% threshold established in subsectio n VIII.B; (ii) only reduce Annual Payments to those Settling States and its Participating Subdivisions that are below the 85% threshold established in subsection V III.B; and (iii) not reduce Annual Payments restricted to future Opioid Remediation.

D. State-Subdivision Enforcement.

1. A Participating Subdivision shall not have enforcement rights against a Settling State in which it is located with respect to the Agreement or any Consent Judgment except: (1) as provided for in a State -Subdivision Agreement, Allocat ion Statute, or Statutory Trust with respect to intrastate allocation; or (2) in the absence of a State-Subdivision Agreement, Allocation Statute, or Statutory Trust, as to allegations that: (a) the Settling State’s use of Abatement Accounts Fund monies were not used for uses similar to or in the nature of those uses contained in Exhibit E; or (b) a Settling State failed to pay funds directly from the Abatement Accounts Fund to a Participating Subdivision eligible to receive a block grant pursuant to subsection VIII.F.2.b.
1923

52 December 20, 2022

2. A Settling State shall have enforcement rights against a Participating Subdivision located in its territory: (1) as provided for in a State -Subdivision Agreement, Allocation Statute, or Statutory Trust; or (2) in the absence of a State -Subdivision Agreement, Allocation Statute, or Statutory Trust, as to allegations that the uses of Abatement Accounts Fund monies by Participating Subdivisions listed on Exhibit G were not for uses similar to or in the nature of those uses contained in Exhibit E.

3. As between Settling States and Participating Subdivisions, the above rights are contractual in nature and nothing herein is intended to limit, restrict, change, or alter any other existing rights under law.

E. Enforcement Committee Actions to Enforce Agreement.

1. The Parties agree that in the event of any failure by Teva to make any required payments under this Agreement, the Enforcement Committee, on its own or through its designee such as a Settling State or Participating Subdivision acting by its authorization and on its behalf , shall have the ability and right to file an action or proceeding in any New York state court, or federal court of the United States of America, sitting in New York, for or related to the enforcement or collection of such payments.

2. If any National Dispute involving a Settling State, Participating Subdivision, and/or Teva is pending before a National Arbitration Panel concerning a given year’s payment to all Settling States, any action or proceeding pursuant to this subsection XV.E shall be stayed as to any disputed amounts only, but may proceed as to any and all undisputed amounts. In the event there is a dispute between the Parties as to the disputed amounts at issue, the Enforcement Committee or any party to that dispute may seek an expedited determination from the National Arbitration Panel for that proceeding as to the disputed and undisputed amounts.

3. The Parties further agree that in the event of Teva’s breach of the Parties’ Agreement for Injunctive Relief (Exhibit P attached hereto), the Enforcement Committee, on its own or through its designee such as a Settling State or Participating Subdivision acting by its authorization and on its behalf, shall have the ability and right t o file a civil action pursuant to Exhibit P, subection K.5, in any New York state court, or federal court of the United States of America, sitting in New York, seeking any appropriate relief to enforce compliance with such Agreement for Injunctive Relief.

4. Teva consents to the jurisdiction of the New York state court, or federal court of the United States of America, sitting in New York, and any appellate court from any thereof, in which any action or proceeding is initiated pursuant to this subsection XV.E, and for enforcement or collection of any related judgment entered by such court. Teva further agrees any service of process or notice required for such action or proceeding, including for any action or proceeding for enforcement or collection of any judgment entered thereon, may be effectuated on Teva through delivery of all required papers by hand or by a nationally recognized private courier on Teva’s representatives identified in subsection XVI.P herein. For the purposes 1924

53 December 20, 2022
of this Agreement only, Teva consents to personal jurisdiction before such courts and will not contend service must be effectuated through personal service or the Hague Convention process.

5. The enforcement rights under this subsection XV.E are in addition to, and not in lieu of, any other enforcement and collection rights of the Parties herein, including but not limited to enforcement rights as to payments as allowed by subsection XV.A.

F. Subdivision Payment Enforcement. A Participating Subdivision shall have the same right as a Settling State pursuant to subsection XV.G.4.a.iv to seek resolution of any failure by Teva to make its required Base Payments and/or Incentive Payments in a Payment Year.

G. Other Dispute Resolution Terms.

1. Except as provided in subsection XV.C, the parties to a dispute shall promptly meet and confer in good faith to resolve any dispute. If the parties cannot resolve the dispute informally, and unless otherwise agreed in writing, they shall follow the remaining provisions of this subsection XV.G to resolve the dispute.

2. Except as provided in subsections XV.C and XV.G.4, disputes not resolved informally shall be resolved in either the Court that entered the relevant Consent Judgment or, if no Consent Judgment was entered, a state or territorial court with jurisdiction located wherever the seat of state government is located. State court proceedings shall be governed by the rules and procedures of the forum. For the avoidance of doubt, disputes to be resolved in state court include, but are not limited to, the following:
a. disputes concerning whether expenditures qualify for Opioid Remediation; b. disputes between a Settling State and Participating Subdivisions located in such Settling State as provided by subsection XV.D, except to the extent the State-Subdivision Agreement provides for other dispute resolution mechanisms. For the avoidance of doubt, disputes between a Settling State and any Participating Subdivision shall not be considered National Disputes;
c. whether this Agreement and relevant Consent Judgment are binding under state law;
d. the extent of the Attorney General’s or other participating entity’s authority under state law, including the extent of the authority to release Claims; e. whether the requirem ents of a Bar, a Case -Specific Resolution, State - Specific Finality, Later Litigating Subdivision, Litigating Subdivision, or a Threshold Motion have been met; and
f. all other disputes not specifically identified in subsections XV.C and XV.G.4.
1925

54 December 20, 2022

3. Any Party may request that the National Arbitration Panel provide an interpretation of any provision of the settlement that is relevant to the state court determination, and the National Arbitration Panel shall make reasonable best efforts to supply such interpretation within the earlier of thirty (30) days or the time period required by the state court proceedings. Any Party may submit that interpretation to the state court to the extent permitted by, and for such weight provided by, the state court’s rules and procedures. If requested by a Party, the National Arbitration Panel shall request that its interpretation be accepted in the form of an amicus curiae brief, and any attorneys’ fees and costs for preparing any such filing shall be paid for by the requesting Party.

4. National Disputes involving a Settling State, Participating Subdivision, and/or Teva shall be resolved by a National Arbitration Panel.
a. “National Disputes” are disputes that are exceptions to subsection XV.G.2’s presumption of resolution in state courts because they involve issues of interpretation of Agreement terms applicable to all Settling States without reference to a particular State’s law. Disputes between a State and any Participating Subdivisions shall not be considered National Disputes.

National Disputes are limited to the following:
(i) the amount of offset and/or credit attributable to Non -Settling States;
(ii) issues involving the scope and definition of “Product”; (iii) interpretation and application of the terms “Covered Conduct” and “Released Entities”;
(iv) disputes over a given year’s Annual Payment or the payment of the Additional Restitution Amount to all Settling States (for the avoidance of doubt, disputes between a Settling State and Teva over the amounts owed to only that State shall not be considered National Disputes);
(v) questions regarding the performance and/or removal of the Settlement Fund Administrator;
(vi) disputes involving liability of successor entities; (vii) disputes that require a determination of sufficient Subdivision and Special District participation to qualify for Incentives A, B, C, or D,; (viii) disputes that require interpretation of Agreement terms (i) that concretely affect four (4) or more Settling States; and (ii) do not turn on unique definitions and interpretations under State law; and (ix) any dispute subject to resolution under subsection XV.G.2 but for which all parties to the dispute agree to arbitration before the 1926

55 December 20, 2022
National Arbitration Panel under the pr ovisions of this subsection XV.G.4.
b. The “National Arbitration Panel ” shall be comprised of three (3) neutral arbitrators. One (1) arbitrator shall be chosen by Teva, one (1) arbitrator shall be chosen by the Enforcement Committee with due input from Participating Subdivisions, and the third arbitrator shall be agreed upon by the first two (2) arbitrators. The membership of the National Arbitration Panel is intended to remain constant throughout the term of this Agreement, but in the event that replacements are required, the retiring arbitrator shall be replaced by the party that selected him/her.
(i) The National Arbitration Panel shall make reasonable best efforts to decide all matters within one hundred eighty (180) days of filing, and in no event shall it take longer than one (1) year. (ii) The National Arbitration Panel shall conduct all proceedings in a reasonably streamlined process consistent with an opportunity for the parties to be heard. Issues shall be resolved without the need for live witnesses where feas ible, and with a presumption in favor of remote participation to minimize the burdens on the parties. (iii) To the extent allowed under state law, a Settling State, Participating Subdivision, and (at any party’s request) the National Arbitration Panel may certify to an appropriate state court any question of state law. The National Arbitration Panel shall be bound by a final state court determination of such a certified question. The time period for the arbitration shall be tolled during the course of the certifi cation process.
(iv) The arbitrators will give due deference to any authoritative interpretation of state law, including any declaratory judgment or similar relief obtained by a Settling State, Participating Subdivision, or Teva on a state law issue.
(v) The decisions of the National Arbitration Panel shall be binding on Settling States, Participating Subdivisions, Teva, and the Settlement Fund Administrator. In any proceeding before the National Arbitration Panel involving a dispute between a Settling Sta te and Teva whose resolution could prejudice the rights of a Participating Subdivision(s) or Participating Special District(s) in that Settling State, such Participating Subdivision(s) or Participating Special District(s) shall be allowed to file a stateme nt of view in the proceeding.
c. Nothing herein shall be construed so as to limit or otherwise restrict a State from seeking injunctive or other equitable relief in state court to protect the health, safety, or welfare of its citizens.
1927

56 December 20, 2022
d. Each party shall bear i ts own costs in any arbitration or court proceeding arising under this subsection XV.G. The costs for the arbitrators on the National Arbitration Panel shall be divided and paid equally by the disputing sides for each individual dispute, e.g., a dispute between Teva and Settling States/Participating Subdivisions shall be split 50% by Teva and 50% by the Settling States/Participating Subdivisions that are parties to the dispute; a dispute between a Settling State and a Participating Subdivision shall be spli t 50% by the Settling State and 50% by any Participating Subdivisions that are party to the dispute.

5. Prior to initiating an action to enforce pursuant to this subsection XV.G, the complaining party must:
a. Provide written notice to the Enforcement Committee of its complaint, including the provision of the Consent Judgment and/or Agreement that the practice appears to violate, as well as the basis for its interpretation of the disputed provision. The Enforcement Committee shall establish a reasonable process and timeline for obtaining additional information from the involved parties; provided, however , that the date the Enforcement Committee establishes for obtaining additional information from the parties shall not be more than forty -five (45) days following t he notice . The Enforcement Committee may advise the involved parties of its views on the complaint and/or seek to resolve the complaint informally. b. Wait to commence any enforcement action until thirty (30) days after the date that the Enforcement Committee establishes for obtaining additional information from the involved parties.

6. If the parties to a dispute cannot agree on the proper forum for resolution of the dispute under the provisions of subsections XV.G.2 or XV.G.4, a committee comprising the Enforcement Committee and sufficient representatives of Teva such that the members of the Enforcement Committee have a majority of one (1) member will determine the forum where the dispute will be initiated within twenty -eight (28) days of receiving notification of the dispute relating to the proper forum. The forum identified by such committee shall be the sole forum for determining where the dispute shall be heard, and the committee’s identification of such forum shall not be entitled to deference by the forum selected.

H. No Effect. Nothing in this Agreement shall be interpreted to limit the Settling State’s Civil Investigative Demand (“CID”) or investigative subpoena authority, to the extent such authority exists under applicable state law and the CID or investigative subpoena is issued pursuant to such authority, and Teva reserves all of its rights in connection with a CID or investigative subpoena issued pursuant to such authority.

XVI. Miscellaneous
A. No Admission. Teva does not admit liability or wrongdoing. Neither this Agreement nor the Consent Judgments shall be considered, construed, or represented to be (1) an 1928

57 December 20, 2022
admission, concession, or evidence of liability or wrongdoing or (2) a waiver or any limitation of any defense otherwise available to Teva.

B. Population of Subdivisions. The population figures for Subdivisions shall be the published U.S. Census Bureau’s population estimates for July 1, 2019, released May 2020. These population figures shall remain unchanged during the term of this Agreement.

C. Population of Special Districts. For any purpose in this Agreement in which the population of a Special District is used , other than the use of “Covered Special District” : (a) School Districts’ population will be measured by the number of students enrolled who are eligible under the Individuals with Disabilities Education Act (“ IDEA”) or Section 504 of the Rehabilitation Act of 1973; (b) Health Districts’ and Hospital Districts’ population will be measured at 25% of discharges; and (c) all other Special Districts’ (including Fire Districts’ and Library Districts’) population will be measured at 10% of the population served.

D. Population Associated with Sheriffs . For any purpose in this Agreement in which the population associated with a lawsuit by a sheriff is used, the population will be measured at 20% of the capacity of the jail(s) operated by the sheriff.

E. Most-Favored-Nation Provision.

1. If Teva enters into any settlement agreement with any Non -Settling State after November 23, 2022 that resolves Claims similar in scope to the Claims released by a Settling State under this Agreement on overall payment terms that are more favorable to such Non-Settling State on a net present value basis (calculated with a 7% discount rate) on overall payment terms the Non -Settling State would have received under this Agreement based on the same level of participation, then the Settling States, individually or collectively, may elect to seek review, pursuant to Section XVI.E.3, of the overall payment terms of this Agreement and the Non - Settling State agreement so that the Settling State(s) may obtain, with respect to Teva, overall payment terms at least as favorable as those obtained by such Non - Settling State. “ Overall payment terms ” refers to consideration of all payment terms of the two agreements, taken together, including, but not limited to the amount of payments, the timing of payments, and conditions or contingencies on payments.

2. For any settlement with a Non-Settling State involving Released Claims, Teva shall provide the Enforcement Committee with a copy of the settlement agreement or relevant Consent Judgment within thirty (30) calendar days of the consummation of such settlement. The Enforcement Committee will promptly dist ribute such copy to all Settling States.

3. In the event that the one or more Settling State(s) believes that the overall payment terms of an agreement by Teva with a Non-Settling State are more favorable to the Non-Settling State, when compared based on the totality of the considerations set forth in Section XVI.E.1, the Settling State(s) and Teva shall engage in the following process:
1929

58 December 20, 2022
a. The Settling State(s) shall provide notice, within sixty (60) calendar days of the date on which a settlement agreement or Consent Judgment is provided to the Enforcement Committee, to Teva of its intent to seek revision of this Agreement to provide payment terms that are, on an overall basis, as favorable as those obtained by the Non-Settling State. Such notice shall be confidential and not disclosed publicly to the extent allowed by law and shall state, in detail, the basis for the Settling State’s belief that it is entitled to a revision of the Agreement.
b. Teva shall, within thirty (30) calendar days, provide a response to the Settling State(s), explaining its position, in detail, as to whether the Settling State(s) is entitled to more favorable overall payment terms than those provided for in this Agreement.
c. In the event the Settling State(s) and Teva do not reach agreement as to the application of Section XVI.E.1, the Settling State(s) may petition the National Arbitration Panel to seek a ruling from the Panel as to the applicability of Section XVI.E.1, provided that the Settling State(s) may seek such review only if at least five (5) Settling States co-sign the petition.

The Panel shall consider submissions and argument by the parties pursuant to the procedures set forth in Section XV.G.4.
d. The Settling State(s) and Teva shall be bound by the determination of the National Arbitration Panel.

4. This Section XVI.E does not apply to, and there is no ability of any Settling State to seek or obtain revision of this Agreement based on, any Non -Settling State agreement with Teva that is entered into: (a) either the earlier o f (i) after the close of expert discovery or (ii) after a date ninety (90) calendar days prior to the scheduled start date of a trial between Teva and the Non -Settling State or any severed or bifurcated portion thereof, provided that, where, in order to co mplete a settlement, a Non -Settling State and Teva jointly request an adjournment of the scheduled start date of a trial within ninety (90) days of that date, this exception will apply as if the trial date had not been adjourned; (b) with a Non-Settling State that previously litigated to judgment a case related to opioids against any manufacturer, distributor, or pharmacy; or, (c) the earlier of: (i) after a Non-Settling State has obtained any court order or judicial determination that grants judgment (in w hole or in part) against Teva in the Non -Settling State’s case; (ii) after a sanctions ruling against Teva in the Non-Settling State’s case against Teva; or, (iii) after any ruling has issued in the Non -Settling State’s case against any manufacturer, distributor, or pharmacy on the issue of joint and several liability.

The National Arbitration Panel shall have no power to review agreements that satisfy any of the conditions described in this paragraph.

5. This Section does not apply to, and there is no ability of any Settling State to seek or obtain revision of this Agreement based on, any agreement between Teva and (a) federally-recognized tribe(s), (b) Non-Participating Subdivisions or (3) Non - 1930

59 December 20, 2022
Participating Special Districts. This Section XVI.E will not apply to any agreement entered into more than six (6) months after the Reference Date.

F. Tax Reporting and Cooperation.

1. Upon request by Teva, the Settling States, Participating Subdivisions, and Participating Special Districts agree to perform such further acts and to execute and deliver such further documents as may be reasonably necessary for Teva to establish the statements set forth in subsection VIII.G to the satisfaction of their tax advisors, their independent financial auditors, the Internal Revenue Service, or any other governmental authority, including as contemplated by Treasury Regulations Section 1.162 -21(b)(3)(ii) and any subseque ntly proposed or finalized relevant regulations or administrative guidance.

2. Without limiting the generality of subsection XVI.F, each Settling State, Participating Subdivision, and Participating Special District shall cooperate in good faith with Teva with respect to any tax claim, dispute, investigation, audit, examination, contest, litigation, or other proceeding relating to this Agreement.

3. The Designated State, on behalf of all Settling States, Participating Subdivisions, and Participating Special Districts, shall designate one of its officers or employees to act as the “appropriate official” within the meaning of Treasury Regulations Section 1.6050X-1(f)(1)(ii)(B) (the “Appropriate Official”).

4. Neither Teva nor the Settling States, Participating Subdivis ions, and Participating Special Districts make any warranty or representation to any Settling jurisdiction or Releasor as to the tax consequences of the payment of the Compensatory Restitution Amount (or any portion thereof).

G. No Third-Party Beneficiaries. Except as expressly provided in this Agreement, no portion of this Agreement shall provide any rights to, or be enforceable by, any person or entity that is not a Settling State or Released Entity. No Settling State may assign or otherwise convey any right to enforce any provision of this Agreement.

H. Calculation. Any figure or percentage referred to in this Agreement shall be carried to seven decimal places.

I. Construction. None of the Parties and no Participating Subdivisio n shall be considered to be the drafter of this Agreement or of any of its provisions for the purpose of any statute, case law, or rule of interpretation or construction that would or might cause any provision to be construed against the drafter of this Ag reement. The headings of the provisions of this Agreement are not binding and are for reference only and do not limit, expand, or otherwise affect the contents or meaning of this Agreement.

J. Cooperation. Each Party and each Participating Subdivision agrees to use its best efforts and to cooperate with the other Parties and Participating Subdivisions to cause this Agreement and the Consent Judgments to become effective, to obtain all necessary approvals, consents and authorizations, if any, and to execute all documents and to take 1931

60 December 20, 2022
such other action as may be appropriate in connection herewith. Consistent with the foregoing, each Party and each Participating Subdivision agrees that it will not directly or indirectly assist or encourage any challenge to this Agr eement or any Consent Judgment by any other person, and will support the integrity and enforcement of the terms of this Agreement and the Consent Judgments.

K. Entire Agreement. This Agreement, its exhibits and any other attachments, including the attorneys’ fees and cost agreement in Exhibit R, embodies the entire agreement and understanding between and among the Parties and Participating Subdivisions relating to the subject matter hereof and supersedes (1) all prior agreements and understandings relating to such subject matter, whether written or oral and (2) all purportedly contemporaneous oral agreements and understandings relating to such subject matter.

L. Execution. This Agreement may be executed in counterparts and by different signatories on separate counterparts, each of which shall be deemed an original, but all of which shall together be one and the same Agreement. One or more counterparts of this Agreement may be delivered by facsimile or electronic transmission with the intent that it or they shall constitute an original counterpart hereof. One or more counterparts of this Agreement may be signed by electronic signature.

M. Good Faith and Voluntary Entry. Each Party warrants and represents that it negotiated the terms of this Agreement in good faith. Each of the Parties and signatories to this Agreement warrants and represents that it freely and voluntarily entered into this Agreement without any degree of duress or compulsion. The Parties state that no promise of any kind or nature whatsoever (other than the written terms of this Agreement) was made to them to induce them to enter into this Agreement.

N. No Prevailing Party. The Parties each agree that they are not the prevailing party in this action, for purposes of any Claim for fees, costs, or expenses as prevailing parties arising under common law or under the terms of any statute, because the Parties have reached a good faith settlement. The Parties each further waive any right to challenge or contest the validity of this Agreement on any ground, includin g, without limitation, that any term is unconstitutional or is preempted by, or in conflict with, any current or future law.

O. Non-Admissibility. The settlement negotiations resulting in this Agreement have been undertaken by the Parties and by certain repre sentatives of the Participating Subdivisions in good faith and for settlement purposes only, and no evidence of negotiations or discussions underlying this Agreement shall be offered or received in evidence in any action or proceeding for any purpose. This Agreement shall not be offered or received in evidence in any action or proceeding for any purpose other than in an action or proceeding arising under or relating to this Agreement or in any litigation or arbitration concerning Teva’s right to coverage under an insurance contract.

P. Notices. All notices or other communications under this Agreement shall be in writing (including but not limited to electronic communications) and shall be given to the recipients indicated below:
1932

61 December 20, 2022

1. For the Attorney(s) General:

Josh Stein, Attorney General
North Carolina Department of Justice
Attn: Daniel Mosteller
PO Box 629
Raleigh, NC 27602
[email protected]

Tom Miller, Attorney General
Office of the Attorney General of Iowa
Attn: Nathan Blake
1305 E. Walnut St.

Des Moines, IA 50319
[email protected]

Jonathan Skrmetti, Attorney General
Office of the Tennessee Attorney General
Attn: Michael Leftwich
P.O. Box 20207
Nashville, TN, 37202-0207
[email protected]

2. For the Plaintiffs’ Executive Committee:

Paul F. Farrell
Farrell Law
P.O. Box 1180
Huntington, WV 25714-1180
[email protected]
Jayne Conroy
Simmons Hanly Conroy LLC
112 Madison Avenue, 7th Floor
New York, NY 10016-7416
[email protected]
Joseph F. Rice
Motley Rice LLC
28 Bridgeside Blvd.

Mount Pleasant, SC 29464
[email protected]
Peter Mougey
Levin Papantonio Rafferty
316 South Baylen St.

Pensacola, FL 32502
[email protected]
1933